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 Investigation of the Pd-catalyzed carboamination reaction for the synthesis of 
substituted piperidines from δ-amino olefins and piperazine heterocycles from amino acid 
derivatives is described. These reactions are believed to proceed via an unprecedented 
insertion into a Pd–N bond of the key Pd-amido species. These reactions also proceed 
with excellent levels of 2,6-diastereocontrol (in many cases, >20:1 dr has been observed). 
The diastereoselectivity of these reactions is also dependent on the protecting group on 
the cyclizing nitrogen, where more electron rich aryl protecting groups provide more of 
the cis-diastereomer, whereas less electron rich protecting groups provide slightly lower 
diastereoselectivity, still favoring the cis-diastereomer. Our stereochemical model differs 
from related pyrrolidine cyclizations which also provide the cis-diastereomer. We 
hypothesized that the nitrogen is pyramidalized in the transition state leading to the 
piperazine and therefore the α-substituent can lie in the pseudoequatorial orientation. 
This hypothesis was tested by varying the protecting group on the cyclizing nitrogen to 
determine whether we could vary the diastereoselectivity by varying the degree of 
pyramidalization in the transition state. In addition to 2,6-disubstituted aryl-protected 
piperazines, we also extended the methodology to include vinyl-halide coupling partners 
(in addition to aryl halide coupling partners), Boc-protected piperazines, 2,3-disubstituted 
piperazines, bicyclic piperazines, and benzopiperazines. 
xxiii 
 
The second part of this thesis details intramolecular Pd-catalyzed 
carboetherification and carboamination reactions for the synthesis of 2-indanyl 
tetrahydrofurans and 2-indanyl pyrrolidines. These reactions are believed to proceed 
through an unprecedented macrocyclic insertion into a Pd–O or Pd–N bond to afford 
products resulting from syn-addition across the olefin. Surprisingly, in the optimization 
of the carboetherification reactions, we discovered an unprecedented catalyst control on 
the stereochemical outcome of the reaction. In cases where a monodentate ligand was 
used in combination with a Pd(0) source, we observed selective formation of the syn-
addition diastereomer. When we switched to a catalyst system composed of Pd(0) and a 
bidentate ligand, we observed formation of the anti-addition diasteromer. We reasoned 
we were observing a catalyst control of mechanism in the oxypalladation reaction. In the 
analogous carboamination reactions, we did not observe a complete reversal of 
diastereoselectivity, but instead erosion of diastereoselectivity. We reasoned this was due 
to several factors, including the reduced pKa of the aniline versus the alcohol. Further 
studies to expand the scope of the intramolecular carboetherification and carboamination 









Pd-Catalyzed Carboamination Reactions: Synthesis of Piperidines and Piperazines 
Chapter I 
Synthesis of Pyrrolidines and Tetrahydrofurans via Pd-Catalyzed Carboamination 
and Carboetherification Reactions of γ-Hydroxy and γ-Amino Alkenes with Aryl 
and Alkenyl Bromides 
Our lab has recently reported the stereoselective synthesis of both pyrrolidines 
and tetrahydrofurans from γ-amino and γ-hydroxy olefins, respectively.1 These Pd-
catalyzed carboamination and carboetherification reactions involve the coupling of an 
aryl or alkenyl halide with a γ-hydroxy or γ-amino alkene in the presence of catalytic 
amounts of Pd2(dba)3 or Pd(OAc)2 and a phosphine ligand. These reactions are extremely 
useful, as they provide heterocyclic scaffolds that are ubiquitous in nature and are found 
in many biologically active natural products and pharmaceuticals.2,3,4 In addition, these 
transformations form two new bonds and one stereocenter in a single operation. The 
carboamination and carboetherification reactions are particularly appealing in that they 
provide the heterocyclic product in one step from easily accessible starting materials and 
allow for the facile construction of analogs.  
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Two representative examples of these reactions are shown below (eq 1 and eq 2). 
The carboamination of γ-amino olefin I-1 with 4-bromoanisole proceeds with high 
diastereoselectivity for formation of 2,5-cis-disubstituted pyrrolidine I-2, whereas the 
analogous carboetherification of γ-hydroxy olefin I-3 proceeds with high 
diastereoselectivity for the generation of 2,5-trans-disubstituted tetrahydrofuran I-4. 
These transformations are effective with a broad range of aryl or alkenyl halides, and 
have all been used for the stereoselective synthesis of 2,3-trans-disubstituted products. 
Both cyclic and acyclic internal alkenes (I-5) react with net syn-addition across the 
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Both the carboamination and the carboetherification reaction proceed through a 
similar mechanism. The proposed catalytic cycle for the Pd-catalyzed carboamination 
 3
reaction is shown in Scheme 1. Oxidative addition of an aryl halide (I-8) to Pd(0) affords 
the electrophilic Pd(II) species I-9. The amine moiety of I-10 coordinates to the metal, 
and is subsequently deprotonated to afford Pd-amido species I-11.5 Coordination of the 
olefin to the metal followed by insertion of the olefin into the Pd–N bond6,7 by way of 
transition state I-12, provides Pd(II)-pyrrolidine species I-13. Reductive elimination of I-
13 releases the pyrrolidine product I-14. 
  
















































While the yields of the pyrrolidine products are generally quite good, competing 
processes have been observed as shown in Scheme 2.1a In addition to the desired 
 4
pyrrolidine I-14, a regioisomer is also generated (I-19). Additionally, N-arylation (I-20) 
of the substrate occasionally competes with the desired carboamination reaction. The 
origin of the regioisomer as well as the N-arylation side product can be easily explained 
when considering the mechanism. Regioisomer formation presumably originates from β-
hydride elimination of intermediate I-13 to afford I-15. At this stage, reinsertion of the 
olefin into the Pd–H bond with the opposite regiochemistry provides I-16. β-Hydride 
elimination from I-16 affords I-17, which upon reinsertion generates I-18. Reductive 
elimination from I-18 provides regioisomer I-19. This competing side reaction is 
minimized when the nitrogen is substituted with a tert-butoxycarbonyl or acyl protecting 
group in place of an aryl group.1c The N-arylation side product likely derives from 



















































Origin of Regioisomeric Side Product I-19


























The current stereochemical model for the carboamination of γ-amino olefins I-10 
to provide 2,5-cis-disubstituted pyrrolidines I-14 (or enantiomer I-14b) is explained by 
an allylic-strain based stereochemical hypothesis (Scheme 3). In these cyclizations two 
transition states are possible, one placing the α-substituent in the pseudoaxial orientation 
as in I-21, and the other placing the α-substituent in the pseudoequatorial position as in I-
22. Transition state I-22 is likely disfavored because of the A(1,3) strain that develops 
between the aryl substituents and the pseudoequatorial substituent, and therefore the α-
substituent prefers to orient itself in the pseudoaxial position. Upon insertion and 
subsequent reductive elimination, 2,5-cis-pyrrolidine I-14b is generated. The same 
 6
argument is used in the explanation of the stereochemistry in the N-Boc pyrrolidine 
series.1a-c 
 








































The Pd-catalyzed carboetherification reaction is believed to proceed through a 
similar mechanism as the pyrrolidine-forming reactions described above.1d-g However, 
the conversion of I-3 to I-4 (or enantiomer I-4b) is believed to proceed through a 
transition state in which the α-substituent orients itself in the pseudoequatorial position 
(I-25 in Scheme 4). Since there is not an allylic strain component in this transformation, 

































Ar = p -(OMe)C6H4  
 
Other Pd-Catalyzed Carboamination and Carboetherification Reactions 
Three groups have also reported metal-catalyzed carboamination reactions for the 
synthesis of pyrrolidines or tetrahydrofurans. Tamaru8 has shown that N-tosyl protected 
alkene substrate I-27 cyclized to afford pyrrolidine I-28, with the reaction proceeding 
through a nucleophilic attack of the heteroatom onto the Pd-activated olefin as shown in 
the conversion of I-29 to I-30 (Scheme 5). Upon nucleophilic attack and loss of HCl, 
insertion of CO occurs into the Pd–C bond to afford I-31, which upon methanolysis 
affords pyrrolidine I-28. It is important to note that the heteroatom and the metal add anti 
across the olefin, which has important consequences with regard to the mechanism of the 
reaction. This type of carboamination is mechanistically distinct from those discussed in 
the previous section, which have been shown to proceed by syn-addition across the 
double bond.1a-c This reaction is very useful for the synthesis of pyrrolidines but is 
limited to the preparation of molecules bearing an ester group in the C1´ position.9  
 8
Scheme 5. Mechanism of Pd-Catalyzed Anti-Aminocarbonylation Reaction 
Ts
H
N 10 mol% PdCl2, CO (1 atm)





































In related cyclizations for the synthesis of tetrahydrofurans, Semmelhack has 
demonstrated the conversion of I-32 to tetrahydrofuran I-33 under an atmosphere of CO 
(Scheme 6). This reaction proceeds via anti-oxypalladation to provide I-35, and is 
mechanistically analogous to the Tamaru reaction discussed in Scheme 5.10,11 
 
Scheme 6. Mechanism of Pd-Catalyzed Anti-Oxycarbonylation Reaction  
OHPh
Me





















I-34 I-35  
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Chemler12 has recently demonstrated the synthesis of pyrrolidines through an 
intramolecular carboamination reaction that is proposed to proceed through a copper(II)–
amido species. While this method is mechanistically distinct from the anti-
aminopalladation pathway of the Tamaru reactions, it is limited in substrate scope; the 
aryl moiety must be tethered to the substrate via a sulfonamide linkage. The mechanism 
as proposed by Chemler involves formation of Cu-amido complex I-39 followed by 
migratory insertion to form the copper alkyl species I-40. Formation of intermediate I-41 
occurs through Cu–C bond homolysis, which is followed by radical cyclization onto the 
aromatic ring to generate the product I-37 (Scheme 7). 
 
Scheme 7. Intramolecular Cu-Mediated Carboamination Reactions Providing Syn-



























The Pd-catalyzed carboamination and carboetherification reactions developed in 
our research group are mechanistically distinct and complementary to other metal-
 10
catalyzed methods for the synthesis of heterocycles because of substitution pattern, scope 
of coupling partners, and stereochemistry of insertion. In addition, the reactions are 
highly efficient and exemplary as evidenced by the excellent yields, regioselectivity, and 
diastereoselectivity observed. However, the Pd-catalyzed carboamination and 
carboetherification reactions developed by our research group have not been previously 
employed for the preparation of six-membered ring heterocycles. In addition, an 
intramolecular version of the reaction, which would ultimately form two bonds, two 
rings, and two contiguous stereocenters in one step has also not been shown. The first 
part of this thesis describes our effort in the development of the carboamination reaction 
for the synthesis of six-membered ring heterocycles. The second part of this thesis 
describes the development of the intramolecular Pd-catalyzed carboamination and 
carboetherification reaction for the synthesis of 2-indan-1-ylpyrrolidines and 2-indan-1-
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Chapter II 
Carboamination Reactions for the Synthesis of Piperidines1 
Introduction: Biologically Active Piperidine Natural Products and Pharmaceuticals 
The piperidine core is an incredibly important motif contained in a wide variety of 
natural products as shown below.2 Cassine (II-1)3,4,5 is an alkaloid isolated from the 
American tropical legume Cassia excelsa Shrad and exhibits antimicrobial activity 
against Staphylococcus aureus. Additionally, other 2,6-disubstituted piperidin-3-ol 
alkaloids display biological activities, such as prosopinine (analgesic, anesthetic, and 
antibiotic activities) and (–)-spectaline (cytotoxic activities). Coniine (II-2) and 
pseudooconhydrine (II-3)6,7 are both poisonous alkaloids from the hemlock (Conium 
maculatum). Coniine (II-2) is one of the most toxic of these alkaloids, and is well known 
for possibly claiming the life of Socrates.2e Sedamine (II-9)8 is a piperidine derivative 
that is one of over 600 alkaloids isolated from the species Sedum, which is a common 
garden plant. Methylphenidate, marketed under the trade name Ritalin (II-8),9 is a well 
known drug used to treat attention deficit disorder. Martinellic acid (II-5) and 
martinelline (II-6) originate from the root extracts of the Martinella iquitosensis vine, 
found in the Amazonian lowland rainforests. These root extracts are used by indigenous 
tribes to treat eye ailments such as inflammation and conjunctivitis, and this positive 
effect is believed to be at least partially due to the guanidine moiety.10 Alkaloids II-5 and 
II-6 have been found to be antibiotics and G-protein coupled receptor antagonists.11 The 
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2-alkyl-4-hydroxypiperidine SS20846A (II-4) was isolated from Streptomyces sp S20846 
and exhibits antibacterial and anticonvulsant properties.12 The Prosopis family of natural 
products, of which the natural product 3-epi-deoxoprosopinine (II-7) is a member, 
exhibit various bioactivities including analgesic, anesthetic, and antibiotic activity.2e 
 


























Martinellic Acid (II-5) R = H
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Background: Classical and Pd-catalyzed Methods for the Synthesis of Piperidines 
There are numerous methods for the stereoselective synthesis of piperidines.2 The 
most commonly used strategies involve reactions of amines with tethered alkyl halides, 
acetates, mesylates, and alcohols under Mitsunobu conditions (eq 4).13 Reductive 
 15  
aminations (eq 5),14 Michael additions (eq 6),15 and radical cyclizations (eq 7) are also 
















































Metal-catalyzed methods have also been developed and a few examples are 
highlighted below. Hirai17 reported the stereoselective synthesis of vinyl piperidine II-21 
from oxazolidinone II-19 in the presence of a Pd-catalyst. Activation of the alkene by 
Pd(II) followed by nucleophilic attack occurs via transition state II-20 to afford II-21 
after β-alkoxide elimination. 






















Interestingly, use of AgOTf as the catalyst with added NaH as base leads to the 
conversion of related substrate I-22 to I-24. This reversal of diastereoselectivity is 
presumably due to the differences in coordination properties of the two metals, which 
consequently results in a difference in transition state leading to the piperidine products. 
When AgOTf is used as the catalyst, both the chloride atom and carbonyl oxygen of the 
substrate bind to the catalyst, and an SN2´ reaction ensues via transition state II-23, which 




























Larock, Weinreb and coworkers18 reported the synthesis of vinyl piperidines such 
as II-27 from N-tosyl amino olefins (e.g. II-26) and vinyl halides (II-25) in the presence 
of a Pd-catalyst. Carbopalladation of II-26 with the (alkenyl)Pd(Br) intermediate 
(generated from oxidative addition of II-25 to Pd(0)) affords II-29. This intermediate 
then undergoes β-hydride elimination and reinsertion to provide II-30. Nucleophilic 
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attack of the pendant sulfonamide on the π-allyl palladium intermediate, affords the 
piperidine product II-27.    
 
Scheme 8. Carboamination Reactions for the Synthesis of 2-Vinyl Piperidines 
























Michael and coworkers recently reported a hydroamination reaction of amino 
olefin substrates to provide piperidines.19 For example, amino olefin II-33 was converted 
to methyl substituted piperidine II-35 in the presence of the tridentate Pd-catalyst II-34 
and AgBF4.  These reactions presumably proceed through nucleophilic attack of the 
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Scheme 9. Hydroamination Reactions for the Synthesis of Piperidines 
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Pd-Catalyzed Carboamination of δ-Amino Alkenes with Aryl Bromides 
As noted in Chapter I, the generation of six-membered rings through Pd-catalyzed 
carboamination or carboetherification reactions between heteroatom-tethered alkenes and 
aryl/alkenyl halides has not been previously described. We believed that we could apply 
the Pd-catalyzed carboamination reaction developed in our lab to the synthesis of larger 
rings. A logical extension from the pyrrolidine synthesis would be to simply insert a 
methylene group in the tether to afford the six-membered ring analog (piperidine). With 
this in mind, we set out to examine the analogous Pd-catalyzed carboamination reactions 
for the synthesis of six membered nitrogen heterocycles. In our initial studies, we chose 
to examine the carboamination reactions for the preparation of N-aryl piperidines.  
 Our goals for the synthesis of piperidines via Pd-catalyzed carboamination 
reactions were: 1) examine and identify suitable reaction conditions for the 
transformation of II-38 to II-39 (eq 10) by screening various ligands, which have been 
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shown to have the largest impact on the chemical yield of the analogous five-membered 
ring transformations; and 2) examine the diastereoselectivity of reactions involving 
















The substrates for these reactions were prepared in 3–5 steps from commercially 
available materials. Hydroxy olefin II-40 was oxidized in the presence of the Jones 
reagent to provide carboxylic acid II-41. Treatment of carboxylic acid II-41 with CDI 
followed by aniline provides an intermediate N-phenyl amide, which was reduced with 
lithium aluminum hydride to provide substrate II-42.20  
 











II-40 II-41 II-42  
Alternatively, carboxylic acid II-41 was treated with oxalyl chloride followed by 
NH4OH to provide primary amide II-43. The amide was further elaborated by lithium 
aluminum hydride reduction to the primary amine II-44 followed by N-arylation of the 
primary amine to afford II-45. Boc protection of II-44 generates Boc-protected amine 
substrate II-33.21 
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Substituted substrates were synthesized in 4 steps using the protocol shown in 
Schemes 12 and 13. Deprotonation of hydrazones II-46 and II-51 (formed in one step 
from acetophenone and acetone, respectively) followed by alkylation with 4-
bromobutene affords ketones II-47 and II-52 after hydrolysis. Treatment of the ketone 
with hydroxylamine hydrochloride followed by lithium aluminum hydride reduction of 
the oxime affords primary amines II-48 and II-53. Boc protection of II-48 and II-53 
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Optimization of Pd-Catalyzed Carboamination Reaction for the Synthesis of 
Piperidines 
With the substrates in hand, we set out to optimize the reaction as shown in Table 
1.23 Treatment of II-42 with 2-bromonaphthalene and NaOtBu in the presence of 
catalytic Pd2(dba)3 and a phosphine ligand provided the piperidine product II-55 as well 
as side products II-56, II-57, II-58. We found the best ligands for this reaction were P(2-
fur)3 and dppe, and use of 2.0 equiv of NaOtBu and ArBr provided optimal results. The 
use of P(2-fur)3 was initially examined with a higher catalyst loading (Table 1), but use of 




























 23  




















































aConditions: 1.0 equiv II-42, 2.0 equiv ArBr, 2.0 equiv NaOtBu, 1 mol % Pd2(dba)3, 4 mol % monodentate 
ligand or 2 mol % bidentate ligand, toluene (0.2–0.5 M), 105 °C, 12h; reaction times have not been 
minimized. bThe yield in parentheses denotes the isolated yield. c2.5 mol % Pd2(dba)3, 10 mol % P(2-fur)3 
was used. d The product was contaminated with ~5% of II-57 + II-58. eThis reaction was conducted at 60 
°C.  f1 mol % Pd2(dba)3, 4 mol % dppe. g2 mol % Pd2(dba)3, 4 mol % dppe. h The product was contaminated 
with ~10% of II-57 + II-58. i II-57 and II-58 have been tentatively assigned as shown. 
Scope and Limitations of Piperidine Synthesis via Pd-Catalyzed Carboamination 
Reactions 
 With optimal conditions in hand, we set out to examine the scope of the 
carbamination reaction for the synthesis of piperidines. We initially examined reactions 
of the N-phenyl protected amino olefin II-42 with various aryl halide coupling partners 
(Table 2). We were able to isolate piperidine products (entries 1-6) in good yield, but in 
some cases it was difficult to separate the desired products from the side products 
(analogous to II-57 and II-58 shown in Table 1). However, the products are generally 
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formed in moderate yields to good yields, and the reactions are effective with several 
different aryl bromides. 
 






















































aConditions: 1.0 equiv II-42, 2.0 equiv ArBr, 2.0 equiv NaOtBu, 1 mol % Pd2(dba)3, 4 mol % P(2-fur)3, 
toluene (0.2–0.5M), 105 °C, 12h; reaction times have not been minimized. bThe pure product was 
contaminated with ~10% of II-57 + II-58 for ArBr = 2-bromonaphthalene and II-57b + II-58b for ArBr = 
4-Br-tBu-benzene. c2 mol % dppe used in place of P(2-fur)3. dThe pure product was contaminated with ~5% 
of N-arylation side product analogous to II-56 but with ArBr = 4-bromobenzophenone (II-56b). eYields 
represent results of a single experiment. 
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We also examined the cyclization of the N-(p-cyanophenyl)-protected amino 
olefin II-45 with various aryl halides (Table 3). The yields were comparable to those 
obtained in reactions of N-phenyl amino derivatives. Vinyl halides were briefly 
examined, and it was found that mono-substituted piperidines could be generated in 
moderate yield (Table 3, entry 4). Substituted substrates were also examined, and 
unfortunately, reaction of α-substituted amino olefins led to complex mixtures of 
products and low yields of the desired piperidine (entry 5). Reactions that proceeded in 
lower yields (Table 3, entries 4–5) were impeded by side products analogous to those 
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aConditions: 1.0 equiv amine, 2.0 equiv ArBr, 2.0 equiv NaOtBu, 1 mol % Pd2(dba)3, 4 mol % P(2-furyl)3 
(entries 2, 4, and 5) or 2 mol % dppe (entries 1 and 3), toluene (0.2–0.5M), 105 °C, 12h; reaction times 
have not been minimized. bYields represent results of a single experiment, except entry 3 which is an 
average of two experiments. cThe assigned stereochemistry is tentative.  
 
Previous studies on related pyrrolidine-forming carboamination reactions 
suggested that N-Boc-protected substrates might undergo cleaner cyclization.24 
Competing N-arylation/vinylation and regioisomer formation are generally not 
problematic in these reactions.25 As such, we examined the carboamination reaction of N-
Boc protected substrates for the formation of piperidines.  
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 Boc-protected amine substrate II-33 was initially examined in the Pd-catalyzed 
carboamination reaction to afford piperidine II-69. We initially screened bidentate and 
monodentate ligands with 4-bromo-t-butylbenzene as the aryl halide, Pd(OAc)2 as the 
precatalyst, and NaOtBu as the base. This initial optimization demonstrated the superior 
reactivity of P(2-fur)3, while DPE-phos and dppe provided modest conversions to the 
piperidine. Heck side product II-70 and trimer side product II-71 as well as a mixture of 
unidentified side products were also observed. 
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aConditions: 1.0 equiv amine, 1.2 equiv ArBr, 2.0 equiv NaOtBu, 6 mol % Pd2(OAc), 8 mol % PPh3, 
toluene (0.2–0.5M), 90 °C, 8–10 h; the reaction times have not been minimized. bAn unidentified mixture 
of products was observed by crude 1H NMR and is represented by this number. 
 
Various monodentate ligands were then screened for the related reaction of II-33 
with 2-bromonaphthalene and we found that PPh3 was the optimal ligand in this coupling 
(Table 5). Amino olefin II-33 was converted in moderate yield (63%) to piperidine II-72 
under these conditions. Minor amounts of the Heck product II-73 and unidentified 
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products were also observed. Use of Pd(OAc)2 as the precatalyst was superior to 
Pd2(dba)3 in the Boc-protected amine cyclizations for the synthesis of piperidines. Other 
reaction parameters, such as lowering the reaction temperature to 60 °C or 80 °C led to 
increased amounts of the Heck product II-73 as well as trimer II-71. Increasing the 
amount of aryl halide (2.0 eq) did not lead to an improvement in the reaction conditions. 
Decreasing the amount of base led to increased Heck product. Therefore, the reaction 
conditions (1.0 equiv amine, 1.2 equiv ArBr, 2.0 equiv NaOtBu, toluene (0.2–0.5M), 90 
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100 49 (24) 42 9
88 4949 2
100 0 2 48 16 34
100 79 (63) 6 0 0 15
100 27 044 29
100 59 26 15
21100 0 1168














LIGAND % conversion (II-72)b (II-71)(II-73) (unidentif ied)c(II-74)





aConditions: 1.0 equiv amine, 1.2 equiv ArBr, 2.0 equiv NaOtBu, 6 mol % Pd2(OAc), 8 mol % 
monodentate ligands, toluene (0.2–0.5M), 90 °C, 8–10 h; the reaction times have not been minimized. 
bThe yield in parentheses denotes the isolated yield. cAn unidentified mixture of products was observed 
by crude 1H NMR and is represented by this number. 
 
The catalyst loading and effect of varying the metal to phosphine ratio was also 
examined using the optimal conditions. Use of 6 mol % catalyst was necessary since use 
of less catalyst (2 mol %) with the same phosphine to metal ratio resulted in mainly 
trimer II-71 formation (71%)26 and minor amounts of the desired piperidines (29%). 
Increasing the concentration and reducing the catalyst to 3 mol % (4 mol % phosphine) 
led to greater amounts of the piperidine product, but still competing trimer formation (II-
71) and Heck reaction (II-73) was problematic. Therefore, 6 mol% Pd(OAc)2 catalyst 
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was necessary for the reaction to proceed optimally. The phosphine to metal ratio was 
also examined. The optimal phosphine to metal ratio was 1.3:1 as shown in Table 6. Use 
of more phosphine did not increase reaction efficiency, but use of less phosphine greatly 
inhibited the cyclization to II-72.  
 




























PPh3 (8 mol%) 100
15
PPh3 (6 mol %) 100 66 17 5
0PPh3 (4 mol %)






79 (63) 6 0 0 15
40 7 0 30
0 12
Ar = naphthyl
LIGAND % conversion (II-72)b (II-71)(II-73) (unidenf ied)c(II-74)





aConditions: 1.0 equiv amine, 1.2 equiv ArBr, 2.0 equiv NaOtBu, 6 mol % Pd2(OAc), various mol % PPh3, 
toluene (0.4 M), 90 °C, 8–10 h; the reaction times have not been minimized. 
 
The scope of aryl bromides in the cyclization of II-33 was briefly examined 
(Table 7). In most cases, the 1H NMR spectrum of crude reaction mixtures was relatively 
clean, but the yields were moderate. This suggested that substrate II-33 could be 
decomposing to volatile materials.27 This methodology is currently limited to the 
synthesis of monosubstituted piperidines, as substituted substrates (Entry 5) did not 
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undergo cyclization under the optimized conditions and instead provided Heck 
byproducts.  
 

















































aConditions: 1.0 equiv amine, 1.2 equiv ArBr, 2.0 equiv NaOtBu, 6 mol % Pd(OAc)2, 8 mol % PPh3 
(entries 1, 2, 4) or P(2-furyl)3 (entry 3), toluene (0.2–0.5M), 105 °C, 8–10 h. bA 10% unidentifiable material 
was inseparable from the pure product. c4-iodo-toluene used as aryl halide. d2.0 equiv ArBr, 2.0 equiv 
NaOtBu, 6 mol % Pd(OAc)2, 8 mol % PPh3. ePd2(dba)3 or Pd(OAc)2, various ligands. fYields represent 
results of a single experiment. 
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The competing formation of II-71 presumably arises from trimerization of 
isocyanate II-80 (eq 11). Generation of isocyanates from decomposition of secondary 






















A possible solution to Boc-decomposition would be to conduct these cyclizations 
with milder bases, and prior studies in our research group demonstrated that Cs2CO3 was 
effective in pyrrolidine-forming reactions.24 Therefore, we turned our attention to 
screening the mild base Cs2CO3 in dioxane solvent with various ligands for the 
conversion of II-33 to II-72. We found that while the product was generated under these 
conditions, continued screening and perhaps catalyst design would be necessary to fully 
optimize this reaction. We also observed Heck product II-73 in this transformation as 
well as N-vinyl piperidine II-81. We also screened other solvents (in combination with 
various ligands) with the mild base conditions (Cs2CO3); however, THF, DMF, tBuOH, 
and DMA did not provide any of the desired piperidine II-72 and Heck product II-73 as 
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Table 8. Optimization of Carboamination of II-33 with 2-Br-Naphthalene using Cs2CO3 



























PPh3 91 55 36 9




aConditions: 1.0 equiv amine, 1.2 equiv ArBr, 2.3 equiv Cs2CO3, 6 mol % Pd2(OAc), 4 mol % monodentate 
ligand or 2 mol % bidentate ligand, dioxane (0.2 M), 100 °C, 8–10 h; the reaction times have not been 
minimized. 
 
Preliminary experiments suggest that Boc decomposition was not a problem in 
these cases, but a general catalyst system for the formation of various Boc-protected 
analogs has not been identified with yields varying widely in these cases. Additionally, 
attempts to probe the stereoselectivity of these reactions by installing a substituent in the 
α position in the amine starting material proved futile and instead led to mixtures of Heck 
product as well as Boc-deprotection/N-arylation of the starting material. Use of Cs2CO3 
provided trace amounts of the desired product in these substituted systems. Preliminary 
experiments utilizing mild base conditions (Pd(OAc)2/DPE-Phos/Cs2CO3/dioxane/2-
bromo-naphthalene) resulted in minor amounts of desired product II-72, Heck side 
products (cis and trans) II-73, and exo olefin side product II-81 resulting from β-hydride 
elimination prior to reductive elimination. 
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Discussion 
The mechanism for the piperidine-forming reactions is likely analogous to the 
pyrrolidine-forming reactions discussed in Chapter I. Oxidative addition of the aryl halide 
II-82 to Pd(0) provides the electrophilic oxidative addition species II-83. Coordination of 
amine II-42 followed by deprotonation affords Pd-amido complex II-84. Insertion of the 
olefin into the Pd–N bond, affords II-85, which undergoes reductive elimination to 
provide II-86.  
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Various side products are observed in the N-aryl and N-Boc piperidine-forming 
reactions. In the case of the N-aryl piperidine forming reactions, the N-arylation side 
product II-56 is likely generated from the Pd-amido species (Scheme 15). Reductive 
elimination of the Pd-amido species II-84 provides N-arylation side product II-56.  
 




















The structure of side product II-57 has been tentatively assigned on the basis of 
1H NMR analysis of an isolated derivative (II-57b) which contained a 33% impurity. In 
addition, comparison to other similar side products studied in our group also led to the 
assignment (see Chapter III). Attempted isolation of side product II-58 by column 
chromatography was not successful. The structure of side product II-58 has therefore 
been tentatively assigned on the basis of 1H NMR analysis of crude reaction mixtures and 
comparison to other reactions studied in our group. As shown in Scheme 16, these side 
products are likely generated from β-hydride elimination of intermediate II-85 to provide 
exo-olefin piperidine II-88.  A Heck reaction on intermediate II-88 could provide side 
product II-57. Alternatively, side product II-57 could arise from carbopalladation of exo-
olefin II-88, to provide II-87, which could then undergo β-hydride elimination to provide 
side product II-57. This later pathway is less likely since insertion into Pd–H bonds is 
typically faster than insertion into Pd–C bonds.29 Side product II-58 is likely generated 
from isomerization of the Pd-aryl hydride species to intermediate II-90, which could then 
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undergo insertion with the opposite regiochemistry and β-hydride elimination to afford 
regioisomer II-58. 
 
















































The common side products observed in the Boc-protected piperidine cyclizations 
presumably arise from the same type of intermediate as discussed above for the N-aryl 
piperidine series. Boc-piperidine intermediate II-91 can undergo β-hydride elimination to 
provide exo-olefin side product II-81 upon displacement of the metal from the double 
bond of II-92.  















It is likely that the N-arylation side product II-74 results from the primary amine 
II-44 which is formed upon decomposition of the Boc-protecting group under the 
reaction conditions.27 Pd-amido complex formation occurs to afford II-93, which upon 
reductive elimination provides the N-arylation side product II-74. 
 




















Heck side product II-73 is also observed in the cyclization of Boc-protected 
δ−amino olefins and likely forms from carbopalladation of II-33 to provide II-94, 
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The piperidine-forming carboamination reaction proceeds to provide the product 
in moderate yield. It is likely that these reactions are more difficult than the analogous 
five-membered ring formation to afford pyrrolidines because of the slower rate of 
cyclization. Formation of six-membered ring piperidines is more challenging than the 
five-membered ring pyrrolidines since the two ends of the γ-amino olefin are closer 
together than in a δ-amino olefin. Therefore, for entropic reasons the six-membered ring 
formation is less favorable and more likely to be outcompeted by other processes. 
Reactions of α-substituted N-aryl derivatives proceed to afford the desired product in low 
yield with modest levels of diastereoselectivity. The increase in side products in the 
reactions of substituted substrates is consistent with the hypothesis that the activation 
energy required to form the six-membered ring is higher than the analogous five-
membered ring and anything done to slow the rate (i.e. placing substituents next a to 
nitrogen which slows Pd-amido formation) will likely thwart the reaction further.  
 The choice of P(2-fur)3 as the ligand in the majority of the N-aryl and PPh3 as the 
ligand in the N-Boc piperidine-forming carboamination reactions discussed in this 
chapter is somewhat curious based on other carboaminations in our research lab, which 
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frequently utilize a bidentate chelating ligand. In addition to the monodentate nature of 
P(2-fur)3, it is also a relatively small, electron poor ligand. It is possible that it may be 
easier to arrive at the key intermediates in a system that requires a greater degree of 
energy to cyclize if the ligand is small and can be easily displaced.  
Conclusion 
In conclusion, preliminary studies on the synthesis of piperidines via the Pd-
catalyzed carboamination reaction were conducted. These transformations were more 
challenging than the analogous five-membered ring forming reactions that afford 
pyrrolidines. However, several monosubstituted 2-benzyl piperidines were generated in 
moderate yields. Further studies towards optimization of catalysts and conditions for 
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Experimental Section 
General Considerations:  All reactions were carried out under an argon or nitrogen 
atmosphere in oven- or flame-dried glassware. All catalysts, reagents, and aryl bromides 
were obtained from commercial sources and were used without further purification. N-
(hex-5-enyl)aniline,20 tert-butyl hex-5-enylcarbamate,21 tert-butyl hept-6-en-2-
ylcarbamate22 were prepared according to published procedures or via minor 
modifications of literature procedures. Toluene, THF, ether, and dichloromethane were 
dried and purified using a GlassContour solvent purification system. Structural and 
stereochemical assignments were made on the basis of 2-D COSY, HSQC, and NOESY 
experiments. Ratios of diastereomers were determined by 1H NMR and/or capillary GC 
analysis of crude reaction mixtures. Yields refer to isolated yields of compounds 
estimated to be ≥95% pure as determined by 1H NMR, GC, and/or combustion analysis, 
unless otherwise noted. The yields reported in the experimental and the tables describe 
the results of a single experiment, with the exception of Table 2, Entry 3, II-66, which is 
an average of two experiments. Thus, the yield in Table 2 (Entry 3) is different from the 
yield in the experimental for this example. 
Synthesis of Substrates (Schemes 10–13) 
General Procedure 1: Conversion of hex-5-en-1-amine (II-44) and 1-phenylhex-5-en-
1-amine (II-48) to 4-(hex-5-enylamino)benzonitrile (II-45) and 4-(1-phenylhex-5-
enylamino)benzonitrile (II-50). A flame dried Schlenk tube equipped with a magnetic 
stirbar was charged with Pd2(dba)3 (1 mol % complex, 2 mol % Pd), (±)-BINAP (2 mol 
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%), sodium tert-butoxide (1.2 equiv), the appropriate aryl bromide (1.0 equiv), and a 
0.3–0.5 M solution of the primary amine (1.25–1.43 equiv) in toluene. The reaction 
mixture was heated to 60 °C or 80 °C with stirring until the starting material had been 
consumed as judged by NMR analysis (ca. 3.5 h–6 h). The mixture was cooled to rt and a 
solution of aqueous ammonium chloride was added (4 mL). The resulting mixture was 
extracted with ethyl acetate and the combined organic layers were dried over anhydrous 
sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified by 
flash chromatography on silica gel. 
4-(Hex-5-enylamino)benzonitrile (II-45). General procedure 1 was used for the N-
arylation of hex-5-en-1-amine (II-44) (1.70 g, 17.14 mmol) with 4-bromobenzonitrile 
(2.50 mg, 13.71 mmol) at 60 °C (3.5 h). This procedure afforded 2.74 g (80%) of the title 
compound as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 8.5 Hz, 2 H), 6.55 
(d, J = 3.5 Hz, 2 H), 5.84–5.76 (m, 1 H), 5.04–4.97 (m, 2 H), 4.26 (s, 1 H), 3.15 (t, J = 
7.0 Hz, 2 H), 2.13–2.08 (m, 2 H), 1.68–1.62 (m, 2 H), 1.53–1.47 (m, 2 H); 13C NMR 
(125 MHz, CDCl3) δ 151.6, 138.4, 133.9, 120.8, 115.2, 112.2, 98.5, 43.2, 33.5, 28.7, 
26.4; IR (film) 3369, 2931, 2209, 1605 cm–1. Anal. Calcd for C13H16N2: C, 77.96; H, 
8.05; N, 13.99.  Found: C, 77.93; H, 8.08; N, 13.74. 
4-(1-Phenylhex-5-enylamino)benzonitrile (II-50). General procedure 1 was used for the 
N-arylation of freshly distilled 1-phenylhex-5-en-1-amine (II-48) (3.14 g, 11.36 mmol) 
with 4-bromobenzonitrile (1.45 g, 7.95 mmol) at 80 °C. This procedure afforded 2.00 g 
(91%) of the title compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.35–7.32 
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(m, 4 H), 7.29–7.24 (m, 3 H), 6.47 (d, J = 8.4 Hz, 2 H), 5.81–5.71 (m, 1 H), 5.02–4.96 
(m, 2 H), 4.57 (m, 1 H), 4.36–4.31 (m, 1 H), 2.11–2.05 (m, 2 H), 1.88–1.76 (m, 2 H), 
1.58–1.36 (m, 2 H). Anal. Calcd for C19H20N2: C, 82.57; H, 7.29; N, 10.14.  Found: C, 
82.56; H, 7.40; N, 9.98. 
tert-Butyl 1-phenylhex-5-enylcarbamate (II-49). A flask was charged with 1.17 g (6.67 
mmol) of 1-phenylhex-5-en-1-amine (II-48),30 diethyl ether (20 mL), and 1.29 g (5.94 
mmol) of Boc-anhydride. The reaction was stirred for 12 h at room temperature. The 
crude material was diluted with ether (100 mL) and washed with 1 M NaOH, brine, and 
dried over Na2SO4. The solvent was evaporated, and THF (100 mL) and 1 M NaOH (100 
mL) were added and the mixture was stirred vigorously for 48 h. The compound was 
purified by flash chromatography to afford 1.14 g (70%) of the title compound. The 
compound was further recrystallized from 2.5% diethyl ether/hexanes to afford the pure 
product. 1H NMR (300 MHz, CDCl3) δ 7.35–7.30 (m, 3 H), 7.25–7.16 (m, 2 H), 5.82–
5.68 (m, 1 H), 5.01–4.92 (m, 2 H), 4.79 (s, 1 H), 4.68–4.52 (m, 1 H), 2.09–2.02 (m, 2 
H), 1.78–1.70 (m, 2 H), 1.43–1.28 (m, 11 H). 
General Procedure for Pd-Catalyzed Synthesis of Aryl-Piperidines. A flame-dried 
Schlenk tube equipped with a magnetic stirbar was cooled under a stream of nitrogen and 
charged with Pd2(dba)3 (1 mol % complex, 2 mol % Pd), P(2-furyl)3 (4 mol %), sodium 
tert-butoxide (2.0 equiv), and the aryl bromide (2.0 equiv). When dppe (2 mol %) was 
used as the ligand, Pd2(dba)3 (1 mol % complex, 2 mol % Pd), sodium tert-butoxide (2.0 
equiv), and aryl bromide (2.0 equiv), were used. The Schlenk tube was purged with 
nitrogen and the amine was added as a solution in toluene (0.2–0.5 M substrate). The 
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Schlenk tube was then heated to 105 °C with stirring until the starting material had been 
consumed as judged by 1H NMR analysis of an aliquot taken from the reaction mixture. 
The reaction mixture was then cooled to room temperature, saturated aqueous ammonium 
chloride (4 mL) was added, and the resulting mixture was extracted with ethyl acetate (3 
x 8 mL). The combined organic layers were dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel. 
2-(4-Methylbenzyl)-1-phenylpiperidine (II-59). The reaction of 100 mg (0.57 mmol) of 
N-(hex-5-enyl)aniline (II-42) with 195 mg (140.3 μL, 1.14 mmol) of 4-bromotoluene 
was conducted for 12 h according to the general procedure. Upon purification, 103 mg 
(68%) of the title compound was obtained as a red solid, m.p. 50–55 °C. 1H NMR (300 
MHz, CDCl3) δ 7.38–7.33 (m, 2 H), 7.16–7.05 (m, 6 H), 6.89 (t, J = 7.5 Hz, 1 H), 4.09–
4.04 (m, 1 H), 3.46–3.42 (m, 1 H), 3.10 (dt, J = 3.0, 11.4 Hz, 1 H), 2.88–2.80 (m, 1 H), 
2.73–2.68 (m, 1 H), 2.38 (s, 3 H), 1.90–1.64 (m, 6 H); 13C NMR (75 MHz, CDCl3) δ 
151.2, 137.2, 135.5, 129.4, 129.24, 129.17, 118.9, 116.9, 58.4, 44.1, 32.7, 26.6, 25.9, 
21.2, 19.2; IR (film) 2932, 1597 cm–1. Anal. Calcd for C19H23N: C, 85.99; H, 8.74; N, 
5.28.  Found: C, 86.02; H, 8.69; N, 5.11.  
2-(4-tert-Butylbenzyl)-1-phenylpiperidine (II-60). The reaction of 100 mg (0.57 mmol) 
of N-(hex-5-enyl)aniline (II-42) with 243 mg (199 μL, 1.14 mmol) of 4-bromo-t-
butylbenzene was conducted for 12 h according to the general procedure. Upon 
purification, 140 mg (80%) of the title compound was obtained as an orange solid. This 
material was judged to be 90% pure and contained ca. 10% of side products II-57b and 
 44  
II-58b, m.p. 37–42 °C. 1H NMR (400 MHz, CDCl3) δ 7.33–7.29 (m, 4 H), 7.08 (d, J = 
8.0 Hz, 2 H), 7.01 (d, J = 8.0 Hz, 2 H), 6.84 (t, J = 7.2 Hz, 1 H), 4.07–4.04 (m, 1 H), 
3.43–3.40 (m, 1 H), 3.07 (dt, J = 2.4, 11.2 Hz, 1 H), 2.85–2.79 (m, 1 H), 2.69–2.65 (m, 1 
H), 1.86–1.72 (m, 2 H), 1.68–1.62 (m, 4 H) 1.33 (s, 9 H). 13C NMR (100 MHz, CDCl3) δ 
151.2, 148.9, 137.2, 129.4, 129.0, 125.4, 118.9, 116.8, 58.2, 44.0, 34.6, 32.7, 31.6, 26.7, 
26.0, 19.2; IR (film) 2949, 1597 cm–1. Anal. Calcd for C22H29N: C, 85.94; H, 9.51; N, 
4.56.  Found: C, 85.78; H, 9.56; N, 4.46. 
6-(4-tert-Butylbenzyl)-1-phenyl-1,2,3,4-tetrahydropyridine (side product II-57b). 
1H NMR (400 MHz, CDCl3) δ 7.25–7.18 (m, 6 H), 7.10 (t, J = 7.2 Hz, 1 H), 6.95 (d, J = 
8 Hz, 2 H), 4.90 (t, J = 6.6 Hz, 1 H), 3.65–3.60 (m, 2 H), 3.23 (s, 2 H), 2.10–2.05 (m, 2 
H), 1.70–1.55 (m, 2 H), 1.28 (s, 9H). 
2-(Naphthalen-2-ylmethyl)-1-phenylpiperidine (II-55). The reaction of 90 mg (0.513 
mmol) of N-(hex-5-enyl)aniline (II-42) with 213 mg (1.03 mmol) of 2-bromo-
naphthalene was conducted for 12 h according to the general procedure using 2 mol % 
dppe in place of P(2-furyl)3. Upon purification, 111 mg (72%) of the title compound was 
obtained as a red solid. This material was judged to be 90% pure and contained ca. 10% 
of side products II-57 and II-58, m.p. 80–89 °C. 1H NMR (400 MHz, CDCl3) δ 7.82–
7.76 (m, 3 H), 7.57 (s, 1 H), 7.49–7.41 (m, 2 H), 7.36–7.32 (m, 2 H), 7.29–7.26 (m, 1 
H), 7.06 (d, J = 8.0 Hz, 2 H), 6.87 (t, J = 7.2 Hz, 1 H), 4.17–4.13 (m, 1 H), 3.43–3.39 (m, 
1 H), 3.12 (dt, J = 3.2, 11.6 Hz, 1 H), 3.03–2.97 (m, 1 H), 2.88–2.84 (m, 1 H), 1.88–1.77 
(m, 2 H), 1.75–1.62 (m, 4 H); 13C NMR (100 MHz, CDCl3) δ 151.2, 137.9, 133.8, 132.2, 
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129.4, 128.2, 127.9, 127.8, 127.6, 126.3, 126.1, 125.4, 119.2, 117.1, 58.4, 44.2, 33.4, 
26.7, 26.0, 19.3; IR (film) 3054, 2930, 1597 cm–1. MS (ESI) 302.1896 (302.1909 calcd 
for C22H23N, M + H+). 
2-(4-Methoxybenzyl)-1-phenylpiperidine (II-61). The reaction of 100 mg (0.57 mmol) 
of N-(hex-5-enyl)aniline (II-42) with 213 mg (143 μL, 1.14 mmol) of 4-bromoanisole 
was conducted for 12 h according to the general procedure. Upon purification, 101 mg 
(63%) of the title compound was obtained as a white solid, m.p. 60–62 °C.  1H NMR 
(300 MHz, CDCl3) δ 7.32–7.26 (m, 2 H), 7.06–6.98 (m, 4 H), 6.86–6.81 (m, 3 H), 4.03–
3.96 (m, 1 H), 3.79 (s, 3 H), 3.41–3.36 (m, 1 H), 3.10–3.01 (m, 1 H), 2.81–2.73 (m, 1 H), 
2.66–2.61 (m, 1 H), 1.85–1.60 (m, 6 H); 13C NMR (75 MHz, CDCl3) δ 158.0, 151.2, 
132.4, 130.2, 129.4, 118.9, 116.9, 114.0, 58.5, 55.4, 44.1, 32.3, 26.6, 25.9, 19.2; IR (film) 
2933, 1597, cm–1. MS (ESI) 282.1846 (282.1858 calcd for C19H23NO, M + H+). 
2-[(6-Methoxynaphthalen-2-yl)methyl]-1-phenylpiperidine (II-62). The reaction of 
100 mg (0.57 mmol) of N-(hex-5-enyl)aniline (II-42) with 270 mg (1.14 mmol) of 2-
bromo-6-methoxynaphthalene was conducted for 12 h according to the general 
procedure. Upon purification, 101 mg (54%) of the title compound was obtained as a red 
solid, m.p. 120–123 °C. 1H NMR (400 MHz, CDCl3) δ 7.72–7.68 (m, 2 H), 7.52 (s, 1 H), 
7.38–7.33 (m, 2 H), 7.27 (dd, J = 1.6, 8.4 Hz, 1 H), 7.19–7.14 (m, 2 H), 7.09–7.07 (m, 2 
H), 6.89 (t, J = 7.6 Hz, 1 H), 4.17–4.13 (m, 1 H), 3.94 (s, 3 H), 3.43 (dd, J = 4, 12 Hz, 1 
H). 3.12 (dt, J = 3.2, 12 Hz, 1 H), 3.01–2.95 (m, 1 H), 2.86–2.82 (m, 1 H), 1.90–1.78 
(m, 2 H), 1.76–1.63 (m, 4 H). 13C NMR (100 MHz, CDCl3) δ 157.4, 151.2, 135.5, 133.2, 
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129.4, 129.3, 129.0, 128.4, 127.4, 127.0, 119.1, 118.9, 117.0, 105.8, 58.4, 55.4, 44.2, 
33.2, 26.7, 26.0, 19.3; IR (film) 2935, 1597 cm–1. MS (ES) 332.2010 (332.2014 calcd for 
C23H25NO, M + H+). 
Phenyl (4-[(1-phenylpiperidin-2-yl)methyl]phenyl) methanone (II-63). The reaction 
of 100 mg (0.57 mmol) of N-(hex-5-enyl)aniline (II-42) with 298 mg (1.14 mmol) of 4-
bromobenzophenone was conducted for 12 h according to the general procedure. Upon 
purification, 114 mg (56%) of the title compound was obtained as a brown solid. The 
material was judged to be 95% pure, and contained ca. 5% of side product II-56b, m.p. 
98–106 °C.  1H NMR (300 MHz, CDCl3) δ 7.83–7.72 (m, 4 H), 7.61–7.56 (m, 1 H), 
7.50–7.45 (m, 2 H), 7.32–7.21 (m, 4 H), 6.99 (d, J = 9.0 Hz, 2 H), 6.85 (t, J = 7.5 Hz, 1 
H), 4.10–4.07 (m, 1 H), 3.41–3.37 (m, 1 H), 3.08 (t, J = 10.8 Hz, 1 H), 2.94–2.76 (m, 2 
H), 1.85–1.64 (m, 5 H); 13C NMR (75 MHz, CDCl3) δ 196.5, 151.1, 145.7, 138.0, 135.5, 
132.4, 130.5, 130.1, 129.4, 129.2, 128.4, 119.3, 117.1, 58.5, 44.2, 33.6, 27.0, 25.8, 19.2; 
IR (film) 2935, 1656, 1597 cm–1. MS (ESI) 356.2014 (356.2014 calcd for C25H25NO, M 
+ H+). 
4-(2-(Naphthalen-2-ylmethyl]piperidin-1-yl)benzonitrile (II-64). The reaction of 100 
mg (0.499 mmol) of 4-(hex-5-enylamino)benzonitrile (II-45) with 207 mg (0.998 mmol) 
of 2-bromonaphthalene was conducted for 12 h according to the general procedure. Upon 
purification, 100 mg (61%) of the title compound was obtained as an orange solid, m.p. 
145–153 °C. 1H NMR (500 MHz, CDCl3) δ 7.82–7.77 (m, 3 H), 7.58 (s, 1 H), 7.49–7.43 
(m, 4 H), 7.28 (d, J = 8.0 Hz, 1 H), 6.88 (d, J = 8.0 Hz, 2 H), 4.30 (s, 1 H), 3.66 (d, J = 
13.5 Hz, 1 H), 3.17 (t, J = 12.0 Hz, 1 H), 3.10–3.03 (m, 1 H), 2.93–2.90 (m, 1 H), 1.88–
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1.80 (m, 2 H), 1.70–1.61 (m, 4 H); 13C NMR (125 MHz, CDCl3) δ 153.2, 136.7, 134.5, 
133.8, 133.7, 132.3, 128.5, 127.9, 127.7, 127.6, 126.4, 125.7, 120.6, 114.2, 98.9, 56.5, 
42.3, 34.4, 26.4, 25.4, 18.7; IR (film) 2938, 2213, 1603 cm–1. MS (ESI) 327.1873 
(327.1861 calcd for C23H22N2, M + H+).  
4-[(2-(4-Methoxybenzyl)piperidin-1-yl]benzonitrile (II-65). The reaction of 94 mg 
(0.499 mmol) of 4-(hex-5-enylamino)benzonitrile (II-45) with 223 mg (125 μL, 0.998 
mmol) of 4-bromoanisole was conducted for 12 h according to the general procedure. 
Upon purification, 98 mg (64%) of the title compound was obtained as a white solid, m.p. 
96–101 °C. 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.8 Hz, 2 H), 7.06 (d, J = 8.4 Hz, 
2 H), 6.84–6.80 (m, 4 H), 4.15–4.13 (m, 1 H), 3.78 (s, 3 H), 3.62 (d, J = 11.6 Hz, 1 H), 
3.11 (dt, J = 2.8, 12.4 Hz, 1 H), 2.87–2.81 (m, 1 H), 2.72–2.68 (m, 1 H), 1.84–1.55 (m, 6 
H). 13C NMR (125 MHz, CDCl3) δ 158.3, 153.2, 133.7, 131.2, 130.2, 120.6, 114.2, 
114.0, 98.6, 56.7, 55.4, 42.1, 33.3, 26.4, 25.4, 18.6; IR (film) 2935, 2213, 1603 cm–1. MS 
(ES) 307.1803 (307.1810 calcd for C20H22N2O, M + H+).  
4-[2-(4-tert-Butylbenzyl)piperidin-1-yl]benzonitrile (II-66). The reaction of 105 mg 
(0.524 mmol) of 4-(hex-5-enylamino)benzonitrile (II-45) with 223 mg (183 μL, 1.05 
mmol) of 4-bromo-t-butylbenzene was conducted for 12 h according to the general 
procedure. Upon purification, 139 mg (80%) of the title compound was obtained as an 
orange solid, m.p. 95–98 °C. 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.8 Hz, 2 H), 
7.31 (d, J = 8.4 Hz, 2 H), 7.10 (d, J = 8.0 Hz, 2 H), 6.82 (d, J = 8.8 Hz, 2 H), 4.22–4.20 
(m, 1 H), 3.64 (d, J = 12.4 Hz, 1 H), 3.13 (dt, J = 2, 12.4 Hz, 1 H), 2.92–2.86 (m, 1 H), 
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2.77–2.72 (m, 1 H), 1.87–1.61 (m, 6 H), 1.34 (s, 9 H). 13C NMR (100 MHz, CDCl3) δ 
153.2, 149.3, 136.0, 133.6, 128.9, 125.5, 120.5, 113.9, 98.4, 56.4, 42.0, 34.5, 33.7, 31.5, 
26.5, 25.3, 18.5; IR (film) 2955, 2213, 1602 cm–1. Anal. Calcd for C23H28N2: C, 83.09; H, 
8.49; N, 8.43.  Found: C, 83.25; H, 8.72; N, 8.34.  
(E)-4-(2-Cinnamylpiperidin-1-yl)benzonitrile (II-67). The reaction of 50 mg (0.249 
mmol) of 4-(hex-5-enylamino)benzonitrile (II-45) with 91 mg (64 μL, 0.498 mmol) of β-
bromo-styrene was conducted for 12 h according to the general procedure, 35 mg (49%) 
of the title compound was obtained as a yellow solid, m.p. 76–85 °C.  1H NMR (300 
MHz, CDCl3) δ 7.45 (d, J = 9.3 Hz, 2 H), 7.32–7.18 (m, 5 H), 6.83 (d, J = 9.3 Hz, 2 H), 
6.42 (d, J = 15.6 Hz, 1 H), 6.12–6.02 (m, 1 H), 4.17–4.13 (m, 1 H), 3.64–3.59 (m, 1 H), 
3.06 (dt, J = 2.4, 12.6 Hz, 1 H), 2.59–2.39 (m, 2 H), 1.86–1.74 (m, 2 H), 1.72–1.56 (m, 4 
H); 13C NMR (75 MHz, CDCl3) δ 153.3, 137.4, 133.7, 132.5, 128.7, 127.4, 127.1, 126.1, 
120.6, 114.0, 98.5, 54.6, 42.0, 32.1, 27.4, 25.3, 18.6; IR (film) 2938, 2213, 1603 cm–1. 
MS (ESI) 303.1838 (303.1861 calcd for C21H22N2, M + H+).  
(S, R)-4-[2-(4-tert-Butylbenzyl)-6-phenylpiperidin-1-yl]benzonitrile (II-68). The 
reaction of 50 mg (0.181 mmol) of 4-(1-phenylhex-5-enylamino)benzonitrile (II-50) with 
4-bromo-t-butylbenzene 77.1 mg (63.2 mL, 1.14 mmol) was conducted for 12 h 
according to the general procedure. Upon purification, this procedure afforded 17 mg (24 
%) of the title compound as a yellow oil. Crude 1H NMR analysis of the reaction mixture 
indicated a 3:1 mixture of diastereomers (5.7:1 dr upon purification). Data are for the 
major isomer. 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 8.8 Hz, 2 H), 7.34 (d, J = 8.0 
Hz, 3 H), 7.27–7.25 (m, 3 H), 7.23–7.16 (m, 1 H), 7.10 (d, J = 8.0 Hz, 2 H), 6.93 (d, J = 
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8.8 Hz, 2 H), 4.73 (t, J = 6.8 Hz, 1H), 3.96–3.90 (m, 1 H), 2.94 (dd, J = 3.2, 13.2 Hz, 1 
H), 2.59–2.53 (m, 1 H), 2.32–2.23 (m, 1 H), 2.08–2.00 (m, 1 H), 1.86–1.76 (m, 1 H), 
1.72–1.67 (m, 2 H), 1.63–1.54 (m, 1 H), 1.32, (s, 9 H).  
General Procedure for Pd-Catalyzed Synthesis of Boc-Piperidines. A flame-dried 
Schlenk tube equipped with a magnetic stirbar was cooled under a stream of nitrogen and 
charged with Pd(OAc)2 (6 mol % complex, 6 mol % Pd), PPh3 (8 mol %), sodium tert-
butoxide (2.0 equiv), and the aryl bromide (1.2 equiv). The Schlenk tube was purged with 
nitrogen and the amine was added as a solution in toluene (0.2–0.5M). The Schlenk tube 
was then heated to 90 °C with stirring until the starting material has been consumed as 
judged by 1H NMR analysis of an aliquot taken from the reaction mixture. The reaction 
mixture was then cooled to room temperature, saturated aqueous ammonium chloride (2–
3 mL) was added, and the resulting mixture was extracted with ethyl acetate (3 x 8 mL). 
The combined organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude product was then purified by flash chromatography on 
silica gel. 
tert-Butyl 2-(naphthalen-2-ylmethyl)piperidine-1-carboxylate (II-72). The reaction of 
100 mg (0.502 mmol) of tert-butyl hex-5-enylcarbamate (II-33) with 125 mg (0.602 
mmol) of 2-bromonaphthalene was conducted for 12 h according to the general 
procedure. Upon purification, 104 mg (64%) of the title compound was obtained as  
yellow solid, m.p. 84–89 °C. This material was obtained in ca. 90% purity. The identity 
of the impurity was not established. 1H NMR (300 MHz, CDCl3) δ 7.82–7.70 (m, 3 H), 
7.62 (s, 1 H), 7.48–7.35 (m, 3 H), 4.46–4.60 (m, 1 H), 4.12–4.07 (m, 1 H), 3.09–2.92 
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(m, 3 H), 1.76–1.41 (m, 6 H), 1.31 (s, 9 H); 13C NMR (75 MHz, CDCl3) δ 155.1, 137.1, 
133.8, 132.3, 128.1, 128.0, 127.75, 127.67, 127.6, 126.0, 125.4, 79.3, 52.5, 39.3, 36.4, 
28.4, 27.2, 25.7, 19.2; IR (film) 2934, 1687 cm–1. MS (ESI) 326.2121 (326.2120 calcd for  
C21H27NO2, M + H+). 
tert-Butyl 2-(4-benzoylbenzyl)piperidine-1-carboxylate (II-75). The reaction of 100 
mg (0.502 mmol) of tert-butyl hex-5-enylcarbamate (II-33) with 162 mg (0.602 mmol) of 
4-bromobenzophenone was conducted for 12 h according to the general procedure. Upon 
purification, 95 mg (50%) of the title compound was obtained as a viscous yellow oil. 1H 
NMR (300 MHz, CDCl3) δ 7.77–7.72 (m, 4 H), 7.59–7.53 (m, 1 H), 7.47–7.42 (m, 2 H), 
7.29 (d, J = 8.4 Hz, 2 H), 4.39–4.54 (m, 1 H), 4.06 (d, J = 11.7 Hz, 1 H), 3.03–2.78 (m, 3 
H), 1.70–1.58 (m, 6 H), 1.33 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ 196.3, 154.8, 144.6, 
137.8, 135.5, 132.2, 130.3, 129.9, 129.2, 128.2, 79.2, 52.1, 39.0, 36.2, 28.3, 27.5, 25.5, 
19.0; IR (film) 2934, 1687, 1659 cm–1. MS (ESI) 402.2038 (402.2045 calcd for 
C24H29NO3, M + Na+).  
tert-Butyl 2-(4-methylbenzyl)piperidine-1-carboxylate (II-76). The reaction of 100 mg 
(0.502 mmol) of tert-butyl hex-5-enylcarbamate (II-33) with 218 mg (1.00 mmol) of 4-
iodotoluene was conducted for 12 h according to the general procedure with the 
exception that 2.0 eq of 4-iodo toluene was used instead of 1.2 eq of the corresponding 
aryl bromide. Upon purification, 66 mg (46%) of the title compound was obtained as 
yellow solid, m.p. 33–35 °C. 1H NMR (300 MHz, CDCl3) δ 7.13–7.00 (m, 4 H), 4.22–
4.46 (m, 1 H), 4.03 (d, J = 12.6 Hz, 1 H), 2.95–2.69 (m, 3 H), 2.30 (s, 3 H), 1.68–1.39 
(m, 6 H), 1.34 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ 155.1, 136.4, 135.7, 129.3, 129.2, 
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79.2, 52.6, 39.2, 35.8, 28.5, 27.1, 25.8, 21.2, 19.1; IR (film) 2931, 1690 cm–1. MS (ESI) 
290.2112 (290.2120 calcd for C18H27NO2, M + H+). 
tert-Butyl 2-(4-cyanobenzyl)piperidine-1-carboxylate (II-77). The reaction of 100 mg 
(0.502 mmol) of tert-butyl hex-5-enylcarbamate (II-33) with 110 mg (0.602 mmol) of 4-
bromobenzonitrile was conducted for 12 h according to the general procedure. Upon 
purification, 75 mg (50%) of the title compound was obtained as a yellow solid, m.p. 67–
73 °C. 1H NMR (300 MHz, CDCl3) δ 7.54 (d, J = 8.4 H, 2 H), 7.27 (d, J = 7.8 Hz, 2 H), 
4.30–4.50 (m, 1 H), 4.02 (d, J = 10.8 Hz, 1 H), 3.01–2.72 (m, 3 H), 1.67–1.34 (m, 6 H), 
1.28 (s, 9 H); 13C NMR (75 MHz, CDCl3) δ 154.8, 144.3, 132.2, 130.2, 119.1, 110.2, 
79.5, 52.1, 39.2, 36.5, 28.4, 27.9, 25.6, 19.1; IR (film) 2935, 2227, 1686 cm–1. MS (ESI) 
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Chapter III 
Carboamination Reactions for the Asymmetric Synthesis of Piperazines1 
Introduction: Biologically Active Piperazine Pharmaceuticals 
Piperazines2 are of profound importance in medicinal chemistry and drug 
development. A 2001 survey of biologically relevant templates in the MDDR revealed 
2271 biologically active molecules that contained substituted N-aryl piperazines; 16 of 
these compounds were drugs on the market and an additional 23 were in phase II or III 
clinical trials.3 For example, ABT-724 (III-1) is a selective dopamine D4 receptor agonist 
that was developed by Abbott for treatment of erectile dysfunction.4 Indinavir (trade 
name Crixivan, (III-2)), is a popular HIV protease inhibitor developed by Merck and is 
very effective in preventing virus replication and minimizing HIV-related infections.5 
Compound III-3 is an oxytocin antagonist discovered by Glaxo-Smith-Kline.6 
Olanzaoine7 (III-4) is among the several in the same class as the drug Olanzapine (trade 
name Zyprexa) which is an antipsychotic developed by Eli Lilly. Compound III-5 is a 
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Methods for the Synthesis of 2,6-Disubstituted Piperazines 
The presence of substituents on C2, C3, C5, and C6 (Figure 3) of the piperazine 
ring is known to have a significant influence on the biological activity of these molecules, 
and the ability to prepare substituted piperazines is of value for the optimization of 
biological properties.8 The asymmetric synthesis of monosubstituted or 2,5-disubstituted 
piperazines can be accomplished in a straightforward manner through coupling of readily 
available amino acids to provide diketopiperazines, which can then be reduced to 
piperazines.9 However, the stereoselective preparation of enantiomerically enriched 2,6-
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disubstituted piperazines remains challenging, particularly when one of the substituents is 
not a carboxylic acid or ester. There are few asymmetric routes to N,N-disubstituted-2,6-
dialkylpiperazines, and the existing syntheses of these molecules typically require >6 
steps.10,11,12 For example, amino alcohol III-6 was homologated in four steps to diamine 
III-7 which was then treated with diethyl azodicarboxylate to afford disubstituted 
piperazine III-8 (total 5 steps).10b,c Similarly, Boc-alanine (III-9) could also be 
homologated to diamino ester III-10 which in another three steps was converted to 
piperazine III-11 (7 steps total).10b,c This chemistry has only been used for the preparation 
of the dimethyl substituted piperazines shown below (Scheme 19). 
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Another strategy that has been used to prepare 2,6-disubstituted piperazines 
involves construction of the core ring followed by alkylation.11a For example, amino 
alcohol III-12 was converted in six steps to piperazine-2-one III-13. This intermediate 
was then deprotonated with t-BuLi and then alkylated with reactive electrophiles to 
generate III-14. Protection of the hydroxyl group followed by a second 
metalation/alkylation sequence, and reduction of the carbonyl provided III-15. This 
sequence requires ten linear steps, and is limited in the types of substituents that can be 
placed in the 2 and 6 positions.  
 


























R’=COOH, R = Bn or Me
R’= CH(OH)Ph, R = Me





Introduction to Pd-Catalyzed Carboamination Reaction for the Synthesis of 
Piperazines 
As described in Chapter II, our efforts to synthesize piperidines via Pd-catalyzed 
carboamination reactions demonstrated the feasibility of preparing six-membered rings 
with this method. However, in most cases, modest yields were obtained due to competing 
side reactions, and formation of 2,6-disubstituted products was very difficult (eq 13).  
 








+ NaOtBu, 1 mol % Pd2(dba)3
105 °C, 12h








We reasoned that the intramolecular syn-aminopalladation step in the catalytic 
cycle might be slow relative to the analogous five-membered ring process due to entropy. 
We hypothesized that we could potentially circumvent the difficulties associated with an 
entropically slower transformation by installing an amine in the tether, which would 
assist in bringing the two ends of the molecule together, therefore facilitating the more 


















In addition to the potential synthetic utility of the above strategy, the key 
cyclization reaction is fundamentally interesting. The construction of heterocyclic rings 
bearing more than one nitrogen atom has not been achieved in Pd-catalyzed 
carboamination or carboetherification reactions between heteroatom-tethered olefins and 
aryl/alkenyl halides.  
Preliminary Studies 
 In order to examine the feasibility of preparing substituted piperazines via Pd-
catalyzed carboamination reactions, we synthesized ethylene diamine derivative III-22 as 
shown in Scheme 21. Glycine was N-arylated with bromobenzene in the presence of CuI 
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(to give III-19), followed by N-allyl amide formation and reduction to provide ethylene 
diamine III-22. 
  




























 With III-22 in hand, we surveyed reaction conditions that had been effective in 
related pyrrolidine and piperidine-forming reactions. We were gratified to find that use of 
a catalyst composed of Pd2(dba)3 and dppb or P(2-fur)3 provided satisfactory results with 
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NaOtBu, toluene, Δ
Pd2(dba)3 (1 mol %)






 To determine whether other protecting groups on N1 would undergo the 
carboamination reaction, Boc-protected substrate III-27 was prepared from Boc-glycine 
in two steps. This substrate underwent the carboamination reaction to provide piperazine 
III-28 in good yield, further demonstrating the greater ease of cyclization of the 1,2-
diamino olefins relative to the carbon analog. These results demonstrated the viability of 
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Scheme 23. Synthesis of Monosubstituted Boc-Piperazines 






























Potential Advantages and Challenges to Use of Carboamination Reactions for the 
Synthesis of 2,6-Disubstituted Piperazines 
Due to the limitations associated with the stereoselective synthesis of 2,6-
disubstituted piperidines (eq 13), we chose to examine the synthesis of these molecules 
using our Pd-catalyzed carboamination reaction. Our approach to the construction of 2,6-
disubstituted piperazines III-29a is shown below (Scheme 24). The key Pd-catalyzed 
carboamination reaction is employed to generate the heterocyclic ring and form two 
bonds simultaneously.13,14 Retrosynthetic analysis of the requisite substrates (III-30) 
suggested these compounds could be prepared in a straightforward and modular fashion 
from simple precursors: amino acids, allylic amines, and aryl halides. Moreover, various 
aryl or vinyl halides (R3-X) could be used in the key Pd catalyzed coupling reaction. All 
of these starting materials (III-32, III-33, and III-34) are readily available, and amino 
acids offer access to a cheap, extensive pool of chirality. This strategy allows for 
installation of many different groups in the 2- and 6- positions by simple modification of 
the amino acid precursor III-34 and the aryl/alkenyl halide coupling partner (R1 and R3 of 
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III-34 and III-31, respectively). Additionally, the protecting groups on the amines could 
also be readily varied (R and R2 of III-33 and III-32, respectively), making the route both 
flexible and amenable to analog synthesis. Finally, the synthesis of III-29a would 
generate enantiopure products, provided the stereochemical integrity of the α-
stereocenter is maintained throughout the course of the synthesis.  
 































While we believed this strategy could be very useful, we also felt there would be 
some challenges associated with the development of the chemistry. First and foremost, it 
was not clear whether the key reaction would be feasible since cyclization of the 
analogous α-substituted piperidine precursors (Chapter II) was difficult. Additionally, if 
in fact the reaction was successful, it was not clear whether the diastereoselectivity of the 
transformations would be high (eq 15). Additionally, it would be critical to employ 
tactics that would maintain the stereochemical integrity of the amino-acid derived 
structure (eq 15).15 It is well known that amino acids can be prone to partial racemization 
in N-arylation (eq 16) and amide-forming reactions (eq 17) under strongly basic and or 
high temperature conditions.15 





























































We were also concerned about difficulties that may arise during coupling of 
amines with N-aryl amino acids since the nucleophilic N-aryl amine moiety could 
undergo intermolecular addition to the activated intermediate to provide oligomers (eq 
18). Finally, reductions of amides such as III-40 are usually effected using BH3 as the 
reducing agent,10b and since the substrates for the carboamination reactions contain an 
olefin that would likely undergo hydroboration under these reaction conditions, it was 
necessary to find an appropriate reducing agent (eq 19).  



















































The substrates for the carboamination reactions were prepared from commercially 
available amino acids by using one of two 3–4-step sequences. As shown in Scheme 25, 
the first route employs unprotected amino acid starting materials, which were subjected 
to Cu-catalyzed N-phenylation using the anhydrous conditions developed by Ma, to 
generate III-42 and III-43 without significant degradation of enantiomeric purity.16 
However, attempts to use biphasic conditions17 for the N-arylation of unhindered amino 
acids such as alanine or phenylalanine provided products with low enantiomeric purity 
(ca. 14–50% ee). Amide bond formation was achieved via coupling of III-42 and III-43 
with N-(benzyl)allylamine using Goodman’s DEPBT reagent.18 Use of other peptide 
coupling reagents such as CDI or DCC/HOBT led to erosion of enantiomeric purity to 
afford products with 85–90% ee. Reduction of amides III-44 and III-45 with lithium 
aluminum hydride at 0 °C afforded III-46 and III-47 (R1 = Bn and R1 = i-Pr), with 98%–
99% ee.  
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Route 1: R1 = Bn, i-Pr
III-44, R1 = Bn, 68%
III-45, R1 = i-Pr, 65%
III-46, R1 = Bn, 86%
III-47, R1 = i-Pr, 88%
III-42, R = Bn, 64%
III-43, R = i-Pr, 64%
Phenylalanine, R = Bn
Valine, R = i-Pr
 
Alternatively, in some instances it was advantageous to employ N-Boc-protected 
amino acids as starting materials due to their commercial availability, or due to partial 
loss of enantiomeric purity during the Cu-catalyzed N-arylation reaction.19 These starting 
materials were converted in two steps via DCC-mediated coupling with an allylic amine 
followed by reduction with LiAlH4 at 0 °C (Scheme 26) to provide Boc-protected 
diamines III-53-III-57, which could be used as substrates for the carboamination 
reaction. If instead an N-arylated precursor was desired, cleavage of the Boc group was 
accomplished by treatment of intermediates III-53-III-57 with HCl/dioxane, and 
subsequent Pd-catalyzed N-arylation20 afforded the requisite substrates (III-63-III-67) in 
high enantiomeric purity.  These two methods for the synthesis of the key precursors 









 66  















Yields over 2 steps:
III-53, R1 = CH2OBn, R2 = Bn, 65%
III-54, R1 = Me, R2 = Allyl, 72%
III-55, R1 = Me, R2 = Bn, 62%
III-56, R1 = Me, R2 = PMP, 72%
III-57, R1 = CH2CHMe2, R
2 = Bn, 62%
CH2Cl2
Route 2: R1 = Me, CH2OBn
III-48, R1 = CH2OBn, R2 = Bn
III-49, R1 = Me, R2 = Allyl
III-50, R1 = Me, R2 = Bn
III-51, R1 = Me, R2 = PMP













Pd2(dba)3 (1 mol %),
BINAP (2 mol %)
ArBr, NaOtBu





III-63, R1 = CH2OBn, R2 = Bn, Ar = p -C6H4CN, 73%
III-64, R1 = Me, R2 = Allyl, Ar = Ph, 69%
III-65, R1 = Me, R2 = Bn, Ar = Ph, 71%
III-66, R1 = Me, R2 = PMP, Ar = p -C6H4Cl, 69%
III-67, R1 = CH2CHMe2, R2 = Bn, Ar = Ph, 79%
III-58, R1 = CH2OBn, R2 = Bn, 100%
III-59, R1 = Me, R2 = Allyl, 85%
III-60, R1 = Me, R2 = Bn, 88%
III-61, R1 = Me, R2 = PMP, 72%
III-62, R1 = CH2CHMe2, R2 = Bn, 100%  
 
Catalyst Optimization 
With suitable precursors in hand, we examined Pd-catalyzed reactions of 
phenylalanine-derived substrate III-46 with 4-bromoanisole using a number of different 
phosphine ligands (Table 9). These reactions provided a mixture of three products: III-
68, III-69, and III-70. In all cases, the desired product III-68 was formed with >20:1 dr 
and retention of enantiomeric purity.  
In contrast to the analogous 2,5-disubstituted pyrrolidine-forming cyclizations, 
which were effectively catalyzed by mixtures of Pd2(dba)3 and dppe or dppb,21 reaction 
of substituted diamines such as III-46 were not efficient with these catalysts. Bidentate 
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ligands that are also effective in other carboamination reactions13a,c,d,f,g,22 such as Dpe-
Phos and Xant-Phos were superior to dppe. However, use of catalysts supported by P(2-
fur)3 provided the best results in the piperazine-forming reactions. Use of a 4:1 ratio of 
phosphine to palladium led to complete consumption of the diamine starting material, 
whereas reactions that employed a 2:1 L:Pd ratio frequently halted at ca. 85–90% 
conversion.23 The reason behind the need for excess phosphine to provide consumption 
of starting material is not entirely clear, but this may help to stabilize the catalyst and 
increase turnover number.24,25  
 







Ligand (4 or 8 mol %)
NaOtBu, Toluene
110 oC, 9 h
Ar1= p -MeOC6H4







































aConditions: 1.0 equiv amine, 1.2 equiv ArBr, 1.2 equiv NaOtBu, 1 mol % Pd2(dba)3, 8 mol % 
monodentate or 4 mol % bidentate ligands, toluene (0.2 M), 105 °C, 12h; reaction times have not been 
minimized. 
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Two experiments were performed to probe the origin of side products III-69 and 
III-70. Resubjection of III-70 to the reaction conditions did not result in the formation of 
III-69 or III-68 (eq 20). Furthermore, III-68 was not converted to III-69 when treated 






Pd2(dba)3 (1 mol %)
NaOtBu, toluene, Δ























Ar1 Pd2(dba)3 (1 mol %)
NaOtBu, toluene, Δ












Scope of Carboamination Reactions for the Synthesis of 2,6-Disubstituted 
Piperazines 
After achieving an efficient, flexible and straightforward route to the substrates 
and optimization of the key reaction, we set out to investigate the reaction scope. As 
shown in Table 10, the carboamination reactions are effective for transformations 
involving derivatives of several different amino acids including phenylalanine (III-46), 
valine (III-47), serine (III-63), alanine (III-64, III-65, III-66), and leucine (III-67). The 
reactions are tolerant of functionalized aryl groups on N1 (e.g., p-chlorophenyl and p-
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cyanophenyl) and several different protecting groups on N4 (e.g., benzyl, allyl, and p-
methoxyphenyl).26 Electron-rich, electron-neutral, and electron-poor aryl bromides can 
be employed as coupling partners, although use of β-bromostyrene provided low yields 
(ca. 25%) of the desired allylpiperazine derivative under these reaction conditions. In 
most cases the cyclizations afforded cis-2,6-disubstituted piperazines with >20:1 dr, 
although cyclizations of III-63 proceed with slightly lower (14:1) diastereoselectivity.27,28 
Interestingly, although the carboamination of N4-allyl substituted substrate III-64 
provided piperazine III-77 with >20:1 dr (Entry 8), a related reaction of N4-benzyl-
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aConditions: 1.0 equiv amine, 1.2 equiv ArBr, 1.2 equiv NaOtBu, 1 mol % Pd2(dba)3, 8 mol % P(2-
furyl)3, toluene (0.2 M), 105 °C, 8–10 h; reaction times have not been minimized. bYields represent average 
isolated yields obtained from two or more experiments. cThe reaction was conducted using 2 mol % 
Pd2(dba)3 and 16 mol % P(2-furyl)3. 
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aConditions: 1.0 equiv amine, 1.2 equiv ArBr, 1.2 equiv NaOtBu, 1 mol % Pd2(dba)3, 8 mol % P(2-
furyl)3, toluene (0.2 M), 105 °C, 8–10 h; reaction times have not been minimized. bYields represent average 
isolated yields obtained from two or more experiments. cThe reaction was conducted using 2 mol % 
Pd2(dba)3 and 16 mol % P(2-furyl)3. 
 
Reactions with vinyl halide electrophiles were also feasible in Pd-catalyzed 
carboamination reactions for the synthesis of substituted piperazines III-81-III-83. Use 
of a slighly higher catalyst loading (2 mol % Pd2(dba)3/4 mol % Pd) was necessary to 
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achieve complete consumption of starting material in these transformations. As shown in 
Table 11, formation of the desired piperazines occurred with high diastereoselectivity and 
excellent enantiopurity. 
 












































aConditions: 1.0 equiv amine, 1.4 equiv ArBr, 1.4 equiv NaOtBu, 2 mol % Pd2(dba)3, 16 mol % P(2-furyl)3, 
toluene (0.2 M), 90 °C, 12-15h; The reaction times have not been minimized. bThis reaction was performed 
with xylenes in place of toluene at 135 °C.  
 
The cyclization of Boc-protected amines III-55 and III-57 was also investigated. 
It was found that a catalyst composed of Pd(OAc)2/P(2-fur)3 and a reaction temperature 
of 90 °C provided optimal yields of the desired piperazine products. In contrast to 
cyclizations of Boc-amines to afford piperidines (Chapter II), in which Boc-
decomposition was a severe limitation, this was not an issue in the analogous Boc-
protected piperazine-forming reactions. The reactions proceeded in good yields to 
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provide the desired piperazine products III-84 and III-85. However, diastereoselectivities 
in the reactions were low (1 to 2:1 dr). 
 
Table 12. Carboamination Reaction of δ-N-Boc-Protected Amino Olefins with 4-Br-



















































aConditions: 1.0 equiv amine, 1.2 equiv ArBr, 1.2 equiv NaOtBu, 6 mol % Pd(OAc)2, 8 mol % P(2-fur)3, 
toluene (0.2 M), 90 °C, 3-12h; the reaction times have not been minimized.b The enantiopurity of each 
diastereomer was measured to be 99%. 
 
Mechanism of Carboamination Reaction for the Synthesis of 2,6-Disubstituted 
Piperazines 
A plausible mechanism for the Pd-catalyzed piperazine forming reactions is shown 
below (Scheme 27). These transformations appear to be mechanistically analogous to 
previously described carboamination reactions of γ-aminoalkenes with aryl bromides, and 
are likely initiated by oxidative addition of the aryl bromide to Pd(0) to generate III-87. 
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This intermediate can react with the amine and NaOtBu to provide a palladium 
(aryl)(amido) complex III-88, which can undergo syn-aminopalladation13a,d to afford III-
89. Carbon-carbon bond-forming reductive elimination would then yield the observed 
piperazine product III-68.  
 













































Side products III-69 and III-70 most likely derive from a common intermediate 
(III-90) which results from competing β-hydride elimination of III-89 (Scheme 28). The 
intermediate III-90 was never detected in the N-aryl piperazine-forming reaction, but the 
 75  
analogous intermediate was isolated in the N-Boc piperazine-forming reaction as the 
major side product (Boc in place of aryl-protected nitrogen). Compound III-70 could be 
generated by insertion of the alkene into the Pd–H bond of III-90 followed by β-hydride 
elimination from the C5 position of III-91. Alternatively, displacement of Pd from III-90 
would afford III-93, which could be converted to the more thermodynamically stable 
derivative III-70 by reaction with NaOtBu. Side product III-69 most likely results from 
Heck-type arylation of III-93, although formation of III-69 via carbopalladation of III-
90 followed by C5 β-hydride elimination from III-92 cannot be ruled out.29 The 
generation of III-69 and III-70 provides further evidence to support the mechanism of 
2,6-disubstituted piperazine formation shown above, rather than a mechanism involving 
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Interestingly, the production of undesired compounds resulting from β-hydride 
elimination of III-89 is more problematic in the N-aryl-piperazine-forming reactions than 
the analogous N-aryl-pyrrolidine-forming reactions.13a,30 This may be due to the fact that 
the transition state for β-hydride elimination from the five-membered pyrrolidine ring to 
form exo-olefin III-95 is more strained (due to rehybridization of the C2-carbon from sp3 
to sp2) than the analogous transition state for conversion of the six-membered ring III-89 
to III-94.  
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III-94 III-95  
 
The piperazine-forming reactions are significantly better reactions than the 
piperidine-forming reactions described in Chapter II. The nitrogen in the tether of the 
piperazine substrate appears to facilitate the six-membered ring forming reaction and 
likely assists in bringing the two ends of the molecule together, thereby combating the 
entropic challenges associated with cyclizing δ-amino olefins to piperidines.  
 
Stereochemical Discussion on Carboamination Reaction for the Synthesis of 2,6-
Disubstituted Piperazines 
The stereochemical outcome of the piperazine-forming reactions contrasts with our 
model for the analogous pyrrolidine-forming reactions, which are believed to proceed via 
a transition state in which the C1-substituent is placed in a pseudoaxial orientation to 
minimize A(1,3) strain between the C1-group and the N-substituent (Ar, Boc, or Cbz) as 
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Scheme 29. Explanation of Stereochemistry for 2,5-Cis-Disubstituted Pyrrolidine-







































 A similar transition state structure (III-96) should afford trans-2,6-disubstituted 
piperazines (Scheme 30), which are not the major products in these reactions. Therefore, 
we needed to establish a new model for the carboamination of diamines to provide 
substituted piperazines. Our current working hypothesis for piperazine formation 
involves cyclization via transition state III-97, in which the N1-Ar group is rotated such 
that N1 is pyramidalized. This conformational change eliminates the A(1,3) strain 
interaction when the α-substituent (R1) is oriented in a pseudoequatorial position, and 
thereby leads to the cis-2,6-disubstitued stereoisomers. This hypothesis is consistent with 
the observation that cyclizations of substrates bearing N1-(p-cyanophenyl) or N1-Boc 
groups, which should have a decreased degree of N1-pyramidalization, proceed with 
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Scheme 30. Explanation of Stereochemistry for 2,6-Cis-Disubstituted Piperazine-



















































In order to further probe this hypothesis, we devised an experiment in which we 
prepared various differentially aryl-protected alanine derivatives and subjected them to 
the optimized reaction conditions (Table 13). Alanine derivatives bearing a benzyl group 
on N4 were chosen because the diastereoselectivity was occasionally lower than 20:1 dr 
with this substrate (Table 10, Entry 9). The substrates were prepared as discussed in 





Me Pd2(dba)3 (1 mol %), BINAP or








III-65, PG = Ph, 71%
III-100, PG = p -C6H4OMe, 70%
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We found the most electron-donating N-aryl protecting group (p-methoxyphenyl) 
provides excellent diastereoselectivity for the cis-diastereomer (III-99) and is therefore 
more likely to react via transition state III-97. In contrast, more delocalized systems may 
have a greater tendency to cyclize via transition state III-96, although this still appears to 
be a relatively high energy pathway. These results are consistent with our hypothesis, as 
the N1-lone pair delocalization should be decreased with a more electron rich protecting 
group such as p-methoxyphenyl. The phenyl-substituted substrate III-65 provides lower 
diastereoselectivity (III-78) and N-p-cyanophenyl, the most e-poor of the aromatic 
systems investigated, generates the product with 6:1 dr (III-103). Attempts to cyclize a p-
nitrophenyl substituted substrate led to decomposition of the substrate. Finally, use of a 
Boc protecting group, provides the product with 1:1 diastereoselectivity (III-104) and in 
modest yield.32,33  
 
Table 13. Dependence of Diastereoselectivity on N1-Protecting Group 
































 81  
The effect of the N4-protecting group on stereochemistry was also briefly 
examined (Table 14). Substrates III-64 and III-65 were examined (prepared as discussed 
in Scheme 26) as well as substrate III-105, which was prepared via N-arylation (eq 23) 
with bromobenzene of intermediate III-61 from Scheme 26. The nature of the N4-
protecting group also has a subtle effect on the diastereoselectivity, but the reasons for 


















Table 14. N4-Protecting Group Diastereoselectivity Study 
























PG Diastereoselectivity Isolated Yield (Piperazine)
P(2-furyl)3 (8 mol %)
 
 
After our preliminary communication on the synthesis of substituted cis-2,6- 
disubstituted piperazines,1 Michael and coworkers35 reported a complementary method 
for the synthesis of trans-2,6-disubstituted piperazines via Pd-catalyzed hydroamination 
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reactions (Scheme 31). The Pd-activated olefin is attacked by the nucleophilic amine as 
shown in III-111 which is followed by protonolysis of III-112 to release the product. 
However, this transformation is limited to the preparation of compounds bearing a methyl 
group in the 2-position. The authors propose an allylic strain argument36 to explain the 
formation of the 2,6-trans disubstituted piperazine whereby the α-substituent orients 
itself in the pseudo-axial position in order to avoid A(1,3) strain in the transition state. The 
tridentate Pd-catalyst is believed to inhibit β-hydride elimination of the intermediate Pd-
alkyl species III-112. 
 













































The trans stereochemistry of the products was determined by X-ray crystal 
structure analysis and it was found that the piperazine ring exists in the twist boat 
conformation. While the molecule adopts a chair conformation for cyclization, the twist 
boat conformation is preferred after cyclization because of an unfavorable A(1,3) 
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interaction between the CBz-group and the methyl group if it were to remain in the 
equatorial position (Figure 4). Though the half-chair is high in energy, the authors argue 
it may be favorable because of the presence of the two nitrogen atoms in the ring which 
would likely reduce the torsional strain of the molecule.  
 









III-113 III-114  
 
Background: Carboamination Reaction for the Synthesis of 2,3-Disubstituted 
Piperazines 
The synthesis of non-symmetrical 2,3-disubstituted piperazines is also limited in 
scope. Common methods involve reduction of 2,3-diketopiperazines (eq 24).37 However, 
the synthesis of unsymmetrical substituted diketopiperazines relies on the availability of 
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Other methods for the synthesis of 2,3-disubstituted piperazines involve reduction 
of the corresponding pyrazine (eq 25),39 substitution of a suitably substituted alkyl halide 
(eq 26),40 via reductive amination (eq 27),41 and via a Bronsted acid/Mn(0) mediated 




a) KOH (aq), 10% Pd/C, H2
b) HNO3











































































We next elected to examine the Pd-catalyzed carboamination reaction for the 
synthesis of 2,3-disubstituted piperazines. As shown in the retrosynthesis in Scheme 32 
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below, our approach relies on access to α-substituted allylic amines, which could be 
coupled with glycine and reduced to afford the diamine derivative III-131.  
 

































The substrates for these reactions were prepared in four steps via amide coupling 
of Boc-glycine (III-26) and readily available α-substituted allylic amines.43 Reduction of 
the resulting amide, followed by cleavage of the Boc-group, and N-arylation provided 
substrates III-140 and III-141. 
 







III-134, R1 = Me, R2 = Bn, 85%









III-136, R1 = Me, R2 = Bn, 51%
III-137, R1 = Cy, R2 = Bn, %
4 M HCl/Dioxane
Pd2(dba)3 (1 mol %)




III-138, R1 = Me,
R2 = Bn, 93%
III-139, R1 = Cy,
R2 = Bn, %
III-140, R1 = Me, R2 = Bn,
Ar = p -C6H4CN, 89%
III-141, R1 = Cy, R2 = Bn, Ar = Ph, %
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The Pd-catalyzed carboamination reactions of III-140 and III-141 were then 
examined using the reaction conditions optimized for the synthesis of 2,6-disubstituted 
piperazines. These conditions required slight modification as it was necessary to employ 
higher temperatures (xylenes, 140 °C) in order to effect consumption of starting material. 
The reactions (eq 29 and eq 30)44 proceed with good to moderate yields and modest 

































Pd2(dba)3 (1 mol %)







Pd2(dba)3 (1 mol %)
P(2-f uryl)3 (8 mol %)
 
 
The major diastereomer observed in the 2,3-disubstituted piperazine cyclizations 
(eq 29 and eq 30) is the trans-diastereomer. The modest stereocontrol likely results from 
equatorial or axial positioning of the allylic substituent in the transition state as shown in 
Scheme 34. The minor diastereomer is less favored due to unfavorable 1,3-diaxial 
interactions. These reactions required more forcing conditions in order that they may go 
to completion and were therefore conducted in xylenes at 140 °C.  
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Scheme 34. Explanation of Stereochemistry for 2,3-Trans-Disubstituted Piperazine-
























































Carboamination Reaction of Cyclic Amines for the Synthesis of Bicylic Piperazines 
In order to generate structurally rigid piperazine scaffolds, we also investigated 
carboaminations of cyclic internal olefin substrate (III-153). This substrate was prepared 
by treatment of N-benzylcyclopent-2-enamine (III-149) (prepared in one step from 
hydroamination of cyclopentadiene)45 with Boc-protected glycine III-26. The resulting 
amide was reduced to provide amine III-151. Boc-protected amine III-151 did not 
undergo the carboamination reaction under various reaction conditions screened. 
Therefore, III-151 was deprotected with 4M HCl/dioxane to afford primary amine III-
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Pd2(dba)3 (1 mol %)
BINAP (2 mol %)




Under optimized reaction conditions (2 mol % Pd2(dba)3: 16 mol % P(2-fur)3), 
substrate III-153 was converted to III-154 and III-155 in good yield and with excellent 
diastereocontrol (eq 31 and 32). A NOESY-2D experiment revealed the stereochemical 
outcome of the transformation to be syn-addition across the olefin, which provides 
additional evidence for the syn-amino-palladation mechanism proposed in Scheme 27. 
Side products in these reactions originate from π-allyl formation and consequently loss of 
the diamine component of the starting material III-153. 

















NaOtBu, toluene (0.2 M),
2 mol % Pd2(dba)3,








NaOtBu, toluene (0.2 M),
2 mol % Pd2(dba)3,










Carboamination Reaction for the Synthesis of Benzopiperazines  
We have also briefly examined the synthesis of benzopiperazines using the Pd-
catalyzed carboamination reaction. The substrates for these reactions were prepared via 
N-arylation of N-allyl phenylenediamines III-157 as shown in Scheme 36, which in turn 
were prepared via allylation of 1,2-diaminobenzene.46  
 







Pd2(dba)3 (1 mol %)
(tBu)2P(o-Biphenyl) (2 mol %)
NaOtBu, toluene
ArX, 80 °C
III-158 R = Ph = 74%
III-159 R = p-C6H4CN = 72%
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Treatment of these substrates with an aryl bromide and NaOtBu and a catalyst 
system composed of Pd2(dba)3/BINAP afforded benzopiperazines III-161-III-164 with 
N4 unprotected. In cases where an electron-poor aryl halide was used, N-arylation of N1 
was a competing side reaction (eq 33) as evidenced by isolation and 1H-1H COSY 
analysis of this side product (III-165).47 Use of P(2-fur)3 as the ligand did not provide any 
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aConditions: 1.0 equiv amine, 1.0 equiv ArBr, 1.2 equiv NaOtBu, 1 mol % Pd2(dba)3, 2 mol % BINAP, 
toluene (0.2 M), 105 °C, 10h; the reaction times have not been minimized. 
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NH














In conclusion, we have developed a new method for the synthesis of substituted 
piperazines, including 2,6-disubstituted aryl protected piperazines, Boc-protected 
disubstituted piperazines, 2,3-disubstituted piperazines, benzopiperazines, and bicyclic 
piperazines. In cases where 2,6-disubstituted piperazines are prepared, our strategy 
allows for the modular construction of a number of derivatives containing different 
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Experimental Section 
General Considerations:  All reactions were carried out under an argon or nitrogen 
atmosphere in oven- or flame-dried glassware. All catalysts, reagents, and aryl bromides 
were obtained from commercial sources and were used without further purification. N-
phenyl-L-phenylalanine and N-phenyl-L-valine were prepared according to published 
procedures.16 DEPBT was prepared according to the procedure of Goodman18 and was 
purified by recrystallization from petroleum ether:ethyl acetate (1:1) followed by 
trituration with ethyl acetate to yield a white solid. Use of pure, colorless, reagent was 
essential to prevent degradation of enantiomeric purity during amide bond formation. 
Toluene, THF, ether, and dichloromethane were dried and purified using a GlassContour 
solvent purification system. Structural and stereochemical assignments were made on the 
basis of 2-D COSY, HSQC, and NOESY experiments. Ratios of diastereomers were 
determined by 1H NMR and/or capillary GC analysis of crude reaction mixtures. Yields 
refer to isolated yields of compounds estimated to be ≥95% pure as determined by 1H 
NMR, GC, and/or combustion analysis. The yields reported in the experimental section 
describe the result of a single experiment, whereas the yields reported in Tables 9-15, 
Schemes 21–23, 25, 26, 33, 35-36, and eq 13, 22, 23, 29-32 are average yields of two or 
more experiments. Thus, the yields reported in the experimental section may differ from 
those shown in Tables 9–15, Schemes 21–23, 25, 26, 33, 35-36, and eq 13, 22, 23, 29-32. 
N,N-diallyl-2-(phenylamino)acetamide (III-21). A flame-dried round-bottomed flask 
equipped with a magnetic stirbar was cooled under a stream of nitrogen and charged with 
the N-phenyl amino acid substrate (1.32 g, 8.73 mmol).48 THF was added to provide a 0.3 
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M solution, which was cooled to 0 °C and stirred. CDI (1.42 g, 8.73 mmol) was added, 
followed immediately by 881 mg diallylamine (1.12 mL, 9.07 mmol), and the resulting 
reaction mixture was stirred for 12 h at room temperature. Aqueous sodium bicarbonate 
was then added at room temperature, and the resulting reaction mixture was extracted 
with ethyl acetate. The combined organic layers were washed with brine, dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was 
then purified via flash chromatography on silica gel to provide 1.31 g (65%) of the title 
compound as a yellow oil and a 1:1 mixture of rotamers. 1H NMR (400 MHz, CDCl3) δ 
7.22–7.18 (m, 2 H), 6.73 (tt, J = 0.8, 7.2 Hz, 1 H), 6.62 (dd, J = 1.2, 8.8 Hz, 2 H), 5.85–
5.74 (m, 2 H), 5.28–5.21 (m, 2 H), 5.20–5.15 (m, 2 H), 4.88 (s, 1 H), 4.07 (d, J = 6 Hz, 2 
H), 3.90–3.89 (m, 4 H); 13C NMR (100 MHz, CDCl3) δ 169.2, 147.5, 132.8, 132.2, 
129.4, 118.0, 117.6, 117.4, 113.1, 48.5, 48.3, 45.2; IR (film) 3387, 2919, 1655 cm–1. Anal 
calcd for C14H18N2O: C, 73.01; H, 7.88; N, 12.16. Found: C, 72.98; H, 7.87; N, 12.07. 
N1, N1-diallyl- N2-phenylethane-1,2-diamine (III-22). A flame-dried flask equipped 
with a magnetic stirbar was cooled under a stream of nitrogen and charged with the N,N-
diallyl-2-(phenylamino)acetamide (III-21) substrate (1.01 g, 4.39 mmol). Diethyl ether 
was added to provide a 0.5 M solution, which was cooled to 0 °C with stirring. A solution 
of lithium aluminum hydride in diethyl ether (9.65 mL, 1 M in diethyl ether, 2.2 equiv) 
was added dropwise, and the resulting mixture was stirred at 0 °C until the starting amide 
was completely consumed as judged by TLC analysis (8 h). Water (2 mL) was added 
dropwise, followed by 10 M aqueous NaOH (5 mL), and additional water (2 mL). The 
resulting suspension was stirred at rt for 5–10 minutes, then decanted, dried over 
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anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was 
purified by flash chromatography on silica gel to afford 805 mg (85%) of the title 
compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.20–7.16 (m, 2 H), 6.70 (t, J 
= 7.2 Hz, 1 H), 6.62 (dd, J = 1.2, 8.8 Hz, 2 H), 5.90–5.80 (m, 2 H), 5.21–5.13 (m, 4 H), 
4.26 (s, 1 H), 3.16–3.12 (m, 6 H), 2.72 (t, J = 6.4 Hz, 2 H); 13C NMR (100 MHz, CDCl3) 
δ 148.7, 135.5, 129.3, 117.8, 117.3, 113.1, 56.7, 51.8, 41.2; IR (film) 3379, 2811, 1602 
cm–1. Anal calcd for C14H20N2: C, 77.73; H, 9.32; N, 12.95. Found: C, 77.50; H, 9.32; N, 
13.02. 
Synthesis of Piperazines via Coupling with Aryl Bromides (eq 23-25) 
General Procedure for Pd-Catalyzed Synthesis of N-Aryl Monosubstituted 
Piperazines. A flame-dried Schlenk tube equipped with a magnetic stirbar was cooled 
under a stream of nitrogen and charged with Pd2(dba)3 (1 mol % complex, 2 mol % Pd), 
dppb (2 mol %), sodium tert-butoxide (1.2 equiv), and the aryl bromide (1.2 equiv). In 
some cases, 4 mol % of P(2-furyl)3 was employed as the ligand is used and this is stated 
in the relevant examples. The Schlenk tube was purged with nitrogen and the amine was 
added as a solution in toluene (2.5 mL/0.5 mmol substrate). The Schlenk tube was then 
heated to 105 °C with stirring until the starting material has been consumed as judged by 
1H NMR analysis of an aliquot taken from the reaction mixture. The reaction mixture was 
then cooled to room temperature, saturated aqueous ammonium chloride (2–3 mL) was 
added, and the resulting mixture was extracted with ethyl acetate (3 x 8 mL). The 
combined organic layers were dried over anhydrous sodium sulfate, filtered, and 
 96  
concentrated in vacuo. The crude product was then purified by flash chromatography on 
silica gel.   
4-allyl-2-(4-tert-butylbenzyl)-1-phenylpiperazine (III-23). The reaction of 100 mg 
(0.462 mmol) of N1,N1-diallyl- N2-phenylethane-1,2-diamine (III-22) with 118.2 mg 
(96.2 μl, 0.554 mmol) of 4-bromo-tert-butylbenzene was conducted for 10 h according to 
the general procedure using dppb as the ligand (2 mol %). Upon purification, 120 mg 
(74%) of the title compound was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 
7.37–7.33 (m, 4 H), 7.14 (d, J = 8.4 Hz, 2 H), 7.02 (d, J = 8 Hz, 2 H), 6.89 (t, J = 7.2 Hz, 
1 H), 6.03–5.93 (m, 1 H), 5.27–5.19 (m, 2 H), 3.98–3.94 (m, 1 H), 3.39 (dt, J = 2.8, 11.6 
Hz, 1 H), 3.31–3.25 (m, 1 H), 3.20–3.11 (m, 2 H), 3.03–2.95 (m, 2 H), 2.88 (dt, J = 2.4, 
9.2 Hz, 1 H), 2.60 (dd, J = 2.8, 12.8 Hz, 1 H), 2.32 (td, J = 3.6, 11.2 Hz, 1 H), 2.16 (dd, J 
= 3.2, 11.6 Hz, 1 H), 1.34 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 149.9, 148.9, 137.2, 
135.4, 129.5, 129.2, 125.4, 119.0, 118.0, 115.9, 61.9, 58.2, 54.0, 53.6, 43.6, 34.5, 32.1, 
31.6; IR (film) 2960, 1598 cm–1. Anal calcd for C24H32N2: C, 82.71; H, 9.25; N, 8.04. 
Found: C, 82.72; H, 9.32; N, 8.01.  
4-allyl-1-phenyl-2-(pyridin-3-ylmethyl)piperazine (III-24). The reaction of 100 mg 
(0.462 mmol) of N1, N1-diallyl-N2-phenylethane-1,2-diamine (III-22) with 73 mg (54.4 
μl, 0.554 mmol) of 3-bromo-pyridine was conducted for 10 h according to the general 
procedure using dppb as the ligand (2 mol %). Upon purification, 90 mg (66 %) of the 
title compound was obtained as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 8.44–8.42 
(m, 2 H), 7.44 (d, J = 7.5 Hz, 1 H), 7.31 (t, J = 7 Hz, 2 H), 7.20–7.17 (m, 1 H), 6.96 (d, J 
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= 9 Hz, 2 H), 6.86 (dt, J = 1, 7.5 Hz, 1 H), 5.93–5.85 (m, 1 H), 5.21–5.15 (m, 2 H), 
3.93–3.90 (m, 1 H), 3.34 (dt, J = 3.5, 12 Hz, 1 H), 3.27–3.22 (m, 1 H), 3.18–3.13 (m, 1 
H), 3.11–3.07 (m, 1 H), 2.99–2.96 (m, 1 H), 2.92–2.88 (m, 1 H), 2.71 (dt, J = 2, 11.5 Hz, 
1 H), 2.59 (dd, J = 3, 12.5 Hz, 1 H), 2.29 (td, J = 3.5, 11 Hz, 1 H), 2.14 (dd, J = 3.2, 11.5 
Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 150.9, 149.8, 147.7, 136.8, 135.7, 135.1, 129.6, 
123.5, 119.5, 118.3, 116.2, 61.9, 58.3, 53.7, 53.5, 43.6, 29.9; IR (film) 3392, 2948, 2801, 
1597 cm–1. Anal calcd for C19H23N3: C, 77.78; H, 7.90; N, 14.32. Found: C, 77.48; H, 
7.85; N, 14.36. 
4-allyl-1-phenyl-2-(pyridin-3-ylmethyl)piperazine (III-25). The reaction of 100 mg 
(0.462 mmol) of N1, N1-diallyl-N2-phenylethane-1,2-diamine (III-22) with 111 mg (0.554 
mmol) of 3-bromo-pyridine was conducted for 10 h according to the general procedure 
using P(2-furyl)3 as the ligand (4 mol %). Upon purification, 87 mg (56 %) of the title 
compound was obtained as an orange solid, m.p. 59–61 °C. 1H NMR (500 MHz, CDCl3) 
δ 7.31 (t, J = 7.5 Hz, 2 H), 7.04 (d, J = 8.5 Hz, 2 H), 6.98 (d, J = 8 Hz, 2 H), 6.84 (t, J = 
7.5 Hz, 1 H), 6.69 (d, J = 8.5 Hz, 2 H), 5.98–5.89 (m, 1 H), 5.22–5.15 (m, 2 H), 3.87–
3.84 (m, 1 H), 3.35 (dt, J = 2.5, 12 Hz, 1 H), 3.25–3.16 (m, 1 H), 3.11–3.01 (m, 2 H), 
3.01–2.90 (m, 8 H), 2.86–2.83 (m, 1 H), 2.49 (dd, J = 2.5, 13 Hz, 1 H), 2.27 (td, J = 3.5, 
11 Hz, 1 H), 2.10 (dd, J = 3, 11 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 149.9, 149.2, 
135.4, 130.1, 129.4, 128.3, 118.8, 118.0, 115.8, 113.1, 61.9, 58.4, 53.8, 53.6, 43.6, 41.0, 
31.5; IR (film) 2952, 2798, 1615 cm–1. Anal calcd for C22H29N3: C, 78.76; H, 8.71; N, 
12.53. Found: C, 78.59; H, 8.59; N, 12.27. 
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tert-Butyl-2-(allyl(benzyl)amino)-2-oxoethylcarbamate (III-27a). A flame-dried flask 
equipped with a magnetic stirbar was cooled under a stream of nitrogen and charged with 
the N-boc glycine (III-26) (3.12 g, 17.81 mmol), DCC (7.34 g, 35.62 mmol) and 36 mL 
dichloromethane (0.5 M). The solution was stirred for 10 min at rt then N-benzyl-allyl 
amine (2.62g, 17.81 mmol) was added. The resulting mixture was stirred at room 
temperature for 12 h then filtered to remove the dicyclohexylurea byproduct. The 
resulting solution was washed with brine, dried over anhydrous sodium sulfate, and 
concentrated in vacuo. The crude N-boc-N’-allyl amino amide product was purified by 
flash chromatography on silica gel to provide a 4.72 g (87%) of the title compound as a 
white solid, which was contaminated with ca. 15% dicyclohexylurea and as a 1.5:1 
mixture of rotamers. 1H NMR (400 MHz, CDCl3) δ 7.38–7.27 (m, 3 H), 7.24–7.22 (m, 1 
H), 7.13 (d, J = 7.6 Hz, 1 H) 5.79–5.65 (m, 1 H), 5.55 (s, 1 H), 5.30–5.09 (m, 2 H), 
4.71–4.58 (m, 1.2 H), 4.50–4.45 (m, 0.8 H), 4.04–4.03 (m, 2 H), 3.84–3.82 (m, 0.4 H), 
3.80–3.77 (m, 1.2 H), 3.69–3.67 (m, 0.4 H), 1.44 (s, 5.4 H), 1.39 (s, 3.6 H). 
tert-Butyl-2-(allyl(benzyl)amino)ethylcarbamate (III-27b). A flame-dried flask 
equipped with a magnetic stirbar was cooled under a stream of nitrogen and charged with 
the tert-butyl 2-(allyl(benzyl)amino)-2-oxoethylcarbamate (III-27a) (4.47 g, 14.68 
mmol). Diethyl ether was added (22 mL) to provide a 0.67 M solution, which was cooled 
to 0 °C. A solution of lithium aluminum hydride in diethyl ether (30 mL, 1 M in diethyl 
ether, 30 mmol) was added dropwise and the reaction was stirred at 0 °C until the starting 
amide was consumed as judged by TLC analysis (ca. 2.5 h). Water (2 mL) was added 
dropwise, followed by 10 M aqueous NaOH (5 mL), and additional water (2 mL). The 
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resulting suspension was stirred at rt for 5–10 minutes, then decanted, dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was 
purified by flash chromatography on silica gel to afford 2.04 g (48%) of the title 
compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.30–7.27 (m, 4 H), 7.25–7.19 
(m, 1 H), 5.87–5.77 (m, 1 H) 5.17–5.10 (m, 2 H), 4.84 (s, 1 H), 3.54 (s, 2 H), 3.18–3.10 
(m, 2 H), 3.05 (d, J = 6.4 Hz, 2 H), 2.51 (t, J = 6 Hz, 2 H), 1.40 (s, 9 H); 13C NMR (100 
MHz, CDCl3) δ 156.2, 139.3, 135.6, 129.0, 128.4, 127.2, 118.0, 79.1, 58.2, 56.8, 52.6, 
38.2, 28.6; IR (film) 3361, 2977, 1715 cm–1. Anal calcd for C17H26N2O2: C, 70.31; H, 
9.02; N, 9.65. Found: C, 70.23; H, 9.09; N, 9.60. 
tert-Butyl-4-benzyl-2-(4-cyanobenzyl)piperazine-1-carboxylate (III-28). A flame-
dried Schlenk tube equipped with a magnetic stirbar was cooled under a stream of 
nitrogen and charged with 11.6 mg Pd(OAc)2 (6 mol % Pd), 18.1 mg PPh3 (8 mol %), 
sodium tert-butoxide (100 mg, 1.03 mmol, 1.2 equiv), and the 4-bromobenzonitrile (188 
mg, 1.03 mmol, 1.2 equiv). The Schlenk tube was purged with nitrogen and 250 mg of 
tert-butyl 2-(allyl(benzyl)amino)ethylcarbamate (III-27b) was added as a solution in 
toluene (2.5 mL/0.5 mmol substrate). The Schlenk tube was then heated to 90 °C with 
stirring until the starting material has been consumed as judged by 1H NMR analysis of 
an aliquot taken from the reaction mixture. The reaction mixture was then cooled to room 
temperature, saturated aqueous ammonium chloride (2–3 mL) was added, and the 
resulting mixture was extracted with ethyl acetate (3 x 8 mL). The combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The 
crude product was then purified by flash chromatography on silica gel to afford 229 mg 
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(68%) of the title compound as a white solid, m.p. 129–133 °C. 1H NMR (400 MHz, 
CDCl3) δ 7.53–7.50 (m, 0.4 H), 7.42 (d, J = 7.6 Hz, 1.6 H), 7.37–7.29 (m, 5 H), 7.14–
7.00 (m, 2 H), 4.30–3.70 (m, 2 H), 3.60 (d, J = 12.8 Hz, 1 H), 3.28 (d, J = 12.4 Hz, 1 H), 
3.18 (td, J = 2.8, 12.8 Hz, 1 H), 3.10–3.00 (m, 1 H), 2.96–2.80 (m, 2 H), 2.53 (d, J = 11.6 
Hz, 1 H), 2.11 (td, J = 3.2, 12 Hz, 1 H), 1.96 (d, J = 9.6, 1 H), 1.37 (s, 9 H); 13C NMR 
(100 MHz, CDCl3) δ 154.4, 144.9, 138.0, 134.6, 132.0, 130.1, 129.3, 127.3, 119.0, 109.8, 
79.8, 62.8, 53.5, 52.1, 40.3, 39.2, 36.2, 28.3; IR (film) 3400, 2916, 1691 cm–1. MS (ESI) 
392.2338 (392.2338 calcd for C24H29N3O2, M + H+). 
Synthesis of Substrates (Scheme 25) 
General Procedure 1: Conversion of N-Phenyl Amino Acids (III-42 and III-43) to N-
Allyl-N-Benzyl-N’-Phenyl Amino Amides (III-44 and III-45). A flame-dried round-
bottomed flask equipped with a magnetic stirbar was cooled under a stream of nitrogen 
and charged with the N-phenyl amino acid substrate (1.0 equiv). THF was added to 
provide a 0.5 M solution, which was cooled to 0 °C and stirred. DEPBT18 (1.2 equiv) was 
added, followed immediately by N-benzylallylamine (1 equiv), and the resulting reaction 
mixture was stirred at 0 °C until the starting amine had been consumed as judged by 
crude 1H NMR analysis of an aliquot (ca. 3–4 h). Aqueous sodium bicarbonate was then 
added at 0 °C, and the resulting yellow reaction mixture was extracted with ethyl acetate. 
The combined organic layers were washed with brine, dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude product was then purified via flash 
chromatography on silica gel. 
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(S)-N-Allyl-N-benzyl-3-phenyl-2-phenylaminopropionamide (III-44). General 
procedure 1 was employed for the coupling of (S)-3-phenyl-2-phenylaminopropionic 
acid16 (3.63 g, 15.0 mmol) with N-benzylallylamine (2.21 g, 15.0 mmol). This procedure 
afforded 3.79 g (68%) of the title compound as a yellow oil. The enantiopurity was 
judged to be 98% ee by chiral hplc analysis (chiralcel OJ-H, 10% isopropanol/hexanes, 1 
mL/min, RT = 11.14 min and 18.44 min). This molecule was observed as a 1.5:1 mixture 
of rotamers; data are for the mixture. 1H NMR (400 MHz, CDCl3) δ 7.31–7.17 (m, 9 H), 
7.14–7.09 (m, 2 H), 6.92–6.91 (m, 1 H), 6.77–6.71 (m, 1 H), 6.66 (d, J = 8.0 Hz, 1 H), 
6.54 (d, J = 7.5 Hz, 1 H), 5.73–5.66 (m, 0.4 H), 5.47–5.39 (m, 0.6 H), 5.15–4.97 (m, 2 
H), 4.74 (d, J = 14.5 Hz, 0.6 H), 4.56–4.53 (m, 1.4 H), 4.49 (s, 0.5 H), 4.32 (d, J = 14.5 
Hz, 0.6 H), 4.22–4.17 (m, 0.7 H), 4.03 (d, J = 17 Hz, 0.5 H), 3.65 (dd, J = 6.5, 15 Hz, 0.5 
H), 3.53 (d, J = 5.5 Hz, 1.2 H), 3.13–3.02 (m, 2 H); 13C NMR (125 MHz, CDCl3) δ 
172.9, 172.8, 146.6, 146.5, 137.4, 137.3, 136.9, 136.2, 132.5, 132.4, 129.54, 129.50, 
129.46, 129.43, 129.0, 128.7, 128.60, 128.56, 128.4, 127.7, 127.5, 126.9, 126.8, 126.5, 
118.4, 118.1, 117.6, 114.3, 55.9, 55.6, 49.5, 48.7, 48.6, 46.4, 39.53, 39.49; IR (film) 
3326, 3027, 1639 cm–1.  Anal. Calcd for C25H26N2O: C, 81.05; H, 7.07; N, 7.56.  Found: 
C, 80.90; H, 7.05; N, 7.50. 
(S)-N-Allyl-N-benzyl-3-methyl-2-phenylaminobutyramide (III-45). General procedure 
1 was employed for the coupling of (S)-3-methyl-2-phenylaminobutyric acid16 (1.27 g, 
6.57 mmol) with N-benzylallylamine (967 mg, 6.57 mmol). This procedure afforded 1.37 
g (65%) of the title compound as a tan solid, m.p. 48–55 °C. The enantiopurity was 
judged to be 99% ee by chiral hplc analysis (chiralcel OJ-H column, 10% 
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isopropanol/hexanes, 1 mL/min, RT = 7.40 min and 10.00 min). This molecule was 
observed as a 1.5:1 mixture of rotamers; data are for the mixture.  1H NMR (500 MHz, 
CDCl3) δ 7.29–7.24 (m, 3 H), 7.16–7.14 (m, 2 H), 7.09–7.06 (m, 2 H), 6.73–6.66 (m, 2 
H), 6.54 (d, 1 H), 5.76–5.66 (m, 1 H), 5.21–5.04 (m, 2 H), 4.88 (d, J = 14.5 Hz, 0.7 H), 
4.70 (d, J = 17 Hz, 0.4 H), 4.46–4.28 (m, 2 H), 4.15 (s, 1 H), 3.97–3.93 (dd, J = 3.0, 17 
Hz, 0.7 H), 3.84–3.79 (dd, J = 3.0, 17 Hz, 0.7 H), 3.60 (dd, J = 6.5, 15 Hz, 0.5 H), 2.09–
2.08 (m, 1 H), 1.06–1.00 (m, 6 H); 13C NMR (125 MHz, CDCl3) δ 173.6, 173.5, 148.25, 
148.21, 137.2, 136.2, 132.7, 132.6, 129.2, 128.9, 128.6, 128.1, 127.7, 127.4, 126.6, 
118.09, 118,07, 117.9, 117.7, 114.5, 114.4, 59.5, 59.2, 49.9, 48.8, 48.1, 48.0, 32.3, 32.2, 
20.2, 20.1, 17.72, 17.68; IR (film) 3350, 2962, 1638 cm–1.  Anal. Calcd for C21H26N2O: 
C, 78.22; H, 8.13; N, 8.69. Found: C, 77.96; H, 8.12; N, 8.68. 
General Procedure 2: Reduction of N-Allyl-N-Benzyl-N’-Phenyl Amino Amides (III-
44 and III-45) to N-Allyl-N-Benzyl-N’-Phenyl-1,2-Diamines (III-46 and III-47). A 
flame-dried flask equipped with a magnetic stirbar was cooled under a stream of nitrogen 
and charged with the N-allyl-N-benzyl-N’-phenyl amino amide substrate (1.0 equiv). 
Diethyl ether was added to provide a 0.5 M solution, which was cooled to 0 °C with 
stirring. A solution of lithium aluminum hydride in diethyl ether (1 M, 2 equiv) was 
added dropwise, and the resulting mixture was stirred at 0 °C until the starting amide was 
completely consumed as judged by TLC analysis (ca. 2 h). Water (2 mL) was added 
dropwise, followed by 10 M aqueous NaOH (5 mL), and additional water (2 mL). The 
resulting suspension was stirred at rt for 5–10 minutes, then decanted, dried over 
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anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was 
purified by flash chromatography on silica gel. 
(S)-N1-Allyl-N1-benzyl-3,N2-diphenyl-propane-1,2-diamine (III-46). General 
procedure 2 was conducted using (S)-N-allyl-N-benzyl-3-phenyl-2-
phenylaminopropionamide (III-44) (3.79 g, 10.22 mmol) as substrate. This procedure 
afforded 3.13 g (86%) of the title compound as a yellow oil that was judged to be 98% ee 
by chiral hplc analysis (chiralcel OD-H, 0.5% isopropanol/hexanes, 1 mL/min, RT = 
11.15 min and 12.72 min), [α]23D –43.08° (c 0.26, CH2Cl2). 1H NMR (400 MHz, CDCl3) 
δ 7.31–7.23 (m, 8 H), 7.21–7.14 (m, 5 H), 6.68 (t, J = 7.6 Hz, 1 H), 6.60 (d, J = 8.4 Hz, 1 
H), 5.89–5.79 (m, 1 H), 5.14–5.11 (m, 2 H), 3.93 (s, 1 H), 3.72–3.65 (m, 1 H), 3.62 (d, J 
= 13.6 Hz, 1 H), 3.51 (d, J = 13.6 Hz, 1 H), 3.14–3.01 (m, 2 H), 2.92 (dd, J = 5.2, 14.0 
Hz, 1 H), 2.80 (dd, J = 7.2, 14.4 Hz, 1 H), 2.57–2.47 (m, 2 H); 13C NMR (100 MHz, 
CDCl3) δ 148.1, 139.3, 138.7, 135.5, 129.6, 129.4, 129.2, 128.4, 127.2, 126.3, 118.0, 
117.3, 113.4, 58.7, 57.4, 56.9, 52.3, 39.2 (one aromatic carbon signal is absent due to 
accidental equivalence); IR (film) 3400, 2957, 1600 cm–1. Anal. Calcd for C25H28N2: C, 
84.23; H, 7.92; N, 7.86. Found: C, 84.23; H, 7.98; N, 7.87. 
 (S)-N1-Allyl-N1–benzyl-3-methyl-N2-phenyl-butane-1,2-diamine (III-47) General 
procedure 2 was conducted using (S)-N-allyl-N-benzyl-3-methyl-2-
phenylaminobutyramide (III-45) (1.34 g, 4.16 mmol) as substrate. This procedure 
afforded 1.13 g (88%) of the title compound as a yellow oil that was judged to be 99% ee 
by chiral hplc analysis (chiralcel OD-H, 0.1% isopropanol/hexanes, 0.2 mL/min, RT = 
31.65 min and 35.18 min), [α]23D –59.5° (c 0.98, CH2Cl2).  1H NMR (500 MHz, CDCl3) 
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δ 7.31–7.23 (m, 5 H), 7.22–7.12 (m, 2 H), 6.65 (t, J = 7.5, 1 H), 6.56 (d, J = 8.5 Hz, 2 
H), 5.88 (ddt, J = 6.0, 10.5, 16.5 Hz, 1 H), 5.18–5.13 (m, 2 H), 3.72 (s, 1 H), 3.63 (d, J = 
13.5 Hz, 1 H), 3.50 (d, J = 13.5 Hz, 1 H), 3.37–3.33 (m, 1 H), 3.11 (dd, J = 6.0, 14.5 Hz, 
1 H), 3.04 (dd, J = 7.0, 13.5 Hz, 1 H), 2.52–2.44 (m, 2 H), 2.13–2.06 (m, 1 H), 0.87 (dd, 
J = 4.5, 7.0 Hz, 6 H); 13C NMR (100 MHz, CDCl3) δ 149.1, 139.7, 136.0, 129.4, 129.2, 
128.4, 127.1, 117.8, 116.8, 113.2, 58.9, 57.5, 55.9, 54.3, 29.5, 18.6, 17.5; IR (film) 3400, 
3025, 1601 cm–1.  Anal. Calcd for C21H28N2: C, 81.77; H, 9.15; N, 9.08. Found: C, 81.73; 
H, 9.21; N, 9.09. 
General Procedure 3: Conversion of N-Boc Amino Acids to N-Boc-N’-Allyl-1,2-
Diamines (III-53-III-57). A flame-dried flask equipped with a magnetic stirbar was 
cooled under a stream of nitrogen and charged with the N-boc amino acid (1.0 equiv), 
DCC (2.0 equiv) and a sufficient volume of dichloromethane to provide a solution with a 
0.5 M amine concentration. The solution was stirred for 30 min at rt then the appropriate 
allylamine derivative (1.0 equiv) was added. The resulting mixture was stirred at room 
temperature for 12 h then filtered to remove the dicyclohexylurea byproduct. The 
resulting solution was washed with brine, dried over anhydrous sodium sulfate, and 
concentrated in vacuo. The crude N-boc-N’-allyl amino amide product was purified by 
flash chromatography on silica gel. In some cases the purified product was contaminated 
with small amounts of dicyclohexyl urea. This material was carried on without further 
purification. 
A flame-dried flask equipped with a magnetic stirbar was cooled under a stream of 
nitrogen and charged with the N-boc-N’-allyl amino amide (1.0 equiv). Diethyl ether was 
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added to provide a 0.5 M solution, which was cooled to 0 °C. A solution of lithium 
aluminum hydride in diethyl ether (1 M, 2.0 equiv) was added dropwise and the reaction 
was stirred at 0 °C until the starting amide was consumed as judged by TLC analysis (ca. 
3 h). Water (2 mL) was added dropwise, followed by 10 M aqueous NaOH (5 mL), and 
additional water (2 mL). The resulting suspension was stirred at rt for 5–10 minutes, then 
decanted, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The 
crude product was purified by flash chromatography on silica gel. 
(R)-tert-Butyl-1-[allyl(benzyl)amino]-3-(benzyloxy)propan-2-ylcarbamate (III-53). 
General procedure 3 was used for the coupling of (S)-3-(benzyloxy)-2-(tert-
butoxycarbonylamino)propanoic acid (5.99 g, 20.28 mmol) with N-benzylallylamine 
(2.98 g, 20.28 mmol). This procedure afforded 7.67 g (89%) of (S)-tert-butyl 1-
[allyl(benzyl)amino]-3-(benzyloxy)-1-oxopropan-2-ylcarbamate (III-48) as a white solid, 
which was contaminated with ca. 15% dicyclohexylurea. This material was carried on 
without further purification. The enantiopurity was judged to be 98% ee by chiral hplc 
analysis (chiralcel OD column, 5% isopropanol/hexanes, 1 mL/min, RT = 7.19 min and 
9.13 min). This molecule was isolated as a 4.6:1 mixture of rotamers; data are for the 
mixture. 1H NMR (400 MHz, CDCl3) δ 7.38–7.28 (m, 6 H), 7.20–7.17 (m, 4 H), 5.82–
5.69 (m, 1 H), 5.43 (m, 0.8 H), 5.26–5.07 (m, 2 H), 4.99–4.97 (m, 0.2 H), 4.71–4.53 (m, 
3.8 H), 4.44–4.40 (m, 0.2 H), 4.17–4.07 (m, 0.2 H), 4.02–3.96 (m, 1.8 H), 3.86–3.79 (m, 
2.8 H), 3.71–3.66 (m, 0.2 H), 1.43 (m, 9 H). 
The (S)-tert-butyl 1-[allyl(benzyl)amino]-3-(benzyloxy)-1-oxopropan-2-ylcarbamate 
(III-48) product of the DCC coupling reaction (7.65 g, 18.0 mmol) was reduced 
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following general procedure 3. This procedure afforded 4.83 g (65%) of the title 
compound as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.31–7.17 (m, 10 H), 5.80 
(dt, J = 6.8, 10.4 Hz, 1 H), 5.15–5.08 (m, 2 H), 4.81 (s, 1 H), 4.42–4.35 (m, 2 H), 3.80 (s, 
1 H), 3.65–3.58 (m, 2 H), 3.51–3.44 (m, 2 H), 3.11 (dd, J = 8.0, 14.4 Hz, 1 H), 3.01 (dd, 
J = 6.4, 14.4 Hz, 1 H), 2.64 (dd, J = 7.6, 12.8 Hz, 1 H), 2.47 (dd, J = 6.0, 12.4 Hz, 1 H), 
1.41 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 155.9, 139.7, 138.5, 136.0, 129.1, 128.5, 
128.4, 127.80, 127.77, 127.1, 117.7, 79.3, 73.4, 70.2, 58.6, 57.3, 54.5, 48.9, 28.6; IR 
(film) 3436, 2976, 1713 cm—1; MS (ESI) 411.2637 (411.2648 calcd for C25H34N2O3, M + 
H+). 
(S)-tert-Butyl-1-(diallylamino)propan-2-ylcarbamate (III-54). General procedure 3 
was used for the coupling of (S)-2-tert-butoxycarbonylaminopropionic acid (1.16 g, 6.13 
mmol), with diallylamine (595 mg, 754 μL, 6.13 mmol). This procedure afforded 1.64 g 
(100%) of (S)-tert-butyl 1-(diallylamino)-1-oxopropan-2-ylcarbamate (III-49) as a white 
solid, which was contaminated with 5% dicyclohexylurea. This material was carried on 
without further purification. This molecule was observed as a 5:1 mixture of rotamers. 
Data are for the mixture 1H NMR (500 MHz, CDCl3) δ 5.83–5.70 (m, 2 H), 5.39 (d, J = 
7.5 Hz, 0.8 H), 5.25–5.11 (m, 4 H), 4.99–4.96 (m, 0.2 H), 4.59–4.57 (m, 0.8 H), 4.43–
4.41 (m, 0.2 H), 4.18–4.10 (m, 0.2 H), 4.06–3.88 (m, 3.6 H), 3.70–3.60 (m, 0.2 H), 1.43 
(s, 9 H), 1.31 (d, J = 6.5 Hz, 3 H). 
The (S)-tert-butyl-1-(diallylamino)-1-oxopropan-2-ylcarbamate product (III-49) of 
the DCC coupling reaction (1.64 g, 6.16 mmol) was reduced with lithium aluminium 
hydride following general procedure 3. This procedure afforded 1.13 g (72%) of the title 
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compound as a white solid, m.p. 45–47 °C.  1H NMR (500 MHz, CDCl3) δ 5.85–5.77 (m, 
2 H), 5.18–5.11 (m, 4 H), 4.68 (s, 1 H), 3.67–3.63 (m, 1 H), 3.12 (dd, J = 6.0, 14 Hz, 2 
H), 3.04 (dd, J = 6.5, 14 Hz, 2 H), 2.40–2.30 (m, 2 H), 1.44 (s, 9 H), 1.12 (d, J = 6.5 Hz, 
3 H); 13C NMR (100 MHz, CDCl3) δ 156.0, 135.9, 117.7, 79.1, 58.7, 57.3, 44.8, 28.7, 
19.7; IR (film) 3326, 2930, 1690 cm–1; MS (EI) 254.2003 (254.1994 calcd for 
C14H26N2O2, M + H+). 
tert-Butyl-1-(allyl(benzyl)amino)propan-2-ylcarbamate (III-55). General procedure 3 
was used for the coupling of 2-(tert-butoxycarbonylamino)propanoic acid (4.5 g, 23.78 
mmol) and N-Benzylallylamine (3.50 g, 23.78 mmol). This procedure afforded 7.57 g 
(100 %) of tert-butyl 1-(allyl(benzyl)amino)-1-oxopropan-2-ylcarbamate (III-50) as a 
white solid, which was contaminated with ca. 15% of dicyclohexylurea as a white solid, 
contaminated with DCU as a 1.25:1 mixture of rotamers 1H NMR (300 MHz, CDCl3) δ 
7.38–7.28 (m, 3 H), 7.20–7.18 (m, 2 H), 5.83–5.68 (m, 1 H), 5.43 (s, 1 H), 5.26–5.06 
(m, 2 H), 4.70–4.52 (m, 3 H), 4.03–3.91 (m, 1 H), 3.87–3.80 (m, 1 H), 1.44 (s, 5 H), 1.42 
(s, 4 H), 1.34 (m, J = 6.9 Hz, 1.8 H), 1.27 (d, J = 6.9 H, 1.2 H); 13C NMR (100 MHz, 
CDCl3) δ 173.8, 155.3, 137.2, 136.4, 132.7, 132.5, 129.1, 128.8, 128.1, 128.0, 127.6, 
127.0, 117.9, 79.8, 50.2, 49.2, 48.4, 48.0, 46.5, 28.6, 19.8; IR (film) 3306, 2978, 1703, 
1648 cm–1. MS (ESI) 341.1834 (341.1841 calcd for C18H26N2O3, M + Na+). 
The (S)-tert-butyl 1-(allyl(benzyl)amino)-1-oxopropan-2-ylcarbamate (III-50) 
coupling product of the DCC reaction (1.52 g, 4.77 mmol) was reduced with lithium 
aluminum hydride following general procedure 3. This procedure afforded 900 mg (62%) 
of the title compound as a white solid, m.p. 37–39 °C.  1H NMR (500 MHz, CDCl3) δ 
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7.31–7.29 (m, 3 H), 7.25–7.22 (m, 2 H), 5.89–5.81 (m, 1 H), 5.19–5.13 (m, 2 H), 4.58 
(s, 1 H), 3.78–3.68 (m, 1 H), 3.64 (d, J = 14 Hz, 1 H), 3.51 (d, J = 14 Hz, 1 H), 3.14–
3.10 (m, 1 H), 3.06–3.02 (m, 1 H), 2.41–2.31 (m, 2 H), 1.46 (s, 9 H), 1.10 (d, J = 6 Hz, 3 
H); 13C NMR (75 MHz, CDCl3) δ 156.0, 139.6, 135.8, 129.1, 128.4, 127.2, 117.9, 79.2, 
59.0, 58.5, 57.2, 44.7, 28.7, 19.7; IR (film) 3350, 2360, 1702 cm–1. Anal. Calcd for 
C18H28N2O2: C, 71.02; H, 9.27; N, 9.20.  Found: C, 71.12; H, 9.55; N, 9.42. 
 (S)-tert-Butyl-1-[allyl(4-methoxyphenyl)amino]propan-2-ylcarbamate (III-56). 
General procedure 3 was used for the coupling of (S)-2-tert-
butoxycarbonylaminopropionic acid (828 mg, 4.38 mmol) and N-p-
methoxyphenylallylamine16,49 (710 mg, 4.38 mmol). This procedure afforded 1.28 g 
(88%) of (S)-tert-butyl 1-[allyl(4-methoxyphenyl)amino]-1-oxopropan-2-ylcarbamate 
(III-51) as a white solid, which was contaminated with ca. 15% of dicyclohexylurea. 1H 
NMR (500 MHz, CDCl3) δ 7.13 (d, J = 8.5 Hz, 2 H), 6.92 (d, J = 9.5 Hz, 2 H), 5.82 (ddt, 
J = 6.0, 11.0, 17 Hz, 1 H), 5.28 (d, J = 8.0 Hz, 1 H), 5.12 (dd, J = 1.5, 11 Hz, 1 H), 5.07 
(dd, J = 1.5, 17 Hz, 1 H), 4.34–4.27 (m, 2 H), 4.18–4.11 (m, 1 H), 3.82 (s, 3 H), 1.41 (s, 
9 H), 1.11 (d, J = 6.5 Hz, 3 H). 
The (S)-tert-butyl 1-[allyl(4-methoxyphenyl)amino-1-oxopropan-2-ylcarbamate (III-
51) coupling product of the DCC reaction (1.28 g, 3.83 mmol) was reduced with lithium 
aluminum hydride following general procedure 3. This procedure afforded 4.83 g (65%) 
of the title compound as a white solid, m.p. 99–102 °C.  1H NMR (400 MHz, CDCl3) δ 
6.84–6.75 (m, 4 H), 5.85–5.76 (m, 1 H), 5.14–5.10 (m, 2 H), 4.46 (s, br, 1 H), 3.95–3.76 
(m, 3 H), 3.74 (s, 3 H), 3.36 (dd, J = 6.0, 14.4 Hz, 1 H), 3.05 (dd, J = 5.6, 14.4 Hz, 1 H), 
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1.43 (s, 9 H), 1.16 (d, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 155.6, 152.0, 
143.5, 134.5, 116.7, 115.2, 114.9, 57.3, 55.9, 55.3, 45.7, 29.9, 28.6, 19.2; IR (film) 3357, 
1676 cm–1; MS (EI) 320.2095 (320.2100 calcd for C18H28N2O3). 
tert-Butyl-1-(allyl(benzyl)amino)-4-methylpentan-2-ylcarbamate (III-57). General 
procedure 3 was used for the coupling of 2-(tert-butoxycarbonylamino)-4-
methylpentanoic acid (1.70 g, 7.35 mmol) with N-benzylallylamine (1.08 g, 7.35 mmol) 
with the only difference being the use of DCC as a 3 M solution (the amount of CH2Cl2 
was adjusted appropriately to provide a 0.5 M solution). This procedure afforded 2.65 g 
(100%) of (S)-tert-butyl 1-[allyl(benzyl)amino]-3-(benzyloxy)-1-oxopropan-2-
ylcarbamate (III-52) as a white solid, which was contaminated with ca. 15% 
dicyclohexylurea. This material was carried on without further purification. This 
molecule was isolated as a 1.2:1 mixture of rotamers; data are for the mixture. 1H NMR 
(400 MHz, CDCl3) δ 7.36–7.28 (m, 2.72 H), 7.22–7.19 (m, 2.27 H), 5.84–5.70 (m, 1 H), 
5.26–5.09 (m, 3 H), 4.70–4.62 (m, 2 H), 4.60–4.51 (m, 1 H), 4.07–3.98 (m, 1 H), 3.87–
3.80 (m, 1 H), 1.78–1.71 (m, 2 H), 1.44 (s, 4.9 H), 1.42 (s, 4.1 H), 1.36–1.27 (m, 1 H), 
0.97–0.88 (m, 6 H), 0.84 (d, J = 6.8 Hz, 0.55 H), 0.77 (d, J = 6.4 Hz, 0.45 H).  
The tert-butyl 1-(allyl(benzyl)amino)-4-methyl-1-oxopentan-2-ylcarbamate (III-
52) product of the DCC coupling reaction (2.62 g, 7.26 mmol) was reduced following 
general procedure 3. This procedure afforded 1.57 g (62%) of the title compound as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.34–7.28 (m, 4 H), 7.24–7.21 (m, 1 H), 
5.90–5.80 (m, 1 H), 5.19–5.12 (m, 2 H), 4.29 (s, 1 H), 3.80–3.70 (m, 1 H), 3.65 (dd, J = 
13.6 Hz, 1 H), 3.53 (dd, J = 13.6 Hz, 1 H), 3.16–3.02 (m, 2 H), 2.37 (d, J = 6.8 Hz, 2 H), 
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1.72–1.62 (m, 1 H), 1.46 (s, 9 H), 1.34–1.29 (m, 1H), 1.22–1.15 (m, 1 H), 0.90 (d, J = 
6.8 Hz, 6 H); 13C NMR (100 MHz, CDCl3) δ 156.0, 139.8, 136.1, 129.1, 128.3, 127.0, 
117.6, 79.0, 58.7, 58.5, 57.4, 47.3, 43.4, 28.7, 25.0, 23.5, 22.5; IR (film) 3359, 2956, 
1703 cm–1. MS (ESI) 347.2702 (347.2699 calcd for C21H34N2O2, M + H+). 
General Procedure 4: Conversion of N-Boc-N’-Allyl-1,2-diamines (III-53-III-57) to 
N-aryl-N’-Allyl-1,2-diamines (III-58-III-62). A flask equipped with magnetic stirbar 
was charged with the appropriate N-Boc-N’-allyl-1,2-diamine (1.0 equiv) and a sufficient 
volume of dioxane to provide a 0.1 M solution. A solution of 4 M aqueous HCl (33 
equiv) was added and the reaction mixture was heated to 50 °C for 2 h. The reaction 
mixture was cooled to room temperature and NH4OH was added dropwise until the 
solution pH was >11. The resulting mixture was extracted with ethyl acetate, and the 
combined organic layers were washed with brine, dried over anhydrous sodium sulfate, 
and concentrated in vacuo to afford the corresponding primary amine product. The crude 
product was immediately carried on without further purification. 
A flame dried Schlenk tube equipped with a magnetic stirbar was charged with 
Pd2(dba)3 (1 mol % complex, 2 mol % Pd), (±)-BINAP (2 mol %), sodium tert-butoxide 
(1.2 equiv), the appropriate aryl bromide (1.0 equiv), and a 0.5 M solution of the primary 
amine (1.0 equiv) in toluene. The reaction mixture was heated to 80 °C with stirring until 
the starting material had been consumed as judged by TLC analysis (ca. 6 h). The 
mixture was cooled to rt and a solution of aqueous ammonium chloride was added (4 
mL). The resulting mixture was extracted with ethyl acetate and the combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The 
crude product was purified by flash chromatography on silica gel. 
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(R)-4-{1-[Allyl(benzyl)amino]-3-(benzyloxy)propan-2-ylamino}benzonitrile (III-63). 
General procedure 4 was used for the deprotection of (R)-tert-butyl 1-
[allyl(benzyl)amino]-3-(benzyloxy)propan-2-ylcarbamate (III-53) (3.9 g, 9.51 mmol). 
This procedure afforded 3.1 g (100%) of (S)-N1-allyl-N1-benzyl-3-benzyloxypropane-1,2-
diamine (III-58) as a yellow oil. The crude product was immediately subjected to the 
subsequent reaction without further purification.  1H NMR (400 MHz, CDCl3) δ 7.37–
7.21 (m, 10 H), 5.86 (dt, J = 6, 11 Hz, 1 H), 5.17–5.12 (m, 2 H), 4.50 (s, 2 H), 3.67 (d, J 
= 13.5 Hz, 1 H), 3.51– 3.48 (m, 2 H), 3.30–3.26 (m, 1 H), 3.20–3.12 (m, 2 H), 3.00 (dd, 
J = 5.4, 7.5 Hz, 1 H), 2.46–2.38 (m, 2 H), 1.60 (s, 2 H); MS (ESI) 311.2116 (311.2123 
calcd for C20H26N2O, M + H+).  
General procedure 4 was used for the N-arylation of (S)- N1-allyl-N1-benzyl-3-
benzyloxypropane-1,2-diamine (III-58) (900 mg, 2.89 mmol) with 4-bromobenzonitrile 
(527 mg, 2.89 mmol). This procedure afforded 864 mg (73%) of the title compound as an 
orange oil. The enantiopurity was judged to be 98% ee by chiral hplc analysis (chiralcel 
AD column, 0.7% isopropanol/hexanes, 1 mL/min, RT = 24.75 min and 28.10 min), 
[α]23D –25.59° (c 0.79, CH2Cl2).  1H NMR (400 MHz, CDCl3) δ 7.35–7.28 (m, 12 H), 
6.40 (d, J = 8.5 Hz, 2 H), 5.85 (dt, J = 6.5, 10.5 Hz, 1 H), 5.22–5.16 (m, 2 H), 4.54 (d, J 
= 6.5 Hz, 1 H), 4.49–4.44 (m, 2 H), 3.67 (dd, J = 3.0, 9.0 Hz, 1 H), 3.65–3.56 (m, 2 H), 
3.53–3.46 (m, 2 H), 3.17–3.10 (m, 2 H), 2.74 (dd, J = 7.5, 13.5 Hz, 1 H), 2.60 (dd, J = 
6.5, 13.5 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 151.0, 139.5, 138.0, 135.6, 133.8, 
129.1, 128.6, 128.5, 127.99, 127.90, 127.4, 120.7, 118.1, 112.7, 98.6, 73.5, 69.9, 59.3, 
58.3, 54.3, 51.4; IR (film) 3365, 2211, 1606 cm–1; MS (ESI) 412.2383 (412.2389 calcd 
for C27H29N3O, M + H+). 
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 (S)-N1,N1-Diallyl-N2-phenylpropane-1,2-diamine (III-64). General procedure 4 was 
used for the deprotection of 1.08 g (4.24 mmol) of (S)-tert-butyl 1-(diallylamino)propan-
2-ylcarbamate (III-54) (1.08 g, 4.24 mmol). This procedure afforded 654 mg (85%) of 
(S)-N1,N1-diallylpropane-1,2-diamine (III-59) as a yellow oil. The crude product was 
immediately subjected to the subsequent reaction without further purification. 1H NMR 
(500 MHz, CDCl3) δ 5.95–5.87 (m, 2 H), 5.19–5.15 (m, 4 H), 3.70 (s, br, 2 H), 3.36–
3.30 (m, 1 H), 3.24–3.20 (m, 2 H), 3.13–3.10 (m, 2 H), 2.66 (dd, J = 10.5, 15 Hz, 1 H), 
2.53 (dd, J = 4.5, 14 Hz, 1 H). 1.40 (d, J = 6.5 Hz, 3 H). 
General procedure 4 was used for the N-arylation of (S)-N1,N1-diallylpropane-1,2-
diamine (III-59) (379 mg, 2.46 mmol) with bromobenzene (386 mg, 2.46 mmol). This 
procedure afforded 390 mg (69%) of the title compound as a yellow oil. The 
enantiopurity was judged to be 99% ee by chiral hplc analysis (chiralcel OJ-H column, 
1% IPA/hexanes, 0.2 mL/min, RT = 38.71 min and 43.68 min), [α]23D –4.61° (c 0.23, 
CH2Cl2).  1H NMR (500 MHz, CDCl3) δ 7.18–7.15 (m, 2 H), 6.69 (t, J = 7.5 Hz, 1 H), 
6.64 (d, J = 8.5 Hz, 2 H), 5.83 (ddt, J = 6.5, 7.0, 10 Hz, 2 H), 5.18–5.12 (m, 4 H), 4.20 (s, 
1 H), 3.50–3.43 (m, 1 H), 3.17 (dd, J = 6.0, 14 Hz, 2 H), 3.04 (dd, J = 7.0, 14.5 Hz, 2 H), 
2.54 (dd, J = 8.5, 13 Hz, 1 H), 2.42 (dd, J = 6.0, 13 Hz, 1 H), 1.19 (d, J = 6.0 Hz, 3 H); 
13C (100 MHz, CDCl3) δ 148.4, 135.7, 129.3, 117.7, 117.3, 113.7, 59.0, 57.2, 46.6, 19.9; 
IR (film) 3350, 2924, 1602 cm–1; MS (EI) 230.1787 (230.1783 calcd for C15H22N2).  
N1-allyl-N1-benzyl-N2-phenylpropane-1,2-diamine (III-65). General procedure 4 was 
used for the deprotection of tert-butyl 1-(allyl(benzyl)amino)propan-2-ylcarbamate (III-
55) (890 mg, 2.93 mmol). This procedure afforded 526 mg (88%) of N1-allyl-N1-
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benzylpropane-1,2-diamine (III-60) as a yellow oil. The crude product was immediately 
subjected to the subsequent reaction without further purification. 1H NMR (500 MHz, 
CDCl3) δ 7.33–7.29 (m, 3 H), 7.25–7.22 (m, 2 H), 5.91–5.83 (m, 1 H), 5.18–5.13 (m, 2 
H), 3.75–3.70 (m, 1 H), 3.43 (d, J = 13.5 Hz, 1 H), 3.21–3.17 (m, 1 H), 3.04–2.99 (m, 1 
H), 2.98–2.94 (m, 1 H), 2.33–2.30 (m, 1 H), 2.26–2.22 (m, 1 H), 1.47 (s, 2 H), 0.99 (d, J 
= 6 Hz, 3 H).  
General procedure 4 was used for the N-arylation of N1-allyl-N1-benzylpropane-
1,2-diamine (III-60) (278 mg, 1.36 mmol) with 214 mg bromobenzene (144 μl, 1.36 
mmol). This procedure afforded 270 mg (71%) of the title compound as a yellow oil. 1H 
NMR (500 MHz, CDCl3) δ 7.37–7.31 (m, 4 H), 7.30–7.27 (m, 1 H), 7.23–7.20 (m, 2 H), 
6.73 (tt, J = 1, 7.5 Hz, 1 H), 6.64 (dd, J = 1, 8.5 Hz, 2 H), 5.96–5.88 (m, 1 H), 5.25–5.19 
(m, 2 H), 4.14 (s, 1 H), 3.73 (d, J = 13 Hz, 1 H), 3.57–3.50 (m, 2 H), 3.23–3.19 (m, 1 H), 
3.12–3.08 (m, 1 H), 2.64–2.60 (m, 1 H), 2.50–2.46 (m, 1 H), 1.22 (d, J = 6.5 Hz, 3 H); 
13C NMR (75 MHz, CDCl3) δ 148.4, 139.5, 135.7, 129.4, 129.2, 128.5, 127.2, 118.0, 
117.3, 113.6, 59.4, 58.7, 57.3, 46.7, 19.9; IR (film) 3360, 2806, 1602 cm–1. MS (ESI) 
281.2015 (281.2018 calcd for C19H24N2, M + H+). 
(S)-N1-Allyl-N2-(4-chlorophenyl)-N1-(4-methoxyphenyl)propane-1,2-diamine (III-
66). General procedure 4 was used for the deprotection of (S)-tert-butyl 1-[allyl(4-
methoxyphenyl)amino]propan-2-ylcarbamate (III-56) (513 mg, 1.60 mmol). This 
procedure afforded 318 mg (91%) of (S)-N1-allyl-N1-(4-methoxyphenyl)propane-1,2-
diamine (III-61) as a yellow oil. The crude product was immediately subjected to the 
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subsequent reaction without further purification.  1H NMR (500 MHz, CDCl3) δ 6.81 (d, 
J = 9.0 Hz, 2 H), 6.75 (d, J = 9.0 Hz, 2 H), 5.86–5.79 (m, 1 H), 5.14–5.11 (m, 2 H), 3.90 
(dd, J = 1.5, 5.0 Hz, 2 H), 3.75 (s, 3 H), 3.26–3.21 (m, 1 H), 3.20 (d, J = 4.5 Hz, 1 H), 
3.00–2.96 (m, 1 H), 1.60 (s, br, 2 H), 1.09 (d, J = 6.0 Hz, 3 H). 





methoxyphenyl)propane-1,2-diamine (III-61) (64 mg, 0.29 mmol) with 4-
chlorobromobenzene (55 mg, 0.29 mmol). This procedure afforded 65 mg (69%) of the 
title compound as a yellow oil. The enantiopurity was judged to be 98% ee by chiral hplc 
analysis (chiralcel OD column, 1% isopropanol/hexanes, 0.2 mL/min, RT = 59.14 min 
and 63.37 min), [α]23D +21.46° (c 0.11, CH2Cl2).  1H NMR (400 MHz, CDCl3) δ 7.08 (d, 
J = 8.8 Hz, 2 H), 6.83 (d, J = 9.2 Hz, 2 H), 6.75 (d, J = 9.2 Hz, 2 H), 6.48 (d, J = 8.8 Hz, 
2 H), 5.86–5.77 (m, 1 H), 5.16–5.11 (m, 2 H), 3.95–3.79 (m, 2 H), 3.77 (s, 3 H), 3.74–
3.63 (m, 2 H), 3.32–3.22 (m, 2 H), 1.22 (d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 152.5, 146.4, 143.6, 134.6, 129.2, 121.9, 116.9, 116.2, 114.9, 114.6, 57.8, 55.9, 
55.7, 48.0, 19.5; IR (film) 3391, 2929, 1598 cm–1; MS (EI) 330.1490 (330.1500 calcd for 
C19H23ClN2).   
N1-allyl-N1-benzyl-4-methyl-N2-phenylpentane-1,2-diamine (III-67). General 
procedure 4 was used for the deprotection of tert-butyl 1-(allyl(benzyl)amino)-4-
methylpentan-2-ylcarbamate (III-57) (1.49 g, 4.30 mmol). This procedure afforded 1.06 
g (100%) of N1-allyl- N1-benzyl-4-methylpentane-1,2-diamine (III-62) as a yellow oil. 
The crude product was immediately subjected to the subsequent reaction without further 
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purification.  1H NMR (500 MHz, CDCl3) δ 7.31–7.28 (m, 4 H), 7.25–7.22 (m, 1 H), 
5.91–5.83 (m, 1 H), 5.18–5.13 (m, 2 H), 3.77 (d, J = 13.5 Hz, 1 H), 3.40 (d, J = 13.5 Hz, 
1 H), 3.23–3.19 (m, 1 H), 2.96–2.91 (m, 2 H), 2.34–2.31 (m, 1 H), 2.27–2.23 (m, 1 H), 
1.75–1.68 (m, 1 H), 1.53 (s, 2 H), 1.15–1.06 (m, 2 H), 0.89 (d, J = 6.5 Hz, 3 H), 0.86 (d, 
J = 7 Hz, 3 H). 
General procedure 4 was used for the N-arylation of N1-allyl-N1-benzyl-4-
methylpentane-1,2-diamine (III-62) (1.06 g, 4.30 mmol) with bromobenzene (453 μl, 
4.30 mmol). This procedure afforded 1.09 g (79%) of the title compound as an yellow oil. 
The enantiopurity was judged to be 99% ee by chiral hplc analysis (chiralcel OJ-H 
column, 5% isopropanol/hexanes, 1 mL/min, RT = 6.16 min and 8.90 min).  1H NMR 
(500 MHz, CDCl3) δ 7.32–7.27 (m, 4 H), 7.25–7.22 (m, 1 H), 7.13 (td, J = 7.5 Hz, 2 H) 
6.65 (t, J = 7.0 Hz, 1 H), 6.54 (d, J = 8 Hz, 2 H), 5.90–5.82 (m, 1 H), 5.18–5.13 (m, 2 H), 
3.72 (d, J = 6 Hz, 1 H), 3.63 (d, J = 13. 5 Hz, 1 H), 3.56 (d, J = 13. 5 Hz, 1 H), 3.48–3.41 
(m, 1 H), 3.14–3.06 (m, 2 H), 2.55–2.45 (m, 2 H), 1.77–1.69 (m, 1 H), 1.50–1.45 (m, 1 
H), 1.38–1.32 (m, 1 H), 0.96 (d, J = 7 Hz, 3 H), 0.88 (d, J = 6.5 Hz, 3 H); 13C NMR (100 
MHz, CDCl3) δ 148.6, 139.8, 135.9, 129.4, 129.2, 128.4, 127.2, 117.8, 117.0, 113.2, 
59.2, 58.3, 57.8, 49.8, 43.6, 25.1, 23.3, 23.1; IR (film) 3400, 2954, 1601 cm–1. MS (ESI) 
323.2471 (323.2487 calcd for: C22H30N2, M + H+). 
Synthesis of Piperazines via Coupling with Aryl Bromides (Table 10) 
General Procedure for Pd-Catalyzed Synthesis of N-Aryl Disubstituted Piperazines. 
A flame-dried Schlenk tube equipped with a magnetic stirbar was cooled under a stream 
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of nitrogen and charged with Pd2(dba)3 (1 mol % complex, 2 mol % Pd), P(2-furyl)3 (8 
mol %), sodium tert-butoxide (1.2 equiv), and the aryl bromide (1.2 equiv). The Schlenk 
tube was purged with nitrogen and the amine was added as a solution in toluene (2.5 
mL/0.5 mmol substrate). The Schlenk tube was then heated to 105 °C with stirring until 
the starting material has been consumed as judged by 1H NMR analysis of an aliquot 
taken from the reaction mixture. The reaction mixture was then cooled to room 
temperature, saturated aqueous ammonium chloride (2–3 mL) was added, and the 
resulting mixture was extracted with ethyl acetate (3 x 8 mL). The combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The 
crude product was then purified by flash chromatography on silica gel.   
 (2S,6R)-2,4-Dibenzyl-6-(4-tert-butylbenzyl)-1-phenylpiperazine (III-71). The reaction 
of 150 mg (0.42 mmol) of N1-allyl-N1-benzyl-3,N2-diphenylpropane-1,2-diamine (III-46) 
with 108 mg (0.51 mmol) of 4-bromo-tert-butylbenzene was conducted for 10 h 
according to the general procedure. The product was formed with >20:1 dr as judged by 
1H NMR analysis of a sample taken from the crude reaction mixture. Upon purification, 
132 mg (64%) of the title compound was obtained as a white solid, m.p. 74–77 °C. This 
material was judged to be of >20:1 dr by 1H NMR analysis. The enantiopurity was 
judged to be 99% ee by chiral hplc analysis (chiralcel OJ-H column, 2 % 
isopropanol/hexanes, 0.1 mL/min, RT = 55.13 min and 101.14 min), [α]23D + 5.48° (c 
0.27, CH2Cl2).  1H NMR (400 MHz, CDCl3) δ 7.47–7.38 (m, 7 H), 7.24–7.17 (m, 5 H), 
7.07–6.99 (m, 6 H), 6.83 (t, J = 7.2 Hz, 1 H), 3.80 (d, J = 6.4 Hz, 2 H), 3.54-3.44 (m, 2 
H), 3.07 (t, J = 12.8 Hz, 2 H), 2.94–2.87 (m, 2 H), 2.79 (t, J = 11.2 Hz, 2 H), 2.15–2.07 
 117  
(m, 2 H), 1.31 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 149.0, 147.1, 140.4, 139.0, 137.3, 
130.1, 129.9, 129.5, 129.1, 128.7, 128.6, 127.5, 126.2, 125.6, 117.4, 113.5, 63.2, 55.6, 
55.5, 54.5, 54.1, 37.5, 36.9, 34.6, 31.6; IR (film) 2960, 1597 cm–1; MS (ESI) 489.3272 
(489.3270 calcd for C35H40N2, M + H+). 
 (2S,6R)-2,4-Dibenzyl-6-(4-methoxybenzyl)-1-phenylpiperazine (III-68). The reaction 
of 150 mg (0.42 mmol) of N1-allyl-N1-benzyl-3,N2-diphenylpropane-1,2-diamine (III-46) 
with 95 mg (0.51 mmol) of 4-bromoanisole was conducted for 10 h according to the 
general procedure. The product was formed with >20:1 dr as judged by 1H NMR analysis 
of a sample taken from the crude reaction mixture. Upon purification, 120 mg (62%) of 
the title compound was obtained as a white solid, m.p. 119–122 °C. This material was 
judged to be of >20:1 dr by 1H NMR analysis. The enantiopurity was judged to be 99% 
ee by chiral hplc analysis (chiralcel OJ-H column, 10 % isopropanol/hexanes, 0.5 
mL/min, RT = 15.12 min and 30.50 min), [α]23D +13.51° (c 0.48, CH2Cl2).  1H NMR 
(400 MHz, CDCl3) δ 7.47–7.38 (m, 7 H), 7.26–7.18 (m, 3 H), 7.06 (d, J = 8.0 Hz, 4 H), 
6.95 (d, J = 8.4 Hz, 3 H), 6.84 (t, J = 6.0 Hz, 1 H), 6.77 (d, J = 8.4 Hz, 1 H), 3.83–3.74 
(m, 5 H), 3.52–3.45 (m, 2 H), 3.11–2.99 (m, 2 H), 2.89 (d, J = 11.6 Hz, 2 H), 2.83-2.73 
(m, 2 H), 2.13–2.10 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 158.1, 147.0, 140.3, 138.9, 
132.4, 130.4, 130.1, 129.9, 129.5, 128.7, 128.6, 127.4, 126.2, 117.4, 114.1, 113.5, 63.2, 
55.8, 55.6, 55.4, 54.3, 54.1, 37.5, 36.5; IR (film) 3026, 2812, 1597 cm–1; MS (ESI) 
463.2744 (463.2749 calcd for C32H34N2O, M + H+). 
(2R,6S)-tert-butyl 4-[(4,6-dibenzyl-1-phenylpiperazin-2-yl)methyl]benzoate (III-72). 
The reaction of 150 mg (0.42 mmol) of N1-allyl-N1-benzyl-3,N2-diphenylpropane-1,2-
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diamine (III-46) with 130 mg (0.51 mmol) of 4-bromo-tert-butylbenzoate was conducted 
for 10 h according to the general procedure. The product was formed with >20:1 dr as 
judged by 1H NMR analysis of a sample taken from the crude reaction mixture. Upon 
purification, 132 mg (59%) of the title compound was obtained as a white solid, m.p. 75–
77 °C. This material was judged to be of >20:1 dr by 1H NMR analysis. The 
enantiopurity was judged to be 99% ee by chiral hplc analysis (chiralcel OD-H column, 5 
% isopropanol/hexanes, 2 mL/min, RT = 1.40 min and 1.94 min), [α]23D + 35.1° (c 0.30, 
CH2Cl2).  1H NMR (500 MHz, CDCl3) δ 7.85 (dd, J = 1.5, 6.5 Hz, 2 H), 7.47–7.40 (m, 7 
H), 7.27–7.25 (m, 2 H), 7.24–7.18 (m, 1 H), 7.08–7.06 (m, 6 H), 6.87 (t, J = 7.0 Hz, 1 
H), 3.82 (t, J = 11 Hz, 2 H), 3.49 (m, 2 H), 3.16–3.06 (m, 2 H), 2.91–2.81 (m, 4 H), 
2.18–2.11 (m, 2 H), 1.61 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 165.9, 146.9, 145.2, 
140.2, 138.7, 130.10, 130.06, 129.96, 129.86, 129.4, 129.3, 128.7, 128.6, 127.6, 126.3, 
117.8, 113.7, 81.0, 63.1, 55.7, 55.5, 54.3, 54.1, 37.6, 37.4, 28.4; IR (film) 2975, 1711, 
1598 cm–1; MS (ESI) 533.3166 (533.3168 calcd for C36H40N2O 2,M + H+). 
(2S,6R)-4-Benzyl-2-(4-tert-butylbenzyl)-6-isopropyl-1-phenylpiperazine (III-73). The 
reaction of 150 mg (0.49 mmol) of N1-allyl-N1-benzyl-3-methyl-N2-phenylbutane-1,2-
diamine (III-47) with 145 mg (0.68 mmol) of 4-bromo-tert-butylbenzene was conducted 
for 10 h according to the general procedure using 2 mol % Pd2(dba)3 and 16 mol % P(2-
furyl)3. The product was formed with >20:1 dr as judged by 1H NMR analysis of a 
sample taken from the crude reaction mixture. Upon purification, 110 mg (51%) of the 
title compound was obtained as a white solid, m.p. 83–86 °C. This material was judged 
to be of >20:1 dr by 1H NMR analysis. The enantiopurity was judged to be 99% ee by 
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chiral hplc analysis (chiralcel OD-H column, 100% hexanes, 1 mL/min, RT = 6.29 min 
and 7.06 min), [α]23D + 3.13° (c 0.17, CH2Cl2).  1H NMR (400 MHz, CDCl3) δ 7.36–7.29 
(m, 7 H), 7.24–7.18 (m, 4 H), 7.01 (t, J = 7.2 Hz, 1 H), 6.95 (d, J = 8.0 Hz, 2 H), 3.57 (d, 
J = 13.2 Hz, 1 H), 3.49–3.47 (m, 1 H), 3.44 (d, J = 16 Hz, 1 H), 3.30–3.27 (m, 1 H), 
2.74–2.62 (m, 2 H), 2.57–2.54 (m, 1 H), 2.49–2.45 (m, 2 H), 2.37–2.32 (m, 1 H), 1.94–
1.89 (m, 1 H), 1.32 (9 H), 0.90 (d, J = 6.8 Hz, 3 H), 0.81 (d, J = 7.2 Hz, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 150.3, 148.8, 138.5, 136.8, 129.4, 129.3, 129.0, 128.3, 127.1, 125.2, 
121.8, 63.4, 63.0, 60.7, 57.2, 53.7, 38.3, 34.5, 31.6, 29.8, 20.8, 18.2 (one aromatic carbon 
signal is absent due to accidental equivalence); IR (film) 2915, 1604 cm–1.  MS (ESI) 
441.3269 (441.3270 calcd for C31H40N2, M + H+). 
(2S,6R)-4-Benzyl-2-isopropyl-6-(6-methoxynaphthalen-2-ylmethyl)-1-
phenylpiperazine (III-74). The reaction of 100 mg (0.32 mmol) of N1-allyl-N1-benzyl-3-
methyl-N2-phenylbutane-1,2-diamine (III-47) with 108 mg (0.45 mmol) of 2-bromo-6-
methoxynapthalene was conducted for 10 h according to the general procedure. The 
product was formed with >20:1 dr as judged by 1H NMR analysis of a sample taken from 
the crude reaction mixture. Upon purification, 77 mg (51%) of the title compound was 
obtained as a white solid, m.p. 114–119 °C. This material was judged to be of >20:1 dr 
by 1H NMR analysis. The enantiopurity was judged to be 99% ee by chiral hplc analysis 
(chiralcel AD column, 5% isopropanol/hexanes, 0.9 mL/min, RT = 4.22 min and 5.78 
min), [α]23D + 33.5° (c 0.34, CH2Cl2).  1H NMR (400 MHz, CDCl3) δ 7.59 (dd, J = 6.4, 
8.8 Hz, 2 H), 7.36–7.26 (m, 7 H), 7.21–7.19 (m, 3 H), 7.13–7.07 (m, 3 H), 7.01 (t, J = 
7.2 Hz, 1 H), 3.91 (s, 3 H), 3.56 (d, J = 12.8 Hz, 1 H), 3.54–3.49 (m, 1 H), 3.35 (d, J = 
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13.2 Hz, 1 H), 3.29–3.25 (m, 1 H), 2.86–2.73 (m, 2 H), 2.55 (dd, J = 3.2, 10.8 Hz, 1 H), 
2.47–2.41 (m, 2 H), 2.35 (dd, J = 6.4, 10.8 Hz, 1 H), 1.93–1.87 (m, 1 H), 0.89 (d, J = 6.8 
Hz, 3 H), 0.79 (d, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 157.4, 150.4, 138.5, 
135.1, 133.2, 129.44, 129.36, 129.17, 129.16, 128.5, 128.4, 127.6, 127.2, 126.8, 122.0, 
118.8, 105.8, 63.5, 63.2, 60.8, 57.3, 55.5, 53.7, 39.0, 29.8, 20.8, 18.2 (one aromatic 
carbon signal is absent due to accidental equivalence); IR (film) 2956, 1604 cm—1; MS 
(ESI) 465.2899 (465.2906 calcd for C32H36N2O, M + H+). 
(2R,6R)-4-[4-Benzyl-2-benzyloxymethyl-6-(4-methylbenzyl)piperazin-1 
yl]benzonitrile (III-75). The reaction of 150 mg (0.37 mmol) of (R)-4-{1-
[allyl(benzyl)amino]-3-(benzyloxy)propan-2-ylamino}benzonitrile (III-63) with 75 mg 
(0.48 mmol) of 4-bromotoluene was conducted for 10 h according to the general 
procedure. The product was formed with 14:1 dr as judged by 1H NMR analysis of a 
sample taken from the crude reaction mixture. Upon purification, 128 mg (70%) of the 
title compound was obtained as a white solid, m.p. 125–133 °C. This material was 
determined to contain a 14:1 mixture of diastereomers as judged by 1H NMR analysis. 
The enantiopurity of the major diastereomer was judged to be 97% ee by chiral hplc 
analysis (chiralcel AD column, 10 % isopropanol/hexanes, 1 mL/min, RT = 5.32 min and 
7.41 min), [α]23D  +168.99° (c 0.17, CH2Cl2). Data are for the major diastereomer:  1H 
NMR (500 MHz, CDCl3) δ 7.53 (d, J = 9.0 Hz, 2 H), 7.40–7.33 (m, 7 H), 7.32–7.28 (m, 
3 H), 6.96 (d, J = 8.0 Hz, 2 H), 6.84 (d, J = 9.0 Hz, 2 H), 6.69 (d, J = 8.0 Hz, 2 H), 4.55–
4.48 (m, 2 H), 3.95–3.89 (m, 2 H), 3.72–3.70 (m, 1 H), 3.61 (d, J = 12 Hz, 1 H), 3.39–
3.35 (m, 2 H), 3.26 (dd, J = 1.5, 11 Hz, 1 H), 2.83 (d, J = 11.5 Hz, 1 H), 2.75 (t, J = 12 
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Hz, 1 H), 2.44 (d, J = 12.5 Hz, 1 H), 2.31–2.28 (M, 1 H), 2.28 (s, 3 H), 1.96 (dd, J = 3.0, 
11 Hz, 1 H); 13C NMR (125 MHz, CDCl3) δ 150.2, 138.6, 138.2, 136.2, 135.8, 134.1, 
129.8, 129.5, 129.2, 128.7, 128.6, 128.13, 128.06, 127.6, 120.6, 112.1, 99.6, 73.7, 68.5, 
62.8, 55.0, 54.4, 53.1, 52.6, 37.0, 21.2; IR (film) 2919, 1603 cm–1; MS (ESI) 524.2679 
(524.2678 calcd for C34H35N3O, M + Na+).  
(2R,6R)-4-[4-Benzyl-2-benzyloxymethyl-6-(4-trifluoromethylbenzyl)piperazin-1-
yl]benzonitrile (III-76). The reaction of 150 mg (0.37 mmol) of (R)-4-{1-
[allyl(benzyl)amino]-3-(benzyloxy)propan-2-ylamino}benzonitrile (III-63) with 98 mg 
(0.44 mmol) of 4-bromobenzotrifluoride was conducted for 10 h according to the general 
procedure. The product was formed with 14:1 dr as judged by 1H NMR analysis of a 
sample taken from the crude reaction mixture. Upon purification, 131 mg (65%) of the 
title compound was obtained as a white solid, m.p. 154–157 °C. This material was 
determined to contain a 14:1 mixture of diastereomers as judged by 1H NMR analysis. 
The enantiopurity of the major diastereomer was judged to be 99% ee by chiral hplc 
analysis (chiralcel AD column, 10 % isopropanol/hexanes, 1 mL/min, RT = 5.99 min and 
8.68 min), [α]23D + 155.58° (c 0.13, CH2Cl2). The diastereomers were subsequently 
separated by careful flash chromatography on silica gel.  
Major (cis) diastereomer (III-76):  1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.0 Hz, 2 
H), 7.41–7.31(m, 12 H), 6.82 (t, J = 8.8 Hz, 4 H), 4.59–4.51 (m, 2 H), 3.97–3.89 (m, 2 
H), 3.74–3.71 (m, 1 H), 3.66 (d, J = 12.4 Hz, 1 H), 3.38 (d, J = 6.8 Hz, 1 H), 3.32–3.27 
(m, 2 H), 2.80 (t, J = 12.4 Hz, 1 H), 2.71 (d, J = 11.6, 1 H), 2.51 (d, J = 12.4 Hz, 1 H), 
2.37 (dd, J = 2.4, 11.6 Hz, 1 H), 1.95 (dd, J = 3.2, 12 Hz, 1 H); 13C NMR (500 MHz, 
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CDCl3) δ 150.0, 142.8, 138.4, 138.1, 134.1, 130.0, 129.6, 129.0, 128.74, 128.69, 128.2, 
128.1, 127.7, 125.6 (q, J = 14.5 Hz), 124.3 (q, J = 270.5 Hz), 120.4, 112.1, 99.1, 73.6, 
68.4, 62.8, 54.7, 54.5, 53.2, 52.1, 37.3; IR (film) 2817, 1603 cm–1; MS (ESI) 578.2402 
(578.2395 calcd for C34H32F3N3O, M + Na+). 
Minor (trans) diastereomer (III-76b):  1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.4 Hz, 
2 H), 7.37–7.26 (m, 11 H), 7.19–7.17 (m, 2 H), 7.10 (d, J = 8.4 Hz, 2 H), 6.79 (d, J = 8.0 
Hz, 2 H), 4.38 (s, 2 H), 3.80–3.76 (m, 1 H), 3.68–3.62 (m, 2 H), 3.49 (dd, J = 2.4, 9.6 
Hz, 1 H), 3.34–3.31 (m, 2 H), 3.19 (dd, J = 2.4, 11.2 Hz, 1 H), 3.03–2.97 (m, 1 H), 2.53–
2.49 (m, 2 H), 2.46–2.41 (m, 1 H), 2.30 (dd, J = 3.2, 11.2 Hz, 1 H).   
(2R,6S)-4-Allyl-2-(4-methoxybenzyl)-6-methyl-1-phenylpiperazine (III-77). The 
reaction of 124 mg (0.54 mmol) of (S)-N1,N1-diallyl-N2-phenylpropane-1,2-diamine (III-
64) with 121 mg (0.65 mmol) of 4-bromoanisole was conducted for 10 h according to the 
general procedure. The product was formed with >20:1 dr as judged by 1H NMR analysis 
of a sample taken from the crude reaction mixture. Upon purification, 91 mg (50%) of the 
title compound was obtained as a yellow oil. This material was judged to be of >20:1 dr 
by 1H NMR analysis. The enantiopurity was judged to be 99% ee by chiral hplc analysis 
(OD-H column, 100% hexanes, 1 mL/min, RT = 19.75 min and 22.39 min), [α]23D + 
112.18 (c 0.26, CH2Cl2).  1H NMR (500 MHz, CDCl3) δ 7.35 (t, J = 8.5 Hz, 2 H), 7.17 (d, 
J = 8.0 Hz, 2 H), 7.07 (t, J = 7.5 Hz, 1 H), 6.98 (d, J = 9.0 Hz, 2 H), 6.79–6.76 (m, 2 H), 
5.90–5.82 (m, 1 H), 5.20–5.12 (m, 2 H), 3.77 (s, 3 H), 3.45–3.40 (m, 1 H), 3.38–3.35 
(m, 1 H), 3.06–3.01 (m, 1 H), 2.92–2.88 (m, 1 H), 2.71 (dd, J = 2.0, 11 Hz, 1 H), 2.57 
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(dd, J = 3.5, 13.5 Hz, 1 H), 2.51 (d, J = 10 Hz, 1 H), 2.44–2.40 (m, 1 H), 2.26–2.18 (m, 2 
H), 0.94 (d, J = 6.5 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 158.1, 149.2, 135.2, 131.8, 
130.2, 129.4, 123.2, 118.1, 113.8, 61.9, 60.5, 60.4, 57.4, 55.4, 54.2, 37.9, 18.8 (one 
carbon signal is absent due to accidental equivalence); IR (film) 3400, 2929, 1597 cm–1; 
MS (ESI) 337.2263 (337.2280 calcd for C22H28N2O, M + H+). 
(2R,6S)-4-benzyl-2-(4-tert-butylbenzyl)-6-methyl-1-phenylpiperazine (III-78). The 
reaction of 100 mg (0.357 mmol) of N1-allyl-N1-benzyl-N2-phenylpropane-1,2-diamine 
(III-65) with 92 mg (75 μl, 0.428 mmol) of 4-bromo-tert-butylbenzene was conducted 
for 10 h according to the general procedure. The product was formed with 9:1 dr as 
judged by 1H NMR analysis of a sample taken from the crude reaction mixture. Upon 
purification, 81 mg (55%) of the title compound as a yellow oil.  1H NMR (400 MHz, 
CDCl3) δ 7.43–7.31 (m, 6 H), 7.23 (d, J = 8 Hz, 2 H), 7.10 (d, J = 7.6 Hz, 2 H), 6.99–
6.92 (m, 3 H), 3.66–3.63 (m, 3 H), 3.43 (d, J = 12.8, 1 H), 2.76–2.66 (m, 2 H), 2.60–2.58 
(m, 2 H), 2.52–2.48 (m, 1 H), 2.38 (d, J = 9.6 Hz, 1 H), 1.32 (s, 9 H), 1.14 (d, J = 6 Hz, 3 
H); 13C NMR (125 MHz, CDCl3) δ 148.8, 148.3, 138.6, 137.1, 129.53, 129.48, 129.0, 
128.4, 127.3, 125.3, 120.4, 118.9, 63.2, 59.8, 58.2, 56.1, 51.5, 37.7, 34.5, 31.6, 18.5; IR 
(film) 2962, 2360, 1596 cm–1. MS (ESI) 413.2957 (413.2957 calcd for C29H36N2, M + 
H+). 
Minor (trans) diastereomer (III-78b): 1H NMR (400 MHz, CDCl3) δ 7.38–7.30 (m, 7 H), 
7.10–7.02 (m, 5 H), 6.70 (d, J = 7.6 Hz, 2 H), 3.68–3.60 (m, 1 H), 3.57–3.50 (m, 2 H), 
3.40–3.34 (m, 1 H), 2.98 (t, J = 11.6 Hz, 1 H), 2.89 (d, J = 11.2 Hz, 1 H), 2.64 (d, J = 
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10.4 Hz, 1 H), 2.53 (d, J = 11.2 Hz, 1 H), 2.32 (d, J = 9.6 Hz, 1 H), 2.08 (t, J = 10.4 Hz, 1 
H), 1.23 (s, 9 H), 0.99 (d, J = 6 Hz, 3 H).   
(2R,6S)-2-Benzyl-1-(4-chlorophenyl)-4-(4-methoxyphenyl)-6-methylpiperazine (III-
79). The reaction of 47 mg (0.14 mmol) of N1-allyl-N2-(4-chlorophenyl)-N1-(4-
methoxyphenyl)propane-1,2-diamine (III-66) with 22 mg (0.17 mmol) of bromobenzene 
was conducted for 10 h according to the general procedure. The product was formed with 
>20:1 dr as judged by 1H NMR analysis of a sample taken from the crude reaction 
mixture. Upon purification, 29 mg (51%) of the title compound was obtained as a yellow 
oil. This material was judged to be of >20:1 dr by 1H NMR analysis. The enantiopurity 
was judged to be 99% ee by chiral hplc analysis (chiralcel OD-H column, 1% 
isopropanol/hexanes, 0.5 mL/min, RT = 9.27 min and 10.30 min), [α]23D + 58.87° (c 
0.55, CH2Cl2).  1H NMR (500 MHz, CDCl3) δ 7.34–7.27 (m, 4 H), 7.21–7.18 (m, 1 H), 
7.12–7.09 (m, 4 H), 6.86–6.81 (m, 4 H), 3.76 (s, 3 H), 3.59–3.55 (m, 1 H), 3.52–3.49 
(m, 1 H), 3.25 (dd, J = 3.5, 12 Hz, 1 H), 3.07 (dd, J = 3.0, 12 Hz, 1 H), 2.92–2.88 (m, 2 
H), 2.68 (dd, J = 3.5, 13.5 Hz, 1 H), 2.58 (dd, J = 10.5, 13.5 Hz, 1 H), 1.05 (d, J = 6.5 Hz, 
3 H); 13C NMR (125 MHz, CDCl3) δ 154.2, 147.5, 146.0, 139.4, 129.5, 129.3, 128.7, 
128.0, 126.5, 123.6, 118.9, 114.7, 60.2, 58.3, 55.8, 54.7, 53.8, 38.6, 18.5; IR (film) 2930, 
1510 cm–1; MS (ESI) 407.1895 (407.1890 calcd for C25H27ClN2O, M + H+). 
 (2R,6S)-4-benzyl-2-(biphenyl-4-ylmethyl)-6-isobutyl-1-phenylpiperazine (III-80). 
The reaction of 150 mg (0.465 mmol) of N1-allyl-N1-benzyl-4-methyl-N2-phenylpentane-
1,2-diamine (III-67) with 130.1 mg (0.558 mmol) of 4-bromobiphenyl was conducted for 
10 h according to the general procedure. The product was formed with >20:1 dr as judged 
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by 1H NMR analysis of a sample taken from the crude reaction mixture. Upon 
purification, 126 mg (57%) of the title compound was obtained as a pale yellow viscous 
oil. This material was judged to be of >20:1 dr by 1H NMR analysis. The enantiopurity 
was judged to be 99% ee by chiral hplc analysis (chiralcel OD-H column, 2 % 
isopropanol/hexanes, 1 mL/min, RT = 3.54 min and 4.23 min). 1H NMR (400 MHz, 
CDCl3) δ 7.56 (d, J = 7.6 Hz, 2 H), 7.45–7.38 (m, 6 H), 7.36–7.31 (m, 6 H), 7.06 (d, J = 
8.4 Hz, 2 H), 6.99 (d, J = 8.4 Hz, 2 H), 6.84 (t, J = 7.2 Hz, 1 H), 3.76–3.66 (m, 2 H), 3.57 
(d, J = 13.2 Hz, 1 H), 3.48 (d, J = 12.8 Hz, 1 H), 2.95 (t, J = 12.8 Hz, 1 H), 2.82–2.73 (m, 
3 H), 2.39 (dd, J = 3.6, 11.2 Hz, 1 H), 2.20 (dd, J = 3.2, 11.2 Hz, 1 H), 1.94–1.84 (m, 1 
H), 1.53–1.44 (m, 1 H), 1.28–1.22 (m, 2 H), 0.95 (d, J = 6.4, 3 H), 0.89 (d, J = 6.4 Hz, 3 
H); 13C NMR (100 MHz, CDCl3) δ 147.7, 141.2, 139.5, 139.1, 138.9, 129.9, 129.6, 
129.5, 128.9, 128.5, 127.4, 127.297, 127.260, 127.2, 118.3, 115.4, 63.1, 56.6, 56.2, 54.8, 
52.8, 40.3, 37.6, 26.2, 24.4, 21.8; IR (film) 2954, 2360, 1595 cm–1. MS (ESI) 475.3114 
(475.3113 calcd for C34H38N2, M + H+). 
Isolation and Characterization of Side Products III-69 and III-70 
Side products III-69 and III-70 were isolated by careful chromatography of the crude 
mixture of products obtained from the Pd2(dba)3/P(o-tol)3-catalyzed reaction of III-46 
with 4-bromoanisole. These compounds were characterized by 1H NMR and 2-D COSY 
analysis. Data are as follows: 
(S)-4-allyl-6-(4-methoxybenzyl)-2-methyl-1-phenyl-1,2,3,4-tetrahydropyrazine (III-
69). 1H NMR (400 MHz, CDCl3) δ 7.33–7.31 (m, 4 H), 7.20–7.12 (m, 5 H), 6.99–6.97 
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(m, 2 H), 6.89–6.85 (m, 1 H), 6.80–6.77 (m, 2 H), 6.75–6.73 (m, 2 H), 6.69 (d, J = 8.0 
Hz, 1 H), 6.60 (dd, J = 1.0, 8.5 Hz, 2 H), 5.82 (s, 1 H), 4.08–3.98 (m, 2 H), 3.79 (s, 3 H), 
3.56–3.52 (m, 1 H), 3.36 (d, J = 10.5, 15.5 Hz, 1 H), 3.14 (d, J = 15 Hz, 1 H), 2.74–2.66 
(m, 2 H), 2.61–2.59 (m, 1 H), 2.49 (dd, J = 5.0, 13 Hz, 1 H). 
(S)-4-allyl-2,6-dimethyl-1-phenyl-1,2,3,4-tetrahydropyrazine (III-70). 1H NMR (500 
MHz, CDCl3) δ 7.34–7.19 (m, 10 H), 7.13–7.10 (m, 2 H), 6.82 (dt, J = 1.0, 7.0 Hz, 1 H), 
6.56 (d, J = 8.0 Hz, 2 H), 5.68 (s, 1 H), 4.04–3.95 (m, 2 H), 3.67–3.64 (m, 1 H), 3.07 (dd, 
J = 4.0, 13 Hz, 1 H), 2.73–2.68 (m, 2 H), 2.62 (dd, J = 2.5, 10.5 Hz, 1 H), 1.73 (s, 3 H). 
Assignment of Stereochemistry 
2-Isopropylpiperazines III-73 and III-74  
The stereochemistry of 2-isopropylpiperazine III-74 was assigned on the basis of 2D 
NOESY experiments. The key nOe signals are shown below. The stereochemistry of 









2-Benzyloxymethylpiperazines III-75 and III-76 
The stereochemistry of 2-benzyloxymethylpiperazine III-76 was assigned on the basis of 
2D NOESY experiments. The key nOe signals are shown below. The stereochemistry of 
piperazine III-75 was assigned based on analogy to III-76. 












The stereochemistry of 2-methylpiperazine III-79 was assigned on the basis of 2D 









2-Methylpiperazine III-77 and 2-Benzylpiperazines III-71, III-68, and III-72 
The stereochemistry of 2-methylpiperazine III-77 was assigned on the basis of 2D 
NOESY experiments. The key nOe signals are shown below. The stereochemistry of 2-
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Synthesis of Piperazines via Coupling with Vinyl Bromides (Table 11) 
General Procedure for Pd-Catalyzed Synthesis of Piperazines. A flame-dried Schlenk 
tube equipped with a magnetic stirbar was cooled under a stream of nitrogen and charged 
with Pd2(dba)3 (2 mol % complex, 4 mol % Pd), P(2-furyl)3 (16 mol %), sodium tert-
butoxide (1.4 equiv), and the aryl bromide (1.4 equiv). The Schlenk tube was purged with 
nitrogen and the amine was added as a solution in toluene (2.5 mL/0.5 mmol substrate) or 
xylenes (2.5 mL/0.5 mmol substrate) as noted in each example. The Schlenk tube was 
then heated to 90 °C (toluene) or 135 °C (xylenes) with stirring until the starting material 
has been consumed as judged by 1H NMR analysis of an aliquot taken from the reaction 
mixture. The reaction mixture was then cooled to room temperature, saturated aqueous 
ammonium chloride (2–3 mL) was added, and the resulting mixture was extracted with 
ethyl acetate (3 x 8 mL). The combined organic layers were dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel.  
(2S,6R)-2,4-dibenzyl-1-phenyl-6-((E)-3-(trimethylsilyl)allyl)piperazine (III-81). The 
reaction of 100 mg (0.281 mmol) of N1-allyl-N1-benzyl-N2,3-diphenylpropane-1,2-
diamine (III-46) with 71 mg (61 μL, 0.393 mmol) of (E)-(2-bromovinyl)trimethylsilane 
in toluene (2.45 mL) at 90 °C was conducted for 10 h according to the general procedure 
to afford 76 mg (59%) of the title compound as a yellow viscous oil. This material was 
judged to be of >20:1 dr by 1H NMR analysis. The enantiopurity was judged to be 97% 
ee by chiral hplc analysis (chiralcel OD-H column, 0.1% isopropanol/hexanes, 0.5 
mL/min, RT = 8.68 min and 9.82 min). 1H NMR (400 MHz, CDCl3) δ 7.48–7.34 (m, 7 
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H), 7.27–7.18 (m, 3 H), 7.05 (d, J = 6.8 Hz, 2 H), 7.01 (d, J = 8.4 Hz, 2 H), 6.89 (t, J = 
7.2 Hz, 1 H), 6.01–5.93 (m, 1 H), 5.62 (d, J = 18.4 Hz, 1 H), 3.82–3.79 (m, 1 H), 3.67–
3.65 (m, 1 H), 3.58–3.50 (m, 2 H), 2.95 (t, J = 12.4 Hz, 1 H), 2.85–2.74 (m, 3 H), 2.69–
2.61 (m, 1 H), 2.41–2.31 (m, 2 H), 2.22 (dd, J = 3.2, 11.2 Hz, 1 H), 0.06 (s, 9 H); 13C 
NMR (100 MHz, CDCl3) δ 147.4, 144.1, 140.3, 138.8, 133.6, 129.74, 129.68, 129.5, 
128.6, 128.5, 127.4, 126.2, 118.3, 115.1, 63.2, 56.3, 55.3, 54.7, 53.7, 39.0, 37.6, -1.0; IR 
(film) 3026, 2953, 1597, 1500 cm–1. MS (ESI) 455.2885 (455.2883 calcd for C30H38N2Si, 
M + H+). 
(2S,6R)-2,4-dibenzyl-6-cinnamyl-1-phenylpiperazine (III-82). The reaction of 98 mg 
(0.274 mmol) of N1-allyl-N1-benzyl-N2,3-diphenylpropane-1,2-diamine (III-46) with 71 
mg (0.384 mmol) of (E)-β-bromostyrene in toluene (2.45 mL) at 90 °C was conducted 
for 10 h according to the general procedure to afford 92 mg (73%) of the title compound 
as a pale yellow solid, m.p. 43–48 °C. This material was judged to be of >20:1 dr by 1H 
NMR analysis. The enantiopurity was judged to be 95% ee by chiral hplc analysis 
(chiralcel OJ-H column, 3% isopropanol/hexanes, 0.2 mL/min, RT = 65.89 min and 
106.91 min). 1H NMR (500 MHz, CDCl3) δ 7.48–7.46 (m, 2 H), 7.44–7.36 (m, 5 H), 
7.34–7.30 (m, 4 H), 7.25–7.17 (m, 4 H), 7.05–7.00 (m, 4 H), 6.87 (t, J = 7 Hz, 1 H), 6.29 
(d, J = 16 Hz, 1 H), 6.21–6.15 (m, 1 H), 3.81 (d, J = 9.5 Hz, 1 H), 3.71 (d, J = 9.0 Hz, 1 
H), 3.57–3.51 (m, 2 H), 3.00–2.93 (m, 2 H), 2.83–2.74 (m, 3 H), 2.42 (dd, J = 6, 13.5 
Hz, 1 H), 2.33 (dd, J = 3, 11 Hz, 1 H), 2.20 (dd, J = 3.0, 11.5 Hz, 1 H); 13C NMR (100 
MHz, CDCl3) δ 147.3, 140.3, 138.9, 137.7, 132.6, 129.8, 129.7, 129.5, 128.7, 128.6, 
128.6, 128.0, 127.4, 127.3, 126.24, 126.21, 118.1, 114.6, 63.1, 56.1, 55.3, 54.4, 54.0, 
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37.6, 35.2; IR (film) 3025, 2923, 2811, 1596 cm–1. MS (ESI) 459.2789 (459.2800 calcd 
for C33H34N2, M + H+). 
(2S,6R)-4-benzyl-2-isopropyl-1-phenyl-6-(2-phenylallyl)piperazine (III-83). The 
reaction of 150 mg (0.487 mmol) of N1-allyl-N1-benzyl-3-methyl-N2-phenylbutane-1,2-
diamine (III-47) with 125 mg (0.682 mmol) of α-bromostyrene in xylenes at 135 °C 
(2.45 mL) was conducted for 10 h according to the general procedure to afford 104 mg 
(52%) of the title compound as a yellow viscous oil. This material was judged to be of 
>20:1 dr by 1H NMR analysis. The enantiopurity was judged to be 97% ee by chiral hplc 
analysis (chiralcel OD-H column, 0.1% isopropanol/hexanes, 0.5 mL/min, RT = 7.44 min 
and 8.68 min).  1H NMR (400 MHz, CDCl3) δ 7.32–7.27 (m, 6 H), 7.24–7.22 (m, 4 H), 
7.10–7.03 (m, 5 H), 5.10 (s, 1 H), 4.92 (s, 1 H), 3.52–3.43 (m, 2 H), 3.12–3.03 (m, 2 H), 
2.68–2.56 (m, 3 H), 2.39–2.32 (m, 1 H), 2.26–2.22 (m, 1 H), 2.10–2.05 (m, 1 H), 1.67–
1.60 (m, 1 H), 0.82 (d, J = 6.8 Hz, 3 H), 0.73 (d, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 150.1, 146.6, 141.0, 138.3, 129.3, 129.1, 128.3, 127.5, 127.1, 126.5, 124.6, 
123.7, 114.8, 64.2, 63.4, 58.3, 57.9, 53.4, 39.1, 28.9, 20.5, 17.0; IR (film) 2958, 2360, 
1596 cm–1. MS (ESI) 411.2794 (411.2800 calcd for C29H34N2, M + Na+). 
Synthesis of Piperazines via Coupling with Aryl Bromides (Table 12) 
General Procedure for Pd-Catalyzed Synthesis of N-Boc Piperazines. A flame-dried 
Schlenk tube equipped with a magnetic stirbar was cooled under a stream of nitrogen and 
charged with Pd(OAc)3 (6 mol % Pd), P(2-furyl)3 (8 mol %), sodium tert-butoxide (1.2 
(for III-85)–1.3 (for III-84) equiv), and the aryl bromide ((1.2 (for III-85)–1.3 (for III-
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84) equiv). The Schlenk tube was purged with nitrogen and the amine was added as a 
solution in toluene (2.5 mL/0.5 mmol substrate). The Schlenk tube was then heated to 90 
°C with stirring until the starting material has been consumed as judged by 1H NMR 
analysis of an aliquot taken from the reaction mixture. The reaction mixture was then 
cooled to room temperature, saturated aqueous ammonium chloride (2–3 mL) was added, 
and the resulting mixture was extracted with ethyl acetate (3 x 8 mL). The combined 
organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in 
vacuo. The crude product was then purified by flash chromatography on silica gel.   
(2R,6S)-tert-butyl-4-benzyl-2-(4-cyanobenzyl)-6-methylpiperazine-1-carboxylate 
(III-84). The reaction of 150 mg (0.493 mmol) of (III-55) with 117 mg (0.641 mmol) of 
4-bromobenzonitrile in toluene (2.70 mL) at 90 °C was conducted for 10 h according to 
the general procedure to afford 135 mg (total yield of both diastereomers = 68%) of the 
title compound as a pale yellow solid, m.p. 180-185 °C. This material was judged to be of 
1:1 dr by 1H NMR analysis. Diastereomer 1 (cis): The enantiopurity both the cis and 
trans (below) diastereomer were judged to be 99% ee by chiral hplc analysis (chiralcel 
OJ-H column, 5% isopropanol/hexanes, 1.0 mL/min, RT = 7.40 min and 8.78 min).  
Diastereomer 1 (cis): 1H NMR (500 MHz, CDCl3) δ 7.38–7.35 (m, 7 H), 6.92 (d, J = 6.5 
Hz, 2 H), 4.18–4.12 (m, 1 H), 3.89 (d, J =10.5 Hz, 1 H), 3.63 (d, J =13 Hz, 1 H), 3.24 (d, 
J = 13 Hz, 1 H), 3.07 (t, J = 11.5 Hz, 1 H), 2.77–2.73 (m, 2 H), 2.46 (d, J = 12 Hz, 1 H), 
2.32 (dd, J = 4.5, 11.5 Hz, 1 H), 1.78 (dd, J = 4.0, 11.5 Hz, 1 H), 1.50 (s, 9 H), 1.37 (d, J 
= 7 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 154.9, 145.8, 138.8, 132.2, 130.4, 129.7, 
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128.6, 127.5, 119.3, 110.0, 80.0, 63.0, 58.9, 53.9, 52.3, 47.4, 40.6, 28.8, 21.1; IR (film) 
2969, 2226, 1686 cm–1. MS (ESI) 406.2496 (406.2495 calcd for C25H31N3O2, M + H+). 
Diastereomer 2 (trans) (III-84b): pale yellow solid, m.p. 109-114 °C. The enantiopurity 
was judged to be 99% ee by chiral hplc analysis (chiralcel OJ-H column, 5% 
isopropanol/hexanes, 0.2 mL/min, RT = 39.29 min and 42.49 min).  1H NMR (500 MHz, 
CDCl3) δ 7.40–7.31 (m, 7 H), 7.05 (d, J = 8.0 Hz, 2 H), 4.09–4.05 (m, 1 H), 3.72–3.65 
(m, 1 H), 3.58 (d, J = 13 Hz, 1 H), 3.25 (d, J = 12.5 Hz, 1 H), 3.19– 3.14 (m, 1 H), 2.86–
2.78 (m, 2 H), 2.44–2.41 (m, 1 H), 2.04–2.00 (m, 2 H), 1.48 (s, 9 H), 1.39 (d, J = 6 Hz, 3 
H); 13C NMR (125 MHz, CDCl3) δ 156.4, 145.3, 138.3, 132.2, 130.3, 129.6, 128.5, 
127.5, 119.3, 110.0, 80.2, 62.9, 61.6, 55.9, 52.7, 48.5, 37.4, 28.7, 20.7; IR (film) 2972, 
2226, 1704 cm–1. MS (ESI) 406.2498 (406.2495 calcd for C25H31N3O2, M + H+). 
(Rac)-tert-butyl 4-benzyl-2-(4-cyanobenzyl)-6-isobutylpiperazine-1-carboxylate (III-
85). The reaction of 54 mg (0.156 mmol) of (III-57) with 35 mg (0.187 mmol) of 4-
bromobenzonitrile in toluene (0.80 mL) at 90 °C was conducted for 10 h according to the 
general procedure to afford 50 mg (total yield of both diastereomers = 72%) the title 
compound as a pale yellow oil. This material was judged to be of 2:1 dr by 1H NMR 
analysis. Major (cis) diastereomer: 1H NMR (300 MHz, CDCl3) δ 7.40–7.30 (m, 7 H), 
7.08–6.92 (m, 2 H), 4.02–3.88 (m, 2 H), 3.56 (d, J = 12.9 Hz, 1 H), 3.30 (d, J =12.6 Hz, 
1 H), 3.06 (t, J = 11.7 Hz, 1 H), 2.78 (t, J = 14.1 Hz, 2 H), 2.49–2.41 (m, 1 H), 2.17 (dd, 
J = 3.9, 11.1 Hz, 1 H), 2.04–1.92 (m, 1 H), 1.83 (dd, J = 4.2, 11.4 Hz, 1 H), 1.50–1.40 
(m, 9 H), 1.17–1.09 (m, 1 H), 0.97–0.92 (m, 6 H). 
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Minor (trans) diastereomer (III-85b): 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 8.4 Hz, 
2 H), 7.39–7.27 (m, 5 H), 7.22 (d, J = 8 Hz, 2 H), 3.95–3.91 (m, 1 H), 3.85–3.80 (m, 1 
H), 3.64 (d, J =12.8 Hz, 1 H), 3.37 (d, J = 13.2 Hz, 1 H), 3.28 (dd, J = 5.2, 12.8 Hz, 1 H), 
3.03–2.97 (m, 1 H), 2.67 (dd, J = 3.6, 11.6 Hz, 1 H), 2.45–2.40 (m, 2 H), 2.37–2.33 (m, 
1 H), 1.78–1.72 (m, 1 H), 1.47 (s, 10 H), 1.25–1.10 (m, 1 H), 0.87 (t, J = 6 Hz, 6 H). 13C 
NMR (125 MHz, CDCl3) δ 156.2, 145.5, 138.6, 132.2, 130.3, 129.1, 128.5, 127.4, 119.3, 
110.1, 80.1, 63.0, 55.6, 55.2, 53.9, 52.6, 41.6, 38.5, 28.7, 25.4, 23.3, 22.5. 
N1-allyl-N1-benzyl-N2-(4-methoxyphenyl)propane-1,2-diamine (III-100). General 
procedure 4 was used for the N-arylation of N1-allyl-N1-benzylpropane-1,2-diamine (185 
mg, 0.905 mmol) with 170 mg 4-bromoanisole (114 μL, 0.905 mmol) using 2 mol of di-
tert-butylphosphino(o-biphenyl) in place of BINAP as the ligand. This procedure 
afforded 228 mg (81%) of the title compound as an orange oil. 1H NMR (500 MHz, 
CDCl3) δ 7.36–7.32 (m, 4 H), 7.30–7.26 (m, 1 H), 6.82–6.79 (m, 2 H), 6.64–6.60 (m, 2 
H), 5.94–5.86 (m, 1 H), 5.23–5.18 (m, 2 H), 3.97 (s, 1 H), 3.78 (s, 3 H), 3.72 (d, J = 13.5 
Hz, 1 H), 3.54 (d, J = 13 Hz, 1 H), 3.45–3.39 (m, 1 H), 3.22–3.18 (m, 1 H), 3.09–3.05 
(m, 1 H), 2.62–2.58 (m, 1 H), 2.47–2.44 (m, 1 H), 1.19 (d, J = 6 Hz, 3 H); 13C NMR (125 
MHz, CDCl3) δ 152.2, 142.6, 139.4, 135.7, 129.1, 128.4, 127.2, 117.9, 115.2, 115.0, 
59.6, 58.7, 57.3, 55.9, 47.6, 20.0; IR (film) 3350, 2928, 2360, 1510 cm–1. MS (ESI) 
311.2126 (311.2123 calcd for C20H26N2O, M + H+). 
4-(1-(allyl(benzyl)amino)propan-2-ylamino)benzonitrile (III-101). General procedure 
4 was used for the N-arylation of N1-allyl-N1-benzylpropane-1,2-diamine (278 mg, 1.36 
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mmol) with 248 mg 4-bromobenzonitrile (1.36 mmol). This procedure afforded 290 mg 
(70%) of the title compound as an orange oil. 1H NMR (500 MHz, CDCl3) δ 7.39–7.37 
(m, 1 H), 7.32–7.24 (m, 5 H), 6.46 (d, J = 7.5 Hz, 2 H), 5.90–5.82 (m, 1 H), 5.21–5.17 
(m, 2 H), 4.49 (d, J = 4.5 Hz, 1 H), 3.68 (d, J = 13.5 Hz, 1 H), 3.50–3.44 (m, 2 H), 3.21–
3.17 (m, 1 H), 3.08–3.04 (m, 1 H), 2.57–2.52 (m, 1 H), 2.50–2.46 (m, 1 H), 1.14 (d, J = 
6 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 151.4, 139.3, 135.4, 133.8, 129.1, 128.5, 
127.4, 120.8, 118.2, 112.7, 98.3, 59.1, 59.0, 57.8, 46.5; IR (film) 3361, 2807, 2211, 1607 
cm–1. MS (ESI) 306.1962 (306.1970 calcd for C20H23N3, M + H+). 
N1-benzyl-N1-(4-methoxyphenyl)-N2-phenylpropane-1,2-diamine (III-105) General 
procedure 4 was used for the N-arylation of N1-benzyl-N1-(4-methoxyphenyl)propane-
1,2-diamine (350 mg, 1.59 mmol) with 250 mg bromobenzene (168 μl, 1.36 mmol). This 
procedure afforded 308 mg (65%) of the title compound as a yellow oil. 1H NMR (500 
MHz, CDCl3) δ 7.19 (t, J = 7.5 Hz, 2 H), 6.88–6.85 (m, 2 H), 6.82–6.78 (m, 2 H), 6.72 
(t, J = 7 Hz, 1 H), 6.62 (d, J = 8 Hz, 2 H), 5.90–5.82 (m, 1 H), 5.20–5.16 (m, 2 H), 3.98–
3.93 (m, 1 H), 3.89–3.85 (m, 1 H), 3.80–3.72 (m, 5 H), 3.39–3.35 (m, 1 H), 3.29–3.25 
(m, 1 H), 1.27 (d, J = 6.5 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 152.3, 147.8, 143.7, 
134.6, 129.4, 117.5, 116.8, 115.9, 114.8, 113.5, 57.8, 55.9, 55.6, 47.8, 19.7; IR (film) 
2929, 2341, 1601 cm–1. MS (ESI) 297.1964 (297.1967 calcd for C19H24N2O, M + H+). 
4-benzyl-2-(4-tert-butylbenzyl)-1-(4-methoxyphenyl)-6-methylpiperazine (III-102). 
The reaction of 65 mg (0.209 mmol) of N1-allyl-N1-benzyl-N2-(4-
methoxyphenyl)propane-1,2-diamine (III-100) with 54 mg (44 μl, 0.251 mmol) of 4-
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bromo-tert-butylbenzene was conducted for 10 h according to the general procedure. The 
product was formed with >20:1 dr as judged by 1H NMR analysis of a sample taken from 
the crude reaction mixture. Upon purification, 45 mg (49%) of the title compound as a 
yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.31 (d, J = 4 Hz, 4 H), 7.25–7.24 (m, 1 H), 
7.21 (d, J = 8.5 Hz, 2 H), 7.17 (d, J = 8.5 Hz, 2 H), 6.92–6.89 (m, 4 H), 3.82 (s, 3 H), 
3.64 (d, J = 13 Hz, 1 H), 3.35–3.29 (m, 2 H), 3.16–3.06 (m, 1 H), 2.76 (t, J = 11 Hz, 2 
H), 2.58 (dd, J = 3.5, 13.5 Hz, 1 H), 2.31–2.26 (m, 1 H), 2.16 (t, J = 10 Hz, 1 H), 2.02 (t, 
J = 9.5 Hz, 1 H), 1.29 (s, 9 H), 0.78 (d, J = 6 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 
156.9, 148.8, 142.6, 138.2, 136.5, 129.4, 129.1, 128.9, 128.3, 127.2, 125.2, 114.4, 63.2, 
62.2, 60.5, 58.9, 56.3, 55.6, 38.6, 34.5, 31.6, 19.0; IR (film) 2961, 2360, 1508 cm–1. MS 
(ESI) 443.3060 (443.3062 calcd for C30H38N2O, M + H+). 
4-allyl-2-(4-tert-butylbenzyl)-6-methyl-1-phenylpiperazine (III-106). The reaction of 
50 mg (0.217 mmol) of N1, N1-diallyl-N2-phenylpropane-1,2-diamine (III-64) with 56 mg 
(46 μl, 0.260 mmol) of 4-bromo-tert-butylbenzene was conducted for 10 h according to 
the general procedure. The product was formed with >20:1 dr as judged by 1H NMR 
analysis of a sample taken from the crude reaction mixture. Upon purification, 35 mg 
(46%) of the title compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.36–7.32 
(m, 2 H), 7.27–7.24 (m, 2 H), 7.16 (d, J = 7.6 Hz, 2 H), 7.04 (t, J = 7.2 Hz, 1 H), 7.00 (d, 
J = 8.4 Hz, 2 H), 5.93–5.82 (m, 1 H), 5.21–5.13 (m, 2 H), 3.51–3.46 (m, 1 H), 3.44–3.36 
(m, 1 H), 3.08–3.03 (m, 1 H), 2.93–2.88 (m, 1 H), 2.69 (d, J = 8.8 Hz, 1 H), 2.62–2.58 
(m, 1 H), 2.53–2.46 (m, 2 H), 2.34–2.30 (m, 1 H), 2.25–2.21 (m, 1 H), 1.29 (s, 9 H), 0.96 
(d, 3 H); 13C NMR (125 MHz, CDCl3) δ 149.0, 148.9, 136.7, 135.3, 129.4, 129.0, 125.3, 
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122.8, 118.1, 114.6, 61.9, 60.2, 60.0, 57.4, 53.9, 38.1, 34.5, 31.6, 18.8; IR (film) 2962, 
1596 cm–1. MS (ESI) 363.2798 (363.2800 calcd for C25H34N2, M + H+). 
4-(4-benzyl-2-(4-tert-butylbenzyl)-6-methylpiperazin-1-yl)benzonitrile (III-103). The 
reaction of 142 mg (0.466 mmol) of 4-(1-(allyl(benzyl)amino)propan-2-
ylamino)benzonitrile (III-101) with 120 mg (98 μl, 0.559 mmol) of 4-bromo-tert-
butylbenzene was conducted for 10 h according to the general procedure. The product 
was formed with 6:1 dr as judged by 1H NMR analysis of a sample taken from the crude 
reaction mixture. Upon purification, 156 mg (76%) of the title compound was isolated as 
a yellow solid (6:1 pure dr) major diastereomer m.p. 59–66 °C.  1H NMR (400 MHz, 
CDCl3) 7.56 (d, J = 8.8 Hz, 2 H), 7.47–7.38 (m, 5 H), 7.21 (d, J = 6.8 Hz, 2 H), 6.88–
6.84 (m, 4 H), 4.04–3.99 (m, 1 H), 3.84–3.78 (m, 1 H), 3.62 (d, J = 12.4 Hz, 1 H), 3.46 
(d, J = 12.4 Hz, 1 H), 3.09 (t, J = 12.4 Hz, 1 H), 2.94–2.86 (m, 2 H), 2.61 (d, J = 12.8 Hz, 
1 H), 2.40 (dd, J = 4.4, 10.8 Hz, 1 H), 1.99 (dd, J = 3.2, 11.6 Hz, 1 H), 1.40 (d, J = 6.8 
Hz, 3 H), 1.31 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 150.2, 149.3, 138.6, 136.4, 134.0, 
129.6, 129.0, 128.6, 127.5, 125.6, 120.7, 112.3, 98.0, 63.0, 58.8, 55.2, 53.2, 48.2, 37.3, 
34.5, 31.5, 18.3; IR (film) 2962, 2360, 1603 cm–1. MS (ESI) 438.2905 (438.2909 calcd 
for C30H35N3, M + H+). 
Minor (trans) diastereomer (III-103b) (isolated as 2:1 mixture with major diastereomer 
III-103):  1H NMR (400 MHz, CDCl3) δ 7.59–7.52 (m, 2 H), 7.44–7.30 (m, 5 H), 7.18 
(d, J = 8.4 Hz, 1 H), 7.11–7.08 (m, 2 H), 6.86–6.82 (m, 2 H), 6.70 (d, J = 8 Hz, 1 H), 
3.70–3.66 (m, 2 H), 3.62–3.54 (m, 1 H), 3.42 (t, J = 14 Hz, 1 H), 3.11–2.99 (m, 1 H), 
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2.95–2.84 (m, 2 H), 2.44–2.36 (m, 2 H), 2.09–2.03 (m, 1 H), 1.24 (s, 9 H), 1.02 (d, J = 
5.6 Hz, 3 H).  
tert-butyl 4-benzyl-2-(4-tert-butylbenzyl)-6-methylpiperazine-1-carboxylate (III-
104). The reaction of 50 mg (0.164 mmol) of N1-allyl-N1-(4-methoxyphenyl)-N2-
phenylpropane-1,2-diamine (III-55) with 42.7 mg (35 μL, 0.197 mmol) of 4-bromo-tert-
butylbenzene was conducted for 10 h according to the general procedure (for N-aryl 
piperazines). The product was formed with 1:1 dr as judged by 1H NMR analysis of a 
sample taken from the crude reaction mixture. Upon purification, 7 mg (9.8%) of the title 
compound as a yellow oil. One diastereomer was isolated as a ~3:1 mixture of 
diastereomers, while the other diastereomer was only isolated as a mixture of 
diastereomers with other material (either the other diastereomer or with a side product 
originating from β-hydride elimination prior to reductive elimination). Data are for the 
more purely isolated diastereomer. The reaction was repeated using conditions more 
suitable for the Boc-protected diamines. Therefore, 100 mg (0.329 mmol) of the amine 
Pd(OAc)2 (4.73 mg, 6 mol%) and PPh3 (6.6 mg, 8 mol %) and 1.3 eq of the 4-Br-t-Bu-
benzene (75 μL, 0.428 mmol) and NaOtBu (42 mg, 0.429 mmol) to afford 50 mg (35%) 
of the title compound. 1H NMR (500 MHz, CDCl3) δ 7.40–7.28 (m, 6 H), 7.20–7.14 (m, 
2 H), 6.91 (d, J = 8.0 Hz, 1 H), 4.18–4.10 (m, 1 H), 3.98–3.93 (m, 1 H), 3.51 (d, J = 12.8 
Hz, 1 H), 3.39 (d, J = 13.2 Hz, 1 H), 3.06 (t, J = 12 Hz, 1 H), 2.73–2.63 (m, 3 H), 2.21 
(dd, J = 4.4, 10.8 Hz, 1 H), 1.83 (dd, J = 4.0, 11.6 Hz, 1 H), 1.51 (s, 9 H), 1.37 (d, J = 6.8 
Hz, 3 H), 1.27 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 155.0, 148.8, 139.0, 137.1, 129.4, 
129.3, 129.2, 128.5, 127.3, 125.4, 125.3, 79.7, 63.1, 58.4, 63.1, 58.4, 54.3, 53.2, 40.2, 
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34.5, 31.6, 28.8, 28.7, 21.0 (13C contains 4 extra peaks from minor diastereomer); IR 
(film) 2965, 1690 cm–1. MS (ESI) 437.3162 (437.3168 calcd for C28H40N2O2, M + H+). 
2-(4-tert-butylbenzyl)-4-(4-methoxyphenyl)-6-methyl-1-phenylpiperazine (III-107). 
The reaction of 68 mg (0.229 mmol) of N1-allyl-N1-(4-methoxyphenyl)-N2-
phenylpropane-1,2-diamine (III-105) with 59 mg (48 μl, 0.275 mmol) of 4-bromo-tert-
butylbenzene was conducted for 10 h according to the general procedure. The product 
was formed with >20:1 dr as judged by 1H NMR analysis of a sample taken from the 
crude reaction mixture. Upon purification, 49 mg (50%) of the title compound as a 
yellow oil.   1H NMR (400 MHz, CDCl3) δ 7.38 (t, J = 8.4 Hz, 2 H), 7.30 (d, J = 8.0 Hz, 2 
H), 7.19 (d, J = 7.6 Hz, 2 H), 7.07 (d, J = 8.0 Hz, 3 H), 6.92–6.89 (m, 2 H), 6.87–6.84 
(m, 2 H), 3.78 (s, 3 H), 3.68–3.57 (m, 2 H), 3.26 (dd, J = 3.2,11.2 Hz, 1 H), 3.09 (dd, J = 
3.2, 12.0 Hz, 1 H), 3.00–2.93 (m, 2 H), 2.71–2.58 (m, 2 H), 1.31 (s, 9 H), 1.09 (d, J = 6 
Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 154.2, 149.1, 148.7, 146.2, 136.6, 129.5, 129.0, 
125.5, 122.5, 121.7, 119.0, 114.6, 59.8, 58.4, 55.8, 54.6, 53.4, 38.0, 34.6, 31.6, 18.6; IR 
(film) 2961, 1596, 1510 cm–1. MS (ESI) 429.2901 (429.2906 calcd for C29H36N2O, M + 
H+). 
Synthesis of 2,3-Disubstituted Piperazines 
tert-butyl 2-(benzyl(but-3-en-2-yl)amino)ethylcarbamate (III-136). General procedure 
3 was used for the coupling of 2-(tert-butoxycarbonylamino)acetic acid (6.95 g, 39.70 
mmol) and N-benzylbut-3-en-2-amine (6.40 g, 39.7 mmol) using 1.40 eq of DCC instead 
of 2 eq. This procedure afforded 10.73 g (85%) of tert-butyl 2-(benzyl(but-3-en-2-
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yl)amino)-2-oxoethylcarbamate (III-134) as a white solid, which was contaminated with 
ca. 15% of dicyclohexylurea and was observed as a 1.2:1 mixture of rotamers. 1H NMR 
(400 MHz, CDCl3) δ 7.37–7.27 (m, 2.27 H), 7.23–7.16 (m, 2.73 H), 5.89–5.67 (m, 1 H), 
5.65–5.58 (m, 1 H), 5.54–5.44 (m, 1 H), 5.31–5.06 (m, 2 H), 4.78 (d, J = 15.6 Hz, 0.40 
H), 4.41 (d, J = 12.4 Hz, 1.1 H), 4.28 (d, J = 15.6 Hz, 0.50 H), 4.19–4.00 (m, 1 H), 3.96–
3.66 (m, 1 H), 1.45 (s, 4.9 H), 1.41 (s, 4.1 H), 1.23 (d, J = 7.2 Hz, 3 H). 
The tert-butyl 2-(benzyl(but-3-en-2-yl)amino)-2-oxoethylcarbamate (III-134) coupling 
product of the DCC reaction (5.14 g, 16.14 mmol) was reduced with lithium aluminum 
hydride following general procedure 3. This procedure afforded 2.50 g (51%) of the title 
compound as a yellow solid, m. p. 38-40 °C. 1H NMR (400 MHz, CDCl3) δ 7.31–7.24 
(m, 4 H), 7.24–7.21 (m, 1 H), 5.90–5.81 (m, 1 H), 5.17–5.05 (m, 2 H), 4.84 (s, 1 H), 
3.63–3.52 (m, 2 H), 3.30 (t, J = 6.4 Hz, 1 H), 3.12–3.06 (m, 2 H), 2.64–2.57 (m, 1 H), 
2.54–2.48 (m, 1 H), 1.44 (s, 9 H), 1.14 (d, J = 6.4 Hz, 3 H); 13C NMR (75 MHz, CDCl3) 
δ 156.1, 140.5, 139.5, 128.6, 128.4, 126.9, 115.9, 78.8, 56.7, 54.6, 49.0, 38.7, 28.5, 15.4; 
IR (film) 3425, 3365, 2974, 1714 cm–1. MS (ESI) 327.2035 (327.2048 calcd for 
C18H28N2O2, M + Na+). 
4-(2-(benzyl(but-3-en-2-yl)amino)ethylamino)benzonitrile (III-140). General 
procedure 4 was used for the deprotection of III-136 (1.35 g, 4.44 mmol). This procedure 
afforded 842 mg (93%) of N1-benzyl-N1-(but-3-en-2-yl)ethane-1,2-diamine (III-138) as a 
yellow oil. The crude product was immediately subjected to the subsequent reaction 
without further purification.  1H NMR (300 MHz, CDCl3) δ 7.39–7.19 (m, 5 H), 5.94–
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5.82 (m, 1 H), 5.16–5.03 (m, 2 H), 3.65–3.53 (m, 2 H), 3.34–3.25 (m, 1 H), 2.72–2.61 
(m, 2 H), 2.60–2.44 (m, 2 H), 1.21 (broad s, 2 H), 1.14 (d, J = 6.9 Hz, 3 H). 
General procedure 4 was used for the N-arylation of N1-benzyl-N1-(but-3-en-2-yl)ethane-
1,2-diamine (III-138) (681 mg, 3.33 mmol) with 4-bromobenzonitrile (606 mg, 3.33 
mmol). This procedure afforded 905 mg (89%) of the title compound as an yellow-orange 
oil. 1H NMR (300 MHz, CDCl3) δ 7.43–7.21 (m, 7 H), 6.41 (d, J = 9 Hz, 2 H), 5.94–5.83 
(m, 1 H), 5.21–5.08 (m, 2 H), 4.65 (s, 1 H), 3.66–3.52 (m, 2 H), 3.39–3.30 (m, 1 H), 
3.08–2.97 (m, 2 H), 2.82–2.63 (m, 2 H), 1.20 (d, J = 6.6 Hz, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 151.5, 140.2, 139.2, 133.5, 128.6, 128.4, 127.1, 120.7, 116.2, 112.2, 97.8, 56.8, 
54.3, 47.8, 40.7, 15.3; IR (film) 3380, 2968, 2212, 1608 cm–1. MS (ESI) 306.1975 
(306.1970 calcd for C20H23N3, M + H+). 
4-((2S,3S)-4-benzyl-2-(4-methoxybenzyl)-3-methylpiperazin-1-yl)benzonitrile (III-
142). The reaction of 100 mg (0.327 mmol) of 4-(2-(benzyl(but-3-en-2-
yl)amino)ethylamino)benzonitrile (III-140) with 61 mg (50 μl, 0.392 mmol) of 4-
bromoanisole was conducted for 10 h according to the general procedure except xylenes 
was used in place of toluene and the reaction was conducted at 140 °C. The product was 
formed with 3:1 dr as judged by 1H NMR analysis of a sample taken from the crude 
reaction mixture. Upon purification, 102 mg (76%) of the title compound was obtained as 
an orange solid, m.p. 118–125 °C. The diastereomers were subsequently separated by 
careful flash chromatography on silica gel.  
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Major (trans) diastereomer (III-142): 1H NMR (400 MHz, CDCl3) δ 7.41–7.29 (m, 5 H), 
7.24 (d, J = 8.8 Hz, 2 H), 6.97 (d, J = 8.4 Hz, 2 H), 6.65 (d, J = 6.8 Hz, 2 H), 6.48 (d, J = 
9.2 Hz, 2 H), 4.16 (d, J = 13.2 Hz, 1 H), 4.06–4.02 (m, 1 H), 3.71 (s, 3 H), 3.42–3.39 (m, 
2 H), 3.20–3.14 (m, 1 H), 3.03–2.96 (m, 2 H), 2.81 (dt, J = 2.8, 11.2 Hz, 1 H), 2.70–2.66 
(m, 1 H), 2.15–2.08 (m, 1 H), 1.28 (d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 
158.1, 152.9, 139.5, 133.8, 133.3, 131.4, 130.5, 129.0, 128.5, 127.2, 120.6, 113.8, 98.0, 
63.2, 60.2, 57.8, 55.4, 52.2, 41.8, 30.5, 18.8; IR (film) 2953, 2212, 1602 cm–1. MS (ESI) 
412.2370 (412.2389 calcd for C27H29N3O, M + H+). 
Minor (cis) diastereomer (III-142b): orange solid, m.p. 92–98 °C, isolated in 
combination with a 5-10% unidentified minor impurity. 1H NMR (400 MHz, CDCl3) δ 
7.49 (d, J = 8.8 Hz, 2 H), 7.46–7.44 (m, 2 H), 7.39 (t, J = 6.8 Hz, 1 H), 7.35–7.31 (m, 2 
H), 6.91 (d, J = 8.4 Hz, 2 H), 6.84 (d, J = 9.2 Hz, 2 H), 6.72 (d, J = 8.8 Hz, 2 H), 3.76 (s, 
3 H), 3.72–3.55 (m, 2 H), 3.49–3.41 (m, 1 H), 3.36–3.26 (m, 2 H), 3.02–2.97 (m, 1 H), 
2.82–2.74 (m, 1 H), 2.72–2.63 (m, 2 H), 2.56 (dd, J = 3.6, 12.8 Hz, 1 H), 1.04 (d, J = 6.4 
Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 158.2, 153.7, 139.2, 133.8, 131.5, 130.4, 129.2, 
129.0, 128.6, 127.4, 120.5, 114.0, 99.1, 63.3, 59.0, 55.4, 51.4, 44.3, 42.3, 33.2, 9.1; IR 
(film) 2917, 2214, 1604 cm–1. MS (ESI) 412.2379 (412.2389 calcd for C27H29N3O, M + 
H+). Noesy-2D experiments on the minor diastereomer revealed a trans-relationship as 
shown below. 









The reaction of 50 mg (0.144 mmol) of (III-141) with 37 mg (0.173 mmol) of 4-bromo-
tert-butyl-benzene was conducted for 10 h according to the general procedure (Toleune, 
105 °C). The product was formed with 2:1 dr as judged by 1H NMR analysis of a sample 
taken from the crude reaction mixture. Upon purification, 35 mg (51%) of the title 
compound was obtained. The diastereomers were not separable by column 
chromatography greater than a 1.3:1 mixture. Data are for the mixture: 1H NMR (400 
MHz, CDCl3) δ 7.48–6.56 (m, 32 H), 4.25–3.89 (m, 6.9 H), 3.74–3.55 (m, 4.6 H), 3.32–
2.50 (m, 11.5 H), 2.08–1.46 (m, 23 H), 1.31 (s, 9 H), 1.27 (s, 7 H). 
tert-butyl 2-(benzyl(cyclopent-2-enyl)amino)ethylcarbamate (III-151). General 
procedure 3 was used for the coupling of N-Boc glycine (III-26) (1.25 g, 7.16 mmol) 
with N-benzylcyclopent-2-enamine (1.25 g, 7.16 mmol) with the only difference being 
the use of DCC as a 3 M solution (the amount of CH2Cl2 was adjusted appropriately to 
provide a 0.5 M solution). This procedure afforded 1.81 g (77%) of tert-butyl 2-
(benzyl(cyclopent-2-enyl)amino)-2-oxoethylcarbamate (III-150) as a white solid, which 
was contaminated with ca. 15% dicyclohexylurea. This material was carried on without 
further purification. This molecule was isolated as a 1.4:1 mixture of rotamers; data are 
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for the mixture. 1H NMR (500 MHz, CDCl3) δ 7.34–7.31 (m, 1 H), 7.29–7.27 (m, 1 H), 
7.22–7.13 (m, 3 H), 5.98–5.95 (m, 1 H), 5.80–5.74 (m, 0.58 H), 5.65 (s, 0.42 H), 5.54–
5.52 (m, 0.42 H), 5.51–5.49 (m, 1 H), 4.96–4.93 (m, 0.58 H), 4.58–4.50 (m, 1 H), 4.42–
4.38 (m, 1 H), 4.22–4.09 (m, 1 H), 4.02–4.01 (m, 0.5 H), 3.91–3.87 (m, 0.5 H), 3.77–
3.73 (m, 1 H), 2.41–2.22 (m, 3 H), 1.45 (s, (5.2 H), 1.41 (s, 3.8 H). 
The tert-butyl 2-(benzyl(cyclopent-2-enyl)amino)-2-oxoethylcarbamate product (III-150) 
of the DCC coupling reaction (1.81 g, 5.48 mmol) was reduced following general 
procedure 3. This procedure afforded 1.21 g (70%) of the title compound as a colorless 
oil. 1H NMR (400 MHz, CDCl3) δ 7.32–7.26 (m, 4 H), 7.25–7.21 (m, 1 H), 5.90–5.88 
(m, 1 H) 5.71–5.68 (m, 1 H), 4.84 (s, 1 H), 4.06–4.05 (m, 1 H), 3.64 (d, J = 13.6 Hz, 1 
H), 3.44 (d, J = 14 Hz, 1 H), 3.16–3.07 (m, 2 H), 2.60–2.50 (m, 1 H), 2.49–2.44 (m, 1 
H), 2.40–2.22 (m, 2 H), 1.97–1.88 (m, 1 H), 1.74–1.59 (m, 1 H), 1.43 (s, 9 H); 13C NMR 
(100 MHz, CDCl3) δ 156.2, 140.5, 133.7, 131.9, 128.8, 128.4, 127.0, 79.0, 67.3, 55.4, 
49.6, 38.6, 31.8, 28.6, 23.8; IR (film) 3367, 2975, 1715 cm–1. MS (ESI) 317.2220 
(317.2229 calcd for C19H28N2O2, M + H+). 
N1-benzyl-N1-(cyclopent-2-enyl)-N2-phenylethane-1,2-diamine (III-153). General 
procedure 4 was used for the deprotection of tert-butyl 2-(benzyl(cyclopent-2-
enyl)amino)ethylcarbamate (III-151) (1.20 g, 3.79 mmol). This procedure afforded 754 
mg (92%) of N1-benzyl- N1-(cyclopent-2-enyl)ethane-1,2-diamine (III-152) as a yellow 
oil. The crude product was immediately subjected to the subsequent reaction without 
further purification.  1H NMR (400 MHz, CDCl3) δ 7.35–7.28 (m, 4 H), 7.25–7.21 (m, 1 
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H), 5.90–5.87 (m, 1 H) 5.73–5.70 (m, 1 H), 4.08–4.04 (m, 1 H), 3.66 (d, J = 14 Hz, 1 H), 
3.46 (d, J = 14 Hz, 1 H), 2.73–2.61 (m, 2 H), 2.56–2.42 (m, 2 H), 2.41–2.23 (m, 2 H), 
1.97–1.88 (m, 1 H), 1.78–1.69 (m, 1 H), 1.31 (s, 2 H).  
General procedure 4 was used for the N-arylation of N1-benzyl-N1-(cyclopent-2-
enyl)ethane-1,2-diamine (III-152) (754 mg, 3.48 mmol) with bromobenzene (367 μl, 
3.48 mmol). This procedure afforded 507 mg (50%) of the title compound as a yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.34–7.29 (m, 4 H), 7.25–7.21 (m, 1 H), 7.16–7.12 (m, 2 
H), 6.67 (td, J = 1.0, 7.5 Hz, 1 H), 6.54 (dd, J = 1.0, 8.5 Hz, 2 H), 5.91–5.88 (m, 1 H), 
5.73–5.71 (m, 1 H), 4.16 (s, 1 H), 4.11–4.08 (m, 1 H), 3.67 (d, J = 13.5 Hz, 1 H), 3.46 (d, 
J = 13.5 Hz, 1 H), 3.12–3.04 (m, 2 H), 2.78–2.73 (m, 1 H), 2.67–2.63 (m, 1 H), 2.41–
2.33 (m, 1 H), 2.32–2.24 (m, 1 H), 1.98–1.91 (m, 1 H), 1.79–1.72 (m, 1 H); 13C NMR 
(100 MHz, CDCl3) δ 148.8, 140.6, 133.8, 131.9, 129.3, 128.9, 128.5, 127.1, 117.2, 113.1, 
67.3, 55.3, 49.0, 41.8, 31.9, 23.9; IR (film) 3392, 2943, 1602 cm–1. MS (ES) 293.2012 
(293.2018 calcd for C20H24N2, M + H+). 
(4-(1-benzyl-4-phenyloctahydro-1H-cyclopenta[b]pyrazin-5yl)phenyl)(phenyl) 
methanone (III-154). A flame-dried Schlenk tube equipped with a magnetic stirbar was 
cooled under a stream of nitrogen and charged with 6.30 mg Pd2(dba)3 (2 mol % 
complex, 4 mol % Pd, 0.00684 mmol), 12.7 mg P(2-furyl)3 (16 mol %, 0.0547 mmol), 40 
mg sodium tert-butoxide (0.410 mmol, 1.2 equiv), and 114 mg of 4-bromobenzophenone 
(0.410 mmol, 1.2 equiv). The Schlenk tube was purged with nitrogen and 100 mg of N1-
benzyl-N1-(cyclopent-2-enyl)-N2phenylethane-1,2-diamine (III-153) was added as a 
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solution in xylenes (2.5 mL/0.5 mmol substrate). The Schlenk tube was then heated to 
135 °C with stirring until the starting material has been consumed as judged by 1H NMR 
analysis of an aliquot taken from the reaction mixture. The reaction mixture was then 
cooled to room temperature, saturated aqueous ammonium chloride (2–3 mL) was added, 
and the resulting mixture was extracted with ethyl acetate (3 x 8 mL). The combined 
organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in 
vacuo. The crude product was then purified by flash chromatography on silica gel 
afforded 104 mg (64%) of the title compound as a solid, m.p. 147–150 °C. 1H NMR (400 
MHz, CDCl3) δ 7.93 (d, J = 7.2 Hz, 1 H), 7.85 (d, J = 8.0 Hz, 1 H), 7.81–7.76 (m, 2 H), 
7.72 (m, J = 7.6 Hz, 1 H), 7.62–7.43 (m, 5 H), 7.39–7.28 (m, 5 H), 7.17 (t, J = 7.6 Hz, 1 
H), 6.68 (t, J = 7.2 Hz, 1 H), 6.62 (d, J = 8.4 Hz, 2 H), 4.59–4.56 (m, 1 H), 4.27 (d, J = 
13.6 Hz, 1 H), 3.86–3.80 (m, 1 H), 2.92 (d, J = 13.6 Hz, 2 H), 2.86 (t, J = 5.2 Hz, 1 H), 
2.76 (d, J = 11.6 Hz, 1 H), 2.47–2.32 (m, 3 H), 2.30–2.17 (m, 2 H), 2.03–1.96 (m, 2 H); 
13C NMR (100 MHz, CDCl3) δ 196.9, 149.0, 148.4, 139.1, 138.2, 135.3, 132.3, 130.9, 
130.2, 129.32, 129.27, 129.0, 128.6, 128.3, 127.2, 116.9, 112.8, 64.6, 61.8, 59.2, 51.2, 
44.8, 43.5, 29.7, 28.8; IR (film) 3027, 2945, 1652, 1598 cm–1. MS (ESI) 473.2591 
(473.2593 calcd for C33H32N2O, M + H+). 
4-(1-benzyl-4-phenyloctahydro-1H-cyclopenta[b]pyrazin-5-yl)benzonitrile (III-155). 
A flame-dried Schlenk tube equipped with a magnetic stirbar was cooled under a stream 
of nitrogen and charged with 6.30 mg Pd2(dba)3 (2 mol % complex, 4 mol % Pd, 0.00684 
mmol), 12.7 mg P(2-furyl)3 (16 mol %, 0.0547 mmol), 40 mg sodium tert-butoxide 
(0.410 mmol, 1.2 equiv), and 75 mg of 4-bromobenzonitrile (0.410 mmol, 1.2 equiv). 
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The Schlenk tube was purged with nitrogen and 100 mg of N1-benzyl-N1-(cyclopent-2-
enyl)- -N2-phenylethane-1,2-diamine (III-153) was added as a solution in xylenes (2.5 
mL/0.5 mmol substrate). The Schlenk tube was then heated to 135 °C with stirring until 
the starting material has been consumed as judged by 1H NMR analysis of an aliquot 
taken from the reaction mixture. The reaction mixture was then cooled to room 
temperature, saturated aqueous ammonium chloride (2–3 mL) was added, and the 
resulting mixture was extracted with ethyl acetate (3 x 8 mL). The combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The 
crude product was then purified by flash chromatography on silica gel afforded 68 mg 
(51%) of the title compound as a solid, m.p. 145–149 °C. 1H NMR (400 MHz, CDCl3) δ 
7.40–7.30 (m, 9 H), 7.20–7.16 (m, 2 H), 6.70 (t, J = 7.6 Hz, 1 H), 6.59 (d, J = 8.0 Hz, 2 
H), 4.57–4.53 (m, 1 H), 4.25 (d, J = 13.6 Hz, 1 H), 3.82–3.76 (m, 1 H), 2.92 (d, J = 14 
Hz, 1H), 2.89–2.88 (m, 1 H), 2.85 (t, J = 5.2 Hz, 1 H), 2.78–2.74 (m, 1 H), 2.41–2.31 
(m, 2 H), 2.27–2.13 (m, 2 H), 2.03–1.92 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 149.0, 
148.7, 138.8, 131.7, 130.7, 129.4, 129.0, 128.6, 127.3, 119.5, 117.1, 112.7, 109.6, 64.6, 
61.7, 59.2, 51.1, 44.9, 43.4, 29.7, 28.7; IR (film) 3060, 2947, 2225, 1597 cm–1. MS (ESI) 
394.2272 (394.2283 calcd for C27H27N3, M + H+). 
N1-allylbenzene-1,2-diamine (III-157). The synthesis of the title compound was 
achieved on a 30.0 g scale according to the published procedure which afforded 11.0 g of 
a purple oil (54%).46 1H NMR (500 MHz, CDCl3) δ 6.82 (td, J = 1.5, 7.5 Hz, 1 H), 6.74–
6.66 (m, 3 H), 6.06–5.99 (m, 1 H), 5.33–5.29 (m, 1 H), 5.20–5.17 (m, 1 H), 3.78 (d, 2 
H), 3.46 (s, 1 H), 3.34 (s, 2 H). 
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General Procedure 5: N-arylation reactions to afford N-allyl phenylenediamines 
substrates (Scheme 36) 
A flame-dried Schlenk tube equipped with a magnetic stirbar was charged with 
Pd2(dba)3 (1 mol % complex, 2 mol % Pd), Pt-Bu2(o-biphenyl) (2 mol %), sodium tert-
butoxide (1.2 equiv), the appropriate aryl bromide (1.0 equiv), and a 0.5 M solution of the 
primary amine (1.0 equiv) in toluene. The reaction mixture was heated to 80 °C with 
stirring until the starting material had been consumed as judged by TLC analysis (ca. 6 
h). The mixture was cooled to rt and a solution of aqueous ammonium chloride was 
added (4 mL). The resulting mixture was extracted with ethyl acetate and the combined 
organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in 
vacuo. The crude product was purified by flash chromatography on silica gel. 
N1-allyl-N2-phenylbenzene-1,2-diamine (III-158). General procedure 5 was used for the 
N-arylation of N1-allylbenzene-1,2-diamine (III-157) (300 mg, 2.02 mmol) with 318 mg 
of bromobenzene (232 μl, 2.20 mmol, 1.09 eq). This procedure afforded 313 mg (69%) 
of the title compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.23–7.19 (m, 2 H), 
7.14–7.09 (m, 2 H), 6.82 (t, J = 7.2 Hz, 1 H), 6.74–6.69 (m, 4 H), 5.96–5.90 (m, 1 H), 
5.26–5.21 (m, 1 H), 5.16– 5.12 (m, 1 H), 5.09 (s, 1 H), 4.33 (s, 1 H), 3.81–3.78 (m, 2 H); 
13C NMR (100 MHz, CDCl3) δ 146.0, 144.1, 135.6, 129.5, 128.3, 126.4, 125.2, 119.4, 
117.5, 116.2, 115.4, 111.5, 46.4; IR (film) 3370, 3045, 1598 cm–1. MS (ESI) 225.1383 
(225.1392 calcd for  C15H16N2, M + H+). 
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4-(2-(allylamino)phenylamino)benzonitrile (III-159). General procedure 5 was used 
for the N-arylation of N1-allylbenzene-1,2-diamine (III-157) (300 mg, 2.02 mmol) with 
368 mg of 4-bromobenzonitrile (2.02 mmol). This procedure afforded 362 mg (72%) of 
the title compound as a orange oil. 1H NMR (300 MHz, CDCl3) δ 7.44 (d, J = 8.4 Hz, 2 
H), 7.19 (t, J = 8.4 Hz, 1 H), 7.10 (d, J = 7.2 Hz, 1 H), 6.74 (d, J = 7.5 Hz, 2 H), 6.66 (d, 
J = 9 Hz, 2 H), 5.96–5.84 (m, 1 H), 5.50 (s, 1 H), 5.26–5.15 (m, 2 H), 4.18 (s, 1 H), 3.78 
(t, J = 12 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ 150.0, 144.7, 135.2, 133.9, 128.3, 
127.1, 125.0, 120.3, 117.6, 116.5, 114.3, 111.9, 100.9, 46.2; IR (film) 3338, 1609 cm–1. 
MS (ESI) 250.1335 (250.1344 calcd for  C16H15N3, M + H+). 
N1-allyl-N2-(4-methoxyphenyl)benzene-1,2-diamine (III-160). General procedure 5 
was used for the N-arylation of N1-allylbenzene-1,2-diamine (III-157) (300 mg, 2.02 
mmol) with 378 mg of 4-bromoanisole (254 μl, 2.02 mmol). This procedure afforded 387 
mg (75%) of the title compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.07 (d, J 
= 7.6 Hz, 2 H), 6.86–6.82 (m, 2 H), 6.80–6.71 (m, 4 H), 6.03–5.93 (m, 1 H), 5.31–5.26 
(m, 1 H), 5.20–5.17 (m, 1 H), 4.95 (s, 1 H), 4.26 (s, 1 H), 3.82 (dd, J = 4.8 Hz, 2 H), 3.80 
(s, 3 H); 13C NMR (100 MHz, CDCl3) δ 153.8, 142.8, 139.0, 135.6, 130.4, 125.0, 122.8, 
118.0, 117.7, 116.2, 114.9, 111.6, 55.8, 46.5; IR (film) 3367, 1508 cm–1. MS (ESI) 
255.1487 (255.1497 calcd for C16H18N2O, M + H+). 
General Procedure 6: Synthesis of Benzopiperazines via Coupling with Aryl 
Bromides (Table 15). A flame-dried Schlenk tube equipped with a magnetic stirbar was 
cooled under a stream of nitrogen and charged with Pd2(dba)3 (1 mol % complex, 2 mol 
% Pd), BINAP (2 mol %), sodium tert-butoxide (1.2 equiv), and the aryl bromide (1.0 
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equiv) unless otherwise noted. The Schlenk tube was purged with nitrogen and the amine 
was added as a solution in toluene (2.5 mL/0.5 mmol substrate). The Schlenk tube was 
then heated to 105 °C with stirring until the starting material has been consumed as 
judged by 1H NMR analysis of an aliquot taken from the reaction mixture. The reaction 
mixture was then cooled to room temperature, saturated aqueous ammonium chloride (2–
3 mL) was added, and the resulting mixture was extracted with ethyl acetate (3 x 8 mL). 
The combined organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude product was then purified by flash chromatography on 
silica gel.  
2-((1-benzyl-1H-indol-5-yl)methyl)-1-phenyl-1,2,3,4-tetrahydroquinoxaline (III-
161). General procedure 6 was used for the coupling of 77 mg (0.344 mmol) of N1-allyl-
N2-phenylbenzene-1,2-diamine (III-158) with 98.3 mg (0.344 mmol) of 1-benzyl-5-
bromo-1H-indole was conducted for 10 h according to the general procedure. Upon 
purification, 70 mg (62%) of the title compound was obtained as an orange solid, m.p. 
60–65 °C. 1H NMR (500 MHz, CDCl3) δ 7.50 (s, 1 H), 7.30–7.23 (m, 3 H), 7.19 (d, J = 
8.5 Hz, 1 H), 7.11–7.08 (m, 3 H), 7.06–7.01 (m, 4 H), 6.95–6.86 (m, 2 H), 6.78–6.72 (m, 
1 H), 6.48 (d, J = 3 Hz, 1 H), 5.30 (s, 2 H), 4.06–4.00 (m, 1 H), 3.32–3.26 (m, 2 H), 
3.11–3.07 (m, 1 H), 2.97–2.93 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 149.2, 137.8, 
135.5, 135.4, 130.6, 129.7, 129.3, 129.2, 128.9, 128.6, 127.7, 126.9, 123.7, 122.8, 122.1, 
121.6, 120.9, 120.2, 118.2, 115.2, 109.8, 101.5, 60.4, 50.3, 41.8, 38.0; IR (film) 3408, 
2916, 1589 cm–1. MS (ESI) 430.2279 (430.2283 calcd for C30H27N3, M + H+). 
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2-(4-methoxybenzyl)-1-phenyl-1,2,3,4-tetrahydroquinoxaline (III-162). General 
procedure 6 was used for the coupling of 77 mg (0.344 mmol) of N1-allyl-N2-
phenylbenzene-1,2-diamine (III-158) with 64.3 mg (44 μL, 0.344 mmol) of 4-
bromoanisole was conducted for 10 h according to the general procedure. Upon 
purification, 70 mg (62%) of the title compound was obtained as an orange oil. 1H NMR 
(300 MHz, CDCl3) δ 7.23–7.12 (m, 4 H), 6.94–6.90 (m, 4 H), 6.87–6.76 (m, 3 H), 6.69–
6.60 (m, 2 H), 3.92–3.87 (m, 2 H), 3.80 (s, 3 H), 3.28–3.15 (m, 2 H), 2.95–2.88 (m, 1 H), 
2.78–2.71 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 158.3, 149.5, 135.6, 131.7, 130.6, 
129.4, 129.3, 122.7, 122.2, 121.2, 120.8, 118.3, 115.2, 114.0, 60.2, 55.4, 42.0, 37.1; IR 
(film) 3407, 2954, 1589 cm–1. MS (ESI) 331.1795 (331.1810 calcd for C22H22N2O, M + 
H+). 
2-(4-methoxybenzyl)-1-(4-methoxyphenyl)-1,2,3,4-tetrahydroquinoxaline (III-164). 
General procedure 6 was used for the coupling of 82 mg (0.322 mmol) of N1-allyl-N2-(4-
methoxyphenyl)benzene-1,2-diamine (III-160) with 60.2 mg (41 μL, 0.322 mmol) of 4-
bromoanisole was conducted for 10 h according to the general procedure. Upon 
purification, 60 mg (52%) of the title compound was obtained as an orange oil. 1H NMR 
(300 MHz, CDCl3) δ 7.10 (d, J = 9 Hz, 3 H), 6.94–6.92 (m, 2 H), 6.84–6.75 (m, 4 H), 
6.71–6.57 (m, 3 H), 3.84–3.73 (m, 8 H), 3.20 (qd, J = 3.5, 11 Hz, 2 H), 2.93– 2.89 (m, 1 
H), 2.77–2.73 (m, 1 H); 13C NMR (75 MHz, CDCl3) δ 158.3, 156.1, 142.2, 134.9, 132.0, 
131.7, 130.6, 126.5, 119.7, 118.8, 118.5, 115.0, 114.8, 114.0, 61.3, 55.7, 55.5, 41.9, 37.4; 
IR (film) 3394, 2952, 1507 cm–1. MS (ESI) 361.1914 (361.1916 calcd for  C23H24N2O2, 
M + H+). 
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4-(2-benzyl-3,4-dihydroquinoxalin-1(2H)-yl)benzonitrile (III-163). General procedure 
6 was used for the coupling of 150 mg (0.602 mmol) of 4-(2-
(allylamino)phenylamino)benzonitrile (III-159) with 104 mg (70 μL, 0.662 mmol, 1.10 
eq) of bromobenzene was conducted for 10 h according to the general procedure. Upon 
purification, 125 mg (64%) of the title compound was obtained as an orange solid, m.p. 
55–60 °C. 1H NMR (500 MHz, CDCl3) δ 7.35–7.30 (m, 4 H), 7.27–7.24 (m, 2 H), 7.22–
7.20 (m, 2 H), 7.08–7.06 (m, 1 H), 6.94–6.91 (m, 1 H), 6.78–6.75 (m, 2 H), 6.72–6.67 
(m, 1 H), 4.07 (s, 1 H), 4.05–4.01 (m, 1 H), 3.36–3.28 (m, 2 H), 2.96–2.91 (m, 1 H), 
2.79–2.75 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 152.2, 139.1, 136.5, 133.3, 129.5, 
128.8, 126.8, 125.1, 124.0, 122.7, 119.9, 119.3, 118.0, 115.5, 102.3, 58.3, 43.4, 37.3; IR 
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Intramolecular Pd-Catalyzed Carboetherification and Carboamination Reactions 
for the Synthesis of Tetrahydrofurans and Pyrrolidines  
Chapter IV 
Intramolecular Pd-Catalyzed Carboetherification and Carboamination Reactions  
Introduction1 
 For the past several years, our research group has explored the synthesis of 
tetrahydrofurans and pyrrolidines via Pd-catalyzed carboetherification and 
carboamination reactions of γ-unsaturated alcohols and amines with aryl and alkenyl 
halides (eq 34).2 We felt that an interesting extension of this chemistry would involve 
alcohol and amine substrates bearing tethered aryl bromides (eq 35). We reasoned that 
this transformation could potentially be employed for the stereoselective construction of 
heterocycles bearing attached carbocyclic rings (IV-5), and would lead to the formation 































While the transformation in eq 35 is conceptually simple, there are several 
challenges associated with its execution. Transformations involving the intermolecular 
carboetherification reactions of internal olefins are currently limited to substrates bearing 
tertiary alcohol nucleophiles. Intermolecular carboamination reactions of N-aryl γ-amino 
internal olefins provided complex mixtures of products when acyclic internal alkenes 
were employed as substrates.4 In addition, the intramolecular reactions,5 if 
mechanistically analogous to the intermolecular reactions (eq 34), would involve a syn-
alkene insertion of an 11-membered palladacyclic intermediate.  
As shown in Scheme 37, oxidative addition of IV-6 to Pd(0) followed by 
deprotonation and Pd–heteroatom bond formation affords IV-8. Syn-oxy- or amino-
palladation followed by reductive elimination could then afford a product resulting from 



































As shown in eq 36, only one previous report has described transformations that 
presumably involve macrocyclic palladacycles6 bearing both Pd–C and Pd–heteroatom 
bonds,7 and transannular syn-alkene insertions of macrocyclic palladacycles bearing 































Product formation could also potentially occur through other mechanistic 
pathways that have not been previously observed to predominate in 
carboamination/carboetherification processes involving alkenes and aryl bromides.8 For 
example, oxidative addition of IV-6 to Pd(0) followed by a Wacker-type anti-
oxypalladation would provide IV-17, which could undergo reductive elimination to 
afford IV-18. Although a priori we could not predict which pathway would predominate, 
both pathways seemed potentially viable, and we felt it might be possible to influence the 
mechanistic and stereochemical course of the reactions by varying catalyst structure.9,10 
 





































Background: Natural Products Containing Heterocycles Bearing Attached 
Carbocycles 
Several interesting natural products contain heterocycles with attached 
carbocycles. The synthesis of these types of structures is challenging and common 
strategies employ methods by which the stereocenters are generated prior to ring 
closure.11 To illustrate this point, several previously reported approaches to the synthesis 
of the molecule testudinariol are outlined below. Testudinariol (IV-19)12 is an 
ichthyotoxic mollusk defensive allomone, and daphniglaucin C (IV-20)13 inhibits the 
polymerization of tubulin and is cytotoxic against lymphoma.  
 
Figure 6. Natural Products containing Heterocycles with Attached Carbocycles 
 
The synthesis of (+)-testudinariol has been undertaken by several groups. Mori14 
reported the synthesis of (+)-testudinariol from (R)-glycidol which was converted to 
aldehyde IV-22 in 5 steps. Horner Wadsworth Emmons olefination of IV-22, followed by 
deprotection provided trisubstituted olefin IV-24. The tetrahydropyran ring was formed 
using an intramolecular Michael addition under thermodynamic conditions to afford IV-
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25 along with its three other diastereomers (5:5:2:2 ratio) epimeric at C5 and C6. 
Separation of the desired diastereomer was possible and the undesired isomers were 
resubjected to the equilibriating reaction conditions to afford an overall yield of 68% of 
the desired isomer. Reduction of the ester at C5 with DIBAL-H provides aldehyde IV-26, 
which undergoes a Lewis-acid mediated ene reaction15 in the presence of Me2AlCl to 
form the carbocyclic ring in IV-27. The molecule is further elaborated to the natural 
product in several steps. 
  
Scheme 39. Synthesis of (+)-Testudinariol A (IV-20) (Mori) 














THF, -10 to -4 °C
5:5:2:2 mixture of diastereomers


































Montgomery prepared (+)-testudinariol using a Ni-catalyzed allenyl aldehyde 
cyclization to form the carbocyclic ring (IV-29) as shown below. The precursor IV-28 
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was prepared using an asymmetric aldol reaction. Deprotection, iodination and protection 
of the alcohol provided compound IV-30, which is used in the key coupling in Scheme 
41.  
 
Scheme 40. Synthesis of (+)-Testudinariol A Part I (Montgomery) 
 
 
As shown in Scheme 41, bis(vinyl) silane is treated with s-BuLi to effect a metal-
halogen exchange followed by treatment with alkyl iodide IV-30 to afford the advanced 
intermediate IV-32. The final two steps involved a double oxycarbenium ion/vinyl silane 
cyclization (IV-33 to IV-35) to form the tetrahydropyran ring followed by deprotection to 










































Background: Intramolecular Wacker-Type Carbopalladation Reactions 
Balme has described elegant studies on related intramolecular reactions of alkenes 
with malonate nucleophiles (eq 37 and eq 38).16 These reactions proceed via oxidative 
addition of aryl bromides IV-36 and IV-38 to Pd(0) to generate IV-40a and IV-40b 
(Scheme 42). This intermediate then undergoes deprotonation followed by anti-addition 
of the malonate nucleophile and the organopalladium fragment across the alkene to 
provide IV-41 or IV-42. Reductive elimination then generates the observed products IV-
37 or IV-39. The nature of the nucleophile is significant, and when Z= CO2Et, five-
membered ring formation occurs by attack through Path A. However, with Z = CN, six-
membered ring formation is favored through Path B. The difference in regioselectivity 
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and its dependence on the nature of the nucleophile is not entirely clear, but the authors 
suggest that severe steric interactions between a bulkier nucleophile and the allylic 
hydrogens could account for preference to undergo the 6-endo mode of cyclization as 












Scheme 42. Intramolecular Wacker-Type Carbopalladation Reactions 
 
Development of Intramolecular Pd-Catalyzed Carboetherification and 
Carboamination Reactions 
Our goals for the intramolecular Pd-catalyzed carboetherification and 
carboamination were to establish the feasibility of transforming unsaturated alcohols and 
amines bearing tethered aryl halides to 2-indan-1-yl tetrahydrofurans and pyrrolidines (eq 
35). While we were concerned that the desired reaction would be outcompeted by various 
side reactions due to the more challenging internal olefin substrates, we felt that due to 
the intramolecular nature of the reaction as well as through proper catalyst optimization, 
we would be able to favor the desired transformation.  Additionally, we hoped that 
through judicious choice of catalyst, we would be able to facilitate formation of either the 




In our initial experiments we sought to examine the reactivity of several different 
types of substrates. For a complete study, we would need to selectively generate both E- 
and Z-alkene geometries (IV-47 and IV-46) of substrates bearing both oxygen and 
nitrogen nucleophiles. In addition, we felt it would be essential to prepare substrates that 
were substituted α to the heteroatom in order to examine the diastereoselectivity of the 
reaction. Aldehyde IV-44, which served as common precursor to all substrates in this 
study was prepared via Heck reaction of allyl alcohol with 1-bromo-2-iodobenzene (IV-
43) using Jeffrey conditions.17 This intermediate was converted to the Z-olefin (IV-46) by 
Wittig olefination using the ylide formed from deprotonation of 4-ethoxy-4-oxobutyl 
triphenylphosphonium bromide (IV-45). Alternatively, E-olefin IV-47 was obtained by 
vinylmagnesium bromide addition into aldehyde IV-44 followed by Johnson ortho ester 










Scheme 43. Substrate Synthesis for Intramolecular Carboetherification and 
Carboamination Reactions-Synthesis of Key Intermediates IV-46 and IV-47 
 
 
E and Z alkenes IV-46 and IV-47 were then transformed through functional group 
interconversions to the substrates needed for the study. Lithium aluminum hydride 
reduction of IV-47 provides primary alcohol IV-48. Oxidation followed by addition of 
phenylmagnesium bromide provides the secondary alcohol IV-49. Methylmagnesium 














Deprotonation of aniline followed by addition of ester IV-47 provided amide IV-
51, which was reduced with lithium aluminum hydride to secondary amine IV-52 
(Scheme 45). The α-substituted secondary amine IV-55 was formed via the reaction of 
methoxymethylamine hydrochloride with trimethylaluminum followed by addition of the 
ester IV-47. The Weinreb amide IV-53 was then treated with phenylmagnesium bromide 
to afford the desired substrate IV-54. The alcohol and amine substrates bearing Z-alkenes 
were prepared from ester IV-46 using an analogous series of transformations (Schemes 

























Intramolecular Carboetherification Reactions 
In our initial experiments we elected to explore the intramolecular 
carboetherification of Z-alkene IV-56 bearing a tethered primary alcohol group. We felt 
that the Z-alkene geometry of IV-56 combined with the high nucleophilicity of the 
unhindered alkoxide (generated in situ upon reaction with NaOtBu) would help to 
facilitate formation of the putative 11-membered palladium-(aryl)(alkoxide) complex 
required for syn-alkoxypalladation as described above in Scheme 37. Our previous 
studies of Pd-catalyzed intermolecular carboetherification reactions demonstrated that the 
choice of phosphine ligand had a large impact on the chemical yield of the desired 
tetrahydrofuran products. Thus, our optimization studies focused on variation of this 




As shown in Table 16, we were gratified to find that Pd-catalyzed reactions of IV-
56 proceeded to generate the desired 2-(1-indanyl)tetrahydrofuran as a mixture of two 
diastereomers (IV-64 and IV-65) in moderate to good yield with stereoselectivities 
dependent on catalyst structure. Use of a catalyst composed of Pd2(dba)3 and P(o-tol)3 
that provided optimal results in intermolecular carboetherification reactions of acyclic 
internal alkenes2b afforded IV-64 as the major diastereomer (entry 3), which derives from 
syn-addition of the arene and the alkoxide across the C–C double bond. The main side 
products observed in this reaction resulted from debromination of the starting material20  
or intramolecular Heck arylation of the alkene (Scheme 48). After some experimentation, 
a mixture of Pd2(dba)3 and P[(4-MeO)C6H4]3 was found to provide product IV-64 in 54% 
isolated yield with 8:1 diastereoselectivity (entry 1). Use of this catalyst system 
diminished the competing Heck arylation, although competing debromination of the 
substrate was still problematic.  
A complete shift in the stereochemical outcome of this reaction was observed 
when (±)-BINAP was employed as the ligand (entry 8). Under these conditions, the 
(1S*,2R*)-diastereomer (IV-65) was formed as the major product. This substance derives 
from anti-addition of the arene and the alcohol across the double bond, and was obtained 
in 60% yield and 18:1 dr. Other chelating phosphine ligands with small bite angles such 







Table 16. Optimization of Carboetherification Reaction of IV-56a,b 
 
aConditions: 1.0 equiv of IV-56, 2.0 equiv of NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand 
(monophosphines) or 2 mol % ligand (bisphosphines), toluene (0.1 M), 105 °C, 3-8 h. 











Scheme 48. Products of Pd-Catalyzed Carboetherification of IV-56 
 
 
The connectivity of IV-64 and IV-65 was determined through 2D COSY and 
HSQC NMR experiments. The stereochemistry of IV-64 and IV-65 was established by 
X-ray crystallographic analysis of related derivative IV-75. This product was prepared as 
shown in Scheme 49. Iodination of 4-bromonitrobenzene (IV-68) provides iodo arene 
IV-69. The nitro functionality in IV-69 was reduced with tin granules in acetic acid to 
provide IV-70. Transamination of IV-70 with benzophenone imine afforded protected 
amine IV-71. Heck reaction of IV-71 under Jeffrey phosphine-free conditions provided 
aldehyde IV-72 which was olefinated with the ylide generated from (4-
acetoxybutyl)triphenylphosphonium bromide and KOtBu. Deprotection of the acylated 
alcohol provided alcohol IV-73. Intramolecular carboetherification of IV-73 using 
catalytic Pd2(dba)3/BINAP afforded IV-74 in modest yield with good diastereoselectivity. 
However, compound IV-74 was not found to be a solid. Cleavage of the benzophenone 
imine functionality followed by N-arylation of the primary amine with 4-bromobiphenyl 
afforded the solid biphenyl derivative IV-75. X-ray crystal structure analysis of this 
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product (X-ray showed both enantiomers in the unit cell) revealed the cyclization 
occurred with anti-addition across the Z-alkene.  
 


























Pd2(dba)3 (1 mol %)




































As expected, use of P[(p-MeO)C6H4)]3 as ligand provided the opposite 
diastereomer (IV-76) in 44% yield and 8:1 dr (eq 39). Connectivity of IV-76 was 
confirmed by 2D COSY and HSQC NMR experiments. With optimized reaction 
176 
 
conditions in hand, we examined the intramolecular carboetherification of several 
different alcohol substrates with varying alkene geometries and varied degrees of alcohol 
substitution. As shown in Scheme 50, the transformations of substrates bearing primary 
alcohols were found to be stereospecific, and either diastereomer could be selectively 
obtained from either the E- or Z-alkene starting material (IV-56 or IV-48) with the 
appropriate choice of catalyst. For example, the (1S*,2R*)-2-indan-1-yl tetrahydrofuran 
IV-65 was generated in 51% yield and >20:1 dr via the Pd/PCy3-catalyzed syn-addition 
reaction of E-alkene substrate IV-4821 and was obtained in 60% yield and 18:1 dr via the 
Pd/(±)-BINAP-catalyzed anti-addition of Z-alkene substrate IV-56. Similarly, the 
(1S*,2S*)-isomer IV-64 was produced in 56% yield (15:1 dr) from IV-48 with DPP-













Scheme 50. Intramolecular Carboetherification of IV-56 and IV-48a, b 
NaOtBu, toluene, 105 oC
(anti-addition)
Pd2(dba)3, BINAP
NaOtBu, toluene, 105 oC
(anti-addition)
Pd2(dba)3, P(4-MeOC6H4)3


























aConditions: 1.0 equiv of IV-56 or IV-48, 2.0 equiv of NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand 
(monophosphines) or 2 mol % ligand (bisphosphines), toluene (0.1 M), 105 °C, 3-8 h. 
bDiastereoselectivities were determined by GC and/or 1H NMR analysis of crude reaction mixtures. 
 
Additional data on ligand effects in the carboetherification of IV-48 are shown 
below (Table 17). While the cyclization of IV-48 proceeded under optimal conditions to 
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provide the anti-diastereomer with DPP-benzene, use of BINAP as ligand also selectively 
afforded the anti-diastereomer IV-64 but with 3:1 dr and in 35% yield. 
 
Table 17. Carboetherification Ligand Screen of IV-48a,b   
Pd2(dba)3, Ligand,




























aConditions: 1.0 equiv of IV-48, 2.0 equiv of NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand 
(monophosphines) or 2 mol % ligand (bisphosphines), toluene (0.1 M), 105 °C, 3-8 h. 
bDiastereoselectivities were determined by GC and/or 1H NMR analysis of crude reaction mixtures. 
 
Substrates IV-50 and IV-58 bearing tethered tertiary alcohols were also 
selectively converted to products of either syn- or anti-addition depending on catalyst 
structure (Scheme 51). However, in contrast to reactions of Z-alkene primary alcohol IV-
56, which afforded syn-addition product IV-64 with most catalyst systems, 
transformations of the analogous tertiary alcohol bearing a Z-alkene (IV-58) gave anti-
addition product IV-77 under most conditions examined (Table 18). After some 
experimentation, the Pd/PMe3·HBF4-catalyzed reaction of IV-58 was found to provide 
IV-78,21 the product of syn-addition across the Z-alkene, in 74% yield with 9:1 dr. Use of 
the ligand PCy3·HBF4 for the Pd-catalyzed cyclization of IV-58 afforded anti-addition 
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product IV-77 in 78% yield and 14:1 dr.  Although both diastereomers IV-77 and IV-78 
could be selectively obtained from either starting material (IV-50 or IV-58), higher yields 
were obtained with the Z-alkene substrate IV-58. 
 
Scheme 51. Intramolecular Carboetherification of IV-50 and IV-58a,b 
Br
Pd2(dba)3, P(Me)3 HBF4
NaOtBu, toluene, 105 oC
Pd2(dba)3, P(Cy)3 HBF4










NaOtBu, toluene, 105 oC
(anti-addition)
Pd2(dba)3, P(4-MeOC6H4)3
















aConditions: 1.0 equiv of IV-50 or IV-58, 2.0 equiv of NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand 
(monophosphines) or 2 mol % ligand (bisphosphines), toluene (0.1 M), 105 °C, 3-8 h. 
bDiastereoselectivities were determined by GC and/or 1H NMR analysis of crude reaction mixtures. 
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Additional data on ligand effects in the cyclization of Z-tertiary alcohol IV-76 are 
provided below (Table 18). As noted above, all ligands except PMe3·HBF4 selectively 
provided the anti-addition product. The Pd2(dba)3/BINAP catalyst system also provided 
the anti-addition product as the major diastereomer, albeit in low yield (24%). Additional 
data on ligand effects in the cyclization of E-tertiary alcohol IV-50 are also provided 
below in Table 19. 
 
Table 18. Carboetherification Ligand Screen of IV-58a,b     
P(Cy)3·HBF4








































aConditions: 1.0 equiv of IV-58, 2.0 equiv of NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand 
(monophosphines) or 2 mol % ligand (bisphosphines), toluene (0.1 M), 105 °C, 3-8 h. 










































aConditions: 1.0 equiv of IV-50, 2.0 equiv of NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand 
(monophosphines) or 2 mol % ligand (bisphosphines), toluene (0.1 M), 105 °C, 3-8 h. 
bDiastereoselectivities were determined by GC and/or 1H NMR analysis of crude reaction mixtures. 
 
In order to definitively establish the stereochemistry of tetrahydrofuran products 
IV-77 and IV-78, X-ray crystal structure analysis of the crystalline derivative (IV-81) 
shown in eq 52 was performed. The E- and Z-tertiary alcohol substrates were prepared 
via addition of p-biphenylmagnesium bromide to esters IV-46 and IV-47 as shown in eq 



























The reaction of tertiary alcohol IV-79 to provide tetrahydrofuran IV-81 proceeds 
with Pd/PMe3·HBF4 as the catalyst to provide the product resulting from syn-addition 
across the Z-olefin. Carboetherification of tertiary alcohol IV-80 using P[(4-MeO)C6H4)]3 
as the ligand provides the product of syn-addition across the E-olefin (IV-82). The 
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Pd2(dba)3 (1 mol %)
P[(4-MeO)C6H4]3 (4 mol %)












To examine the possibility of stereoselectively generating products with three 
stereocenters, the secondary alcohol IV-49 bearing an E-alkene was prepared and 
subjected to the carboetherification reaction conditions. The best results were obtained 
with a catalyst composed of Pd2(dba)3/PCy3·HBF4, which provided a 40% isolated yield 
of IV-83 with 92:5:2:1 selectivity favoring syn-addition across the alkene and trans-
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stereochemistry around the tetrahydrofuran ring (eq 43). The modest yield can be 
attributed to the formation of large amounts of side products that derive from reduction of 
the aryl bromide with concomitant oxidation of the alcohol (eq 43). Use of (±)-BINAP 
for this transformation led to complex mixtures of products; only small amounts of the 
desired tetrahydrofuran derivatives were detected by 1H NMR analysis of crude reaction 
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The cyclization of the corresponding Z-alkene IV-57 proceeded in 40% yield with 
good selectivity (17:2:1:1 dr)22 for syn-addition/trans-THF formation (eq 45); the two 
most prevalent diastereomers both contained trans-tetrahydrofuran rings. As noted above, 







Pd2(dba)3 (1 mol %)
P[(4-MeO)C6H4)]3 (4 mol %)














In contrast to the related Pd/BINAP-catalyzed reaction of the E-alkene substrate 
IV-49, treatment of IV-57 with catalytic Pd2(dba)3/(±)-BINAP provided IV-83 as the 
major diastereomer, which results from anti-addition with trans-THF formation, albeit in 
low yield (25%) (eq 46). High selectivity for anti-addition was observed (94:6), although 
trans/cis-selectivity was modest (ca. 2:1). The major side products in this transformation 
resulted from competing intramolecular Heck arylation of the starting material. A 
summary of the ligand effects for both the E- and Z-secondary alcohols is shown in 
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Ligand Diastereomeric Ratio Isolated Yield Syn/Anti Trans:Cis
PCy3 92: 5: 2: 1 40% 32:1 15:1
P[(4-MeO)C6H4]3 75: 0: 25: 0 25% 4:1 4:0
BINAP 21: 28: 9: 42 --- 1:1 2:1
IV-83:IV-83b:IV-85:IV-85b
# # # #
IV-49
IV-83 IV-83b IV-85 IV-85b
 
aConditions: 1.0 equiv of IV-49, 2.0 equiv of NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand 
(monophosphines) or 2 mol % ligand (bisphosphines), toluene (0.1 M), 105 °C, 3-8 h. 















































Ligand Diastereomeric Ratio Isolated Yield Syn/Anti Trans:Cis
PCy3
75: 6: 12: 7 40% 4:1 7:1P[(4-MeO)C6H4]3
40: 8: 40: 12 23% 1:1 4:1
BINAP 5: 1: 65: 29 24% 1:33 3:1
A: B: C: D
IV-85:IV-85b:IV-83:IV-83b
IV-85 IV-85b IV-83 IV-83b
IV-57
 
aConditions: 1.0 equiv of IV-57, 2.0 equiv of NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand 
(monophosphines) or 2 mol % ligand (bisphosphines), toluene (0.1 M), 105 °C, 3-8 h. 
bDiastereoselectivities were determined by GC and/or 1H NMR analysis of crude reaction mixtures. 
 
The stereochemistry of tetrahydrofuran product IV-83 was established by X-ray 
crystal structure analysis of the crystalline derivative below IV-88 (Scheme 54). The E- 
and Z-secondary alcohol substrates were prepared from alcohol IV-73, which was 
prepared above in Scheme 49. Alcohol IV-73 was converted to aldehyde IV-86 using 
SO3·pyridine, and the resulting aldehyde IV-86 was treated with phenylmagnesium 























Pd-catalyzed carboetherification of IV-87 using catalytic Pd2(dba)3/PCy3·HBF4 
afforded IV-88 in 43% yield with 92:5:2:1 dr. Crystallographic analysis of the major 
diastereomer revealed syn-addition across the olefin. 
 
Scheme 54. Proof of Stereochemistry-Preparation and X-ray Structure of IV-88   
 
 
The stereochemistry for the other three benzhydrylidene[1-(5-
phenyltetrahydrofuran-2-yl)indan-5-yl] stereoisomers was assigned through a 
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combination of 1H NMR nOe experiments and correlation of NMR spectra to those 
obtained for the products from cyclization of primary alcohol derivatives IV-64 and IV-
65. A Table of relevant NMR data for the four benzhydrilidene[1-(5-
phenyltetrahydrofuran-2-yl)indan-5-yl] stereoisomers (IV-83, IV-85, IV-83b, and IV-
85b) is shown below. The chemical shift of HB was downfield in molecules bearing 
trans-thf rings (IV-83 and IV-85) relative to the chemical shift of HB in cis-thf-
containing products IV-83b and IV-85b. The chemical shift of Hc was downfield in 
molecules resulting from anti-addition across the E-alkene (IV-85 and IV-85b) relative to 
molecules that derive from syn-addition across the E-alkene (IV-83 and IV-83b). In 
addition, nOe enhancements were observed between HA and HC in IV-85 (evidence for 
trans-thf stereochemistry). The THF-ring stereochemistry of IV-83b was further 
confirmed by NMR experiments that were conducted on the product mixture obtained by 
the Pd/BINAP-catalyzed cyclization of IV-57. This transformation afforded a ~2:1 
mixture of IV-83 and IV-83b, with small amounts (ca 6% of total mixture) of IV-85 and 
IV-85b also present. The resolution of the relevant signals was sufficient to observe nOe 








Table 22. Assignment of All Benzhydrilidene[1-(5-phenyltetrahydrofuran-2-yl)indan-5-














































δ HA 5.12 5.02 4.96 4.87 
δ HB 4.31 4.37 4.18 4.13 
δ HC 3.40 3.48 3.40 3.48 
 
 
Intramolecular Pd-Catalyzed Carboamination Reactions 
Having demonstrated the feasibility of intramolecular carboetherification 
reactions, we sought to determine whether intramolecular carboamination reactions could 
also be achieved. Thus, the Z-alkene substrate IV-60 bearing a tethered aniline moiety 
was treated with a catalytic amount of Pd2(dba)3 and several different phosphine ligands 
under reaction conditions similar to those described above (Table 23). Interestingly, in 
contrast to the results obtained in cyclizations of alcohol-containing substrates, all 
catalysts examined for the cyclization of IV-60 provided selectivity for formation of the 
(1S*,2S*)-stereoisomer IV-89, which derives from syn-addition across the Z-alkene. 
While the use of BINAP leads to erosion of diastereoselectivity, it does not lead to 
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complete reversal to the opposite diastereomer IV-90. As observed in the related 
transformations of substrates bearing alcohol nucleophiles, the major side products 
formed in these reactions result from debromination of the starting material (IV-92) or 
intramolecular Heck arylation (IV-91a, IV-91b) (Figure 7). Use of PCy3·HBF4 (entry 8) 
provided the optimal results for this transformation (88% yield, >20:1 dr) and effectively 
suppressed the formation of both side products. The stereochemistry in the amine series 
was established by X-ray crystal structure analysis of the analogous N-biphenyl 
derivatives. 
 



















































aConditions: 1.0 equiv of IV-60, 2.0 equiv of NaOtBu, 1 mol % Pd2(dba)3, 4 mol % ligand 
(monophosphines) or 2 mol % ligand (bisphosphines), toluene (0.1 M), 105 °C, 3-8 h. 
bDiastereoselectivities were determined by GC and/or 1H NMR analysis of crude reaction mixt;ures. 
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The intramolecular carboamination reactions also proved to be stereospecific, as 
E-alkene derivative IV-52 underwent cyclization under optimized conditions to afford 
(1S*,2R*)-diastereomer IV-90, the product of syn-addition across the E-alkene, in 71% 
yield with >20:1 dr (eq 47). As observed with the analogous alcohol substrates, the 
chemical yield obtained in the reaction of the E-alkene was slightly lower than the yield 
of the reaction of Z-alkene IV-60. Reaction E-olefin IV-52 with a catalyst system 





Pd2(dba)3 (1 mol %)
P(Cy)3·HBF4 (4 mol %)











The stereochemistry of the carboamination products was determined by X-ray 
crystal structure analysis of the analogous biphenyl derivatives. The substrates were 
prepared via deprotonation of 4-aminobiphenyl with methylmagnesium bromide followed 
by addition of ester IV-46 to provide amide IV-91. Reduction of the amide provides the 
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Z-olefin carboamination substrate IV-92. The analogous procedure was performed using 
E-ester IV-47 to provide the E-olefin carboamination substrate IV-94.  
 













































X-ray crystallographic analysis was performed on the carboamination products 
described above (Scheme 55 and 56) and definitively established syn-addition across the 
Z-olefin to give IV-95 and syn-addition across the E-olefin to provide IV-96. 
 










Scheme 58.  Proof of Stereochemistry-Preparation and X-ray Structure of IV-96 
 
 
We also examined Boc-protected amines23 in the intramolecular carboamination 
reactions. We prepared Boc-protected substrate IV-99 from ester IV-46 in three steps. 
Primary amide IV-97 was prepared via treatment of ester IV-46 with AlMe3/NH4Cl 
followed by lithium aluminum hydride reduction of the resulting amide to provide amine 
IV-98. Protection of amine IV-98 with Boc-anhydride provided the protected substrate 
IV-99.  



























The cyclization reaction of Boc-protected amine substrate IV-99 was conducted 
under two sets of reaction conditions that provide both the syn and anti-addition products 
in the carboetherification reactions: Pd2(dba)3/PCy3·HBF4 and Pd2(dba)3/BINAP. We 
were pleased to see that when BINAP was used as the ligand, the cyclization yields the 
Boc-protected pyrrolidine (anti-addition) in modest yield and good diastereoselectivity 
(9:1 dr), whereas when PCy3 was used as the ligand, the syn-addition product was 
generated in good yield and modest diastereoselectivity (2:1 dr).  
 
Pd2(dba)3 (1 mol %)
BINAP (2 mol %)
31%, 9.7:1 dr (anti:syn)Br
N
H
Pd2(dba)3 (1 mol %)










NaOtBu, toluene, 105 oC
NaOtBu, toluene, 105 oC










Boc-cleavage and N-arylation provided N-aryl pyrrolidines IV-90 and IV-89 
which have already been prepared via intramolecular carboamination of the N-phenyl 
protected substrates IV-52 and IV-60. However, resolution of the diastereomers on the 
column prohibited determination of diastereoselectivity via this method. Therefore, the 
diastereoselectivity was determined via GC analysis of the crude N-H pyrrolidines IV-
102 and IV-103. Interestingly, the diastereoselectivity in the Pd(0)/BINAP-catalyzed 
reaction was good (9:1 dr) and the diastereoselectivity in the Pd(0)/PCy3 reaction was 
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mediocre (2:1). This result greatly contrasts from our results with the N-aryl pyrrolidine 
products, which provide high diastereoselectivity for the syn-addition product. It is likely 














































Reactions involving aniline-bearing substrates that are branched at C-1 proceeded 
with complete syn-selectivity. For example, treatment of E-alkene IV-55 with catalytic 
Pd2(dba)3/PCy3·HBF4 afforded product IV-104 in 55% yield and 5:1 diastereoselectivity 
(eq 52). Interestingly, the major product diastereomer was found to possess 2,5-trans-
disubstitution around the pyrrolidine ring; the minor diastereomer results from syn-
addition with cis-pyrrolidine formation. In contrast, the analogous intermolecular 
carboamination reactions of γ-(N-arylamino)alkenes have been shown to provide 



















Pd2(dba)3 (1 mol %)
P(Cy)3·HBF4 (4 mol %)
 
The stereochemistry was determined by synthesis and X-ray crystal structure analysis of 
the analogous N-biphenyl derivative IV-108. As shown in Scheme 60, this product was 
prepared via intramolecular carboamination of IV-107, which was synthesized via 

















Scheme 60. Preparation of IV-107 and Proof of Stereochemistry-Preparation and X-ray 














Pd2(dba)3 (1 mol %)
















Minor Diastereomer: syn addition
cis-pyrrolidine











 The reaction of Z-alkene IV-63 proceeded in high yield (81%) but modest 
diastereoselectivity (2:1 dr) favoring product IV-100, which results from syn-addition 
across the alkene with cis-stereochemistry around the pyrrolidine ring (Scheme 61). As 
seen in the reaction of IV-55 to IV-104, both observed diastereomers resulting from the 
cyclization of IV-63 derive from syn-addition but differ in their relative stereochemistry 
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about the pyrrolidine ring. Crystallographic analysis of pyrrolidine IV-110 confirmed the 
stereochemistry as shown in eq 61. 
 
Scheme 61. Proof of Stereochemistry-Preparation and X-ray Structure of IV-110 



















X-Ray Structure of Major Diastereomer
IV-63
IV-110 IV-111
Pd2(dba)3 (1 mol %)
P(Cy)3·HBF4 (4 mol %)
 
The stereochemistry for N,5-diphenyl-2-indan-1-ylpyrrolidine stereoisomers IV-
111 and IV-112 was assigned through correlation of NMR spectra to those obtained for 
IV-104 and IV-110. A table of relevant NMR data for IV-104, IV-111, IV-112, and IV-
110 is shown below (Table 24). The chemical shift of HB was downfield in molecules 
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bearing trans-pyrrolidine rings (IV-104 and IV-111) relative to the chemical shift of HB 
in cis-pyrrolidine-containing products IV-112 and IV-110.  
 
Table 24. Assignment of All N,5-diphenyl-2-indan-1-ylpyrrolidine Stereoisomers (IV-













































δ HA 5.17 4.92 4.66 4.60 
δ HB 4.87 4.51 4.39 4.05 
δ HC 4.14 4.19 3.95 3.49 
 
 
Reactivity and Stereoselectivity 
The intramolecular palladium-catalyzed carboetherifications and carboaminations 
of γ-hydroxy- or γ-aminoalkenes with tethered aryl bromides provides a new, 
stereoselective means to generate carbocycles bearing attached heterocycles. These 
reactions effect the conversion of acyclic precursors to bicyclic products with formation 
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of two bonds, two rings, and two stereocenters in a single step. The yields and 
selectivities are dependent on a number of factors, but under optimal conditions the 
desired products are obtained in moderate to good yields with good to excellent 
stereocontrol. Several trends in reactivity have been observed during the course of these 
experiments. From the results described above, it appears that the chemical yield is 
affected by the alkene geometry, the nature of the heteroatom, and the degree of 
substitution adjacent to the heteroatom. For example, substrates bearing Z-alkenes are 
usually transformed in higher chemical yield than the analogous E-alkenes. In addition, 
reactions involving starting materials with tethered aniline nucleophiles produce higher 
yields than analogous reactions of alcohol bearing substrates (with a similar degree of 
substitution). Finally, in many cases substitution next to the heteroatom decreases the 
chemical yield. The stereochemical outcome of these reactions is influenced by both the 
nature of the heteroatom and the catalyst. All substrates containing nitrogen nucleophiles 
that were examined in these studies are selectively converted to products resulting from 
syn-addition across the double bond. Although the catalyst structure has an effect on the 
diastereoselectivity of the pyrrolidine-forming reactions, with diastereomeric ratios 
varying from 1:1 to >20:1, no catalyst examined led to selective formation of the anti-
addition product. In contrast, primary and tertiary alcohol substrates were transformed to 
products of syn-addition when catalysts bearing electron-rich monodentate ligands such 
as PCy3, PMe3, or P[(p-MeO)C6H4]3 were employed, but reactions of these starting 
materials gave products of anti-addition when chelating phosphines with small bite 
angles (e.g., BINAP, DPP-benzene, or DPPE; bite angles < 93°) were used as supporting 
ligands. Notably, in carboetherification reactions of primary and tertiary alcohols either 
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product diastereomer could be obtained selectively from either starting alkene 
stereoisomer. Reactions involving α-substituted alcohols catalyzed by Pd/PCy3 or P[(p-
MeO)C6H4]3 proceed with good to excellent levels of selectivity for the formation of one 
of four possible diastereomeric products; the major diastereomer results from syn-
addition with trans-THF formation. However, use of Pd/BINAP with these substrates 
leads to low yields and modest selectivities. The analogous Pd/PCy3-catalyzed reactions 
of α-branched anilines proceed in good yields with very high syn-selectivity, but give 
mixtures of cis- and trans-pyrrolidine products. 
 
Mechanism of Intramolecular Carboetherification Reactions 
That Provide syn-Addition Products 
In our previous studies on intermolecular Pd-catalyzed carboetherification and 
carboamination reactions, we obtained results that were most consistent with a 
mechanistic pathway involving syn-insertion of the alkene moiety into the Pd-heteroatom 
bond of intermediate Pd(Ar)(OR) or Pd(Ar)(NRR´) complexes (e.g. IV-113, Figure 8).2 
Other mechanistic scenarios such as product formation via a Wacker type anti-addition or 
via intermolecular carbopalladation followed by C–O or C–N bond-forming reductive 
elimination were ruled out on the basis of the observed product stereochemistry, the side 
products formed in the reactions, and the high regioselectivity for formation of five-
membered ring products. The fact that syn-addition products are also obtained in the 
intramolecular reactions suggests that a similar mechanism may operate. However, this 
pathway would necessitate the formation of 11-membered ring intermediates (e.g. IV-
114, Figure 8), which may be entropically unfavorable, and would require transannular 
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alkene insertion of a macrocyclic palladacycle bearing an internal alkene, which is 
unprecedented.24 Thus, two plausible mechanisms for the formation of the observed syn-
addition products of intramolecular reactions merit consideration. 
  











IV-113 IV-114  
 
As shown in Scheme 62, oxidative addition of the aryl bromide IV-115 to the 
LnPd(0) species generated in situ from Pd2(dba)3 and a monodentate phosphine ligand, 
followed by coordination of the tethered alkene, would afford the 16-electron 
intermediate IV-116, a species common to both mechanistic scenarios. This intermediate 
could potentially be converted to the observed products via a Heck-type 5-exo 
carbopalladation24 and deprotonation by NaOtBu to provide IV-117 (Path A), which 
could undergo nucleophilic displacement of the bromide by the tethered alkoxide to 
afford IV-118.25 An unprecedented sp3 carbon–oxygen bond-forming reductive 
elimination from Pd(II) complex IV-118 (with retention of configuration) would generate 
the observed product IV-119.26,27 However, the fact that the cyclizations of secondary 
alcohol substrates IV-49 and IV-57 proceed with good to excellent stereoselectivity for 
trans-tetrahydrofuran formation and syn-addition suggests that this pathway is unlikely. 
If the reactions proceed via the mechanism outlined in Path A, the 5-exo carbopalladation 
event would determine both the syn/anti-stereochemistry as well as the stereochemistry 
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around the THF ring. If the stereochemistry-determining event occurs via intramolecular 
carbopalladation of intermediate IV-116 with no communication between the alcohol and 
the metal, it is unlikely that high selectivity for trans-THF formation would be observed. 
A mechanism involving fast and reversible carbopalladation followed by selective Pd 
heteroatom bond formation of one possible diastereomeric intermediate could also 
account for the high diastereoselectivity. However, reversible carbopalladation reactions 
have only been observed in complexes lacking β-hydrogen atoms; carbopalladation is 
believed to be irreversible in most other systems. The fact that oxidized/reduced side 
products are observed instead of Heck-type side products also suggests this pathway is 
less plausible than Path B.28 In addition, Heck-type side products that would result from 
slow reductive elimination following the 5-exo carbopalladation are not formed in 


























































In contrast, the mechanistic pathway outlined in Scheme 62, Path B, which is 
analogous to that proposed for the intermolecular reactions,2 can account for both high 
syn-selectivity and high selectivity for trans-THF formation. In this scenario, the 16-
electron intermediate IV-116 could undergo deprotonation followed by associative ligand 
substitution29 of the alkoxide for the bromide to afford 11-membered palladacycle IV-
120 in which the alkyl group is oriented in the pseudoequatorial position. The vast 
majority of ligand substitutions at 16-electron Pd(II) complexes proceed via an 
associative mechanism. The very rare examples of dissociative ligand substitution at 16-
electron Pd(II) complexes involve the extremely bulky, monodentate, and unusually 
labile ligands tris(2,4,6-trifluoromethylphenyl)phosphine and P(o-tol)3. Formation of the 
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11-membered palladacycle IV-120 is presumably facilitated by complexation of the 
alkene to the metal, which allows for Pd–O bond formation via an effectively smaller 
ring. Transannular insertion of the alkene into the palladium-oxygen bond would generate 
IV-121, which could undergo C–C bond-forming reductive elimination to form the 
observed product IV-122. Pseudoequatorial orientation of the α-substituent in the 
transition state for alkene insertion would lead to the observed products bearing trans-
2,5-disubstituted tetrahydrofuran groups and should be lower in energy than the related 
transition state with axial orientation of the α-group due to developing transannular 
interactions. The side products that comprise the remainder of the mass balance in these 
reactions result from oxidation of the alcohol with concomitant reduction of the aryl 
bromide and are consistent with competing β-hydride elimination of IV-120 prior to 
alkene insertion.  
The experiments described above cannot rule out another possible mechanism for 
product formation that would provide IV-122 via alkene insertion into the Pd–C bond of 
macrocycle IV-120 (Scheme 63). However, literature precedent suggests that alkene 
insertion into the metal–heteroatom bond of late-metal M(R)(OR) complexes is usually 
































In order to further probe the relative rates of C–O bond insertion versus C–C 
bond insertion, a simple experiment was designed. The aryl bromide IV-123 was 
synthesized via Wittig olefination of aldehyde IV-44. Treatment of IV-123 with alcohol 
IV-124, NaOtBu, and catalytic Pd2(dba)3/PCy3 afforded tetrahydrofuran IV-125 as the 
sole product. The carbocycle IV-129 which would result from intramolecular Heck 
reaction of IV-123, was not observed under these reaction conditions as determined by 
1H NMR analysis. This suggests that intramolecular carbopalladation (Pd–C bond 
insertion) is slow relative to the rate of Pd-alkoxide formation and oxypalladation (Pd–O 
bond insertion) under the reactions conditions described above. This provides further 





























Mechanism of Intramolecular Carboetherification Reactions 
That Provide anti-Addition Products 
In contrast to all previously described intermolecular carboetherification reactions 
of internal alkenes with aryl bromides,2,32,33,34 which provide syn-addition products, the 
intramolecular carboetherifications provide products resulting from anti-addition when 
chelating ligands with small bite angles (e.g., BINAP or DPP-benzene) are employed. 
Our group has previously shown that anti-addition products observed in intramolecular 
carboetherification reactions are actually generated through syn-oxypalladation followed 
by reversible β-hydride elimination/reinsertion/σ-bond rotation processes. This was 
established through deuterium labeling experiments (Scheme 53) which established that 
the deuterium migration in the minor diastereomer was consistent with palladium 
migration occurring after the key oxypalladation event.2f However, formation of anti-
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addition products in the intramolecular reactions described in this chapter are unlikely as 
this pathway would require a 7-endo-hydridopalladation of an aryl-(hydrido)palladium 
alkene complex (IV-135), which is energetically unfavorable.35 Endo carbopalladation 
reactions are extremely rare, and 7-endo hydridopalladation reactions are unknown. In 
addition, side products that would result from reductive elimination of IV-135 prior to 7-
endo-hydridopalladation are not observed; the major side products in reactions that afford 


















































Scheme 65. Formation of Anti-Addition Products from β-Hydride 




















































Instead, it appears likely that the change in observed product stereochemistry 
arises from a fundamental change in the mechanism through which the products are 
formed. This change can be attributed to the notion that tightly chelating ligands are 
expected to inhibit the associative ligand substitution process required for palladium 
alkoxide formation.29 As outlined in Scheme 66, Path A, oxidative addition of the aryl 
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bromide IV-115 to a (L–L)Pd(0) complex followed by alkene coordination would 
generate 18-electron complex IV-134. This coordinatively saturated complex could not 
be converted to a palladium(aryl)(alkoxide) analogous to IV-141 via an associative 
ligand substitution process, and it is unlikely that the 11-membered palladacycle IV-141 
would be generated in the absence of alkene coordination, as 11-membered ring 
formation is entropically unfavorable. Thus, conversion of IV-115 to IV-141 is likely to 
be relatively slow. Conversion of IV-134 to IV-141 could occur via dissociation of one 
arm of the chelating ligand followed by associative substitution of alkoxide for bromide, 
or by dissociation of the bromide followed by associative ligand substitution. Either of 
these pathways is likely to be higher in energy than the analogous conversion of IV-116 
to IV-120. Instead, a mechanistic pathway involving a Wacker-type anti-
alkoxypalladation may be more accessible in this system than in other carboetherification 
processes. The anti-alkoxypalladation of IV-134 via an ordered transition state such as 
IV-142 could generate IV-143, which would provide anti-addition product IV-144 upon 
C-C bond-forming reductive elimination. The stereochemistry around the tetrahydrofuran 
ring would again be dictated by nonbonding interactions in the transition state, with a 
preference for pseudoequatorial orientation of substituents. However, prior studies have 
shown that differences in transition-state energies for pseudoaxial versus 
pseudoequatorial orientation of the α-substituents or the alkene moiety in related 
Wacker-type cyclizations may be relatively small, as the preference for trans-THF 










































































Alternatively, the products of anti-addition could derive from Heck-type 
carbopalladation of IV-134 to generate IV-145, followed by C–O bond-forming 
reductive elimination through an SN2 mechanism, which would lead to inversion of the 
C2 stereocenter to provide IV-147 (Scheme 66, Path B). Although we cannot rule out 
product formation via this mechanism, we currently favor the hypothesis involving a 
Wacker-type anti-oxypalladation pathway, as the sp3 C–O bond-forming reductive 
elimination required for product formation via Path B is not known to occur from Pd(II) 
complexes26,27 and would require SN2 substitution to occur at a hindered secondary 
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carbon atom flanked by an adjacent secondary carbon stereocenter. The fact that Heck-
type side products (e.g., IV-148) are generated in these transformations suggests that 
complex IV-148 is kinetically accessible, but mechanistic Pathway B cannot account for 
control of relative stereochemistry around the tetrahydrofuran ring. The observed 
selectivity for formation of trans-disubstituted tetrahydrofuran products in the 
Pd/BINAP-catalyzed reaction of IV-115 is more consistent with an ordered transition 
state similar to IV-142. Thus, although IV-145 may be accessible under the reaction 
conditions, it is not necessarily an intermediate along the pathway between IV-115 and 
IV-144. 
 
Mechanism and Stereochemistry of Intramolecular Carboamination 
Reactions 
The intramolecular carboamination reactions described above provide products 
that derive from syn-addition of the amine and the arene across the carbon-carbon double 
bond. It is likely that these transformations proceed via a mechanism similar to that 
outlined above (Scheme 62, Path B) for syn-addition reactions of alcohol substrates, 
which involves a transannular alkene insertion of an 11-membered palladium-
(aryl)(amido) intermediate through transition state IV-149 or IV-150. However, in 
reactions of substrates bearing tethered anilines with α-stereocenters, the factors leading 
to a preference for either trans-pyrrolidine stereochemistry (E-alkenes) or cis-pyrrolidine 
stereochemistry (Z-alkenes) are more complicated than in the related transformations of 
secondary alcohols, and the origin of the observed stereochemistry is not entirely clear. 
One possible explanation for these results is that pseudoequatorial orientation of the C1–
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R-group (IV-149) would minimize developing transannular interactions in the transition 
state,36 but could lead to developing A(1,3)-strain between the Nsp2 aryl group and the 
pseudoequatorial R-substituent.37 Alternatively, pseudoaxial orientation of the R-group 
(IV-150) may minimize allylic strain at the expense of increased unfavorable 
transannular interactions. The results of the experiments shown in eq 52 and Scheme 61 
are consistent with preferred pseudoequatorial orientation of the substituent when the 
substrate contains the E-alkene geometry, which suggests that the energetic effects of the 
transannular interactions outweigh the effects of A(1,3)-strain for this system. In contrast, 
there appears to be a slight preference for pseudoaxial orientation with the Z-alkene 
geometry, which implies that the transannular interactions may be lessened relative to the 
degree of allylic strain in this case.38  
 



















In contrast to Pd/BINAP or Pd/DPP-benzene-catalyzed reactions of alcohol 
substrates, which provide good selectivity for products of anti-addition, use of BINAP or 
DPP-benzene with substrates bearing aniline nucleophiles results in low syn/anti 
stereoselectivity. The differences in the stereochemical outcome of these transformations 
may be due to the effect of heteroatom nucleophilicity (anionic alkoxide versus neutral 
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amine) on the rate of anti-heteropalladation. In the presence of NaOtBu there is likely a 
significant equilibrium concentration of highly nucleophilic alkoxides that results from 
deprotonation of the substrate alcohol.39 In contrast, deprotonation of the less acidic 
aniline nucleophile would occur to a lesser extent, and hence the concentration of anilide 
anion is likely to be low, which may result in relatively slower rates of Wacker-type 
addition of the nitrogen nucleophiles. The fact that yields of anti-addition products of 
intramolecular carboetherification reactions decrease (under identical conditions) with 
increasing steric bulk of the alcohol nucleophile is also consistent with this notion, as is 
the observation that substrate IV-99 bearing an N-Boc group was selectively converted to 
anti-addition product with catalytic Pd2(dba)3/BINAP.40 The pKa of the carbamate is 
considerably lower than that of the aniline and a sufficient amount of anionic nitrogen is 
presumably present to facilitate anti-aminopalladation in this system (Scheme 67). 
 










































Intramolecular Carboetherification and Carboamination: Other Systems41 
We were interested in applying the Pd-catalyzed carboetherification and 
carboamination reaction to other systems. The possibility of replacing the carbon atom at 
C1 of the intramolecular substrates with a heteroatom which would afford heterocycles 




X = Br, I








 We examined both the aryl bromide and aryl iodide substrates for these 
transformations as well as both oxygen and nitrogen nucleophiles. The substrates were 
prepared in 3–4 steps from allylated alcohols IV-157 and IV-158, which in turn were 
prepared via allylation of either iodophenol or bromophenol as shown in Figure 68. 
Ozonolysis of IV-157 and IV-158 followed by reductive workup provided aldehydes IV-
159 and IV-160. Wittig olefination of aldehydes IV-159 and IV-160 provides IV-161 






















X = Br, 100% IV-157




X = Br, 41% IV-159
X = I, 79% IV-160
X = Br, 24% IV-161
X = I, 36% IV-162
CO2Et(CH2)3PPh3Br
KOtBu
X = Br, I
 
Esters IV-161 and IV-162 were converted to amines and alcohols IV-163-IV-166 
using a sequence of reactions analogous to those employed for conversion of simple 
substrates (Scheme 44-47). Conversion of ester IV-161 to the N-phenyl amide, followed 
by lithium aluminum hydride reduction provided amines IV-163 and IV-164. Ester IV-
161 was converted to tertiary alcohol IV-165 via addition of methylmagnesium bromide. 





1) PhNH2, MeMgBr, THF
then ester
2) LAH, Et2O
X = Br, 55% (2 steps)
















X = I, 47%
IV-166
X = Br IV-161







The carboamination and carboetherification of substrates IV-163 and IV-165 
were examined using standard reaction conditions with various different ligands. In the 
attempted carboamination reaction of IV-163, vinyl pyrrolidine IV-167 was isolated 
rather than the desired product. Presumably formation of the volatile vinyl 
tetrahydrofuran IV-168 also occurs in the related carboetherification of IV-165, as only 
phenol was observed by 1H NMR analysis of crude reaction mixtures. Vinyl pyrrolidine 
IV-167 likely arises from nucleophilic attack of the amine nucleophile on the π-allyl 
palladium complex IV-169 that results from oxidative addition of Pd(0) to IV-163 as 








Pd, various ligands, NaOtBu















































We felt that the cyclization could be facilitated by substituting an iodide for the 
bromide on the arene, since the rate of oxidative addition is faster with iodides relative to 
bromides. However, upon subjection of amine substrate IV-164 to the carboamination 
conditions, vinyl pyrrolidine IV-167 was again formed. Attempted carboetherification of 
substrate IV-166 also generated phenol as the only observed product. Conducting the 





























We briefly examined the carboetherification of heterocycle-containing substrates 
such as pyrrole IV-175, which was prepared in 4 steps from 2-bromoaniline. As shown 
below, reaction of 2-bromoaniline with 2,5-dimethoxyfuran provides pyrrole IV-172. 
Formylation provides aldehyde IV-173, which undergoes Wittig olefination to afford 
ester IV-174. Lithium aluminum hydride reduction generates alcohol substrate IV-167. 
Unfortunately, all attempts to cyclize this substrate resulted in no reaction and starting 
material was recovered unchanged (eq 62). 
 






































We also examined the intramolecular carboamination reaction of cyclohexanone-
derived trisubstituted olefin substrate IV-179, which was prepared in 4 steps from 
cyclohexanone. As shown below, N,N-Dimethylhydrazine was condensed with 
cyclohexanone followed by deprotonation and alkylation with 2-bromobenzyl bromide. 
Wittig reaction of IV-176 with the ylide generated from reaction of 4-ethoxy-4-oxobutyl 
triphenylphosphonium bromide with potassium tert-butoxide provides IV-177 as a 2:1 
mixture of diastereomers. The stereochemistry of the major diastereomer was assigned by 
NOESY-2D analysis of the major diastereomer. The ester was then treated with the anion 
of aniline to provide IV-178 which was then reduced with lithium aluminum hydride. 
Unfortunately, the attempted carboamination of amine IV-179 under standard conditions 
provided a mixture of the reduction of the starting material IV-180 as well as Heck 







































































Although, the reaction of cyclohexanone derivative IV-179 was unsuccessful, the 
analogous intramolecular carboamination reaction of cyclopentanone-derived 
trisubstituted olefin substrate IV-186, which was prepared in 4 steps from 
cyclopentanone, was feasible. The substrate was prepared in the same manner as the 
cyclohexanone derivative. N,N-Dimethylhydrazine was condensed with cyclopentanone 
followed by deprotonation and alkylation with 2-bromobenzyl bromide. Wittig reaction 
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of IV-182 with the ylide generated from reaction of 4-ethoxy-4-oxobutyl 
triphenylphosphonium bromide with potassium tert-butoxide provided IV-183 as a 2:1 
mixture of diastereomers. The ester was then treated with the anion of aniline to provide 
IV-185, which was then reduced to IV-186 with lithium aluminum hydride. 
Alternatively, reduction of ester IV-183 provides alcohol IV-184, which was used for the 
carboetherification reaction. The stereochemistry was assigned by analogy to IV-179 
which was prepared using the same methods. 
 













































Treatment of amine IV-186 with typical carboamination conditions provides 
pyrrolidine IV-167 in 50% yield and excellent diastereoselectivity. It is probable the 
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yield of the carboamination reaction of IV-186 to IV-187 is higher (eq 64). The 
inseparable mixture of olefin diastereomers complicates the analysis of the reaction. The 
geometry of the olefin was assigned by analogy to the six-membered ring derivative on 
which a NOESY-2D was obtained. It appears that one olefin isomer (IV-186), which is 
assumed to be the E-olefin reacts to provide pyrrolidine IV-187. The other olefin isomer 
also reacts, as evidenced by the lack of starting material remaining. Since the 
stereoselectivity of the reaction is 22:1 dr, it is reasonable to assume that Z-olefin is not 
undergoing the carboamination reaction under these reaction conditions and actually 
provides the Heck product, which was also isolated. This example nicely illustrates a 
potential solution in complex molecule synthesis. In a situation such as this, when one 
olefin geometry does not undergo the desired transformation in an otherwise 
stereospecific cyclization, simply changing the catalyst in order to get the desired 





















Pd2(dba)3 (1 mol %)
P(Cy)3·HBF4 (4 mol %)
 
Many attempts to cyclize substrate IV-184 with catalysts composed of Pd2(dba)3 
and various ligands led to complex mixtures. Although the carboamination of IV-186 to 
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afford IV-187 was successful, the analogous carboetherification of IV-184 could not be 










Cyclic olefin-containing substrates (IV-192) were also examined in the 
intramolecular carboetherification reaction. Compound IV-192 was prepared in 5 steps 
via condensation of N,N-dimethylhydrazine with cyclopentanone, followed by 
deprotonation with butyllithium and alkylation with 2-bromobenzyl bromide. Hydrolysis 
provided ketone IV-182, which was treated with LDA followed by PhSeBr.42 Oxidation 
and α-elimination of the alkyl selenide provided enone IV-189. Reduction of IV-189 
with 9-BBN provided the allylic alcohol (to IV-190) and the stereochemistry of the major 
diastereomer was confirmed by a NOESY-2D experiment of the major diastereomer as 
shown in Scheme 73.  The major diastereomer was converted to ester IV-191 via a 
Johnson ortho ester Claisen reaction. Reduction with lithium aluminum hydride afforded 
substrate IV-192. The carboetherification reaction was conducted under standard 
conditions to yield tetrahydrofuran IV-193 in good yield and excellent 
diastereoselectivity in six steps from cyclopentanone. This example illustrates that 
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reactions can proceed via anti-oxypalladation if a syn-oxypalladation mechanistic 
manifold cannot be accessed due to substrate geometry. 
 
Scheme 73. Synthesis and Carboetherification of IV-191 to IV-192  
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In conclusion, we have demonstrated the feasibility of a new strategy for the 
stereoselective construction of products bearing two attached rings via Pd-catalyzed 
carboetherification and carboamination reactions. Depending on the structure of the 
catalyst and the substrate, selectivity for either syn-addition or anti-addition is observed. 
The products of syn-addition appear to derive from unprecedented transannular alkene 
insertions of unusual 11-membered Pd(Ar)(YR) intermediates. In contrast, the products 
of anti-addition are consistent with reaction via a different mechanistic pathway that may 
involve Wacker-type anti-heteropalladation of the alkene. These studies represent the 
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first examples of phosphine ligand control of syn-insertion versus anti-addition pathways 
in catalytic reactions involving olefin oxypalladation, which allows for stereoselective 
construction of either of two possible product diastereomers from a given alcohol 
substrate. We have also demonstrated that it is possible to reverse the diastereoselectivity 
of the Pd-catalyzed carboamination reaction by replacing the group on nitrogen with a 
Boc-protecting group. We have also demonstrated the utility of the intramolecular Pd-
catalyzed carboamination and carboetherification reaction for the synthesis of compound 
IV-187 and IV-193 via a five and six step route, respectively from cyclopentanone. 
Throughout the course of our studies of the Pd-catalyzed carboetherification and 
carboamination reaction, we have learned many things. There are several complicated 
factors and features relevant to these systems and we have in our work simply touched 
the surface. In effect, this study though initially unplanned has allowed us to better 
understand the factors that control syn versus anti-oxypalladation and aminopalladation. 
We have learned that various factors affect these systems, including but not limited to: 
heteroatom (oxygen versus nitrogen), acidity, nucleophilicity, protecting group, and 
substitution or sterics. 
This study has also proven that the catalyst and the phosphine ligand in particular 
greatly affect the course and consequently the mechanism of the reaction. In this realm, 
the electronics, sterics, bite angle, cone angle, and coordination number all play a role in 







General Considerations. All reactions were carried out under an argon or nitrogen 
atmosphere in oven- or flame-dried glassware. All reagents were purchased from 
commercial sources and were used as obtained unless otherwise noted. 
Tris(dibenzylideneacetone)dipalladium (0) and all phosphine ligands were purchased from 
Strem Chemical Co. and used without further purification. 3-(2-bromophenyl)propanal 
(IV-44)43 and E-7-(2-bromophenyl)hept-4-enoic acid ethyl ester (IV-47)44 were prepared 
according to literature procedures. Toluene, diethyl ether, THF, and methylene chloride 
were purified using a Glass Contour solvent purification system. Aniline was purified by 
distillation from calcium hydride under nitrogen. The regiochemistry of the heterocyclic 
products was assigned on the basis of 1H NMR 2-D COSY experiments; stereochemistry 
was assigned on the basis of X-ray crystallography and/or 1H NMR nOe experiments. 
Ratios of diastereomers were determined by 1H NMR and/or capillary GC analysis. Yields 
refer to isolated yields of compounds estimated to be ≥95% pure as determined by 1H 
NMR, and either capillary GC or combustion analysis. The yields reported in the 
supporting information describe the result of a single experiment, whereas the optimized 
yields reported in Tables 16-21 and 23 and Schemes 50, 51 and 61, and eq 43,45, 46,47 
are average yields of two or more experiments. Thus, the yields reported in the supporting 
information may differ from those shown in Tables 16-21 and 23 and Schemes 50, 51 and 





Synthesis of Substrates 
Synthesis of Substrate Precursors IV-46 and IV-47 
The substrates employed in these studies were generated from E-7-(2-
bromophenyl)hept-4-enoic acid ethyl ester (IV-47) or Z-7-(2-bromophenyl)hept-4-enoic 
acid ethyl ester (IV-46), which served as common intermediates for the generation of all 
substrates employed in the intramolecular carboetherification and carboamination 
reactions. The esters were prepared from 3-(2-bromophenyl)propanal (IV-44),43 which 
was synthesized via Heck-coupling of allyl alcohol with 1-bromo-2-iodobenzene. 
Aldehyde IV-44 was elaborated to E-ester IV-47 via vinyl Grignard addition followed by 
orthoester Claisen rearrangement,44 and the Z-ester IV-46 was obtained via Wittig 
olefination of IV-44.  
Z-7-(2-Bromophenyl)hept-4-enoic acid ethyl ester (IV-46).  A flame-dried flask 
equipped with a magnetic stirbar was cooled under a stream of nitrogen and charged with 
4-(ethoxycarbonyl)butyltriphenylphosphonium bromide45 (17.72 g,  38.77 mmol) and 
THF (180 mL). The flask was cooled to –78 °C, solid potassium t-butoxide (4.34 g, 38.77 
mmol) was added, and the resulting yellow solution was stirred at –78 °C for 45 minutes. 
A solution of 3-(o-bromophenyl)propanal44 (7.12 g, 33.43 mmol) in THF (20 mL) was 
then added and the reaction mixture was stirred for an additional 45 minutes at –78 °C 
then warmed to room temperature over several hours. After the starting aldehyde had 
been consumed as judged by TLC analysis (ca. 8 h) the reaction mixture was quenched 
with water and extracted with ethyl acetate (3 x 200 mL). The combined organic layers 
were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated 
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in vacuo. The crude product was purified by flash column chromatography using 5% 
ethyl acetate/hexanes as the eluant to afford 8.46 g (81%) of the title compound  as a 
colorless oil. The alkene configuration was judged to be >95% Z by NMR and GC 
analysis. 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 1 H), 7.25–7.20 (m, 2 H), 
7.07–7.03 (m, 1 H), 5.52–5.35 (m, 2 H), 4.12 (q, J = 7.2 Hz, 2 H), 2.80–2.76 (m, 2 H), 
2.41–2.22 (m, 6 H), 1.25 (t, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, CDCl3) d 173.4, 
141.2, 133.0, 130.8, 129.8, 128.9, 127.8, 127.5, 124.6, 60.5, 36.3, 34.5, 27.7, 23.0, 14.5; 
IR (film) 2978, 1734 cm–1; MS (EI) 310.0562 (310.0568 calcd for C15H19BrO2). 
Synthesis of Substrates Bearing Tethered Alcohols (Scheme 44 and Scheme 46). 
Esters IV-46 and IV-47 were converted to substrates bearing tethered alcohol groups as 
shown in Schemes 44 and Scheme 46. Treatment of IV-47 and IV-46 with LiAlH4 
provided primary alcohols IV-48 and IV-56. Tertiary alcohols IV-50 and IV-58 were 
prepared by treatment of IV-44 and IV-47 with methylmagnesium bromide. Secondary 
alcohols IV-49 and IV-57 were generated by oxidation of IV-48 and IV-56 with 
SO3•pyr/dmso followed by treatment of the resulting aldehydes with phenylmagnesium 
bromide. Experimental procedures and characterization data are given below. 
E-7-(2-Bromophenyl)hept-4-en-1-ol (IV-48). A flame-dried flask equipped with a 
magnetic stirbar was cooled under a stream of nitrogen and charged with E-7-(2-
bromophenyl)hept-4-enoic acid ethyl ester (1.04 g, 3.34 mmol) and diethyl ether (15 
mL). The solution was cooled to 0 °C, a solution of LiAlH4 (6.6 mL, 6.6 mmol, 1 M in 
diethyl ether) was added dropwise, and the reaction mixture was warmed to room 
temperature and stirred for 8 h. The reaction mixture was then cooled to 0 °C and water 
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(1 mL) was added dropwise followed by 10 M NaOH (2 mL) and additional water (3 
mL). The resulting mixture was decanted, dried over anhydrous sodium sulfate, filtered, 
and concentrated in vacuo. The crude product was then purified by flash chromatography 
using 10% ethyl acetate/hexanes as the eluant to afford 620 mg (69%) of the title 
compound as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.0 Hz, 1 H), 
7.24–7.18 (m, 2 H), 7.07–7.03 (m, 1 H), 5.55–5.41 (m, 2 H), 3.62 (app. q, J = 6.0 Hz , 2 
H), 2.81–2.77 (m, 2 H), 2.34–2.28 (m, 2 H), 2.11–2.05 (m, 2 H), 1.65–1.57 (m, 2 H), 
1.26–1.22 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 141.4, 133.0, 130.6, 130.7, 129.9, 
127.7, 127.5, 124.7, 62.7, 36.4, 32.9, 32.5, 29.0; IR (film) 3341, 2931, 1566 cm–1. Anal 
calcd for C13H17BrO: C, 58.01; H, 6.37. Found: C, 58.21; H, 6.37. 
Z-7-(2-Bromophenyl)hept-4-en-1-ol (IV-56). Treatment of Z-7-(2-bromophenyl)hept-4-
enoic acid ethyl ester (3.81 g, 12.25 mmol) with LiAlH4 (24 mL, 24 mmol, 1 M in diethyl 
ether) using a procedure analogous to that described above for the synthesis of IV-48 
afforded 2.64 g (80%) of the title compound as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.53 (d, J = 8.0 Hz, 1 H), 7.25–7.20 (m, 2 H), 7.07–7.03 (m, 1 H), 5.51–5.39 
(m, 2 H), 3.58 (t, J = 6.4 Hz, 2 H), 2.80–2.76 (m, 2 H), 2.41–2.35 (m, 2 H), 2.11–2.05 (m, 
2 H), 1.60–1.52 (m, 2 H), 1.24 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 141.3, 132.9, 
130.8, 130.3, 129.1, 127.7, 127.5, 124.6, 62.6, 36.3, 32.6, 27.7, 23.7; IR (film) 3336, 
3005 cm–1. Anal calcd for C13H17BrO: C, 58.01; H, 6.37. Found: C, 58.41; H, 6.48. 
E-8-(2-Bromophenyl)-2-methyloct-5-en-2-ol (IV-50). A flame-dried flask equipped 
with a magnetic stirbar was cooled under a stream of nitrogen and charged with E-7-(2-
bromophenyl)hept-4-enoic acid ethyl ester (0.723 g, 2.32 mmol) and diethyl ether (8 
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mL). The reaction mixture was cooled to 0 °C and methylmagnesium bromide (2.3 mL, 
6.97 mmol, 3 M in THF) was added slowly. The resulting mixture was warmed to room 
temperature and stirred for 8 h. The reaction mixture was then quenched with aqueous 
NH4Cl and transferred to a separatory funnel. The aqueous layer was extracted with ethyl 
acetate (3 x 100 mL) and the combined organic extracts were dried over anhydrous 
sodium sulfate, filtered and concentrated in vacuo. The crude reaction mixture was 
purified by flash chromatography using 5% ethyl acetate/hexanes as the eluant to afford 
525 mg (76%) of the title compound as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 
7.52 (d, J = 8.0 Hz, 1 H), 7.24–7.18 (m, 2 H), 7.07–7.02 (m, 1 H), 5.56–5.44 (m, 2 H), 
2.78 (t, J = 7.6 Hz, 2 H), 2.33-2.28 (m, 2 H), 2.12–2.05 (m, 2 H), 1.55–1.51 (m, 2 H), 
1.31 (s, 1 H), 1.22 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 141.4, 132.9, 131.4, 130.6, 
129.3, 127.7, 127.5, 124.7, 71.2, 43.6, 36.4, 32.9, 29.5, 27.8; IR (film) 3380, 2966, 1566 
cm–1. Anal calcd for C15H21BrO: C, 60.61; H, 7.12. Found: C, 60.78; H, 7.21. 
Z-8-(2-Bromophenyl)-2-methyloct-5-en-2-ol (IV-58). Treatment of 1.22 g (3.92 mmol) 
of Z-7-(2-bromophenyl)hept-4-enoic acid ethyl ester with methylmagnesium bromide 
(3.9 mL, 11.8 mmol, 3 M in Et2O) using a procedure analogous to that described above 
for the synthesis of IV-50 afforded 827 mg (71%) of the title compound as a colorless oil. 
1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 8.0 Hz, 1 H), 7.24–7.18 (m, 2 H), 7.07–7.02 
(m, 1 H), 5.48–5.39 (m, 2 H), 2.79 (t, J = 7.6 Hz, 2 H), 2.42–2.36 (m, 2 H), 2.08–2.02 (m, 
2 H), 1.43 (s, br, 1 H), 1.40–1.36 (m, 2 H), 1.18 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 
141.4, 133.0, 131.0, 130.9, 128.6, 127.8, 127.5, 124.7, 71.1, 43.7, 36.4, 29.4, 27.7, 22.5; 
IR (film) 3388, 2966, 1566 cm–1. Anal calcd for C15H21BrO: C, 60.61; H, 7.12. Found: C, 
60.80; H, 7.10. 
234 
 
E-7-(2-Bromophenyl)-1-phenylhept-4-en-1-ol (IV-49). A flame-dried flask equipped 
with a magnetic stirbar was cooled under a stream of nitrogen and charged with alcohol 
IV-48 (2.19 g, 8.17 mmol), methylene chloride (20 mL), and triethylamine (5.1 mL, 36.8 
mmol). The flask was cooled to 0 °C and DMSO (23.2 mL, 327 mmol) was added to the 
reaction mixture followed by SO3·pyridine (4.03 g, 25.3 mmol). The resulting suspension 
was stirred at 0 °C for 1 h then warmed to room temperature and stirred for 7 h. The 
reaction mixture was quenched with aqueous NaHCO3 and transferred to a separatory 
funnel. The layers were separated and the aqueous layer was extracted with ethyl acetate 
(3 x 200 mL). The combined organic layers were dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo. The crude product was purified by flash 
chromatography using 5% ethyl acetate/hexanes as the eluant to provide 1.63 g (74%) of 
E-7-(2-Bromophenyl)-1-phenylhept-4-en-1-al as a yellow oil. 1H NMR (300 MHz, 
CDCl3) δ 9.75 (s, 1 H), 7.54–7.50 (m, 1 H), 7.25–7.16 (m, 2 H), 7.08–7.02 (m, 1 H), 
5.58–5.38 (m, 2 H), 2.81–2.75 (m, 2 H), 2.51–2.46 (m, 2 H), 2.36–2.27 (m, 4 H). 
A flame-dried flask equipped with a magnetic stirbar was charged with 
phenylmagnesium bromide (12 mL, 12.0 mmol, 1 M in THF) and cooled to 0 °C. A 
solution of E-7-(2-bromophenyl)-1-phenylhept-4-en-1-al (965 mg, 3.61 mmol) in THF 
(10 mL) was added, and the reaction mixture was warmed to room temperature and 
stirred for 8 h. The reaction mixture was quenched with aqueous NH4Cl, and transferred 
to a separatory funnel. The layers were separated and the aqueous layer was extracted 
with ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous 
sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified by 
flash chromatography using 5% ethyl acetate/hexanes as the eluant to afford 1.19 g (96%) 
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of the title compound as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 6.8 Hz, 
1 H), 7.37–7.32 (m, 4 H), 7.29–7.27 (m, 1 H), 7.24–7.18 (m, 2 H), 7.06–7.02 (m, 1 H), 
5.54–5.43 (m, 2 H), 4.65 (dd, J = 4.4, 6.0 Hz, 1 H), 2.80–2.77 (m, 2 H), 2.34–2.29 (m, 2 
H), 2.14–2.02 (m, 2 H), 1.89–1.82 (m, 1 H), 1.79–1.72 (m, 2 H); 13C NMR (100 MHz, 
CDCl3) δ 144.8, 141.3, 132.9, 130.6, 130.5, 129.9, 128.6, 127.7, 127.6, 127.4, 126.1, 
124.6, 74.1, 38.8, 36.3, 32.9, 29.0; IR (film) 3365 cm–1. Anal calcd for C19H21BrO: C, 
66.09; H, 6.13. Found: C, 66.42; H, 6.15.  
Z-7-(2-Bromophenyl)-1-phenylhept-4-en-1-ol (IV-57).  Alcohol IV-56 (2.64 g, 9.85 
mmol) was converted to Z-7-(2-Bromophenyl)-1-phenylhept-4-en-1-al (2.23 g, 85% 
yield, colorless oil) in a manner analogous to that described above for the synthesis of E-
7-(2-Bromophenyl)-1-phenylhept-4-en-1-al. 1H NMR (400 MHz, CDCl3) δ 9.69 (s, 1 H), 
7.52 (d, J = 7.6 Hz, 1 H), 7.27–7.19 (m, 2 H) 7.07–7.03 (m, 1 H), 5.41–5.34 (m, 2 H), 
2.80–2.76 (m, 2 H), 2.39–2.25 (m, 6 H). 
Z-7-(2-Bromophenyl)-1-phenylhept-4-en-1-al (1.63 g, 6.06 mmol) was converted  to the 
title compound (1.46 g, 70% yield) in a manner analogous to that described above for the 
synthesis of IV-49. 1H NMR (400 MHz, CDCl3) δ 7.46–7.44 (m, 1 H), 7.30–7.26 (m, 2 
H), 7.25–7.17 (m, 3 H) 7.15–7.10 (m, 2 H), 6.99–6.95 (m, 1 H), 5.45–5.34 (m, 2 H), 
4.57–4.53 (m, 1 H), 2.72–2.67 (m, 2 H), 2.31–2.26 (m, 2 H), 2.06–1.96 (m, 2 H), 1.78–
1.77 (m, 1 H), 1.76–1.67 (m, 1 H), 1.64–1.55 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 
144.8, 141.3, 132.9, 130.8, 130.3, 129.2, 128.6, 127.8, 127.7, 127.5, 126.1, 124.6, 74.3, 
39.0, 36.4, 27.7, 23.9; IR (film) 3369, 2930, 1470 cm–1. Anal calcd for C19H21BrO: C, 
66.09; H, 6.13.  Found: C, 66.39; H, 6.21. 
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Synthesis of Substrates Bearing Amine Nucleophiles 
As shown in Schemes 45 and Scheme 47, unbranched aniline derivatives IV-52 and IV-
60 were generated via amidation of IV-47 and IV-46 followed by reduction with LiAlH4. 
Branched substrates IV-55 and IV-63 were prepared via conversion of esters IV-47 and 
IV-46 to the corresponding Weinreb Amides followed by addition of phenylmagnesium 
bromide to generate phenyl ketone derivatives. Conversion of these intermediates to N-
aryl imines followed by reduction with LiAlH4 generated IV-55 and IV-63. Experimental 
procedures and characterization data are given below. 
E-[7-(2-Bromophenyl)hept-4-enyl]aniline (IV-52). A flame-dried flask was cooled 
under a stream of nitrogen and charged with aniline (0.6 mL, 6.52 mmol) and 
tetrahydrofuran (6 mL). The mixture was cooled to 0°C, a solution of methylmagnesium 
bromide (2.2 mL, 6.6 mmol, 3 M in diethyl ether) was added dropwise, and the reaction 
mixture was warmed to room temperature and stirred for 12 h. A solution of E-7-(2-
bromophenyl)hept-4-enoic acid ethyl ester (1.03 g, 3.31 mmol) in tetrahydrofuran (6 mL) 
was added to the reaction mixture, and the resulting solution was stirred at room 
temperature for 12 h. The reaction was quenched with water, the layers were separated, 
and the aqueous layer was extracted with diethyl ether (3 x 200 mL). The combined 
organic extracts were washed sequentially with 2M HCl (2 x 100 mL) aqueous NaHCO3, 
and brine, and were then dried over anhydrous Na2SO4, filtered, and concentrated in 
vacuo. The crude product was purified by flash chromatography using 5% 10% ethyl 
acetate/hexanes as the eluant to afford 710 mg (60%) of E-7-(2-bromophenyl)hept-4-
enoic acid phenyl amide as a gray solid, m.p. 80–85 °C. 1H NMR (400 MHz, CDCl3) δ 
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7.58–7.50 (m, 3 H), 7.44–7.31 (m, 2 H), 7.22–7.18 (m, 3 H), 7.06–7.00 (m, 1 H), 5.64–
5.55 (m, 2 H), 2.79 (t, J = 7.2 Hz, 2 H), 2.48–2.42 (m, 4 H), 2.36–2.32 (m, 2 H); 13C 
NMR (100 MHz, CDCl3) δ 171.2, 141.2, 138.1, 132.8, 130.8, 130.6, 129.3, 129.1, 127.7, 
127.5, 124.6, 124.4, 120.2, 37.5, 36.2, 32.8, 28.6; IR (film) 3296, 1652 cm–1. Anal calcd 
for C19H20BrNO: C, 63.70; H, 5.63; N, 3.91. Found: C, 63.49; H, 5.67; N, 3.85. 
A flame-dried flask was cooled under nitrogen and charged with E-7-(2-
bromophenyl)hept-4-enoic acid phenyl amide (690 mg, 1.93 mmol) and diethyl ether (10 
mL). The solution was cooled to 0 °C and LiAlH4 (5.78 mL, 5.78 mmol, 1 M in diethyl 
ether) was added dropwise. The reaction mixture was warmed to room temperature and 
stirred for 10 h, then was cooled to 0 °C and water (1 mL) was added dropwise followed 
by 10 M NaOH (2 mL) and additional water (3 mL). The resulting mixture was decanted, 
dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
product was purified by flash chromatography using 5% 10% ethyl acetate/hexanes as 
the eluant to afford 523 mg (70%) of the title compound as an orange oil. 1H NMR (400 
MHz, CDCl3) δ 7.52 (d, J = 6.0 Hz, 1 H), 7.24–7.16 (m, 4 H), 7.06–7.02 (m, 1 H), 6.70 
(t, J = 7.2 Hz, 1 H), 6.61 (d, J = 7.6 Hz, 2 H), 5.56–5.42 (m, 2 H), 3.84 (s, br, 1 H), 3.09 
(t, J = 7.2 Hz, 2 H), 2.82–2.78 (m, 2 H), 2.35–2.29 (m, 2 H), 2.13–2.08 (m, 2 H), 1.70–
1.65 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 148.6, 141.4, 132.9, 130.6, 130.5, 130.0, 
129.4, 127.7, 127.5, 124.7, 117.4, 113.0, 43.6, 36.4, 32.9, 30.2, 29.3; IR (film) 3411, 
2928, 1603 cm–1. Anal calcd for C19H22BrN: C, 66.28; H, 6.44; N, 4.07. Found: C, 66.53; 
H, 6.40; N, 4.12. 
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Z-[7-(2-Bromophenyl)hept-4-enyl]aniline (IV-60). Z-7-(2-bromophenyl)hept-4-enoic 
acid ethyl ester (941 mg, 3.02 mmol) was converted to Z-7-(2-bromophenyl)hept-4-enoic 
acid phenyl amide (755 mg, 70% yield, colorless oil) in a manner analogous to that 
described above for the synthesis of E-7-(2-bromophenyl)hept-4-enoic acid phenyl 
amide. 1H NMR (400 MHz, CDCl3) δ 7.54–7.48 (m, 3 H), 7.32–7.18 (m, 4 H), 7.10–7.03 
(m, 2 H), 5.56–5.41 (m, 2 H), 2.79 (t, J = 8.0 Hz, 2 H), 2.44–2.36 (m, 4 H), 2.23–2.19 (m, 
2 H); 13C NMR (100 MHz, CDCl3) δ 170.9, 141.2, 138.1, 132.9, 131.0, 130.2, 129.2, 
128.9, 127.8, 127.5, 124.6, 124.4, 120.0, 37.7, 36.2, 27.6, 23.5; IR (film) 3302, 1651 cm–
1.   
Z-7-(2-bromophenyl)hept-4-enoic acid phenyl amide (585 mg, 1.63 mmol) was converted  
to the title compound (498 mg, 89% yield) in a manner analogous to that described above 
for the synthesis of IV-52. 1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 8.0 Hz, 1 H), 7.25–
7.15 (m, 4 H), 7.06–7.03 (m, 1 H), 6.70–6.66 (m, 1 H), 6.58 (d, J = 8.0 Hz, 2 H), 5.51–
5.40 (m, 2 H), 3.56 (s, br, 1 H), 3.07–3.05 (m, 2 H), 2.78 (t, J = 6.4 Hz, 2 H), 2.40–2.35 
(m, 2 H), 2.12–2.07 (m, 2 H), 1.61–1.55 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 148.6, 
141.3, 133.0, 130.8, 130.2, 129.4, 129.2, 127.8, 127.5, 124.6, 117.3, 112.9, 43.7, 36.4, 
29.6, 27.8, 25.0; IR (film) 3409, 2928, 1601 cm–1. Anal calcd for C19H22BrN: C, 66.28; 
H, 6.44; N, 4.07.  Found: C, 66.46; H, 6.62; N, 4.07. 
E-[7-(2-Bromophenyl)-1-phenylhept-4-enyl]aniline (IV-55). A flame-dried flask was 
cooled under a stream of nitrogen and charged with N,O-dimethylhydroxylamine 
hydrochloride (2.3 g, 23.6 mmol) and toluene (30 mL). The mixture was cooled to 0 °C, 
and a solution of trimethylaluminum (11.8 mL, 23.6 mmol, 2 M in toluene) was added 
dropwise. The resulting mixture was stirred at 0 °C for 10 min, then a solution of ester 
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IV-47 (2.94 g, 9.45 mmol) in toluene (16 mL) was added to the reaction mixture via 
cannula. The resulting solution was allowed to slowly warm to room temperature over 10 
h with stirring. The reaction mixture was then cooled to 0 °C and 1M HCl was added 
dropwise. The resulting mixture was transferred to a separatory funnel, the layers were 
separated, and the aqueous layer was extracted with methylene chloride (3 x 400 mL).  
The combined organic extracts were washed with brine, dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude product was purified by flash 
chromatography using 20% ethyl acetate/hexanes as the eluant to provide 1.88g (61%) of 
E-7-(2-bromophenyl)hept-4-enoic acid (methoxy)methylamide as a yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 7.53–7.50 (m, 1 H), 7.24–7.17 (m, 2 H), 7.06–7.02 (m, 1 H), 5.58–
5.44 (m, 2 H), 3.67 (s, 3 H), 3.18 (s, 3 H), 2.80–2.76 (m, 2 H), 2.49–2.45 (m, 2 H), 2.35–
2.27 (m, 4 H). 
A flame-dried flask was cooled under a stream of nitrogen and charged with E-7-(2-
bromophenyl)-hept-4-enoic acid (methoxy)methylamide (1.88 g, 5.76 mmol) and THF 
(10 mL). The mixture was cooled to 0 °C, a solution of phenylmagnesium bromide (17.3 
mL, 17.3 mmol, 1 M in THF) was added dropwise, and the reaction mixture was warmed 
to room temperature with stirring over 8 h. The reaction mixture was then cooled to 0 °C, 
water (5 mL) was added dropwise, and the reaction mixture was transferred to a 
separatory funnel. The layers were separated and the aqueous layer was extracted with 
ethyl acetate (3 x 300 mL). The combined organic extracts were washed with brine, dried 
over anhydrous sodium sulfate, filtered, and concentrated in vacuo.  The crude product 
was purified by flash chromatography using 10% ethyl acetate/hexanes as the eluant to 
provide 1.34 g (69%) of E-7-(2-bromophenyl)-1-phenylhept-4-en-1-one as a colorless oil. 
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1H NMR (400 MHz, CDCl3) δ 7.97–7.95 (m, 2 H), 7.61–7.43 (m, 4 H), 7.21–7.19 (m, 2 
H) 7.05–7.01 (m, 1 H), 5.60–5.48 (m, 2 H), 3.04–3.00 (m, 2 H), 2.80–2.76 (m, 2 H), 
2.46–2.41 (m, 2 H), 2.33–2.28 (m, 2 H). 
A flame-dried flask equipped with Dean-Stark apparatus and reflux condenser was 
cooled under a stream of nitrogen and charged with E-7-(2-bromophenyl)-1-phenylhept-
4-en-1-one (1.34 g, 3.90 mmol), aniline (397 mg, 389 mL, 4.27 mmol), benzene (20 mL), 
and trifluoroacetic acid (29.0 µL, 0.390 mmol). The mixture was heated to reflux under 
nitrogen for 48h with azeotropic removal of water. The reaction mixture was then cooled 
to room temperature, concentrated in vacuo, and diluted with diethyl ether. The resulting 
solution was cooled to 0 °C and a solution of lithium aluminum hydride (11.7 mL, 11.7 
mmol, 1 M in ether) was added dropwise. The reaction mixture was then warmed to room 
temperature and stirred for 8 h. The reaction mixture was then cooled to 0°C, and H2O (2 
mL) followed by 10 M NaOH (3 mL) and additional water. The resulting suspension was 
decanted, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The 
crude product was purified by flash chromatography using 10% ethyl acetate/hexanes as 
the eluant to afford 958 mg (59%) of the title compound as a yellow oil. 1H NMR (400 
MHz, CDCl3) δ 7.53–7.51 (m, 1 H), 7.32–7.28 (m, 4 H), 7.24–7.20 (m, 1 H), 7.19–7.17 
(m, 2 H), 7.10–7.02 (m, 3 H), 6.63 (t, J = 7.6 Hz, 1 H), 6.50 (d, J = 7.6 Hz, 2 H), 5.53–
5.42 (m, 2 H), 4.30 (t, J = 6.8 Hz, 1 H), 4.06 (s, 1 H), 2.80–2.76 (m, 2 H), 2.33–2.28 (m, 
2 H), 2.10–2.05 (m, 2 H), 1.89–1.81 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 147.6, 
144.2, 141.3, 133.0, 130.6, 130.32, 130.28, 129.3, 128.7, 127.7, 127.5, 127.1, 126.6, 
124.7, 117.4, 113.4, 57.8, 38.6, 36.4, 32.9, 29.5; IR (film) 3412, 2929, 1600 cm–1. Anal 




bromophenyl)hept-4-enoic acid ethyl ester (1.44 g, 4.63 mmol) was converted to Z-7-(2-
bromophenyl)hept-4-enoic acid (methoxy)methylamide (1.02 g, 68% yield, colorless oil) 
in a manner analogous to that described above for the synthesis of E-7-(2-
bromophenyl)hept-4-enoic acid (methoxy)methylamide. 1H NMR (400 MHz, CDCl3) δ 
7.52 (d, J = 7.6 Hz, 1 H), 7.25–7.16 (m, 2 H), 7.06–7.02 (m, 1 H), 5.51–5.40 (m, 2 H), 
3.66 (s, 3 H), 3.17 (s, 3 H), 2.80–2.76 (m, 2 H), 2.42–2.39 (m, 3 H), 2.37–2.25 (m, 3 H). 
Z-7-(2-bromophenyl)hept-4-enoic acid (methoxy)methylamide (1.02 g, 3.13 mmol) was 
converted to Z-7-(2-bromophenyl)-1-phenylhept-4-en-1-one (760 mg, 71% yield, 
colorless oil) in a manner analogous to that described above for the synthesis of E-7-(2-
bromophenyl)-1-phenylhept-4-en-1-one. 1H NMR (400 MHz, CDCl3) δ 7.94–7.91 (m, 2 
H), 7.58–7.44 (m, 4 H), 7.21–7.19 (m, 2 H) 7.04–7.00 (m, 1 H), 5.53–5.43 (m, 2 H), 
2.91–2.87 (m, 2 H), 2.81–2.77 (m, 2 H), 2.45–2.38 (m, 4 H). 
Z-7-(2-bromophenyl)-1-phenylhept-4-en-1-one (750 mg, 2.19 mmol) was converted to 
the title compound (531 mg, 58% yield, colorless oil) in a manner analogous to that 
described above for the synthesis of IV-55. 1H NMR (500 MHz, CDCl3) δ 7.48–7.46 (m, 
1 H), 7.24–7.20 (m, 4 H), 7.19–7.12 (m, 2 H), 7.07–6.97 (m, 4 H), 6.57 (dt, J = 1.0, 7.5 
Hz, 1 H), 6.46 (d, J = 8.5 Hz, 2 H), 5.45–5.34 (m, 2 H), 4.23 (t, J = 6.5 Hz, 1 H), 3.97 (s, 
1 H), 2.70–2.66 (m, 2 H), 2.30–2.21 (m, 2 H), 2.05–1.96 (m, 2 H), 1.70–1.63 (m, 2 H); 
13C NMR (125 MHz, CDCl3) δ 147.5, 144.1, 141.2, 132.9, 130.8, 129.9, 129.4, 129.2, 
128.7, 127.8, 127.4, 127.1, 126.5, 124.6, 117.3, 113.4, 57.9, 38.8, 36.3, 27.7, 24.3; IR 
(film) 3413, 2927 cm–1. Anal calcd for C25H26BrN: C, 71.43; H, 6.23; N, 3.33. Found: C, 
71.35; H, 6.21; N, 3.20. 
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General Procedure for Pd-Catalyzed Cyclization Reactions 
A flame-dried Schlenk tube equipped with a magnetic stirbar was cooled under a stream 
of nitrogen and charged with Pd2(dba)3 (1 mol % complex, 2 mol % palladium), ligand (4 
mol %), and NaOtBu (2.0 equiv). The tube was purged with nitrogen and a solution of 
the alcohol substrate in toluene (2.5 mL/0.5 mmol substrate) was added via cannula. An 
additional 1.0 mL of toluene was added and the resulting mixture was heated to 105 °C 
with stirring for 3–8 hours until the starting material had been consumed as determined 
by GC analysis. The reaction mixture was cooled to room temperature, aqueous NH4Cl (2 
mL) and ethyl acetate (10 mL) were added, and the layers were separated. The aqueous 
layer was extracted with ethyl acetate (3 x 10 mL) and the combined organic layers were 
dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.  The crude 
product was then purified by flash chromatography. 
(±)-(1S*,2R*)-2-Indan-1-yltetrahydrofuran (IV-65). The cyclization of IV-48 (150 
mg, 0.56 mmol) following the general procedure using PCy3•HBF4 as the ligand afforded 
54 mg (52%) of the title compound as a colorless oil. This compound was judged to be a 
>20:1 mixture of diastereomers by GC analysis. 1H NMR (400 MHz, CDCl3) δ 7.51–7.49 
(m, 1 H), 7.22–7.19 (m, 1 H), 7.18–7.13 (m, 2 H), 3.98–3.90 (m, 2 H), 3.82–3.77 (m, 1 
H), 3.32–3.26 (m, 1 H), 2.98–2.83 (m, 2 H), 2.24–2.15 (m, 1 H), 2.00–1.83 (m, 3 H), 
1.81–1.72 (m, 1 H), 1.64–1.54 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 145.2, 144.4, 
126.8, 126.3, 125.6, 124.5, 83.1, 68.3, 49.8, 31.8, 29.9, 28.3, 25.8; IR (film) 2952, 2858, 
1474, 1457 cm–1. Anal calcd for C13H16O: C, 82.94; H, 8.57.  Found: C, 83.07; H, 8.69. 
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(±)-(1S*,2R*)-2-Indan-1-yltetrahydrofuran (IV-65). The cyclization of IV-56 (190 
mg, 0.71 mmol) following the general procedure using (±)–BINAP as the ligand afforded 
79 mg (59%) of the title compound as a colorless oil. This compound was judged to be an 
18:1 mixture of diastereomers by GC analysis. Spectroscopic data were identical to those 
given above. 
(±)-(1S*,2S*)-2-Indan-1-yltetrahydrofuran (IV-64). The cyclization of IV-56 (132 mg, 
0.492 mmol) following the general procedure using [(p-MeO)C6H4]3P as ligand afforded 
48 mg (57%) of the title compound as a colorless oil. This compound was judged to be an 
8:1 mixture of diastereomers by GC analysis. Data are for the major isomer. 1H NMR 
(400 MHz, CDCl3) δ 7.32–7.29 (m, 1 H), 7.23–7.19 (m, 1 H), 7.17–7.15 (m, 2 H), 4.03–
3.98 (m, 1 H), 3.91–3.85 (m, 1 H), 3.79–3.74 (m, 1 H), 3.38–3.33 (m, 1 H), 3.02–2.94 
(m, 1 H), 2.89–2.81 (m, 1 H), 2.28–2.19 (m, 1 H), 2.08–1.97 (m, 2 H), 1.93–1.85 (m, 2 
H), 1.68–1.59 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 145.7, 144.2, 126.9, 126.2, 125.0, 
124.7, 81.7, 68.2, 49.8, 31.4, 29.5, 28.3, 26.4; IR (film) 2925 cm–1; Anal calcd for 
C13H16O: C, 82.94; H, 8.57. Found: C, 82.98; H, 8.25. 
(±)-(1S*,2S*)-2-Indan-1-yltetrahydrofuran (IV-64). The cyclization of IV-48 (70 mg, 
0.26 mmol) following the general procedure using dpp-benzene as the ligand afforded 28 
mg (58%) of the title compound as a colorless oil. This compound was judged to be a 
15:1 mixture of diastereomers by GC analysis. Spectroscopic data were identical to those 
given above. 
(±)-(1S*,5R*)-2,2-Dimethyl-5-indan-1-yltetrahydrofuran (IV-77). The cyclization of 
IV-50 (150 mg, 0.51 mmol) following the general procedure using [(p-MeO)C6H4]3P as 
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ligand afforded 56 mg (51%) of the title compound as a colorless oil. This compound was 
judged to be a >20:1 mixture of diastereomers by 1H NMR analysis. 1H NMR (400 MHz, 
CDCl3) δ 7.49–7.47 (m, 1 H), 7.21–7.19 (m, 1 H), 7.18–7.13 (m, 2 H), 4.18–4.13 (m, 1 
H), 3.37–3.31 (m, 1 H), 2.97–2.83 (m, 2 H),  2.22–2.14 (m, 1 H), 1.93–1.87 (m, 1 H),  
1.85–1.79 (m, 1 H),  1.79–1.61 (m, 3 H), 1.30 (s, 3 H), 1.27 (s, 3 H); 13C NMR (125 
MHz, CDCl3) δ 145.5, 144.5, 126.7, 126.2, 125.6, 124.4, 82.1, 80.9, 50.1, 38.6, 31.9, 
29.6, 29.4, 28.4, 27.7; IR (film) 2966, 2865 cm–1. Anal calcd for C15H20O: C, 83.28; H, 
9.32. Found: C, 83.01; H, 9.32. 
(±)-(1S*,5R*)-2,2-Dimethyl-5-indan-1-yltetrahydrofuran (IV-77). The cyclization of 
IV-58 (150 mg, 0.51 mmol) following the general procedure using PCy3•HBF4 as the 
ligand afforded 86 mg (79%) of the title compound as a colorless oil. This compound was 
judged to be a 14:1 mixture of diastereomers by 1H NMR analysis. Spectroscopic data 
were identical to those given above. 
(±)-(1S*,5S*)-2,2-Dimethyl-5-indan-1-yltetrahydrofuran (IV-78). The cyclization of 
IV-58 (200 mg, 0.673 mmol) following the general procedure using PMe3•HBF4 as 
ligand afforded 110 mg (76%) of the title compound as a colorless oil. This compound 
was judged to be a 9:1 mixture of diastereomers by 1H NMR analysis. Data are for the 
major isomer. 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 6.8 Hz, 1 H), 7.22 (d, J = 6.8 
Hz, 1 H), 7.19–7.12 (m, 2 H), 4.13–4.08 (m, 1 H), 3.37–3.32 (m, 1 H), 3.01–2.93 (m, 1 
H), 2.88–2.80 (m, 1 H), 2.28–2.19 (m, 1 H), 2.05–1.95 (m, 2 H), 1.72–1.61 (m, 3 H), 1.27 
(s, 3 H), 1.25 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 145.2, 145.1, 126.8, 126.0, 125.4, 
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124.6, 81.0, 80.5, 49.9, 38.9, 31.4, 29.4, 29.2, 28.6, 28.2; IR (film) 2967 cm–1. Anal calcd 
for C15H20O: C, 83.28; H, 9.32.  Found: C, 83.03; H, 9.26. 
(±)-(1S*,5S*)-2,2-Dimethyl-5-indan-1-yltetrahydrofuran (IV-78). The cyclization of 
IV-50 (150 mg, 0.51 mmol) following the general procedure using (±)–BINAP as the 
ligand afforded 35 mg (32%) of the title compound as a colorless oil. This compound was 
judged to be a 6:1 mixture of diastereomers by 1H NMR analysis. Spectroscopic data 
were identical to those given above. 
(±)-(1S*,2R*,5R*)-2-Indan-1-yl-5-phenyltetrahydrofuran (IV-83). The cyclization of 
IV-49 (150 mg, 0.434 mmol) following the general procedure using PCy3•HBF4 as ligand 
afforded 46 mg (40%) of the title compound as a yellow oil. This compound was 
obtained as a 92:5:2:1 mixture of diastereomers IV-83: IV-83b: IV-85: IV-85b as judged 
by 1H NMR analysis. Data are for the major isomer. 1H NMR (500 MHz, CDCl3) δ 7.62–
7.59 (m, 1 H), 7.38–7.31 (m, 4 H), 7.25–7.20 (m, 2 H), 7.18–7.14 (m, 2H), 5.14–5.11 (m, 
1 H), 4.34–4.28 (m, 1 H), 3.44–3.38 (m, 1 H), 3.00–2.86 (m, 2 H), 2.44–2.38 (m, 1 H), 
2.27–2.18 (m, 1 H), 2.12–2.06 (m, 1 H), 1.89–1.74 (m, 3 H); 13C NMR (125 MHz, 
CDCl3) δ 145.5, 144.5, 144.4, 128.5, 127.2, 126.8, 126.4, 125.8, 125.7, 124.5, 83.9, 80.8, 
50.2, 35.4, 31.9, 31.0, 28.2; IR (film) 3024, 2958, 1602 cm–1. Anal calcd for C19H20O: C, 
86.32; H, 7.63. Found: C, 86.45; H, 7.65. 
(±)-(1S*,2R*,5R*)-2-Indan-1-yl-5-phenyltetrahydrofuran (IV-83). The cyclization of 
IV-57 (122 mg, 0.35 mmol) following the general procedure using (±)–BINAP as the 
ligand afforded 23 mg (25%) of the title compound as a colorless oil. This compound was 
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obtained as a 65:29:5:1 mixture of diastereomers IV-83: IV-83b: IV-85: IV-85b as 
judged by 1H NMR analysis. Spectroscopic data for the major diastereomer (IV-83) were 
identical to those given above. 
(±)-(1S*,2S*,5S*)-2-Indan-1-yl-5-phenyltetrahydrofuran (IV-85). The cyclization of 
IV-57 (182 mg, 0.529 mmol) following the general procedure using [(p-MeO)C6H4]3P as 
ligand afforded 55 mg (40%) of the title compound as yellow oil. Analysis of the crude 
reaction mixture by 1H NMR revealed that a 9:2:2:1 ratio of diastereomers IV-85: IV-
85b: IV-83: IV-83b was formed. Upon purification the title compound was obtained as a 
17:2:1:1 mixture of diastereomers IV-85: IV-85b: IV-83: IV-83b as judged by 1H 
analysis. Data are for the major diastereomer. 1H NMR (500 MHz, CDCl3) δ 7.39–7.37 
(m, 1 H), 7.35–7.31 (m, 4 H), 7.26–7.23 (m, 2 H) 7.20–7.17 (m, 2 H), 5.02 (dd, J = 2.5, 
8.5 Hz, 1 H), 4.39–4.35 (m, 1 H), 3.51–3.47 (m, 1 H), 3.04–2.97 (m, 1 H), 2.92–2.85 (m, 
1 H), 2.38–2.31 (m, 1 H), 2.30–2.24 (m, 1 H), 2.15–2.09 (m, 2 H), 1.90–1.75 (m, 2 H); 
13C NMR (125 MHz, CDCl3) δ 145.3, 144.2, 144.0, 128.5, 127.3, 127.0, 126.2, 125.8, 
125.3, 124.7, 82.5, 80.9, 50.0, 36.0, 31.4, 30.3, 28.5; IR (film) 3026, 2942 cm–1. Anal 
calcd for C19H20O: C, 86.32; H, 7.63. Found: C, 86.12; H, 7.61. 
 (±)-(1S*,2R*)-N-Phenyl-2-indan-1-ylpyrrolidine (IV-90). The cyclization of IV-52 
(150 mg, 0.436 mmol) following the general procedure using PCy3•HBF4 as ligand 
afforded 85 mg (74%) of the title compound as a colorless oil. This compound was 
judged to be a >20:1 mixture of diastereomers by 1H NMR analysis. 1H NMR (400 MHz, 
CDCl3) δ 7.25–7.17 (m, 4 H), 7.15–7.11 (m, 2 H), 6.68–6.63 (m, 3 H), 4.32–4.28 (m, 1 
H), 3.85–3.80 (m, 1 H), 3.62–3.57 (m, 1 H), 3.31–3.25 (dd, J = 7.6, 16.8 Hz, 1 H), 2.98–
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2.91 (m, 1 H), 2.86–2.77 (m, 1 H), 2.09–1.99 (m, 2 H), 1.97–1.81 (m, 3 H), 1.69–1.63 
(m, 1 H); 13C NMR (100 MHz, CDCl3) δ 148.0, 145.2, 144.9, 129.2, 126.7, 126.4, 124.7, 
124.4, 115.9, 112.6, 60.8, 50.1, 46.8, 31.8, 27.7, 27.3, 24.5; IR (film) 2960, 1597 cm–1.  
Anal calcd for C19H21N: C, 86.65; H, 8.04; N, 5.32. Found: C, 86.42; H, 8.13; N, 5.34. 
(±)-(1S*,2S*)-N-Phenyl-2-indan-1-ylpyrrolidine (IV-89). The cyclization of IV-60 
(155 mg, 0.450 mmol) following the general procedure using PCy3•HBF4 as ligand 
afforded 108 mg (92%) of the title compound as an orange oil. This compound was 
judged to be a >20:1 mixture of diastereomers by 1H NMR analysis. 1H NMR (400 MHz, 
CDCl3) δ 7.31–7.27 (m, 2 H), 7.21 (d, J = 7.6 Hz, 1 H), 7.17–7.14 (m, 1 H), 7.06 (d, J = 
4.0 Hz, 2 H), 6.76 (d, J = 8.0 Hz, 2 H), (6.73–6.69 (m, 1 H), 4.06–4.04 (m, 1 H), 3.93–
3.89 (m, 1 H), 3.44 (dd, J = 4.0, 8.0 Hz, 1 H), 3.21–3.15 (m, 1H), 3.11–3.02 (m, 1 H), 
2.95–2.88 (m, 1 H), 2.39–2.28 (m, 1 H), 1.96–1.85 (m, 2 H), 1.70–1.61 (m, 2 H), 1.32–
1.27 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 147.7, 145.1, 144.4, 129.4, 126.8, 126.2, 
126.0, 124.4, 115.8, 112.6, 63.0, 50.3, 45.6, 32.0, 28.2, 27.6, 24.1; IR (film) 3063, 2942, 
1597 cm–1. Anal calcd for C19H21N: C, 86.65; H, 8.04; N, 5.32. Found: C, 86.44; H, 8.16; 
N, 5.31.  
(Z)-tert-butyl 7-(2-bromophenyl)hept-4-enylcarbamate (IV-99).  
A flame-dried flask was charged with ammonium chloride (1.53 g, 28.54 mmol), and 
toluene (29 mL) and cooled to 0 °C and a solution of AlMe3 in toluene (14.3 mL, 28.54 
mmol, 2 M in toluene) was added dropwise. The reaction was stirred at 0 °C then 
warmed to room temperature and stirred 0.5 h. Ester  IV-46 (3.55 g, 11.41 mmol) 
dissolved in 10 mL of toluene was added and the reaction mixture was heated to 50 °C 
248 
 
for 12 h. The reaction mixture was cooled to room temperature and 1 M HCl was added 
slowly until bubbling ceased. The organic product was extracted with ethyl acetate (3 X 
150 mL) and then washed with saturated sodium chloride, followed by drying over 
sodium sulfate, and concentrated in vacuo. The crude product was purified by column 
chromatography to yield 2.72 g (84%) of (Z)-7-(2-bromophenyl)hept-4-enamide as a 
yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.56–7.52 (m, 1 H), 7.28–7.19 (m, 2 H), 7.07–
7.04 (m, 1 H), 5.54–5.49 (m, 1 H), 5.43–5.38 (m, 1 H), 5.33 (broad s, 2 H), 2.79 (t, J = 
7.0 Hz, 2 H), 2.40 (q, J = 7.0 Hz, 2 H), 2.31 (q, J = 7.5 Hz, 2 H), 2.12 (t, J = 8.0 Hz, 2 H). 
A flame-dried flask equipped with a magnetic stirbar was cooled under a stream of 
nitrogen and was charged with (Z)-7-(2-bromophenyl)hept-4-enamide (2.72 g, 9.65 
mmol) and diethyl ether (20 mL). The reaction mixture was cooled to 0 °C, and a 
solution of LiAlH4 (25 mL, 25 mmol, 1 M in diethyl ether) was added dropwise, and the 
reaction mixture was warmed to room temperature and stirred for 8 h. The reaction 
mixture was then cooled to 0 °C and water (1 mL) was added dropwise followed by 10 M 
NaOH (2 mL) and additional water (3 mL). The resulting mixture was decanted, dried 
over anhydrous sodium sulfate, filtered, and concentrated in vacuo to provide 1.54 g 
(60%) of the crude product ((Z)-7-(2-bromophenyl)hept-4-en-1-amine) which was used 
without further purification. 1H NMR (400 MHz, CDCl3) 7.53 (d, J = 8 Hz, 1 H), 7.25–
7.19 (m, 2 H), 7.08–7.03 (m, 1 H), 5.48–5.37 (m, 2 H), 2.78 (t, J = 7.6 Hz, 2 H), 2.64 (t, J 
= 7.6 Hz, 2 H), 2.39–2.34 (m, 2 H), 2.02 (q, J = 7.2 Hz, 2 H), 1.51–1.28 (m, 4 H). 
A flask equipped with a magnetic stirbar was placed under nitrogen and was charged with 
(Z)-7-(2-bromophenyl)hept-4-en-1-amine (1.54 g, 5.75 mmol) and THF (40 mL). Boc2O 
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was added (1.26 g, 5.77 mmol) and the reaction was stirred overnight at room 
temperature. 1H NMR (300 MHz, CDCl3) δ 7.51 (d, J = 7.5 Hz, 1 H), 7.28–7.18 (m, 2 H), 
7.08–7.01 (m, 1 H), 5.50–5.33 (m, 2 H), 4.49 (broad s, 1 H), 3.08–3.02 (m, 2 H), 2.77 (t, 
J = 7.2 Hz, 2 H), 2.35 (q, J = 7.5 Hz, 2 H), 2.00 (q, J = 6.9 Hz, 2 H), 1.50–1.37 (m, 11 
H); 13C NMR (75 MHz, CDCl3) δ 156.1, 141.3, 132.9, 130.8, 130.0, 129.2, 127.8, 127.5, 
124.6, 79.2, 40.3, 36.4, 30.1, 28.6, 27.7, 24.6; IR (film) 3356, 2931, 1703 cm–1. MS (ESI) 
390.1057 (390.1045 calcd for C18H26BrNO2, M + Na+). 
 (R)-tert-butyl 2-((S)-2,3-dihydro-1H-inden-1-yl)pyrrolidine-1-carboxylate (IV-100). 
The cyclization of IV-99 (100 mg, 0.272 mmol) following the general procedure using 
BINAP as ligand afforded 24 mg (31%) of the title compound as a yellow oil. This 
compound was judged to be a 1.25:1 mixture of rotamers by 1H NMR analysis. The 
diastereoselectivity was not determined at this point. Instead a sample of the crude 
material was subjected to Boc-cleavage (see below). Data are for the mixture. 1H NMR 
(500 MHz, CDCl3) δ 7.22–7.12 (m, 4 H), 4.29–3.98 (m, 2 H), 3.60–3.34 (m, 2 H), 3.00–
2.90 (m, 2 H), 2.88–2.82 (m, 2 H), 2.18–2.04 (m, 1 H), 1.90–1.70 (m, 3 H), 1.46 (s, 4 H), 
1.29 (s, 5 H); 13C NMR (75 MHz, CDCl3) δ 155.0, 145.1, 144.7, 126.6, 126.4, 124.7, 
124.6, 79.2, 77.4, 60.0, 48.3, 47.0, 31.6, 28.5, 27.7, 23.6; IR (film) 2918, 1692 cm–1. MS 
(ESI) 310.1780 (310.1783 calcd for C18H25NO2, M + Na+). 
(S)-tert-butyl 2-((S)-2,3-dihydro-1H-inden-1-yl)pyrrolidine-1-carboxylate (IV-101). 
The cyclization of IV-99 (75 mg, 0.204 mmol) following the general procedure using 
PCy3•HBF4 as ligand afforded 30 mg (52%) of the title compound as a yellow oil. This 
compound was judged to be a 3:1 mixture of rotamers by 1H NMR analysis. The 
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diastereoselectivity was not determined at this point. Instead a sample of the crude 
material was subjected to Boc-cleavage (see below). Data are for the pure mixture. 1H 
NMR (400 MHz, CDCl3) δ 7.21–7.11 (m, 4 H), 4.29–4.00 (m, 0.75 H), 3.88–3.76 (m, 
0.25 H), 3.60–3.35 (m, 1 H), 3.16–3.10 (m, 1 H), 3.04–2.92 (m, 1 H), 2.89–2.82 (m, 1 H), 
2.26–2.21 (m, 1 H), 1.87–1.80 (m, 3 H), 1.52 (s, 9H), 1.49–1.26 (m, 3 H); 13C NMR (100 
MHz, CDCl3) δ 155.2, 145.1, 144.6, 126.9, 126.3, 125.7, 124.59, 124.55, 79.2, 77.4, 
61.7, 47.8, 47.4, 47.2, 46.2, 31.9, 28.8, 28.5, 27.8, 26.8, 24.3, 23.6; IR (film) 2927, 1692 
cm–1. MS (ESI) 310.1776 (310.1783 calcd for C18H25NO2, M + Na+). 
(S)-2-((R)-2,3-dihydro-1H-inden-1-yl)pyrrolidine (IV-102). A sample of crude product 
IV-100 was dissolved in 2 mL CH2Cl2 and several drops of TFA were added and the 
reaction was stirred until consumption of the starting material by 1H NMR analysis. GC 
analysis of the crude material revealed a 1: 9.7 (syn:anti)  mixture of diastereomers, 
which was also confirmed by conversion to the N-Ph pyrrolidine IV-90 via N-arylation of 
the pure IV-102. 1H NMR (400 MHz, CDCl3) δ 7.43–7.28 (m, 2 H), 7.24–7.10 (m, 2 H), 
3.20–3.14 (m, 2 H), 3.11–3.06 (m, 2 H), 3.01–2.93 (m, 2 H), 2.88–2.80 (m, 2 H), 2.26–
2.20 (m, 1 H), 1.92–1.81 (m, 2 H), 1.81–1.66 (m, 2 H); 13C NMR (75 MHz, CDCl3) δ 
145.1, 144.4, 128.6, 126.7, 126.2, 125.0, 124.7, 63.0, 50.4, 46.9, 31.6, 30.0, 29.3, 25.2; 
IR (film) 2917, 1651 cm–1. MS (ESI) 188.1431 (188.1439 calcd for C13H17N, M + H+). 
(S)-2-((S)-2,3-dihydro-1H-inden-1-yl)pyrrolidine (IV-103).  A sample of crude product 
IV-101 was dissolved in 2 mL CH2Cl2 and several drops of TFA were added and the 
reaction was stirred until consumption of the starting material by 1H NMR analysis. GC 
analysis of the crude material revealed a 2.15:1.0 (syn: anti) mixture of diastereomers, 
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which was also confirmed by conversion to the N-Ph pyrrolidine IV-89 via N-arylation of 
the pure IV-103. 1H NMR (400 MHz, CDCl3) δ 7.34–7.27 (m, 1 H), 7.23–7.12 (m, 3 H), 
3.26–3.18 (m, 2 H), 3.05–2.93 (m, 2 H), 2.89–2.79 (m, 2 H), 2.27–2.17 (m, 1 H), 2.05–
1.93 (m, 3 H), 1.91–1.66 (m, 3 H); 13C NMR (75 MHz, CDCl3) δ 145.0, 144.9, 128.6, 
126.8, 126.24, 126.15, 124.8, 124.6, 62.4, 50.1, 46.4, 31.4, 30.4, 30.2, 29.3, 26.5, 25.6, 
25.1; IR (film) 2930, 1688 cm–1. MS (ESI) 188.1431 (188.1439 calcd for C13H17N, M + 
H+). 
(±)-(1S*,2R*,5R*)-N,5-Diphenyl-2-indan-1-ylpyrrolidine (IV-104). The cyclization of 
IV-55 (123.8 mg, 0.295 mmol) following the general procedure using PCy3·HBF4 as 
ligand afforded 59 mg (59%) of the title compound as yellow foam. This compound was 
judged to be a 5:1 mixture of diastereomers IV-104 and IV-112 by 1H NMR analysis. 
Data are for the major diastereomer. 1H NMR (500 MHz, CDCl3) δ 7.49–7.46 (m, 1 H), 
7.41–7.36 (m, 2 H), 7.31–7.16 (m, 4 H), 7.14–7.10 (m, 4 H), 6.74–6.59 (m, 3 H), 5.17 (d, 
J = 6.8 Hz, 1 H), 4.87 (dd, J = 3.6, 8.0 Hz, 1 H), 4.14 (dt, J = 3.6, 7.2 Hz, 1 H), 2.98–2.90 
(m, 1 H), 2.87–2.79 (m, 1 H) 2.65–2.54 (m, 1 H), 2.16–2.01 (m, 2 H), 1.97–1.90 (m, 1 
H), 1.85 –1.80 (m, 1 H), 1.66–1.61 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 145.5, 
145.3, 145.1, 144.9, 129.0, 128.6, 126.7, 126.6, 126.42, 126.39, 124.8, 123.9, 116.0, 
115.0, 63.4, 61.1, 45.3, 35.3, 31.9, 27.4, 24.7; IR (film) 2963 cm–1. Anal calcd for 
C25H25N: C, 88.45; H, 7.42; N, 4.13.  Found: 88.16; H, 7.46; N, 4.13. 
(±)-(1S*,2S*,5R*)-N,5-Diphenyl-2-indan-1-yl-pyrrolidine (IV-110). The cyclization of 
IV-63 (100 mg, 0.24 mmol) following the general procedure using PCy3·HBF4 as ligand 
afforded 60 mg (75%) of the title compound as an orange solid, m.p. 114–119 °C.  This 
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compound was judged to be a 2:1 mixture of diastereomers IV-110 and IV-111 by 1H 
analysis. 1H NMR (500 MHz, CDCl3) δ 7.38–7.35 (m, 4 H), 7.34–7.29 (m, 2 H), 7.25–
7.20 (m, 2 H), 7.16–7.13 (m, 3 H), 6.71 (t, J = 7.0 Hz, 1 H), 6.67 (d, J = 8.0 Hz, 2 H), 
4.60 (t, J = 7.5 Hz, 1 H), 4.05 (dt, J = 2.0, 8.5 Hz, 1 H), 3.49 (dt, J = 3.5, 12.0 Hz, 1 H), 
3.22–3.15 (m, 1 H), 2.95–2.89 (m, 1 H), 2.52–2.47 (m, 1 H), 2.44–2.40 (m, 1 H), 2.39–
2.31 (m, 1 H), 2.10–2.06 (m, 1 H), 2.05–1.92 (m, 2 H); 13C NMR (125 MHz, CDCl3) 
δ 149.8, 145.5, 145.3, 144.9, 129.0, 128.9, 127.1, 126.8, 126.2, 125.8, 125.7, 125.0, 
117.1, 113.8, 67.3, 64.8, 50.2, 35.0, 31.6, 29.8, 28.9. IR (film) 2941, 1598 cm-1. Anal 
calcd for C25H25N: C, 88.45; H, 7.42; N, 4.13.  Found: C, 88.39; H, 7.40, N, 4.17. 
Determination of Stereochemistry 
The stereochemistry of 2-(1-indanyl)tetrahydrofuran products IV-64 and IV-65 was 
assigned by preparing the related tetrahydrofurans IV-74 and IV-76 with subsequent 
conversion of IV-74 to the crystalline solid IV-75 (Scheme 49). Connectivity of IV-64–
IV-65 and IV-74 and IV-76 was determined by 2D-NMR COSY and HSQC 
experiments, and the stereochemical configuration of IV-75 was established by X-ray 
crystallography. The unit cell contained both enantiomers of the racemic product. 
Tetrahydrofuran derivatives IV-74 and IV-76 were prepared using a sequence of 
reactions similar to those described above for the synthesis of IV-64 and IV-65. 
Z-7-[5-(Benzhydrilideneamino)-2-bromophenyl]hept-4-en-1-ol (IV-73). 1H NMR 
(500 MHz, CDCl3) δ 7.73–7.71 (m, 2 H), 7.49–7.46 (m, 1 H), 7.42–7.39 (m, 1 H) 7.33–
7.26 (m, 5 H), 7.11–7.09 (m, 2 H), 6.60 (d, J = 2.5 Hz, 1 H), 6.43 (dd, J = 2.5, 8.5 Hz, 1 
H), 5.37–5.30 (m, 2 H), 3.61–3.58 (m, 2 H), 2.63–2.60 (m, 2 H), 2.24–2.19 (m, 2 H), 
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2.09–2.05 (m, 2 H), 1.60–1.53 (m, 2 H), 1.49 (s, 1 H); 13C NMR (125 MHz, CDCl3) 
δ 169.1, 150.6, 141.3, 139.6, 136.2, 132.8, 131.1, 130.2, 129.6, 129.5, 129.1, 129.0, 
128.5, 128.3, 123.4, 120.7, 118.6, 62.7, 36.1, 32.8, 24.5, 23.8. IR (film) 3370, 2933, 1614 
cm–1; MS (ESI) 470.1093 (470.1095 calcd for C26H26BrNO, M + Na+). 
(±)-(1S*,2S*)-Benzhydrilidene[1-(tetrahydrofuran-2-yl)indan-5-yl]amine (IV-76). 1H 
NMR (400 MHz, CDCl3) δ 7.73–7.71 (m, 2 H), 7.47–7.43 (m, 3 H), 7.40–7.36 (m, 2 H), 
7.24–7.21 (m, 2 H), 7.13–7.11 (m, 2 H), 6.58 (s, 1 H), 6.49 (dd, J = 2.0, 8.0 Hz, 1 H), 
3.91–3.85 (m, 2 H), 3.79–3.74 (m, 1 H), 3.22–3.16 (m, 1 H), 2.79–2.67 (m, 2 H) 2.16–
2.04 (m, 1 H), 1.89–1.79 (m, 3 H), 1.74–1.65 (m, 1 H), 1.54–1.48 (m, 1 H); 13C NMR 
(125 MHz, CDCl3) δ 167.8, 150.1, 144.8, 140.4, 140.2, 136.7, 130.7, 129.8, 129.5, 128.6, 
128.3, 128.0, 125.2, 119.3, 117.2, 83.4, 68.3, 49.2, 31.8, 29.6, 28.3, 25.9; IR (film) 2953, 
1652 cm–1. Anal calcd for C26H25NO: C, 84.98; H, 6.86; N, 3.81. Found: C, 84.92; H, 
6.84; N, 3.71. 
 (±)-(1S*,2R*)-Benzhydrilidene[1-(tetrahydrofuran-2-yl)indan-5-yl]amine (IV-74). 
1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 7.2 Hz, 2 H), 7.47–7.44 (m, 1 H), 7.41–7.37 
(m, 2 H), 7.34–7.30 (m, 1 H), 7.27–7.24 (m, 2 H), 7.13–7.11 (m, 2 H), 7.03 (d, J = 7.6 
Hz, 1 H), 6.61 (s, 1 H), 6.46 (d, J = 8.4 Hz, 1 H), 3.90–3.84 (m, 1 H), 3.84–3.79 (m, 1 H), 
3.74–3.68 (m, 1 H), 3.27–3.22 (m, 1 H), 2.82–2.77 (m, 1 H), 2.72–2.66 (m, 1 H), 2.20–
2.15 (m, 1 H), 1.97–1.87 (m, 2 H), 1.86–1.77 (m, 2 H), 1.63–1.46 (m, 1 H); 13C NMR 
(100 MHz, CDCl3) δ 167.9, 150.3, 145.6, 140.2, 138.9, 136.7, 130.7, 129.8, 129.5, 128.6, 
128.4, 128.0, 124.9, 119.1, 117.4, 82.1, 68.1, 49.2, 31.4, 29.1, 28.7, 26.4; IR (film) 2942, 
1652 cm–1; MS (EI) 367.1942 (367.1936 calculated for C26H25NO). 
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 (±)-(1S*,2R*)-Biphenyl-4-yl[1-(tetrahydrofuran-2-yl)indan-5-yl]amine (IV-75). 1H 
NMR (400 MHz, CDCl3) δ 7.58–7.55 (m, 2 H), 7.51–7.48 (m, 2 H), 7.44–7.40 (m, 3 H), 
7.31–7.28 (m, 1 H), 7.12–7.08 (m, 2 H), 7.01 (s, 1 H), 6.95–6.93 (m, 1 H), 5.73 (s, br, 1 
H), 4.00–3.94 (m, 1 H), 3.93–3.88 (m, 1 H), 3.83–3.78 (m, 1 H), 3.27–3.21 (m, 1 H), 
2.95–2.81 (m, 2 H), 2.26–2.17 (m, 1 H), 2.03–1.85 (m, 3 H), 1.82–1.73 (m, 1 H), 1.65–
1.56 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 145.8, 143.6, 141.6, 141.2, 139.1, 133.2, 
128.9, 128.1, 126.7, 126.6, 126.4, 117.5, 117.3, 114.8, 83.3, 68.3, 49.4, 32.0, 30.0, 28.7, 
25.9; IR (film) 2951, 1605 cm–1; MS (EI): 355.1924 (355.1936 calculated for C25H25NO); 
mp 87–90 °C. 
The stereochemistry of the 2-(1-indanyl)tetrahydrofuran products IV-77 and IV-78 was 
established by comparison of the 1H NMR spectra of IV-77 and IV-78 to the related 
tetrahydrofuran derivatives IV-81 and IV-82, which were in turn assigned by X-ray 
crystallographic analysis of IV-81. The connectivity of these molecules was further 
confirmed by 2D-NMR COSY and HSQC experiments. Biphenyl tetrahydrofuran 
derivatives IV–79 and IV-80 were prepared using a sequence of reactions analogous to 
those described above for the synthesis of IV-58 and IV-50. 
 
E-1,1-Bis(biphenyl-4-yl)-7-(2-bromophenyl)hept-4-en-1-ol (IV-80). 1H NMR (500 
MHz, CDCl3) δ 7.63–7.59 (m, 8 H), 7.56–7.54 (m, 5 H), 7.47–7.46 (m, 4 H) 7.38–7.35 
(m, 2 H), 7.26–7.20 (m, 2 H), 7.09–7.05 (m, 1 H), 5.58–5.50 (m, 2 H), 2.83–2.80 (m, 2 
H), 2.45–2.42 (m, 2 H), 2.36–2.31 (m, 2 H), 2.12–2.10 (m, 2 H); 13C NMR (125 MHz, 
CDCl3) δ 146.1, 141.4, 140.9, 139.9, 132.9, 131.1, 130.6, 129.8, 128.9, 127.7, 127.5, 
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127.4, 127.2, 127.1, 126.6, 124.7, 78.4, 41.8, 36.4, 33.0, 27.3; IR (film) 3447, 2928 cm–1. 
MS (EI) 572.1703 (572.1715 calcd for C37H33BrO). 
Z-1,1-Bis(biphenyl-4-yl)-7-(2-bromophenyl)hept-4-en-1-ol (IV-79). 1H NMR (500 
MHz, CDCl3) δ 7.59–7.55 (m, 8 H), 7.51–7.44 (m, 5 H), 7.44–7.41 (m, 4 H) 7.35–7.32 
(m, 2 H), 7.13–7.10 (m, 2 H), 7.00–6.96 (m, 1 H), 5.53–5.45 (m, 2 H), 2.73–2.70 (m, 2 
H), 2.29–2.23 (m, 4 H), 2.08–2.03 (m, 2 H); 13C NMR (125 MHz, CDCl3) δ 146.0, 141.2, 
140.9, 139.9, 132.9, 130.8, 130.6, 129.3, 128.9, 127.8, 127.4, 127.3, 127.2, 126.6, 124.6, 
78.4, 42.0, 36.3, 27.7, 22.2 (one carbon signal is absent due to accidental equivalence); 
IR (film) 3563, 2928 cm-1. Anal calcd for C37H33BrO: C, 77.48; H, 5.80.  Found: C, 
77.51; H, 5.61.  
(±)-(1R*,5S*)-2,2-Bis(biphenyl-4-yl)-5-indan-1-yltetrahydrofuran (IV-82). 1H NMR 
(400 MHz, CDCl3) δ 7.85 (d, J = 6.8 Hz, 1 H), 7.62–7.50 (m, 12 H), 7.43–7.40 (m, 4 H), 
7.34–7.31 (m, 2 H), 7.25–7.22 (m, 3 H), 4.30–4.25 (m, 1 H), 3.51–3.45 (m, 1 H), 2.99–
2.87 (m, 2 H), 2.76–2.62 (m, 2 H), 2.26–2.18 (m, 1 H), 2.12–2.04 (m, 1 H), 1.88–1.72 
(m, 2 H); 13C NMR (125 MHz, CDCl3) δ 146.6, 146.0, 145.7, 144.7, 141.11, 141.09, 
139.8, 139.7, 128.9, 127.4, 127.3, 127.28, 127.23, 127.1, 126.9, 126.5, 126.46, 126.42, 
126.1, 124.5, 88.4, 83.0, 50.6, 39.1, 31.9, 30.3, 28.7; IR (film) 3027, 2948 cm-1; MS (EI): 
492.2445 (492.2453 calculated for C26H25NO); m.p. 155–159 °C. 
(±)-(1S*,5S*)-2,2-Bis(biphenyl-4-yl)-5-indan-1-yltetrahydrofuran (IV-81). 1H NMR 
(400 MHz, CDCl3) δ 7.64–7.55 (m, 13 H), 7.46–7.42 (m, 4 H), 7.36–7.28 (m, 3 H), 7.21–
7.17 (m, 1 H), 7.14–7.11 (m, 1 H), 4.28–4.22 (m, 1 H), 3.52–3.47 (m, 1 H), 3.10–3.02 
(m, 1 H), 2.95–2.87 (m, 1 H), 2.81–2.75 (m, 1 H), 2.62–2.55 (m, 1 H), 2.42–2.26 (m, 2 
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H), 2.15–2.07 (m, 1 H), 1.97–1.88 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 146.5, 146.0, 
145.3, 144.1, 141.11, 141.08, 139.8, 139.6, 128.9, 127.4, 127.3, 127.27, 127.25, 127.1, 
127.0, 126.5, 126.4, 126.1, 125.1, 124.7, 87.6, 81.2, 50.4, 39.2, 31.4, 29.9, 28.9; MS (EI) 
492.2448 (492.2453 calcd for C37H32O); m.p. 145–147 °C. 
The stereochemistry of the 2-(1-indanyl)tetrahydrofuran product IV-83 was established 
by comparison of the 1H NMR spectra of IV-83 to the related tetrahydrofuran derivative 
88, which was in turn assigned by X-ray crystallographic analysis. The connectivity of 
these molecules was further confirmed by 2D-NMR COSY and HSQC experiments. 
Derivative IV-88 was prepared by oxidation of IV-73 followed by addition of 
phenylmagnesium bromide. 
E-7-[5-(Benzhydrilideneamino)-2-bromophenyl]-1-phenylhept-4-en-1-ol (IV-87). 1H 
NMR (500 MHz, CDCl3) δ 7.60–7.60 (m, 2 H), 7.47–7.44 (m, 1 H), 7.38–7.29 (m, 8 H) 
7.28–7.23 (m, 3 H), 7.07–7.05 (m, 2 H), 6.65 (d, J = 3.0 Hz, 1 H), 6.31 (dd, J = 2.5, 8.5 
Hz, 1 H), 5.46–5.30 (m, 2 H), 4.52–4.48 (m, 1 H), 2.75–2.69 (m, 1 H), 2.63–2.57 (m, 2 
H), 2.23–2.05 (m, 4 H), 1.87–1.80 (m, 1 H), 1.71–1.64 (m, 1 H); 13C NMR (125 MHz, 
CDCl3) δ 169.4, 150.2, 145.5, 141.3, 136.1, 132.7, 131.2, 130.8, 130.1, 129.64, 129.60, 
129.1, 129.0, 128.6, 128.5, 128.4, 127.5, 126.1, 124.0, 120.3, 73.4, 38.7, 36.2, 32.8, 29.0; 
IR (film) 3392, 2926 cm–1. MS (EI) 523.1506 (523.1511 calcd for C32 H30BrNO). 
(±)-(1S*,2R*,5R*)-Benzhydrilidene[1-(5-phenyltetrahydrofuran-2-yl)indan-5-
yl]amine (IV-88). 1H NMR (400 MHz, CDCl3) δ 7.74–7.71 (m, 2 H), 7.47–7.44 (m, 1 
H), 7.41–7.37 (m, 2 H), 7.33–7.30 (m, 5 H), 7.27–7.22 (m, 6 H), 7.21–7.12 (m, 2 H), 
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5.05–5.02 (m, 1 H), 4.28–4.23 (m, 1 H), 3.39–3.28 (m, 1 H), 2.80–2.73 (m, 2 H), 2.39–
2.32 (m, 1 H), 2.20–2.12 (m, 1 H), 2.03–1.97 (m, 1 H), 1.86–1.70 (m, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 167.8, 150.2, 144.9, 144.3, 140.4, 140.2, 136.7, 130.7, 129.8, 129.5, 
128.6, 128.5, 128.4, 128.0, 127.2, 125.7, 125.4, 119.3, 117.2, 84.1, 80.8, 49.6, 35.4, 31.9, 
29.9, 28.2; IR (film) 2926 cm–1; MS (EI) 443.2255 (443.2249 calculated for C32H29NO); 
m.p. 117–121 °C. 
The stereochemistry of the 2-(1-indanyl)pyrrolidine products IV-89 and IV-90 was 
established by comparison of the 1H NMR spectra of IV-89 and IV-90 to the analogous 
N-biphenyl pyrrolidine derivatives IV-95 and IV-96, which were in turn assigned by X-
ray crystallographic analysis. The connectivity of these four molecules was confirmed by 
2D-NMR COSY and HSQC experiments. Biphenyl pyrrolidine derivatives IV-95– IV-96 
were prepared using a sequence of reactions analogous to those described above for the 
synthesis of IV-89 and IV-90.  
(E)-Biphenyl-4-yl-[7-(2-bromophenyl)hept-4-enyl)]amine (IV-94). 1H NMR (400 
MHz, CDCl3) δ 7.59–7.55 (m, 3 H), 7.49–7.46 (m, 2 H), 7.44–7.40 (m, 2 H) 7.30–7.22 
(m, 3 H), 7.09–7.05 (m, 1 H), 6.71–6.67 (m, 2 H), 5.60–5.46 (m, 2 H), 3.75 (s, 1 H), 3.16 
(t, J = 5.6 Hz, 2 H), 2.86–2.82 (m, 2 H), 2.39–2.34 (m, 2 H), 2.18–2.12 (m, 2 H), 1.75–
1.68 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 148.0, 141.5, 141.4, 132.9, 130.6, 130.5, 
130.2, 130.0, 128.8, 128.1, 127.7, 127.5, 126.4, 126.2, 124.7, 113.1, 43.5, 36.4, 32.9, 
30.2, 29.3; IR (film) 3410, 2928, 1612 cm–1; MS (ESI) 420.1333 (420.1327 calcd for 
C25H26BrN, M + H+). 
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(Z)-Biphenyl-4-yl-[7-(2-bromophenyl)hept-4-enyl)]amine (IV-92). 1H NMR (400 
MHz, CDCl3) δ 7.56–7.53 (m, 3 H), 7.45 (d, J = 8.4 Hz, 2 H), 7.40 (t, J = 7.6 Hz, 3 H) 
7.28–7.18 (m, 2 H), 7.08–7.04 (m, 1 H), 6.67 (d, J = 8.8 Hz, 2 H), 5.55–5.42 (m, 2 H), 
3.72 (s, br, 1 H), 3.12 (t, J = 7.2 Hz, 2 H), 2.82–2.78 (m, 2 H), 2.43–2.37 (m, 2 H), 2.15–
2.10 (m, 2 H), 1.65–1.57 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 148.0, 141.5, 141.3, 
133.0, 130.8, 130.23, 130.19, 129.3, 128.8, 128.1, 127.8, 127.5, 126.5, 126.2, 124.6, 
113.2, 43.7, 36.4, 29.5, 27.8, 25.0; IR (film) 3411, 2859, 1612 cm–1. Anal calcd for 
C25H26BrN: C, 71.43; H, 6.23; N, 3.33. Found: C, 71.67; H, 6.18; N, 3.39. 
(±)-(1R*,2S*)-N-(4-Phenyl)phenyl-2-indan-1-ylpyrrolidine (IV-96). 1H NMR (400 
MHz, CDCl3) δ 7.57 (d, J = 8.4 Hz, 2 H), 7.50–7.48 (m, 2 H), 7.41 (t, J = 8.0 Hz, 2 H), 
7.30–7.20 (m, 3 H), 7.20–7.14 (m, 2 H), 6.72 (d, J = 8.4 Hz, 2 H), 4.38–4.34 (m, 1 H), 
3.90–3.85 (m, 1 H), 3.69–3.64 (m, 1 H), 3.39–3.32 (m, 1 H), 3.02–2.95 (m, 1 H), 2.90–
2.82 (m, 1 H), 2.13–2.04 (m, 2 H), 2.02–1.87 (m, 3 H), 1.74–1.68 (m, 1 H); 13C NMR 
(100 MHz, CDCl3) δ 147.4, 145.0, 144.9, 141.6, 128.8, 128.7, 127.9, 126.8, 126.4, 126.3, 
126.0, 124.7, 124.4, 112.9, 60.9, 50.2, 46.9, 31.8, 27.8, 27.3, 24.5; IR (film) 2940, 1609 
cm–1; MS (EI): 339.1989 (339.1987 calcd for C25H25N); m.p. 103–110 °C. 
(±)-(1R*,2R*)-N-(4-Phenyl)phenyl-2-indan-1-ylpyrrolidine (IV-95). 1H NMR (400 
MHz, CDCl3) δ 7.56–7.54 (m, 4 H), 7.41 (t, J = 8.0 Hz, 2 H), 7.28–7.21 (m, 2 H), 7.18–
7.14 (m, 1 H), 7.01–7.07 (m, 2 H), 6.83 (d, J = 8.8 Hz, 2 H), 4.11–4.08 (m, 1 H), 3.97–
3.93 (m, 1 H), 3.51–3.45 (m, 1 H), 3.27–3.20 (m, 1 H), 3.10–3.04 (m, 1 H), 2.97–2.89 
(m, 1 H), 2.39–2.31 (m, 1 H), 1.98–1.87 (m, 2 H), 1.72–1.55 (m, 2 H), 1.34–1.27 (m, 1 
H); 13C NMR (100 MHz, CDCl3) δ 147.1, 145.1, 144.2, 141.6, 128.8, 128.6, 128.0, 
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126.9, 126.4, 126.2, 126.0, 125.9, 124.5, 112.9, 63.0, 50.3, 45.6, 32.0, 28.2, 27.6, 24.1; 
IR (film) 2941, 1609 cm–1; MS (EI): 339.1994 (339.1987 calculated for C25H25N); m.p. 
93–98 °C. 
The stereochemistry for (±)-(1S*,2S*,5R*)-N,5-Diphenyl-2-indan-1-yl-pyrrolidine (IV-
10) was established by X-ray crystallographic analysis as shown below. Data are given 
above. 
The stereochemistry of (1S*,2R*,5R*)-N,5-Diphenyl-2-indan-1-ylpyrrolidine (IV-104) 
was established by comparison of the 1H NMR spectra of IV-104 to that obtained for the 
analogous N-biphenyl pyrrolidine derivative IV-108, which was in turn assigned by X-
ray crystallographic analysis. Derivative IV-108 was prepared using a sequence of 
reactions analogous to those described above for the synthesis of IV-104.  
E-Biphenyl-4-yl[7-(2-bromophenyl)-1-phenylhept-4-enyl]amine (IV-107). 1H NMR 
(400 MHz, CDCl3) δ 7.54–7.51 (m, 1 H), 7.49–7.47 (m, 2 H), 7.37–7.31 (m, 8 H), 7.25–
7.18 (m, 4 H), 7.06–7.02 (m, 1 H), 6.58–6.55 (m, 2 H), 5.55–5.43 (m, 2 H), 4.35 (t, J = 
6.8 Hz, 1 H), 4.18 (s, br, 1 H), 2.80–2.77 (m, 2 H), 2.35–2.29 (m, 2 H), 2.15–2.03 (m, 2 
H), 1.93–1.80 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 147.0, 144.1, 141.4, 141.3, 132.9, 
130.6, 130.3, 130.24, 130.19, 128.78, 128.77, 128.0, 127.7, 127.5, 127.2, 126.6, 126.4, 
126.1, 124.7, 113.6, 57.8, 38.6, 36.4, 32.9, 29.5; IR (film) 3413, 2930, 1612 cm–1. MS 
(ESI) 496.1646 (496.1640 calcd for C31H30BrN, M + H+). 
(1S*,2R*,5R*)-N-(Biphenyl-4-yl)-2-indan-1-yl-5-phenylpyrrolidine (IV-108). 1H 
NMR (400 MHz, CDCl3) δ 7.49–7.47 (m, 3 H), 7.38–7.32 (m, 6 H), 7.26–7.16 (m, 5 H), 
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7.13–7.11 (m, 2 H), 6.70 (d, J = 8.8 Hz, 2 H), 5.18 (d, J = 8 Hz, 1 H), 4.89–4.86 (m, 1 H), 
4.17–4.12 (m, 1 H), 2.98–2.87 (m, 1 H), 2.86–2.78 (m, 1 H), 2.65–2.54 (m, 1 H), 2.13 –
2.01 (m, 2 H), 1.96–1.89 (m, 1 H), 1.85–1.80 (m, 1 H), 1.66–1.61 (m, 1 H); 13C NMR 
(125 MHz, CDCl3) δ 145.2, 145.1, 144.9, 144.8, 141.3, 128.8, 128.7, 127.6, 126.8, 126.7, 
126.5, 126.4, 126.3, 126.0, 124.9, 123.9, 115.1, 114.5, 63.5, 61.2, 45.4, 35.3, 31.9, 27.5, 
24.7; IR (film) 2918, 1609 cm–1. MS (ESI) 416.2370 (416.2378 calcd for C31H29N, M + 
H+); mp 148–152 °C.  
(Schemes 69–73) 
The substrates and products described in (Schemes 69–73) were prepared using 
analogous transformations and procedures as those discussed in the first part of the 
experimental (pages 229-252) for the intramolecular carboetherification and 
carboamination reactions.  
1-(allyloxy)-2-bromobenzene (IV-157). 1H NMR (500 MHz, CDCl3) δ 7.55–7.53 (dd, J 
= 1.5, 6.4 Hz, 1 H), 7.26–7.23 (m, 2 H), 6.90 (dd, J = 1.5, 8.5 Hz, 1 H), 6.84 (dt, J = 1.0, 
8.0 Hz, 1 H), 6.11–6.03 (m, 1 H), 5.51–5.47 (m, 1 H), 5.33–5.30 (m, 1 H), 4.62–4.61 (m, 
1 H). 
1-(allyloxy)-2-iodobenzene (IV-158). 1H NMR (300 MHz, CDCl3) δ 7.78 (dd, J = 1.8, 
8.1 Hz, 1 H), 7.31–7.25 (m, 1 H), 6.81 (dd, J = 1.2, 8.1 Hz, 1 H), 6.71 (dt, J = 1.5, 7.8 Hz, 
1 H), 6.13–6.00 (m, 1 H), 5.56–5.49 (m, 1 H), 5.34–5.29 (m, 1 H), 4.61–4.59 (m, 2 H). 
2-(2-bromophenoxy)acetaldehyde (IV-159). 1H NMR (500 MHz, CDCl3) 9.91 (s, 1 H), 
7.60–7.52 (m, 1 H), 6.93–6.78 (m, 3 H), 4.61 (s, 2 H). 
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2-(2-iodophenoxy)acetaldehyde (IV-160). 1H NMR (300 MHz, CDCl3) 1H NMR (300 
MHz, CDCl3) δ 9.92 (s, 1 H), 7.84–7.72 (m, 1 H), 7.33–7.28 (m, 1 H), 6.85–6.69 (s, 2 H), 
4.61 (s, 2 H). 
(Z)-ethyl 6-(2-bromophenoxy)hex-4-enoate (IV-161). 1H NMR (400 MHz, CDCl3) δ 
7.54–7.52 (m, 1 H), 7.26–7.22 (m, 1 H), 6.91 (d, J = 8 Hz, 1 H), 6.85–6.81 (m, 1 H), 
5.80–5.74 (m, 1 H), 5.67–5.61 (m, 1 H), 4.68 (d, J = 6 Hz, 2 H), 4.13 (q, J = 7.2 Hz, 2 H), 
2.49–2.38 (m, 4 H), 1.25 (t, J = 7.2 Hz, 3 H). 
(Z)-ethyl 6-(2-iodophenoxy)hex-4-enoate (IV-162). 1H NMR (400 MHz, CDCl3) δ 
7.55–7.49 (m, 1 H), 7.33–7.24 (m, 1 H), 6.82 (d, J = 8.4 Hz, 1 H), 6.71–6.67 (m, 1 H), 
5.82–5.72 (m, 1 H), 5.66–5.54 (m, 1 H), 4.66 (d, J = 6.4 Hz, 2 H), 4.15–4.03 (m, 2 H), 
2.49–2.30 (m, 4 H), 1.24 (t, J = 5.6 Hz, 3 H). 
(Z)-N-(6-(2-bromophenoxy)hex-4-enyl)aniline (IV-163). 1H NMR (400 MHz, CDCl3) 
δ 7.56–7.53 (m, 1 H), 7.30–7.15 (m, 3 H), 6.97–6.82 (m, 2 H), 6.69 (t, J = 7.2 Hz, 1 H), 
6.59 (d, J = 8.4 Hz, 2 H), 5.82–5.67 (m, 2 H), 4.65 (d, J = 6, 1 H), 4.58 (d, J = 6 Hz, 1 H), 
3.64 (s, 1 H), 3.20–3.12 (m, 2 H), 2.31–2.25 (m, 2 H), 1.78–1.71 (m, 2 H). 
(Z)-6-(2-bromophenoxy)-N-phenylhex-4-enamide (IV-163b). 1H NMR (400 MHz, 
CDCl3) δ 7.55–7.49 (m, 2 H), 7.31 (t, J = 8 Hz, 2 H), 7.25–7.21 (m, 2 H), 7.10 (t, J = 7.2 
Hz, 1 H), 6.92 (d, J = 8.4 Hz, 1 H), 6.84 (dt, J = 1.2, 7.6 Hz, 1 H), 5.86–5.80 (m, 1 H), 
5.78–5.71 (m, 1 H), 4.70 (d, J = 5.6 Hz, 1 H), 3.76–3.73 (m, 1H), 2.62–2.56 (m, 2H), 
2.49–2.45 (m, 2H), 1.87–1.84 (m, 1 H). 
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 (Z)-N-(6-(2-iodophenoxy)hex-4-enyl)aniline (IV-164). 1H NMR (400 MHz, CDCl3) δ 
7.31–7.27 (m, 1 H), 7.19–7.15 (m, 2 H), 6.98–6.89 (m, 3 H), 6.70 (t, J = 7.2 Hz, 1 H), 
6.59 (d, J = 8.8 Hz, 2 H), 5.80–5.67 (m, 2 H), 4.58 (d, J = 5.6 Hz, 2H), 3.68 (t, J = 6.4 
Hz, 2 H), 3.16 (t, J = 7.2 Hz, 1 H), 2.28 (q, J = 7.2 Hz, 2 H), 1.78–1.66 (m, 2 H). 
(Z)-7-(2-bromophenoxy)-2-methylhept-5-en-2-ol (IV-165). 1H NMR (400 MHz, 
CDCl3) δ 7.54 (dd, J = 1.6, 8 Hz, 1 H), 7.27–7.23 (m, 1 H), 6.92 (dd, J = 1.2, 8.4 Hz, 1 
H), 6.84 (dt, J = 1.6, 7.6 Hz, 1 H), 5.77–5.67 (m, 2 H), 4.68 (d, J = 4.8 Hz, 2H), 2.27–
2.22 (m, 2 H), 1.60–1.56 (m, 3 H), 1.24 (s, 6 H). 
(Z)-6-(2-iodophenoxy)hex-4-en-1-ol (IV-166). 1H NMR (400 MHz, CDCl3) δ 7.31–7.27 
(m, 1 H), 6.98–6.91 (m, 3 H), 5.80–5.67 (m, 2 H), 4.60 (d, J = 6.0 Hz, 2 H), 3.68 (q, J = 
5.6 Hz, 2 H), 2.27 (d, J = 7.2 Hz, 2 H), 1.73–1.66 (m, 2 H), 1.48 (t, J = 5.6 Hz, 1 H). 
1-(2-bromophenyl)-1H-pyrrole (IV-172).46  1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 
8 Hz, 1 H), 7.44–7.37 (m, 2 H), 7.30–7.26 (m, 1 H), 6.93–6.92 (m, 2 H), 6.39–6.38 (m, 2 
H). 
1-(2-bromophenyl)-1H-pyrrole-2-carbaldehyde (IV-173). 1H NMR (400 MHz, CDCl3) 
δ 9.54 (s, 1 H), 7.76–7.73 (m, 1 H), 7.49–7.45 (m, 1 H), 7.42–7.37 (m, 2 H), 7.18 (dd, J = 
1.6, 4 Hz, 2 H), 7.01–7.00 (m, 1 H). 
(Z)-ethyl 5-(1-(2-bromophenyl)-1H-pyrrol-2-yl)pent-4-enoate (IV-174). 1H NMR (400 
MHz, CDCl3) δ 7.69 (dd, J = 1.6, 4.4 Hz, 1 H), 7.42–7.38 (m, 1 H), 7.34–7.27 (m, 2 H), 
6.73–6.72 (m, 1 H), 6.45– 6.43 (m, 1 H), 6.36 (t, J = 3.6, 1 H), 5.84–5.74 (m, 1 H), 5.39–
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5.33 (m, 1 H), 4.14 (q, J = 7.2 Hz, 2 H), 2.74–2.69 (m, 2 H), 2.48–2.44 (m, 2 H), 1.26 (t, 
J = 7.2 Hz, 3 H). 
(Z)-5-(1-(2-bromophenyl)-1H-pyrrol-2-yl)pent-4-en-1-ol (IV-175). 1H NMR (400 
MHz, CDCl3) δ 7.70 (dd, J = 1.2, 8 Hz, 1 H), 7.46–7.28 (m, 3 H), 6.73–6.72 (m, 1 H), 
6.45–6.43 (m, 2 H), 5.78–5.75 (m, 1 H), 5.44–5.38 (m, 1 H), 3.73–3.68 (m, 2 H), 2.53–
2.46 (m, 2 H), 1.81–1.72 (m, 2 H), 1.65 (s, 1 H). 
(E)-ethyl 4-(2-(2-bromobenzyl)cyclohexylidene)butanoate (IV-177). 2:1 mixture of 
diastereomers. 1H NMR (400 MHz, CDCl3) δ 7.77–7.64 (m, 1 H), 7.56–7.43 (m, 2 H), 
7.33–7.00 (m, 1 H), 4.96 (t, J = 7.2 Hz, 1 H), 4.13–4.06 (m, 2 H), 3.36–3.32 (m, 1 H), 
2.98–2.93 (m, 1 H), 2.76–2.65 (m, 2 H), 2.58–2.52 (m, 1 H), 2.45–2.22 (m, 3 H), 2.16–
1.92 (m, 2 H), 1.70–1.55 (m, 4 H), 1.26–1.22 (m, 4 H). 
(E)-4-(2-(2-bromobenzyl)cyclohexylidene)-N-phenylbutanamide (IV-178). 2:1 
mixture of diastereomers. Data are for the major isomer. 1H NMR (500 MHz, CDCl3) δ 
7.53–7.45 (m, 3 H), 7.35–6.98 (m, 6 H), 5.04 (t, J = 7.5 Hz, 1 H), 3.35 (dd, J = 5.1, 13.8 
Hz, 2 H), 3.02–2.91 (m, 2 H), 2.78–2.65 (m, 1 H), 2.59–2.52 (m, 1 H), 2.46–2.24 (m, 2 
H), 2.20–1.98 (m, 2 H), 1.87–1.82 (m, 2 H), 1.75–1.48 (m, 4 H). 
(E)-4-(2-(2-bromobenzyl)cyclohexylidene)-N-phenylbutanamide (IV-179). 2:1 
mixture of diastereomers. Data are for the major isomer. 1H NMR (500 MHz, CDCl3) δ 
7.52–7.50 (m, 1 H), 7.35–7.28 (m, 3 H), 7.19–7.08 (m, 4 H), 7.05–6.99 (m, 1 H), 6.58 
(dd, J = 1.5, 9 Hz, 1 H), 5.01 (t, J = 4.2 Hz, 1H), 3.56 (s, 1 H), 3.03–2.98 (m, 2 H), 2.94–
2.88 (m, 1 H), 2.78–2.73 (m, 1 H), 2.48–2.43 (m, 1 H), 2.33–2.26 (m, 1 H), 2.17–2.05 
(m, 2 H), 1.75–1.67 (m, 1 H), 1.63–1.40 (m, 3 H), 1.54–1.25 (m, 4 H). 
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2-(2-bromobenzyl)cyclopentanone (IV-182).47  
A flame-dried flask was charged with 9.31 g (8.85 mL, 100 mmol) of cyclopentanone, N-
N-dimethylhydrazine (11.85 g, 9.25 mL, 120 mmol), benzene (40 mL) and TFA (0.05 
mL) and was then equipped with a magnetic stirbar, reflux condenser and Dean Stark 
trap. The reaction mixture was heated at reflux for 1 hour. Potassium carbonate was 
added to the cooled reaction mixture which was then filtered and concentrated in vacuo. 
The organic residue was then dissolved in diethyl ether and washed with brine, dried over 
sodium sulfate, and concentrated in vacuo providing 11.8 g (90%) of 2-cyclopentylidene-
1,1-dimethylhydrazine as a yellow oil.  
A flame-dried flask was charged with 2-cyclopentylidene-1,1-dimethylhydrazine (7.4 g, 
58.6 mmol) and THF (117 mL) and cooled to 0 °C, whereupon a solution of Butyllithium 
in hexanes (38.5 mL, 61.53 mmol, 1.6 M) was added. The reaction mixture was stirred 
for 50 min at 0 °C. At this point 2-Bromobenzyl-bromide (15.1 g, 60.4 mmol) in 10 mL 
THF was added via cannula. The reaction was stirred for 12 h, quenched with 1M HCl, 
and stirred for 2h followed by extraction with ethyl acetate, washing with saturated 
sodium chloride, and dried over anhydrous sodium sulfate. The crude material was 
purified by column chromatography to yield 11.26 g (76%) of the title compound. 1H 
NMR (500 MHz, CDCl3) δ 7.53 (d, J = 8 Hz, 1 H), 7.24–7.19 (m, 2 H), 7.08–7.05 (m, 1 
H), 3.33 (dd, J = 4.5, 14 Hz, 1 H), 2.64–2.60 (m, 1 H), 2.52–2.46 (m, 1 H), 2.39–2.33 (m, 




(E)-ethyl 4-(2-(2-bromobenzyl)cyclopentylidene)butanoate (IV-183). 2:1 mixture of 
inseparable diastereomers. Data are for the mixture. 1H NMR (300 MHz, CDCl3) δ 7.52 
(d, J = 7.8 Hz, 1 H), 7.35–7.30 (m, 1 H), 7.24–7.16 (m, 1 H), 7.10–7.02 (m, 1 H), 5.22–
5.17 (m, 1 H), 4.17–4.08 (m, 2 H), 3.15–2.97 (m, 2 H), 2.87–2.80 (m, 2 H), 2.65–2.49 
(m, 2 H), 2.41–2.12 (m, 2 H), 1.81–1.64 (m, 2 H), 1.61–1.48 (m, 3 H), 1.25 (t, J = 7.2 Hz, 
3 H). 
(E)-4-(2-(2-bromobenzyl)cyclopentylidene)butan-1-ol (IV-184). 2:1 mixture of 
inseparable diastereomers. Data are for the mixture. 1H NMR (400 MHz, CDCl3) δ 7.52 
(d, J = 8 Hz, 1 H), 7.23–7.16 (m, 2 H), 7.07–7.02 (m, 1 H), 5.27–5.23 (m, 1 H), 3.66–
3.58 (m, 2 H), 3.11–3.00 (m, 1 H), 2.88–2.82 (m, 1 H), 2.69–2.52 (m, 1 H), 2.47–2.40 
(m, 1 H), 2.32–2.19 (m, 1 H), 2.11–2.02 (m, 1 H), 1.97–1.88 (m, 1 H), 1.80–1.71 (m, 1 
H), 1.67–1.47 (m, 5 H), 1.40–1.24 (m, 2 H). 
 (E)-N-(4-(2-(2-bromobenzyl)cyclopentylidene)butyl)aniline (IV-186). 2:1 mixture of 
inseparable diastereomers. Data are for the mixture.  1H NMR (300 MHz, CDCl3) δ 7.59 
(d, J = 8.1 Hz, 1 H), 7.40–7.36 (m, 1 H), 7.29–7.20 (m, 3 H), 7.13–7.08 (m, 1 H), 6.78–
6.72 (m, 1 H), 6.68–6.64 (m, 2 H), 5.35–5.26  (m, 1 H), 3.64 (s, 1 H), 3.19–3.08 (m, 3 H), 
2.95–2.78 (m, 1 H), 2.71–2.48 (m, 1 H), 2.39–2.26 (m, 1 H), 2.26–2.08 (m, 1 H), 2.05–
1.96 (m, 1 H), 1.92–1.76 (m, 2 H), 1.76–1.55 (m, 5 H); 13C NMR (75 MHz, CDCl3) δ 
148.6, 146.6, 146.1, 140.9, 140.5, 134.0, 133.8, 132.9, 131.9, 131.4, 129.4, 128.9, 128.7, 
128.6, 127.8, 127.6, 127.3, 127.2, 125.0, 121.5, 120.1, 117.23, 117.18, 112.9, 112.8, 44.5, 
43.8, 41.2, 40.4, 40.2, 32.8, 32.5, 31.3, 29.9, 29.5, 29.4, 27.2, 27.0, 24.0, 23.5; IR (film) 




(IV-187). The cyclization of IV-186 (45 mg, 0.117 mmol) following the general 
procedure using PCy3·HBF4 as ligand afforded 18 mg (50%) of the title compound as a 
colorless oil. This compound was judged to be a 22:1 mixture of diastereomers by 1H 
NMR analysis analysis. 1H NMR (400 MHz, CDCl3) δ 7.25–7.21 (m, 2 H), 7.19–7.10 (m, 
4 H), 6.86 (d, J = 7.6 Hz, 2 H), 6.69 (t, J = 7.6 Hz, 1 H), 4.27–4.25 (m, 1 H), 3.50–3.45 
(m, 1 H), 3.37–3.31  (m, 1 H), 3.13–3.06 (m, 1 H), 2.68–2.56 (m, 2 H), 2.21–2.14 (m, 1 
H), 2.05–1.93 (m, 1 H), 1.85–1.75 (m, 3 H), 1.63–1.52 (m, 2 H), 1.35–1.19 (m, 2 H), 
1.06–0.93 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 150.5, 148.6, 144.5, 129.0, 127.0, 
126.6, 125.3, 124.5, 116.1, 113.7, 68.0, 64.9, 52.8, 46.6, 40.2, 39.2, 36.3, 29.0, 26.4, 
24.0; IR (film) 2941, 1597 cm–1. MS (ESI) 304.2057 (304.2065 calcd for C22H25N, M + 
Na+). 
5-(2-bromobenzyl)cyclopent-2-enone (IV-189).48 A flame-dried flask was charged with 
diisopropylamine (6.04 g, 4.35 mL, 30.9 mmol) and THF (103 mL) and cooled to 0 °C, 
whereupon a solution of Butyllithium in hexanes (19.3 mL, 30.94 mmol, 1.6 M) was 
added. The reaction mixture was stirred for 40 min at 0 °C. At this point a solution of 2-
(2-bromobenzyl)cyclopentanone in THF (10.3 mL) was added and the reaction mixture 
was stirred for an additional 20 min. This was followed by the addition of a solution of 
phenyl selenium bromide (7.3 g, 30.94 mmol) in 21 mL THF via cannula in one portion. 
This was followed by an immediate decolorization followed by stirring 5-10 min. The 
reaction mixture was then added to 0.5 M HCl/1:1 mixture of ether:pentanes and was 
then extracted with ethyl acetate and washed with brine, dried over sodium sulfate and 
purified by column chromatography.  
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The purified phenyl selenide was dissolved in CH2Cl2 (97 mL) and pyridine was added 
(3.9 mL). This solution was added to a mixture of 30% H2O2 (5.30 mL) in H2O (5.30 
mL) over a 10 min period at 0 °C (Caution: no more than 10% of the H2O2 solution 
was added prior to commencement of oxidation). After stirring for an additional 10 
min at room temperature, the reaction mixture was poured into CH2Cl2 and 20 ml of 10% 
Na2CO3 with stirring. The aqueous layer was washed with 50 ml of CH2C12. The 
combined organic layers were washed with 50 ml of saturated NaCl solution and dried 
over Na2SO4, and concentrated in vacuo to provide the crude compound which was 
purified by column chromatography to provide 3.8 g (79%) of the title compound as a 
yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.68–7.66 (m, 1 H), 7.55 (dd, J = 1, 8.5 Hz, 1 
H), 7.24–7.22 (m, 2 H), 7.11–7.07 (m, 1 H), 6.24–6.22 (m, 1 H), 3.36 (dd, J = 4, 13.5 Hz, 
1 H), 2.82–2.77 (m, 1 H), 2.75–2.67 (m, 2 H), 2.50–2.45 (m, 2 H). 
5-(2-bromobenzyl)cyclopent-2-enol (IV-190).49 A flame-dried flask was charged with 
5-(2-bromobenzyl)cyclopent-2-enone (1 g, 3.98 mmol) and THF (4 mL) and cooled to 0 
°C, whereupon a solution of 9-BBN in THF (8 mL, 4.00 mmol. 0.5 M) was added via 
syringe pump over 5 h. Methanol was added to destroy the excess borane and the reaction 
mixture was then concentrated. The reaction mixture was diluted with pentane and 2-
aminoethanol  (244 μL, 4 mmol) was added.  The ethanolamine derivative of 9-BBN then 
precipitated out and was washed successively with pentanes. The pentane layers were 
decanted, combined and concentrated in vacuo to afford the title compound as a 2:1 
mixture of diastereomers. The crude material was purified to afford the major 
diastereomer which was then taken on in the subsequent reactions. Data are for the major 
diastereomer. 1H NMR (300 MHz, CDCl3) δ 7.55 (d, J = 7.5 Hz, 1 H), 7.29–7.22 (m, 2 
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H), 7.10–7.05 (m, 1 H), 5.93–5.90 (m, 1 H), 5.81–5.77 (m, 1 H), 4.65–4.57 (m, 1 H), 
3.04–2.97 (m, 1 H), 2.85–2.77 (m, 1 H), 2.61–2.39 (m, 3 H), 1.38 (m, 1 H). 
2-((1S,4R)-4-(2-bromobenzyl)cyclopent-2-enyl)ethanol (IV-191).49  A flame-dried 
flask was charged with 5-(2-bromobenzyl)cyclopent-2-enol (251 mg, 0.991 mmol), 
triethylorthoacetate (6.11 g, 5.43 mL, 29.75 mmol) and propionic acid (7.1 μL, 0.089 
mmol), equipped with a reflux condenser and heated to 140 °C overnight until the 
starting material was consumed as judged by 1H NMR of an aliquot of the reaction 
mixture. The reaction mixture was cooled to rt, transferred to an Erlenmeyer flask and 
diluted with THF, and 1M HCl was added and the reaction was stirred for several hours. 
The crude product was extracted with diethyl ether (3 X 100 mL), washed with NaHCO3, 
dried over Na2SO4, and concentrated in vacuo. The material was then used in the next 
step without further purification. 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 7.6 Hz, 1 H), 
7.24–7.18 (m, 2 H), 7.08–7.04 (m, 1 H), 5.72–5.68 (m, 2 H), 4.13 (q, J = 7.2 Hz, 2 H), 
3.19–3.13 (m, 2 H), 2.82–2.70 (m, 2 H), 2.37–2.24 (m, 2 H), 1.90–1.83 (m, 1 H), 1.69–
1.62 (m, 1 H), 1.25 (t, J = 7.2 Hz, 3 H). 
2-(4-(2-bromobenzyl)cyclopent-2-enyl)ethanol (IV-192). A flame-dried flask equipped 
with a magnetic stirbar was cooled under a stream of nitrogen and was charged with 2-
((1S,4R)-4-(2-bromobenzyl)cyclopent-2-enyl)ethanol (319 mg, 0.987 mmol) and diethyl 
ether (3 mL). The reaction mixture was cooled to 0 °C, and a solution of LiAlH4 (3 mL, 
3.04 mmol, 1 M in diethyl ether) was added dropwise, and the reaction mixture was 
warmed to room temperature and stirred for 8 h. The reaction mixture was then cooled to 
0 °C and water (1 mL) was added dropwise followed by 10 M NaOH (2 mL) and 
additional water (3 mL). The resulting mixture was decanted, dried over anhydrous 
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sodium sulfate, filtered, and concentrated in vacuo. The crude product was then purified 
by flash chromatography using ethyl acetate/hexanes as the eluant to afford 113 mg (41% 
over two steps) of the title compound as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 
7.56–7.52 (m, 1 H), 7.30–7.16 (m, 2 H), 7.10–7.03 (m, 1 H), 5.75–5.64 (m, 2 H), 3.71–
3.59 (m, 2 H), 3.13–3.07 (m, 1H), 3.04–2.80 (m, 2 H), 2.77–2.73 (m, 2H), 1.85–1.50 (m, 
4H). 
Benzodecahydropentaleno[1,2-b]furan (IV-193). The cyclization of IV-192 (56 mg, 
0.199 mmol) following the general procedure using PCy3·HBF4 as ligand afforded 21 mg 
(53%) of the title compound as a colorless oil. This compound was judged to be a >20:1 
mixture of diastereomers by 1H NMR analysis analysis. 1H NMR (400 MHz, CDCl3) δ 
7.32–7.28 (m, 1 H), 7.22–7.15 (m, 3 H), 4.57 (d, J = 6.4 Hz, 1 H), 3.98–3.93 (m, 1 H), 
3.76–3.70 (m, 1 H), 3.64 (d, J = 7.2 Hz, 1 H), 3.14–3.01 (m, 2 H), 2.66 (d, J = 14.8 Hz, 2 
H), 2.10–2.02 (m, 1 H), 1.86–1.80 (m, 1 H), 1.69–1.61 (m, 1 H), 1.55–1.48 (m, 1 H); 13C 
NMR (100 MHz, CDCl3) δ 143.8, 143.3, 127.0, 126.7, 125.4, 125.2, 90.9, 68.5, 58.5, 
43.9, 42.2, 38.9, 38.4, 33.8; IR (film) 2933, 2848 cm–1. MS (EI) 200.1199 (200.1201 
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Chapter V 
Stoichiometric Studies Towards the Synthesis of Likely Intermediates in 
Intramolecular Pd-Catalyzed Carboetherification and Carboamination Reactions1 
Introduction to Stoichiometric Study: Goals and Challenges 
As outlined in the previous chapter, we have developed a Pd-catalyzed 
intramolecular carboetherification and carboamination reaction of substrates such as V-1 
(eq 66). We had observed that catalyst structure has a large impact on the stereochemical 
outcome of these reactions, which we attributed to a catalyst dependent change in 
mechanism. To further probe this hypothesis, we sought to generate and study the 





R = H or Me when Y = O















This chapter details our preliminary investigations on stoichiometric 
heteropalladation reactions of V-1. In our first experiments, we wanted to examine 
stoichiometric reactions providing access to the products resulting from syn-addition 
across the olefin. The goals, therefore, of this project were to characterize and/or isolate 
oxidative addition complexes such as V-3, form and attempt to characterize macrocyclic 
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Pd-alkoxide or Pd-amido species V-4, and observe alkene insertion (to V-5) followed by 
reductive elimination to heterocycle V-2. 
 
Scheme 74. Proposed Mechanism for Carboetherification/Carboamination Reaction 



















R = H or Me when Y = O



























While our goals as proposed above were well-founded, we felt that the chemistry 
could be challenging to carry out. We realized that it may be difficult to observe the 
oxidative addition complex or other proposed intermediates, and full characterization of 
these species (V-3, V-4, V-5) would only be possible upon isolation, which would require 
a certain degree of stability for these intermediates. Additionally, as mentioned in 
Chapter IV, only one previous report has described transformations that presumably 
involve macrocyclic palladacycles bearing both Pd–C and Pd–heteroatom bonds,2 and 
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transannular syn-alkene insertions of macrocyclic palladacycles bearing internal olefins 
are unknown.  
 
Results 
Stoichiometric Reactions: Examination of Oxidative Addition 
We began our study by examining substrates introduced in Chapter IV that 
contain an aryl halide moiety appended to an unsaturated alcohol or amine as shown in 
Figure 10. We sought to investigate the reactivity of these substrates with various 
palladium complexes that are available either commercially, or could be prepared in few 
steps from other palladium sources.3 Figure 11 contains a list of palladium complexes 
(along with the respective cone angle of the phosphine ligands) which were examined in 
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Figure 10. Substrates Used in  Figure 11. Catalysts Used in 

























Our initial experiments focused on reaction of Z-alkene V-6, which contains a 
pendant primary alcohol. This substrate was chosen due to its reactivity in the catalytic 
reaction with Pd2(dba)3/PCy3·HBF4 and the ready availability of Pd(PCy3)2. However, 
the use of commercially available Pd(PCy3)2 was initially complicated by the presence of 
an impurity in the Pd-complex. Certain batches of Pd(PCy3)2 were green in color, 
whereas the pure complex is known to be a white solid. In addition, 31P NMR analysis of 
this material showed the presence of an extra peak at δ 45.60 ppm; the chemical shift of 
pure Pd(PCy3)2 is δ 39.60 ppm. After a thorough search of the literature, it was 
discovered that binding of O2 to the metal produces a green-colored complex (eq 67). 
However, the authors did not publish the 31P NMR spectral data for the O2-bound 
complex.4 The binding of O2 to Pd(PCy3)2 is known to be reversible. Therefore, this 
impurity could be removed simply by placing the complex under vacuum in the glovebox 
for several minutes. If the green color did not completely dissipate, the complex was 
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dissolved in the solvent to be used for a given experiment. Removal of the solvent under 




With pure substrates in hand, we found that treatment of V-6 with Pd(PCy3)2 at 
25°C in d6-benzene or d8-THF led to clean conversion to PdII-oxidative addition complex 
V-9 (eq 68). However, only starting material was observed in the attempted oxidative 





d6-PhH: 100% conversion by 1H NMR spectroscopy
d8-THF: 100% conversion by 1H NMR spectroscopy
CD2Cl2: 0% by 1H NMR spectroscopy










The synthesis of V-9 on a preparative scale was accomplished by treatment of 2.0 
eq (80.3 mg) of V-6 with 1.0 eq (100 mg) of Pd(PCy3)2 in 14 mL of anhydrous benzene 
in a Schlenk flask for 12 h. After the benzene solvent was removed, a 3:1 mixture of 
pentanes: diethyl ether was added and the flask was placed in the glove box freezer for 2 
h. Filtration afforded 68 mg (49%) of the oxidative addition complex as a grey solid. 
Analysis of this material by 31P NMR provided a spectrum with a single peak at δ 20.58. 
This value is comparable to the 31P NMR spectra reported for Ph(Br)Pd(PCy3)2 (δ 20.6 
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ppm).5 Additional structural data for this compound were obtained through 1H NMR and 
2D-COSY NMR experiments. Copies of these spectra are provided in the experimental 

















20.58 ppm  
 
Similar oxidative addition studies were conducted with substrates V-7 and V-8. 
Oxidative addition proceeds cleanly with Pd(PCy3)2 (eq 70 and 71) to afford V-10 and V-
11. These compounds were also characterized by 31P NMR (as shown below) and 1H 







































Stoichiometric Reactions: Examination of Oxypalladation/Aminopalladation 
After successful preparation of oxidative addition complexes V-9, V-10 and V-11, 
we sought to investigate other reaction intermediates en route to the product heterocycles 
V-2. In particular, we sought to observe palladacycle intermediate V-4 by reaction of the 



















A new product was generated upon addition of base to a solution of the oxidative 
addition complex V-9, and the 1H NMR spectrum of this new species was very different 
from the 1H NMR spectrum of V-6. However, there were only very minor changes in the 
31P NMR spectrum of the molecule relative to V-6. In addition, free PCy3 was not 
observed. Therefore, we do not currently believe we have accessed the palladacyclic 
intermediate analogous to V-4 with Y = O. The 31P NMR spectra of most L2Pd(Ar)(OR) 
complexes are shifted by 5-10 ppm relative to that of the analogous L2Pd(Ar)(Br) 
complexes.6 We reasoned that significant changes in the 1H NMR coupled with minor 
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changes in the 31P NMR spectrum could be a result of complexation of the activated 
olefin with the alkoxide species as in the proposed structure V-12. Efforts to drive the 
conversion of V-6 to the Pd-alkoxide complex by heating (to 60 °C) instead led to 












V-4 with Y = O does not form: 1H NMR spectrum very dif f erent
from V-6, but 31P spectrum (1 peak)-very minor











We hypothesized that perhaps we were not accessing an L1 palladium complex 
containing a free site on the metal that could then form the Pd-alkoxide species 
quantitatively. However, attempts to facilitate phosphine disassociation from complex V-
12 via addition of sulfur as a phosphine scavenger led to the formation of complex 
mixtures of products; phosphine sulfide was detected (δ 62 ppm).7 In a separate 
experiment, a complex mixture of products was also formed when AgOTf was added to 
V-12. 
 





2) KHMDS or NaOtBu
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Due to our lack of success in preparing macrocycle V-4 from primary alcohol V-
6, we elected to examine a related tertiary alcohol substrate (V-7). It is worth noting (as 
described in Chapter IV) that the Pd2(dba)3/PCy3-catalyzed reaction of V-7 in the 
presence of NaOtBu affords anti-addition diastereomer V-14 in 78% yield and 14:1 dr 
(eq 75). Treatment of tertiary alcohol V-7 with stoichiometric Pd(PCy3)2 at room 
temperature led to formation of oxidative addition complex V-10, which was 
characterized by 1H NMR and 31P NMR spectroscopy. Interestingly, heating this complex 
to 40 °C in the absence of base led to selective formation of the syn-addition product V-
15 (eq 76). On the other hand, the anti-addition diastereomer was generated upon 
addition of an external base (KHMDS) to the complex formed from the reaction of V-7 













































40 °C 45°C (77)
V-14




In addition to our efforts to prepare macrocyclic Pd(Ar)(OR) complexes with 
PCy3 ligands, we also examined the preparation of analogous Pd(Ar)(NRR’) complexes 
as shown below in eq 78. Treatment of V-8 with Pd(PCy3)2 led to formation of oxidative 
addition complex V-11, which was characterized by 1H NMR and 31P NMR spectroscopy 
(peak at δ 20.62 ppm in 31P NMR). However, when NaOtBu was added to V-8, syn- and 
anti-addition pyrrolidines V-16 and V-17 immediately began forming at room 
temperature.8 In addition, Heck product V-18 was also observed in the 1H NMR. When 
the experiment was repeated but with addition of AgOTf as a halide scavenger (eq 79), 
formation of syn- and anti-addition pyrrolidines V-16 and V-17, was observed by 1H 
NMR analysis, and a complex mixture of phosphine-containing species was observed by 
31P NMR spectroscopy.  


































2) KHMDS or NaOtBu




















Oxidative Addition and Oxypalladation/Aminopalladation Investigation with Other 
Complexes 
Due to the stability of complex V-9, we hypothesized that we may more easily 
arrive at a detectable Pd-alkoxide species if we could access an L1Pd complex. Therefore 
other bulky metal complexes were utilized in this effort, such as Pd[P(t-Bu)2Cy]2. 
However, the use of Pd[P(t-Bu)2Cy]2 did not lead to any detectable quantity of the 
oxidative addition complex V-19 at room temperature or with heating. Rather, heating V-
6 led to the formation of Heck side product V-18b, oxidation product 18c, as well as 
unidentified product(s) and recovered starting material. Similarly, treatment of V-6 with 
stoichiometric Pd[P(t-Bu)3]2 did not lead to any detectable amount of oxidative addition 
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complex V-20, and heating to 75 °C to help initiate oxidative addition led to formation of 










+ unidentif ied + V-6
(80)75 °C, 5h
Not observed at rt




















Not observed at rt







Other attempts to arrive at an L1Pd complex with palladium complexes composed 
of electron-rich monodentate phosphine ligands were also investigated. Use of Pd[P(t-
Bu)Cy2]2 with V-6 led to slow conversion (~6-8 h) to the oxidative addition complex V-
21 (2:1 ratio of V-6: V-21 at 6-8 h). Analysis of this material by 31P NMR provided a 
spectrum with a peak at δ 61.18. This value is comparable to the 31P NMR spectra 
reported for the aryl palladium iodide dimer Ph(I)Pd(Pt-Bu2Cy) (δ 64.4 ppm).9 
Additionally, a broad peak was observed in 31P NMR at δ 27.6 ppm which indicated the 
 287  
presence of free phosphine. Additional structural data for this compound were obtained 
through 1H NMR spectroscopy. It is evident that complex V-21 is monoligated since the 
Ph(I)Pd(Pt-BuCy2)2 complex is reported to have a 31P chemical shift of δ 32.6 ppm. 
Heating the mixture of V-6 and V-21 in hopes of driving the quantitative formation to the 
oxidative addition complex V-21 or to the palladium alkoxide (e. g. V-4, Y = O) led to 
complex mixtures of products. When the experiment was repeated (V-6  V-21) and left 
at room temperature for 12 hours, cyclization to syn-addition product V-13 occurred 
concurrently (experiment was monitored over 12 h period and no intermediates were 















































Reaction of V-6 with stoichiometric Pd[P(o-tol)3]2 without the addition of base at 
rt (eq 84) led to the monoligated oxidative addition species V-22. Analysis of this 
material by 31P NMR provided a spectrum with a peak at δ 20.29. This value is 
comparable to the 31P NMR spectra reported for other aryl palladium halide complexes 
 288  
ligated to P(o-tol)3 (e.g. δ 28.5 ppm).10 Additionally, free phosphine was observed in the 
31P NMR at δ -29.09 ppm. Additional structural data for this compound were obtained 
through 1H NMR spectroscopy. However, Heck cyclization afforded product V-18 rather 
than the desired tetrahydrofuran V-13. In conclusion, in cases where L1Pd complexes 
















+ unidentif ied  
 
Attempts to prepare L1PdAr(NRR’) complexes with bulky ligands were also 
unsuccessful. An L1Pd complex was also generated (V-23) with V-8 and Pd[P(o-tol)3]2 
but this lead primarily to the Heck product V-18a and reduction of starting material V-24. 
Analysis of the reaction mixture indicated a peak in the 31P NMR spectrum at δ 20.69 
ppm, corresponding to the oxidative addition species V-23. This value is comparable to 
the 31P NMR spectra reported for other monoligated P(o-tol)3 oxidative addition 
complexes as already discussed above.10 Additionally, free phosphine was observed in 
the 31P NMR spectrum at δ -29.09 ppm, further supporting the formation of the 
monoligated species V-23.  



























 The oxidative addition of substrates V-6, V-7, and V-8 to Pd(PCy3)2 provides 
stable complexes such as V-9, which are isolable (PCy3)2Pd(Ar)(X) complexes bearing 
pendant alcohols. Surprisingly, intramolecular carbopalladation of this complex was not 
observed, which adds further support to the hypothesis that alkene insertion into Pd–O or 
Pd–N bonds is faster than alkene insertion into Pd-Ar bonds (Chapter IV, Schemes 63 
and 64). The fact that two PCy3 ligands are bound to V-9 likely contributes to the 
stability of the complex, which presumably facilitates isolation but slows the rate of Pd–
O bond formation.  Use of bulkier ligands that may affect generation of analogous L1Pd 
complexes has not yet led to isolable derivatives.  
Interestingly, syn addition across the Z-olefin of substrate V-6 and V-7 is 
observed when no external base is added to the reaction. It is likely that the syn-addition 
products discussed in eq 76 and 77 (shown below for 3° alcohol substrate V-7) is 
generated through a mechanism involving a Pd-macrocycle as proposed in Chapter IV. 
Oxidative addition of the Pd(PCy3)2 to V-9 affords oxidative addition complex V-10. It is 
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likely that due to the pKa differences between +HPCy3 (pKa = 9.7) and the alcohol (pKa 
= 16-17), that deprotonation does not occur substantially without coordination of the 
alcohol to the metal. Phosphine disassociation likely occurs to a non-detectable degree 
which would allow for the alcohol to bond to the metal and undergo deprotonation by the 
phosphine (as in V-26) to afford Pd-macrocycle V-27. Deprotonation of the alcohol 
forms +HPCy3. The formation of Br
-
 occurs via associative ligand substitution upon 
coordination of the alcohol to the metal. Reaction of this species with Pd(PCy3)2 accounts 
for the formation of V-30 (eq 86). Insertion into the Pd–O bond provides palladacyclic 
intermediate V-28, which is followed by reductive elimination to provide tetrahydrofuran 
V-13, the product of syn-addition across the Z-olefin. 
Byproducts observed in the NMR spectra which lend credence to the mechanism 
below include the formation of palladium hydride V-30 characterized by both 1H and 31P 
NMR spectroscopy and the product of its decomposition, the dibromide V-31 (eq 86), 
which was characterized by 31P NMR spectroscopy.11 A mechanism involving insertion 
of the olefin into the Pd-aryl bond of macrocycle V-27 cannot be ruled out, but has been 
shown to be non-competitive in a probe experiment (see Chapter IV, Schemes 63 and 
64), which indicated the rate of Pd–O bond insertion is faster with our optimal catalyst 
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V-30 V-31  
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The mechanism below describes what we believe to be occurring in the 
stoichiometric experiment using a tertiary alcohol when an external base is added, which 
results in anti-addition across the Z-olefin. Oxidative addition of the L2Pd complex 
affords oxidative addition complex V-10. Deprotonation of the alcohol by KHMDS 
affords bisphosphine complex V-32. The deprotonated alcohol likely attacks the Pd-
activated olefin to afford V-33 which then undergoes anti-oxypalladation to afford V-34 
and upon reductive elimination, tetrahydrofuran V-14 is generated, resulting from anti-
addition across the Z-olefin. A possible explanation for this difference in reactivity 
between Scheme 75 (syn-addition) and Scheme 76 (anti-addition) may be that in the syn-
addition mechanism, the alcohol is only deprotonated upon coordination of the alcohol to 
the metal. Therefore, once it is coordinated, the phosphine is likely in the coordination 
sphere and can deprotonate the alcohol and funnel the reaction towards Pd-macrocycle 
formation and the syn-addition product. On the other hand, the anti-addition product 
forms upon addition of base, which suggests that once deprotonated, an anti-mechanism 
is faster than phosphine disassociation and alkoxide coordination. Alternative 
mechanisms involving isomerization of the olefin to give the more thermodynamically 
stable E-olefin cannot be ruled out at this point. Preliminary studies were conducted to 
determine if the olefin was isomerizing under basic conditions in the absence of 
palladium. However, no isomerization was observed when V-7 was heated with KHMDS 
at 45 °C in toluene overnight. Nonetheless, we cannot rule out isomerization via 
reversible Pd-mediated C-H bond activation at this point.  
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Conclusion 
The stoichiometric experiments discussed in this chapter suggest that oxidative 
addition is rate limiting, at least in many of the systems examined in this chapter. In 
addition, since most substitutions at square planar Pd(II) proceed by an associative 
mechanism, it is imperative that we arrive at the monoligated Pd-species in order to 
observe the intermediate palladacycle V-4. The results in this chapter suggest that the 
phosphine is slowly disassociating from the metal to a non-detectable amount allowing 
for nucleophilic attack on the metal by the heteroatom, displacement of Br-, reassociation 
of the phosphine, and funneling to the syn-addition product. The results obtained with an 
external base as in Scheme 76 suggest that we can control the mechanism by which the 
reaction proceeds under stoichiometric conditions as well with the same complex. When 
the phosphine behaves as the base, one accesses the syn-addition pathway as in Scheme 
75; on the other hand, when an external base such as KHMDS is added after formation of 
the oxidative addition complex, the anti-product forms as in Scheme 76.   
 The characterization and analysis of intermediates discussed in this chapter is a 
worthwhile challenge and will likely lead to interesting results. Future work on this 
project will include full isolation and characterization of the oxidative addition species 
discussed in this chapter and Chapter IV. Additionally, it will be necessary to determine 
the source of the anti-addition product in Scheme 76. The results of other substrates such 
as V-6 under conditions which provided both the syn and anti diastereomer in the 3° 
alcohol case will need to be investigated.  Additional attempts to prepare L1Pd complexes 
with various alcohol and amine substrates bearing tethered aryl bromides that do not 
generate other side products will likely be a challenge in this chemistry but results in this 
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chapter suggest this may be possible. Attempting this investigation at lower temperature 
by Variable Temperature (VT) NMR (such as, the experiment in eq 82 with Pd[(P(t-
Bu)Cy2]2) will likely be a necessary tool in accessing the elusive intermediates and is sure 
to generate an interesting study in the unchartered territory of Pd-macrocyclic 
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Experimental 
General Considerations. All reactions were carried out under an argon or nitrogen 
atmosphere in oven- or flame-dried glassware. All reagents were purchased from 
commercial sources and were used as obtained unless otherwise noted. Pd(PCy3)2 was 
purchased from Strem Chemical Co. and used after pumping on in the glove box and 
other complexes were synthesized according to literature procedures (Pd[(P(t-Bu)Cy2]2, 
Pd[P(t-Bu)2Cy]2, Pd[P(t-Bu)2Cy]2, Pd[P(o-tol)3]2).3 Toluene, diethyl ether, THF, and 
methylene chloride were purified using a Glass Contour solvent purification system and 
deuterated solvents were used from Cambridge Isotope Effects, stored over molecular 
sieves, and used without further purification. The substrates and cyclized products used 
and formed in this chapter were initially characterized in Chapter IV and therefore full 
data in CDCl3 can be found in the experimental section of that chapter. The 
regiochemistry of the heterocyclic products was assigned on the basis of 1H NMR 2-D 
COSY experiments (Chapter IV); stereochemistry was assigned on the basis of x-ray 
crystallography (see Chapter IV). Ratios of diastereomers were determined by 1H NMR. 
The experiments described in this chapter were done with stoichiometric metal and thus 
in many cases it was not possible to get full characterization data, at least in these 
preliminary investigations. The substrates below were initially characterized in Chapter 
IV, but since the experiments in this chapter were performed in C6D6, the NMR data of 
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Substrate Synthesis: See Chapter IV. 
NMR Data (1H for Substrates V-6, V-7, V-8 in d6-Benzene). 
Z-7-(2-Bromophenyl)hept-4-en-1-ol (V-6). 1H NMR (400 MHz, d6-C6H6) δ 7.38 (d, J = 
8.0 Hz, 1 H), 6.90–6.86 (m, 2 H), 6.68–6.64 (m, 1 H), 5.44–5.32 (m, 2 H), 3.27 (q, J = 6 
Hz, 2 H), 2.70 (t, J = 7.2 Hz, 2 H), 2.32 (q, J = 8.0 Hz, 2 H), 1.97 (q, J = 7.2 Hz, 2 H), 
1.35–1.29 (m, 2 H), 0.52 (t, J = 5.2 Hz, 1 H). 
Z-8-(2-Bromophenyl)-2-methyloct-5-en-2-ol (V-7). 1H NMR (400 MHz, d6-C6H6) δ 
7.37 (d, J = 7.6 Hz, 1 H), 6.90–6.85 (m, 2 H), 6.67–6.63 (m, 1 H), 5.46–5.37 (m, 2 H), 
2.71 (t, J = 7.2 Hz, 2 H), 2.39–2.34 (m, 2 H), 2.06–2.00 (m, 2 H), 1.26–1.22 (m, 2 H), 
1.00 (s, 6 H), 0.63 (broad s, 1 H). 
Z-[7-(2-Bromophenyl)hept-4-enyl]aniline (V-8). 1H NMR (400 MHz, d6-C6H6) δ 7.37 
(d, J = 8.4 Hz, 1 H), 7.20–7.16 (m, 2 H), 6.90–6.85 (m, 2 H), 6.75 (t, J = 7.2 Hz, 1 H), 
6.67–6.63 (m, 1 H), 6.47 (d, J = 8.4 Hz, 2 H), 5.44–5.28 (m, 2 H), 3.03 (s, 1 H), 2.75 (t, J 
= 8 Hz, 1 H), 2.68 (t, J = 8.0 Hz, 2 H), 2.30 (q, J = 8.0 Hz, 2 H), 1.88 (q, J = 7.2 Hz, 2 H), 
1.28–1.21 (m, 2 H), 0.41 (s, 1 H). 
(±)-(1S*,2S*)-2-Indan-1-yltetrahydrofuran (V-13). 1H NMR (400 MHz, d6-C6H6) δ 
7.35–7.33 (m, 1 H), 7.11–7.09 (m, 3 H), 3.81–3.75 (m, 1 H), 3.74–3.68 (m, 1 H), 3.55–
3.50 (m, 1 H), 3.32–3.27 (m, 1 H), 2.86–3.79 (m, 1 H), 2.74–2.61 (m, 1 H), 2.09–2.00 
(m, 1 H), 1.69–1.66 (m, 1 H), 1.61–1.54 (m, 1 H), 1.50–1.41 (m, 1 H), 1.40–1.28 (m, 2 
H). 
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(±)-(1S*,2R*)-2-Indan-1-yltetrahydrofuran (V-13b). 1H NMR (500 MHz, d6-C6H6) δ 
7.84 (d, J = 7.5 Hz, 1 H), 7.18–7.10 (m, 3 H), 3.80–3.72 (m, 2 H), 3.61–3.56 (m, 1 H), 
3.20 (q, J = 8 Hz, 1 H), 2.78–2.72 (m, 1 H), 2.70–2.64 (m, 1 H), 1.94–1.87 (m, 1 H), 
1.58–1.47 (m, 3 H), 1.46–1.38 (m, 1 H), 1.28–1.21 (m, 1 H). 
(±)-(1S*,5R*)-2,2-Dimethyl-5-indan-1-yltetrahydrofuran (V-14). 1H NMR (500 MHz, 
d6-C6H6) δ 7.80 (dd, J =0.5, 1 Hz, 1 H), 7.17–7.11 (m, 3 H), 3.98–3.94 (m, 1 H), 3.20 (q, 
J = 7.5 Hz, 1 H), 2.80–2.75 (m, 1 H), 2.71–2.65 (m, 1 H),  2.22–2.14 (m, 1 H), 1.96–1.89 
(m, 1 H),  1.66–1.62 (m, 1 H),  1.59–1.52 (m, 1 H), 1.50–1.40 (m, 3 H), 1.23 (s, 3 H), 
1.19 (s, 3 H). 
(±)-(1S*,5S*)-2,2-Dimethyl-5-indan-1-yltetrahydrofuran (V-15). 1H NMR (500 MHz, 
d6-C6H6) δ 7.40–7.38 (m, 1 H), 7.14–7.11 (m, 1 H), 3.97–3.93 (m, 1 H), 3.30–3.26 (m, 1 
H), 2.87–2.81 (m, 1 H), 2.68–2.62 (m, 1 H), 2.09–2.02 (m, 2 H), 1.69–1.62 (m, 1 H), 
1.53–1.47 (s, 1 H), 1.45–1.39 (m, 2 H), 1.20 (s, 3 H), 1.15 (s, 3 H). 
(±)-(1S*,2S*)-N-Phenyl-2-indan-1-ylpyrrolidine (V-16). 1H NMR (400 MHz, d6-C6H6) 
δ 7.33–7.28 (m, 2 H), 7.11–7.04 (m, 3 H), 6.99–6.95 (m, 1 H), 6.82 (td, J = 0.8, 7.6 Hz, 1 
H), 6.72 (d, J = 8.0 Hz, 1 H), 3.86–3.80 (m, 2 H), 3.24–3.19 (m, 1 H), 2.94–2.88 (m, 1 
H), 2.86–2.78 (m, 1 H), 2.68–2.60 (m, 1 H), 2.04–1.94 (m, 1 H), 1.61–1.49 (m, 2 H), 
1.43–1.36 (m, 1 H), 1.32–1.24 (m, 1 H), 1.14–1.04 (m, 1 H). 
Isolation of Oxidative Addition Complex V-9. A flame-dried Schlenk flask under N2 
was charged with Pd(PCy3)2 (100 mg, 0.149 mmol), Z-7-(2-Bromophenyl)hept-4-en-1-ol 
(V-6), and 14 mL d6-benzene in the glove box. The reaction mixture was stirred 
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overnight in a fume hood (outside of glove box). An aliquot was removed to ensure 
completion of oxidative addition and this was followed by removal of the benzene under 
reduced pressure. The complex was then dissolved in 3 mL diethyl ether in which it 
completely dissolved. Therefore the ether was removed under reduced pressure and a 3:1 
mixture of pentanes: diethyl ether (4 mL total) was added to the complex. Most of the 
complex dissolved and the schlenk flask was placed in the glove box freezer. An off-
white solid was precipitated and recovered via filtration. The solid was washed with cold 
pentanes to produce 68 mg of the title compound as a white-grey solid (49%). Data for 
this molecule is listed below. 
Reaction of Z-7-(2-Bromophenyl)hept-4-en-1-ol (V-6) with Pd(PCy3)2. A flame-dried 
vial equipped with a stirbar was charged with alcohol V-6 (3.4 mg, 0.0127 mmol), 
Pd(PCy3)2 (10.0 mg, 0.015 mmol) and 1 mL dry d6-benzene in the glove box. The mixture 
was stirred in the glove box and then subsequently transferred to an oven-dried NMR 
tube. The NMR tube was left overnight at room temperature (~10h) until oxidative 
addition was complete as determined by 1H and 31P NMR spectroscopy. 1H,1H COSY 
taken of oxidative addition complex. 1H NMR (400 MHz, d6-C6H6) δ 7.62 (d, J = 7.6 Hz, 
1 H), 7.07–6.95 (m, 3 H), 5.91–5.85 (m, 1 H), 5.60–5.54 (m, 1 H), 3.66 (t, J = 8.0 Hz, 2 
H), 3.40 (q, J = 6 Hz, 2 H), 2.68 (q, J = 6.4 Hz, 2 H), 2.22–2.19, 2.05–2.02, 1.90–1.53, 
1.52–1.48, 1.35–1.04 (all m, 70 H, PCy3 and two methylene units). 31P{1H} NMR (161.9 
MHz, C6D6): δ 20.58 (s, oxidative addition complex V-9). Other signals observed in 31P 
spectrum (very minor): δ 45.6 (s, O2-bound Pd(PCy3)2 complex from eq 67), 39.6 (s, 
Pd(PCy3)2). 
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Reaction of Z-8-(2-Bromophenyl)-2-methyloct-5-en-2-ol (V-7) with Pd(PCy3)2 (No 
External Base; Phosphine Behaves as Base). A flame-dried vial equipped with a stirbar 
was charged with alcohol V-7 (3 mg, 0.0101 mmol), Pd(PCy3) 2 (7 mg, 0.0104 mmol) and 
1 mL dry d6-benzene in the glove box. The mixture was stirred in the glove box and then 
subsequently transferred to an oven-dried NMR tube. The NMR tube was left overnight 
at room temperature (~12h) until oxidative addition was complete as determined by 1H 
and 31P spectroscopy. 1H NMR (400 MHz, d6-C6H6) δ 7.63 (d, J = 6.8 Hz, 1 H), 7.08–
6.98 (m, 3 H), 5.93–5.86 (m, 1 H), 5.69–5.62 (m, 1 H), 3.69 (t, J = 8.4 Hz, 2 H), 2.74–
2.68 (m, 2 H), 2.36–2.30 (m, 2 H), 2.22–2.19, 2.05–2.02, 1.90–1.53, 1.52–1.48, 1.35–
1.04 (all m, 74 H, PCy3, one methylene unit, and two methyl units). 31P{1H} NMR (161.9 
MHz, C6D6): δ 20.54 (s, oxidative addition complex V-10). Other signals observed in 31P 
spectrum: δ 39.6 (left over Pd(PCy3)2 complex, δ 45.6 (s, O2-bound Pd(PCy3)2 complex), 
45.5 (s, unidentified minor). 
 The NMR tube was heated to 40 °C and other signals began to form in the 31P 
spectrum, and the oxidative addition peak at δ 20.54 began to get smaller: 31P{1H} NMR 
(161.9 MHz, C6D6): δ 25.47 (s, complex Pd(PCy3)2Br2), 42.77 (s, complex 
Pd(PCy3)2HBr). Other products observed: δ 39.6 (left over Pd(PCy3)2 complex, 45.6 (O2-
bound Pd(PCy3)2 complex, 46.5 (s, unidentified minor), 20.93 (s, unidentified). After 
continued heating at 50 °C, the product resulting from syn-addition across the Z-olefin 
(V-15) was observed.  
Reaction of Z-8-(2-Bromophenyl)-2-methyloct-5-en-2-ol (V-7) with Pd(PCy3)2 (With 
Added External Base-KHMDS). A flame-dried vial equipped with a stirbar was 
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charged with alcohol V-7 (3 mg, 0.0101 mmol), Pd(PCy3) 2 (6.7 mg, 0.0101 mmol) and 1 
mL dry d6-benzene in the glove box. The mixture was stirred in the glove box then 
subsequently transferred to an oven-dried NMR tube. The NMR tube was left overnight 
at room temperature (~12h) until oxidative addition was complete as determined by 1H 
and 31P spectroscopy. 1H NMR (400 MHz, d6-C6H6) (same as above complex) δ 7.63 (d, 
J = 6.8 Hz, 1 H), 7.08–6.98 (m, 3 H), 5.93–5.86 (m, 1 H), 5.69–5.62 (m, 1 H), 3.69 (t, J = 
8.4 Hz, 2 H), 2.74–2.68 (m, 2 H), 2.36–2.30 (m, 2 H), 2.22–2.19, 2.05–2.02, 1.90–1.53, 
1.52–1.48, 1.35–1.04 (all m, 74 H, PCy3, one methylene unit, and two methyl units). 
31P{1H} NMR (161.9 MHz, C6D6): δ 20.53 (s, oxidative addition complex V-10). Other 
peaks observed: δ 45.6 (s, O2-bound Pd(PCy3)2 complex).  
 The following day, potassium hexamethyldisilazide was added (2 mg, 0.0101 mmol) 
to the NMR tube and 1H NMR analysis revealed the alcohol was deprotonated. The NMR 
tube was heated to 40 °C for 10 min and the product resulting from anti-addition (V-14) 
across the Z-olefin was beginning to form by 1H NMR spectroscopy as well as the 
regenerated complex Pd(PCy3)2. Data for the deprotonated complex: 1H NMR (300 MHz, 
d6-C6H6) δ 7.65 (d, J = 7.5 Hz, 1 H), 7.22–7.19 (m, 1 H), 7.09–6.98 (m, 2 H), 6.01–5.93 
(m, 1 H), 5.91–5.82 (m, 1 H), 3.82–3.67 (m, 2 H), 2.93–2.80 (m, 2 H), 2.39–2.10, 1.91–
1.48, 1.35–1.06 (all m, 74 H, PCy3, one methylene unit, and two methyl units). 31P{1H} 
NMR (161.9 MHz, C6D6): δ 20.53 (s, oxidative addition complex V-10), δ 39.7 (s, 
complex Pd(PCy3)2 regenerated), 20.89 (s, unidentified).  
  The NMR tube was left overnight at 45 °C and the following day, complete 
conversion to the anti-addition product V-14 was observed, along with concomitant 
regeneration of Pd(PCy3)2. 
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Reaction of Z-[7-(2-Bromophenyl)hept-4-enyl]aniline (V-8) with Pd(PCy3)2. A flame-
dried vial equipped with a stirbar was charged with Pd(PCy3)2 (7.0 mg, 0.0104 mmol) and 
0.75 mL dry d6-benzene in the glove box. The solution was stirred in the glove box and 
then subsequently transferred to an oven-dried NMR tube. 31P NMR analysis revealed 
two peaks, one corresponding to the complex and the other, the O2-bound complex. 
Amine V-8 was added in aliquots until all the complex was used up and the oxidative 
addition was complete (1.90 mg total, 0.005 mmol)12 which took exactly 3 h at RT. At 
this point NaOtBu (3 mg, 0.031 mmol) was added as a solution in d6-benzene (1 mL) and 
pyrrolidine V-16 resulting from syn-addition across the Z-olefin began to form at room 
temperature. VT 1H NMR was performed heating to 30 °C  40 °C  50 °C  60 °C 
which resulting in complete conversion to the product pyrrolidine. 1H NMR of V-11 (400 
MHz, d6-C6H6) δ 7.62 (d, J = 7.2 Hz, 1 H), 7.20–7.15 (m, 3 H), 7.11–6.95 (m, 2 H), 6.73 
(t, J = 7.2 Hz, 1 H), 6.51 (d, J = 7.2 Hz, 2 H), 5.91–5.84 (m, 1 H), 5.57–5.51 (m, 1 H), 
3.65 (t, J = 8.8 Hz, 2 H), 2.96–2.90 (m, 2 H), 2.69–2.63 (m, 2 H), 2.21–2.18, 2.05–2.01, 
1.83–1.57, 1.29–1.09 (all m, 70 H, PCy3 and two methylene units). 31P{1H} NMR (161.9 
MHz, C6D6): δ 20.62 (s, oxidative addition complex V-11). Other peaks observed: δ 45.6 
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